Value histogram for uniProt.citationRp.val

Home
Genomes
Genome Browser
Tools
Mirrors
- Euro/Asia Mirrors
- Mirroring Instructions
- US Server
- European Server
- Asian Server
Downloads
My Data
Projects
Help
About Us
- News
- Publications
- Blog
- Cite Us
- Credits
- Release Log
- Staff
- Conditions of Use
- Our History
- Jobs
- Licenses
- Contact Us

value

count

graph

Joint Center for Structural Genomics (JCSG);

************************************************************

Seattle structural genomics center for Infectious Disease (SSGCID);

************************************************************

Fishbol;

************************************

NISC comparative sequencing program;

************************

The German cDNA consortium;

************************

The rice annotation project (RAP);

************************

Center for eukaryotic structural genomics (CESG);

************************

Structural genomics consortium (SGC);

************************

The Danio rerio sequencing project at the Sanger Institute;

************************

Northeast structural genomics consortium (NESG);

************************

Midwest center for structural genomics (MCSG);

************************

New York structural genomics research consortium (NYSGRC);

************************

The international Medicago genome annotation group;

************************

Southeast collaboratory for structural genomics (SECSG);

************************

Center for Structural Genomics of Infectious Diseases (CSGID);

************************

WormBase consortium;

************************

Structural genomics of pathogenic protozoa consortium (SGPP);

************************

New york sgx research center for structural genomics (NYSGXRC);

************************

Plant Chromatin Consortium (NSF Plant Genome project 9975930);

************************

LONG DRUG Study Group;

************************

ANRS AC11 Resistance Study Group;

************************

Hellenic Multicenter Study on HIV-resistance;

************************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].

************

GENOME REANNOTATION.

************

FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA].

************

NUCLEOTIDE SEQUENCE [MRNA].

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 22-30 AND 297-302.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 22-480, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].

************

FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-6; 13-39; 56-63; 71-112; 199-213; 252-280; 351-372; 395-405; 500-516; 532-567 AND 598-607.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-525, AND X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1-524.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 348-538.

************

PROTEIN SEQUENCE, FUNCTION, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 1-17.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).

************

The Arabidopsis Information Resource (TAIR);

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA], AND SEQUENCE REVISION TO 45-46 AND 131.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-138.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).

************

SEQUENCE REVISION TO N-TERMINUS.

************

INTERACTION WITH TPK1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-267, AND MASS SPECTROMETRY.

************

The C. elegans sequencing consortium;

************

IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH DAF-16 AND SIR-2.1, AND SUBCELLULAR LOCATION.

************

International rice genome sequencing project (IRGSP);

************

NOMENCLATURE.

************

IDENTIFICATION BY MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 17-18 AND 169-170.

************

FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH DAF-16 AND SIR-2.1, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].

************

NUCLEOTIDE SEQUENCE [MRNA] OF 14-261.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT, AND SUBCELLULAR LOCATION.

************

SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INDUCTION, AND NOMENCLATURE.

************

SEQUENCE REVISION TO 11-12 AND 58-60.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-238, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 83-169.

************

NUCLEOTIDE SEQUENCE OF 11-240.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-260.

************

SEQUENCE REVISION TO 23 AND 245.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-248, AND MASS SPECTROMETRY.

************

The rice chromosomes 11 and 12 sequencing consortia;

************

SEQUENCE REVISION TO 73; 182 AND C-TERMINUS.

************

INTERACTION WITH SERK1, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND IDENTIFICATION IN THE SERK1 COMPLEX.

************

FUNCTION, AND INTERACTION WITH TPK1.

************

The rice chromosome 3 sequencing consortium;

************

SUBUNIT, AND SUBCELLULAR LOCATION.

************

SEQUENCE REVISION TO 3-4; 13-14; 18-20; 47; 57 AND 234.

************

IDENTIFICATION IN THE SERK1 COMPLEX.

************

The rice full-length cDNA consortium;

************

SEQUENCE REVISION TO 53; 72; 121 AND 154.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA], AND SEQUENCE REVISION TO 20 AND 76.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-131.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-239, AND MASS SPECTROMETRY.

************

NIH - Mammalian Gene Collection (MGC) project;

************

PROTEIN SEQUENCE OF 2-246.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).

************

The MGC Project Team;

************

PROTEIN SEQUENCE OF 1-11; 14-57; 63-70; 106-117; 130-169 AND 215-246, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 3-20.

************

INTERACTION WITH AANAT.

************

INTERACTION WITH CRTC2.

************

INTERACTION WITH SSH1.

************

SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.

************

INTERACTION WITH YAP1.

************

INTERACTION WITH ROR2, FUNCTION, PHOSPHORYLATION, DIMERIZATION, AND MASS SPECTROMETRY.

************

INTERACTION WITH GAB2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH SRPK2.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-70 AND LYS-117, AND MASS SPECTROMETRY.

************

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-239, MASS SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.

************

VARIANT ILE-99.

************

International consortium for macaque cDNA sequencing and analysis;

************

PROTEIN SEQUENCE OF 1-12; 14-57; 61-70; 84-117; 128-169; 196-246 AND 215-224, AND MASS SPECTROMETRY.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-84 AND TYR-106, AND MASS SPECTROMETRY.

************

INTERACTION WITH PRKCE.

************

INTERACTION WITH SAMSN1.

************

PROTEIN SEQUENCE OF 14-57; 63-70; 86-117; 130-159; 161-189 AND 196-224, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 30-43, INTERACTION WITH AANAT, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 3-193.

************

PROTEIN SEQUENCE OF 3-24 (ISOFORM LONG).

************

PHOSPHORYLATION AT SER-149, AND MASS SPECTROMETRY.

************

ACETYLATION OF N-TERMINUS, AND MASS SPECTROMETRY.

************

Sanger Xenopus tropicalis EST/cDNA project;

************

NIH - Xenopus Gene Collection (XGC) project;

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).

************

IDENTIFICATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM D), AND MUTAGENESIS OF GLU-183; PHE-199 AND TYR-214.

************

GENOME REANNOTATION, AND ALTERNATIVE SPLICING.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-262, AND MASS SPECTROMETRY.

************

INTERACTION WITH YKI.

************

FUNCTION, AND INTERACTION WITH YKI.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SV), AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND SV).

************

PROTEIN SEQUENCE OF 1-19.

************

PROTEIN SEQUENCE OF 1-19; 30-50 AND 131-170, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 103-108; 120-123; 131-141 AND 143-153.

************

PROTEIN SEQUENCE OF 131-141 AND 154-190, AND MASS SPECTROMETRY.

************

INTERACTION WITH HCV CORE PROTEIN.

************

INTERACTION WITH CDKN1B, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH GRB10.

************

INTERACTION WITH ABL1, AND MASS SPECTROMETRY.

************

INTERACTION WITH YWHAZ.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-38 AND SER-210, AND MASS SPECTROMETRY.

************

INTERACTION WITH SRPK2.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-50; LYS-69; LYS-118 AND LYS-123, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-233, MASS SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND DEVELOPMENTAL STAGE.

************

PROTEIN SEQUENCE OF 131-141; 154-170 AND 197-215, AND MASS SPECTROMETRY.

************

INTERACTION WITH ARHGEF28.

************

INTERACTION WITH NDEL1.

************

INTERACTION WITH TIAM2.

************

PROTEIN SEQUENCE OF 1-12; 30-42; 95-106; 143-153 AND 216-225, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 20-50; 62-73; 87-94; 107-123; 131-170 AND 197-225, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 131-142 AND 154-170, INTERACTION WITH AANAT, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-152; 165-184 AND 216-255.

************

PROTEIN SEQUENCE OF 1-23 AND 125-140.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.

************

SIMILARITY TO KINASE INHIBITOR.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 27-225.

************

PROTEIN SEQUENCE OF 2-10.

************

PROTEIN SEQUENCE OF 2-10; 29-50; 62-69; 126-132; 144-155; 163-172 AND 218-227, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLY-2, AND MASS SPECTROMETRY.

************

INTERACTION WITH AR; ESR1; ESR2; MC2R; NRIP1; NR3C1; PPARBP AND THRA.

************

FUNCTION, AND INTERACTION WITH PDPK1.

************

INTERACTION WITH CDKN1B.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-25, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS), MASS SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH CDK16.

************

PROTEIN SEQUENCE OF 13-56; 62-69; 92-106; 111-120; 133-172 AND 199-227, AND MASS SPECTROMETRY.

************

INTERACTION WITH KCNK18.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-117, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 13-56; 62-69; 111-120; 126-132; 144-155; 163-172 AND 197-227, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION, AND INTERACTION WITH RAF1.

************

NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 1-10; 13-56; 62-69; 133-172 AND 199-227, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT MET-1 AND VAL-2, PHOSPHORYLATION AT THR-145, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-12.

************

PROTEIN SEQUENCE OF 2-10; 13-19; 29-42; 62-69; 133-143 AND 218-227, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT VAL-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 92-110; 199-217 AND 228-247, AND MASS SPECTROMETRY.

************

CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT VAL-2, AND MASS SPECTROMETRY.

************

FUNCTION IN TP53 ACTIVATION, AND INTERACTION WITH MDM4.

************

X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS), MASS SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 13-50; 43-56; 62-69; 78-83; 92-120 AND 133-247, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 5-10; 13-56; 62-69; 78-83; 89-120; 133-142 AND 126-247, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 144-162, INTERACTION WITH AANAT, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 19-25; 42-49; 118-122; 130-139; 149-159; 161-181; 196-199; 225-229 AND 231-239.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).

************

PROTEIN SEQUENCE OF 42-49 AND 118-122.

************

IDENTIFICATION IN A COMPLEX WITH XPO7; ARHGAP1; EIF4A1; VPS26A; VPS29 AND VPS35.

************

INTERACTION WITH COPS6 AND RFWD2.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH PHOSPHOSERINE PEPTIDE.

************

PROTEIN SEQUENCE OF 1-12; 42-49; 61-68 AND 215-224, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64 AND SER-216, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH KRT17, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

PROTEIN SEQUENCE OF 1-18.

************

PROTEIN SEQUENCE OF 1-9; 28-49; 61-68; 104-115; 139-167 AND 213-222, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 73-245.

************

PHOSPHORYLATION AT SER-232, AND MASS SPECTROMETRY.

************

TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1; LYS-3; LYS-49; LYS-68 AND LYS-115, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-234, MASS SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDK16.

************

PROTEIN SEQUENCE OF 12-49; 61-68; 75-80; 84-115; 128-167 AND 194-245, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 4-9; 12-18; 28-49; 61-68; 84-115; 128-157; 159-167 AND 194-222, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 104-115; 140-157 AND 194-212.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (3.35 ANGSTROMS) IN COMPLEX WITH PHOSPHORYLATED RAF1, INTERACTION WITH PHOSPHOSERINE PEPTIDE, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH PHOSPHORYLATED ITGB2, AND INTERACTION WITH PHOSPHORYLATED ITGB2.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VI).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS VI AND VI').

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM C).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS VI AND VI').

************

FUNCTION, AND INTERACTION WITH SLOB.

************

HOMODIMERIZATION, AND MUTAGENESIS OF ARG-59 AND ARG-63.

************

PROTEIN SEQUENCE OF 1-9; 12-18; 28-49; 61-68; 86-91; 128-158 AND 213-222, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 92-103; 140-157; 194-212 AND 223-245, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION AT THR-232, INTERACTION WITH RAF1, AND FUNCTION.

************

INTERACTION WITH TLK2.

************

PHOSPHORYLATION AT SER-58, AND INTERACTION WITH AKT1.

************

PHOSPHORYLATION AT SER-58, AND DIMERIZATION.

************

INTERACTION WITH AANAT, AND FUNCTION.

************

PHOSPHORYLATION AT SER-184, INTERACTION WITH BAX, FUNCTION, AND MUTAGENESIS OF SER-184.

************

INTERACTION WITH MLLT7.

************

PHOSPHORYLATION AT SER-58, AND MUTAGENESIS OF SER-58.

************

INTERACTION WITH ABL1, MASS SPECTROMETRY, PHOSPHORYLATION AT SER-184, AND MUTAGENESIS OF SER-184.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-232, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION AT SER-58, DIMERIZATION, INTERACTION WITH TP53 AND YWHAE, FUNCTION, AND MUTAGENESIS OF SER-58.

************

INTERACTION WITH NOXA1, AND MUTAGENESIS OF LYS-49.

************

INTERACTION WITH ARHGEF2.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3; LYS-49; LYS-68; LYS-115 AND LYS-120, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH AANAT.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH HISTONE H3 PHOSPHOPEPTIDE.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-230 IN COMPLEX WITH PSEUDOMONAS AERUGINOSA EXOS.

************

NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH WEE1.

************

PROTEIN SEQUENCE OF 12-55; 61-68; 84-115; 128-167 AND 194-245, AND MASS SPECTROMETRY.

************

INTERACTION WITH MLF1.

************

INTERACTION WITH BCL2L11.

************

PROTEIN SEQUENCE OF 1-9; 12-49; 61-68; 92-115; 128-157 AND 213-222, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 12-55; 57-68; 84-115; 121-167; 159-187 AND 194-245, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 28-41; 61-68 AND 128-139, INTERACTION WITH AANAT, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 58-245.

************

TISSUE SPECIFICITY, AND INTERACTION WITH BSPRY.

************

PROTEIN SEQUENCE OF 1-22 AND 122-137.

************

PHOSPHORYLATION AT SER-184.

************

POST-TRANSLATIONAL MODIFICATIONS.

************

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NIH - Zebrafish Gene Collection (ZGC) project;

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-8.

************

PROTEIN SEQUENCE OF 61-108.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND IMMUNOGENICITY.

************

LECTIN-LIKE ACTIVITY, POSSIBLE FUNCTION IN LPS SYNTHESIS, AND DISRUPTION PHENOTYPE.

************

REVIEW.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH HOST SCL TRANSCRIPTION FACTORS SCL6 AND SCL21.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-30.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-156.

************

NUCLEOTIDE SEQUENCE [GENOMIC RNA].

************

PARTIAL NUCLEOTIDE SEQUENCE.

************

NUCLEOTIDE SEQUENCE (ALLELE A*01:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*01:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*01:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:06).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:07).

************

SULFATION.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 25-298 IN COMPLEX WITH MAGE ANTIGENIC PEPTIDE AND ANTIBODY, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*02:01).

************

NUCLEOTIDE SEQUENCE (ALLELE A*02:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 91-365.

************

NUCLEOTIDE SEQUENCE (ALLELES A*02:01; A*02:11 AND A*02:12).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 39-365 (ALLELE A*02:01).

************

PROTEIN SEQUENCE OF 25-295 (ALLELE A*02:01).

************

SEQUENCE REVISION (ALLELE A*02:01).

************

SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELES A*02:02 AND A*02:03).

************

NUCLEOTIDE SEQUENCE (ALLELES A*02:03 AND A*02:05).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 9-365 (ALLELE A*02:04).

************

NUCLEOTIDE SEQUENCE OF 9-365 (ALLELE A*02:04).

************

NUCLEOTIDE SEQUENCE (ALLELE A*02:06).

************

PARTIAL PROTEIN SEQUENCE (ALLELE A*02:06).

************

PARTIAL PROTEIN SEQUENCE (ALLELE A*02:07).

************

PARTIAL PROTEIN SEQUENCE (ALLELE A*02:08).

************

PARTIAL PROTEIN SEQUENCE (ALLELE A*02:09).

************

NUCLEOTIDE SEQUENCE (ALLELE A*02:10).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 9-365 (ALLELE A*02:11).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:13).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:16).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:17).

************

NUCLEOTIDE SEQUENCE (ALLELE A*02:18).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:20).

************

NUCLEOTIDE SEQUENCE (ALLELE A*02:21).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*02:31).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELE A*02:34).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*02:35; A*02:36 AND A*02:37).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF A*02:01.

************

INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I.

************

INTERACTION WITH HUMAN HERPESVIRUS 8 MIR1 PROTEIN, AND UBIQUITINATION.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 25-300 OF HLA-A/B2M HETERODIMER IN COMPLEX WITH TRAC AND TRBC1, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF A*02:01.

************

NUCLEOTIDE SEQUENCE (ALLELE A*03:01).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE A*03:01).

************

NUCLEOTIDE SEQUENCE (ALLELE A*03:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-341 (ALLELE A*03:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*03:05).

************

NUCLEOTIDE SEQUENCE OF 26-298 (ALLELE A*03:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*03:06).

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 25-298 (ALLELE A*03:01) IN COMPLEX WITH PLP1 ANTIGENIC PEPTIDE, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2-365.

************

LACK OF ACS ACTIVITY, TISSUE SPECIFICITY, AND INDUCTION.

************

ENZYME ACTIVITY, TISSUE SPECIFICITY, INDUCTION, AND PUTATIVE PROTEOLYTIC PROCESSING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 290-495.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ABSENCE OF ENZYME ACTIVITY, AND MUTAGENESIS OF SER-205.

************

NUCLEOTIDE SEQUENCE OF 57-88.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 100-152.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES A*11:01 AND A*11:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*11:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*11:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:07).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:04) (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-365 (ALLELE A*11:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*11:04).

************

X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 25-299 (ALLELE A*11:01) IN COMPLEX WITH SARS NUCLEOCAPSID PEPTIDE, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 53-99.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND VARIANT ILE-136.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 1).

************

MUTAGENESIS OF 206-THR--PRO-208.

************

PHOSPHORYLATION AT SER-483; SER-488 AND SER-491.

************

NUCLEOTIDE SEQUENCE.

************

HOMODIMERIZATION, AND MUTAGENESIS OF TYR-92 AND LYS-278.

************

MUTAGENESIS OF ARG-286.

************

PHOSPHORYLATION AT SER-460.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 11-438.

************

PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], TISSUE SPECIFICITY, AND INDUCTION.

************

ERRATUM.

************

NUCLEOTIDE SEQUENCE OF 50-81.

************

ENZYME ACTIVITY, AND INDUCTION.

************

INTERACTION WITH ETO1 AND EOL1.

************

INTERACTION WITH XBAT32, AND UBIQUITINATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-159.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 235-307, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 50-81.

************

MUTANT ETO2.

************

DEGRADATION, AND INTERACTION WITH ETO1; EOL1 AND EOL2.

************

INTERACTION WITH FEI1 AND FEI2.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-495, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 53-418, AND INDUCTION.

************

FUNCTION, PHOSPHORYLATION AT SER-480; SER-483 AND SER-488, AND MUTAGENESIS OF SER-480; SER-483 AND SER-488.

************

ENZYME ACTIVITY, TISSUE SPECIFICITY, AND INDUCTION.

************

MUTANT ETO3.

************

INTERACTION WITH ETO1 AND EOL1, AND MUTAGENESIS OF VAL-457.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-473.

************

X-RAY CRYSTALLOGRAPHY (2.37 ANGSTROMS).

************

US DOE Joint Genome Institute;

************

NUCLEOTIDE SEQUENCE, CHARACTERIZATION, AND ACETYLATION AT SER-1.

************

X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF GLY-44.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.

************

VARIANTS [LARGE SCALE ANALYSIS] GLU-221 AND LEU-393.

************

LACK OF ENZYME ACTIVITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-529.

************

NUCLEOTIDE SEQUENCE (ALLELE A*23:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*23:02 AND A*23:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*23:04 AND A*23:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*2401).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELES A*24:02 AND A*24:03).

************

NUCLEOTIDE SEQUENCE (ALLELE A*24:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*24:02).

************

NUCLEOTIDE SEQUENCE (ALLELE A*24:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-337 (ALLELE A*24:29).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*24:10).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES A*24:06; A*24:13 AND A*24:14).

************

X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS) OF 25-298 (ALLELE A*24:02) IN COMPLEX WITH B2M AND CD8, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*25:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*25:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*25:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*25:03).

************

NUCLEOTIDE SEQUENCE (ALLELES A*26:01 AND A*26:02).

************

NUCLEOTIDE SEQUENCE (ALLELE A*26:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES A*26:01; A*26:02; A*26:03 AND A*26:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*26:03).

************

NUCLEOTIDE SEQUENCE (ALLELE A*26:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*26:07).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*26:08).

************

NUCLEOTIDE SEQUENCE (ALLELE A*26:08).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*26:12).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*26:15).

************

NUCLEOTIDE SEQUENCE OF 26-298 (ALLELE A*26:07).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 27-365 (ALLELE A*26:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*29:01).

************

SEQUENCE REVISION TO 345.

************

NUCLEOTIDE SEQUENCE (ALLELE A*29:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*29:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELE A*29:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*29:04).

************

NUCLEOTIDE SEQUENCE (ALLELE A*30:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*30:01).

************

NUCLEOTIDE SEQUENCE (ALLELE A*30:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-279 (ALLELE A*30:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*30:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 26-206 (ALLELE A*30:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-205 (ALLELE A*30:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*30:06).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*30:07).

************

NUCLEOTIDE SEQUENCE (ALLELE A*30:08).

************

NUCLEOTIDE SEQUENCE (ALLELE A*31:01).

************

NUCLEOTIDE SEQUENCE OF 9-365 (ALLELE A*31:01).

************

NUCLEOTIDE SEQUENCE (ALLELE A*31:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*31:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*31:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*31:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*31:05).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*31:06).

************

ASSOCIATION OF ALLELE A*31:01 WITH CARBAMAZEPINE-INDUCED HYPERSENSITIVITY REACTIONS.

************

NUCLEOTIDE SEQUENCE (ALLELE A*32:01).

************

NUCLEOTIDE SEQUENCE OF 25-298 (ALLELE A*32:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*32:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*32:03 AND A*32:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*32:03).

************

NUCLEOTIDE SEQUENCE (ALLELE A*32:05).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*32:06).

************

NUCLEOTIDE SEQUENCE (ALLELE A*33:01).

************

SEQUENCE REVISION TO 178-179; 210 AND 345.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*3302).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*33:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-99 AND 122-205 (ALLELES A*33:01 AND A*33:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*33:01 AND A*33:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES A*34:01 AND A*34:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*36:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*36:02).

************

NUCLEOTIDE SEQUENCE (ALLELE A*43:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*43:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES A*66:01 AND A*66:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*66:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-322 (ALLELE A*66:01).

************

NUCLEOTIDE SEQUENCE (ALLELE A*68:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*68:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*68:08).

************

NUCLEOTIDE SEQUENCE (ALLELE A*68:011).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*68:17).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*68:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*68:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*68:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*68:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*68:09 AND A*68:10).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3-206 (ALLELE A*68:16).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*68:07 AND A*68:17).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-297 (ALLELE A*68:01).

************

PROTEIN SEQUENCE OF 25-294 (A*68:01).

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-294 (A*68:01).

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 25-199 (A*68:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*69:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELE A*69:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*74:01).

************

NUCLEOTIDE SEQUENCE (ALLELE A*74:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-206 (ALLELES A*74:02 AND A*74:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-206 (ALLELE A*74:04).

************

NUCLEOTIDE SEQUENCE OF 25-206 (ALLELE A*74:05).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-345; SER-356 AND SER-359, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*80:01).

************

FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RNA-DIRECTED RNA POLYMERASE 2A, AND MUTAGENESIS OF 396-LEU--LEU-407; LEU-400; LYS-403 AND LYS-406.

************

INTERACTION WITH ARABIDOPSIS TIP1-1; TIP1-2; TIP1-3; TIP2-1; TIP2-2 AND TIP2-3.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:02).

************

NUCLEOTIDE SEQUENCE (ALLELE B*07:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*07:03 AND B*07:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:06).

************

NUCLEOTIDE SEQUENCE (ALLELE B*07:18).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*07:24).

************

PROTEIN SEQUENCE OF 25-295 (B*07:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*08:01).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE B*08:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*08:04).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 33-257 (ALLELE B*08:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*08:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*08:07 AND B*08:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 116-206 (ALLELE B*08:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*08:09; B*08:12; B*08:13 AND B*08:14).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*08:10).

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-300.

************

NUCLEOTIDE SEQUENCE (ALLELE B*13:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*13:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*13:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*13:01 AND B*13:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*13:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*13:04).

************

NUCLEOTIDE SEQUENCE (ALLELE B*13:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*14:01 AND B*14:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*14:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*14:03).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*15:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*15:01; B*15:11 AND B*15:19).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*15:01; B*15:02 AND B*15:11).

************

NUCLEOTIDE SEQUENCE (ALLELE B*15:03).

************

NUCLEOTIDE SEQUENCE (ALLELE B*15:04).

************

NUCLEOTIDE SEQUENCE (ALLELE B*15:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*15:66).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-362 (ALLELE B*15:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 25-362 (ALLELE B*15:01).

************

ASSOCIATION OF ALLELE B*15:02 WITH STEVENS-JOHNSON SYNDROME.

************

X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 25-300 (ALLELE B*15:01) IN COMPLEX WITH EBV NUCLEAR ANTIGEN AND UBE2 PEPTIDES, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE (ALLELE B*18:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*18:02).

************

NUCLEOTIDE SEQUENCE (ALLELE B*18:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*18:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*18:07; B*18:10; B*18:11; B*18:12 AND B*18:13).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*27:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 25-361 (ALLELE B*27:01).

************

PROTEIN SEQUENCE OF 25-295 (B*27:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*27:01 AND B*27:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:02).

************

PROTEIN SEQUENCE OF 86-107 AND 171-181 (B*27:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*27:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*27:04 AND B*27:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-298 (ALLELE B*27:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:06).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:07).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:08).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:09).

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-300.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-300.

************

3D-STRUCTURE MODELING OF 115-206.

************

DISEASE, AND POSSIBLE PROTECTIVE ROLE OF ALLELE B*27:07.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*35:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*35:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*35:03).

************

NUCLEOTIDE SEQUENCE (ALLELE B*35:03).

************

NUCLEOTIDE SEQUENCE (ALLELES B*35:05 AND B*35:06).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*35:07 AND B*35:08).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*35:08).

************

NUCLEOTIDE SEQUENCE OF 9-362 (ALLELE B*35:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*35:29 AND B*35:32).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES B*35:25; B*35:28; B*35:29; B*35:30 AND B*35:36).

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 25-300.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*37:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*37:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*37:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*37:05).

************

NUCLEOTIDE SEQUENCE OF 1-322 (ALLELE B*37:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*37:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*38:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*38:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*38:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*38:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 26-206 (ALLELE B*38:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES B*38:04 AND B*38:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELE B*38:05).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*38:07).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*38:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-298 (ALLELE B*38:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*39:01 AND B*39:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*39:02 AND B*39:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:09).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:06).

************

NUCLEOTIDE SEQUENCE (ALLELE B*39:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:10).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:10).

************

NUCLEOTIDE SEQUENCE (ALLELE B*39:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:24).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 10-362 (ALLELE B*39:08).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*39:12).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*39:23).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 60-196 (ALLELE B*39:07).

************

NUCLEOTIDE SEQUENCE (ALLELE B*40:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*40:01).

************

PROTEIN SEQUENCE OF 25-295 (B*40:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*40:02).

************

NUCLEOTIDE SEQUENCE OF 13-318 (ALLELE B*40:02).

************

NUCLEOTIDE SEQUENCE (ALLELES B*40:03 AND B*40:04).

************

NUCLEOTIDE SEQUENCE (ALLELE B*40:05).

************

NUCLEOTIDE SEQUENCE (ALLELE B*40:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*40:08).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-206 (ALLELE B*40:09).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*40:16).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*40:27).

************

NUCLEOTIDE SEQUENCE (ALLELE B*41:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*41:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*41:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*41:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*41:05).

************

X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 25-298, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE (ALLELE B*42:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*42:02).

************

NUCLEOTIDE SEQUENCE (ALLELE B*44:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*44:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*44:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*44:07).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*44:08).

************

NUCLEOTIDE SEQUENCE (ALLELE B*44:12).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*44:13).

************

NUCLEOTIDE SEQUENCE (ALLELES B*44:02 AND B*44:09).

************

NUCLEOTIDE SEQUENCE (ALLELE B*44:05).

************

NUCLEOTIDE SEQUENCE (ALLELE B*44:04).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-362 (ALLELE B*44:02).

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 25-300, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE (ALLELE B*45:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*45:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*45:03).

************

NUCLEOTIDE SEQUENCE (ALLELE B*46:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*46:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*47:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*47:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-302 (ALLELE B*47:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*47:03).

************

NUCLEOTIDE SEQUENCE (ALLELE B*48:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-206 (ALLELE B*48:03).

************

NUCLEOTIDE SEQUENCE (ALLELE B*49:01).

************

SEQUENCE REVISION TO 78.

************

NUCLEOTIDE SEQUENCE OF 1-322 (ALLELE B*49:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*49:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*49:03).

************

NUCLEOTIDE SEQUENCE (ALLELE B*50:01).

************

NUCLEOTIDE SEQUENCE OF 1-322 (ALLELE B*50:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*50:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*50:02).

************

NUCLEOTIDE SEQUENCE (ALLELE B*50:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*50:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*50:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*50:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*51:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*51:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*51:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*51:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*51:08).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-206 (ALLELE B*51:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*51:24).

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-300 (B*51:01).

************

INVOLVEMENT IN BEHCET DISEASE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*52:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*52:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*52:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*53:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-206 (ALLELE B*53:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*53:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*53:03 AND B*53:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*53:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*53:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*53:06 AND B*53:07).

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 25-302.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*54:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*54:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*55:01 AND B*55:02).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE B*55:01).

************

NUCLEOTIDE SEQUENCE (ALLELES B*55:01 AND B*55:12).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*55:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*55:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*55:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*55:09).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*56:01 AND B*56:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*56:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*56:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*56:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*56:06).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*56:07).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*57:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*57:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*57:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*57:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*57:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*57:05).

************

X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 25-300 (ALLELE B*57:03) IN COMPLEX WITH HIV-1 PEPTIDES, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*58:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*58:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*58:02).

************

NUCLEOTIDE SEQUENCE OF 1-206 (ALLELE B*58:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*58:05).

************

ASSOCIATION OF ALLELE B*58:01 WITH SEVERE CUTANEOUS ADVERSE REACTIONS TO ALLOPURINOL.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*59:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*67:01).

************

NUCLEOTIDE SEQUENCE OF 26-205 (ALLELE B*67:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*67:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*67:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*73:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*78:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*78:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*78:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*78:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*81:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELE B*82:01).

************

NUCLEOTIDE SEQUENCE (ALLELE B*82:01).

************

NUCLEOTIDE SEQUENCE OF 1-24 (ALLELE B*82:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*82:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*82:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*82:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*01:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*01:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*01:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-206 (ALLELE CW*01:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*01:03).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*01:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*02:01).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*02:02).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-83, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE (ALLELE CW*03:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*03:02).

************

NUCLEOTIDE SEQUENCE (ALLELES CW*03:03 AND CW*03:04).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*03:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-206 (ALLELE CW*03:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*03:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES CW*03:05; CW*03:06; CW*03:08 AND CW*03:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*03:13).

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 25-302 IN COMPLEX WITH KIR2DL2, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE (ALLELE CW*04:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*04:01).

************

NUCLEOTIDE SEQUENCE OF 1-365 (ALLELE CW*04:01).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*04:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES CW*04:04 AND CW*04:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*04:06).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*05:01).

************

NUCLEOTIDE SEQUENCE OF 1-298 (ALLELE CW*05:01).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*05:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*05:03).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*05:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*06:02).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*06:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 22-366 (ALLELE CW*06:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*06:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*06:04).

************

ASSOCIATION OF ALLELE CW*06:02 WITH PSORIASIS.

************

INVOLVEMENT IN PSORS1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES CW*07:02 AND CW*07:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*07:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:11).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES CW*07:02 AND CW*07:04).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-206 (ALLELE CW*07:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 25-366 (ALLELE CW*07:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*07:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-338 (ALLELE CW*07:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 77-309 (ALLELE CW*07:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES CW*08:01 AND CW*08:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*08:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*12:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*12:02).

************

NUCLEOTIDE SEQUENCE OF 1-298 (ALLELE CW*12:02).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*12:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*12:03).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*12:03).

************

NUCLEOTIDE SEQUENCE OF 1-298 (ALLELE CW*12:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*12:04).

************

NUCLEOTIDE SEQUENCE OF 1-227 (ALLELE CW*12:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES CW*12:04 AND CW*12:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELE CW*12:05).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*12:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*12:08).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*12:09).

************

VARIANTS [LARGE SCALE ANALYSIS] PRO-208 AND THR-363.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*14:02), AND VARIANT MET-272.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*14:02).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*14:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-298 (ALLELE CW*14:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*14:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*14:03).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*14:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*14:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*15:02).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*15:02).

************

NUCLEOTIDE SEQUENCE OF 1-275 (ALLELE CW*15:02).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*15:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*15:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*15:05).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*15:10).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*15:11).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*16:01), AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*16:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-338 (ALLELE CW*16:04).

************

NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE CW*16:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*16:04).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*17:01).

************

NUCLEOTIDE SEQUENCE OF 26-298 (ALLELE CW*17:01).

************

NUCLEOTIDE SEQUENCE OF 1-289 (ALLELE CW*17:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-338 (ALLELE CW*17:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*18:01).

************

NUCLEOTIDE SEQUENCE (ALLELE CW*18:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*18:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*18:02).

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INTERACTION WITH ICAM3; HIV-1 AND SIV.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 32-81.

************

PROTEIN SEQUENCE, AND INDUCTION.

************

PROTEIN SEQUENCE, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-61.

************

INTERACTION WITH AALPHA.

************

PROTEIN SEQUENCE OF 47-56; 129-132; 347-354; 448-462 AND 471-480.

************

PHOSPHORYLATION, AND SUBCELLULAR LOCATION.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH SGOL1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41 AND SER-42, AND MASS SPECTROMETRY.

************

IDENTIFICATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-1).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-2), AND PARTIAL PROTEIN SEQUENCE.

************

INTERACTION WITH SGOL1.

************

FUNCTION, PHOSPHORYLATION AT SER-32; SER-35; SER-44; SER-46; SER-47 AND SER-48, AND INTERACTION WITH AKT1.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INTERACTION WITH AALPHA.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA-1).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS DELTA-1 AND DELTA-3).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA-2), AND PROTEIN SEQUENCE OF 501-508; 550-559; 573-580 AND 584-601 (DELTA-1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM DELTA-2).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM DELTA-1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-598, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-553, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SUBCELLULAR LOCATION.

************

Saccharomyces Genome Database;

************

FUNCTION, SUBUNIT, AND PHOSPHORYLATION.

************

LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-272, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-242, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-257 AND THR-272, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; THR-242; THR-257 AND THR-272, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND NOMENCLATURE.

************

IDENTIFICATION IN A COMPLEX WITH ARL2; PPP2CB; PPP2R1A; PPP2R2A AND TBCD, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 449-455.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-7, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-436.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 51-437.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GAMMA-3).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GAMMA-1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GAMMA-3).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-524 (ISOFORM GAMMA-2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 11-524 (ISOFORM GAMMA-1).

************

IDENTIFICATION AS A RENAL CANCER ANTIGEN.

************

IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH SGOL1, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH IER3 AND ERK KINASES, AND PHOSPHORYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-348; TYR-349 AND TYR-354, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH TP53, AND INDUCTION.

************

INTERACTION WITH TP53.

************

X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 1-442 IN COMPLEX WITH PPP2CA AND PPP2R1A.

************

X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 30-436 IN COMPLEX WITH PPP2CA AND PPP2R1A.

************

X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 34-436 IN COMPLEX WITH PPP2CA; PPP2R1A AND SGOL1.

************

X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 11-380.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 11-524 (ISOFORMS 2 AND 3).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 18-524 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 32-524 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 326-524 (ISOFORM 4), AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-497, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GAMMA-1; GAMMA-3; GAMMA-4 AND GAMMA-5).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 265-588.

************

INTERACTION WITH PP2A SUBUNITS B AND C.

************

INTERACTION WITH CYP20-1/ROC7.

************

FUNCTION, AND TISSUE SPECIFICITY.

************

INTERACTION WITH PHOSPHATIDIC ACID.

************

INTERACTION WITH CHIP, AND PTM.

************

IDENTIFICATION IN A COMPLEX WITH ARL2; PPP2CB; PPP2R2A; PPP2R5E AND TBCD, MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.

************

SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 242-255.

************

PROTEIN SEQUENCE OF 34-46, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 204-214; 261-272 AND 521-527.

************

BINDING DOMAINS.

************

INTERACTION WITH IPO9.

************

IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SGOL1.

************

INTERACTION WITH PLA2G16.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-280, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 9-589 IN COMPLEX WITH WITH PPP2CA AND PPME1.

************

IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH FOXO1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-8; SER-65; ASP-90; PRO-101; GLU-343; ALA-448; GLY-504 AND ALA-545.

************

NHLBI resequencing and genotyping service (RS&G);

************

NUCLEOTIDE SEQUENCE [MRNA] OF 31-601 (ISOFORM 1).

************

INTERACTION WITH RAF1.

************

VARIANT ASP-90.

************

VARIANTS ALA-15; PRO-365; GLU-498; ILE-499 AND GLY-500.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 80-587.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-460, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS A AND B).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 200-210, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 80-272.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBUNIT.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-134, AND MASS SPECTROMETRY.

************

INTERACTION WITH YND1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-155 AND SER-440, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-197 (ISOFORM 2).

************

INVOLVEMENT IN SCA12.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INDUCTION, MUTAGENESIS OF 165-ARG-ARG-166, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 8-177 (ISOFORM 1), AND TISSUE SPECIFICITY.

************

INTERACTION WITH TOMM22, MUTAGENESIS OF ISOFORM 2, AND SUBCELLULAR LOCATION.

************

FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 34-453.

************

NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.

************

FUNCTION, AND IDENTIFICATION IN SOME PP2A COMPLEX.

************

FUNCTION, AND INTERACTION WITH ARPP19 AND ENSA.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.

************

IDENTIFICATION, FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-96; SER-99; SER-109 AND SER-542, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE, FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 215-627.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*01:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*01:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*01:01), AND VARIANT ARG-262.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*01:04).

************

PROTEIN SEQUENCE OF 30-64.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELE DRB1*01:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 37-266 (ALLELE DRB1*01:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-115 (ALLELES DRB1*01:01 AND DRB1*01:02).

************

DISEASE.

************

UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 32-219.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF COMPLEX WITH SEB.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*03:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*03:01).

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-48, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 34-220 OF HLA-DRA/HLA-DRB1 HETERODIMER IN COMPLEX WITH CD74 PEPTIDE (CLIP), SUBUNIT, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*04:01).

************

ERRATUM, AND SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE DRB1*04:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*04:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*04:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*04:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-115 (ALLELE DRB1*04:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-122 (ALLELE DRB1*04:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*04:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*04:04).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-123 (ALLELE DRB1*04:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*04:11).

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF COMPLEX WITH A COLLAGEN PEPTIDE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*07:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*07:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-117 (ALLELE DRB1*07:04).

************

Hepatitis C European Network for Cooperative Research;

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*08:02).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 32-115 (ALLELE DRB1*08:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*08:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*08:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-208 (ALLELE DRB1*08:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-115 (ALLELE DRB1*08:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-120 (ALLELE DRB1*08:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 47-122 (ALLELE DRB1*08:04).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 124-217.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 256-266.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*09:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-115 (ALLELE DRB1*09:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-115.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 45-266.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*10:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*10:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*10:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*11:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*11:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*11:04).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*12:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*12:10).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*12:17).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-262 (ALLELE DRB1*12:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-208 (ALLELE DRB1*12:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:11).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:15).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:19).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:18).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:12).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:13).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:14).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:16).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELE DRB1*12:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELE DRB1*12:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 88-197 (ALLELE DRB1*12:06).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DRB1*13:01 AND DRB1*13:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*13:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES DRB1*13:27 AND DRB1*13:56).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*13:02).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB1*13:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-148 (ALLELE DRB1*13:21).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-123 (ALLELE DRB1*13:19).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-130 (ALLELE DRB1*13:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-217 (ALLELE DRB1*13:87).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-216 (ALLELES DRB1*13:03; DRB1*13:06; DRB1*13:08; DRB1*13:10; DRB1*13:11; DRB1*13:14; DRB1*13:17; DRB1*13:20; DRB1*13:29 AND DRB1*13:36).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-124 (ALLELE DRB1*13:12).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:18).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:22).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:42 AND DRB1*13:43), NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELES DRB1*13:35; DRB1*13:37 AND DRB1*13:49), AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*13:38).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:46).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:44).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:60).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:57).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:50).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:51).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:66).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:64).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:68).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:70).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:77).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:75).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:71).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:76).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:82).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:32).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:34).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:39).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:14).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:41).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:48).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:47).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:07).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:01 AND DRB1*13:16).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:69).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:58).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:54).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:61).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:62 AND DRB1*13:63).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:59).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:65).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:67).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:74).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:79).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:78).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:83).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:31; DRB1*13:72; DRB1*13:73; DRB1*13:80; DRB1*13:81; DRB1*13:84; DRB1*13:85; DRB1*13:86 AND DRB1*13:88).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELES DRB1*13:23 AND DRB1*13:24).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-120 (ALLELE DRB1*13:13).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-120 (ALLELE DRB1*13:52).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-116 (ALLELE DRB1*13:25).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*13:33).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELE DRB1*13:40).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELE DRB1*13:53).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELES DRB1*13:15 AND DRB1*13:55).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-120 (ALLELE DRB1*13:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-119 (ALLELE DRB1*13:30).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-119 (ALLELE DRB1*13:28).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-116 (ALLELE DRB1*13:26).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-116 (ALLELE DRB1*13:45).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*14:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DRB1*14:01 AND DRB1*14:04), AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-264 (ALLELES DRB1*14:02 AND DRB1*14:03).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*14:05).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*14:11), AND NUCLEOTIDE SEQUENCE [MRNA] OF 1-265 (ALLELE DRB1*14:46).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-217 (ALLELE DRB1*14:57).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-208 (ALLELE DRB1*14:54).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-123 (ALLELE DRB1*14:19).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-217 (ALLELE DRB1*14:82).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-216 (ALLELES DRB1*14:06; DRB1*14:07; DRB1*14:10; DRB1*14:13; DRB1*14:14 AND DRB1*14:21).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-124 (ALLELE DRB1*14:85).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:22).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:36).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:37).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:41), AND NUCLEOTIDE SEQUENCE [MRNA] OF 35-123 (ALLELE DRB1*14:42).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:43).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:47 AND DRB1*14:48).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:50).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:49).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:56).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:60).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:65).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:74).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:67).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:75).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:61).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:78).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:26; DRB1*14:27 AND DRB1*14:29).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:32).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:34).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:17).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:18).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:15).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:23).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:12).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:53).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:55).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:58).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:59).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:63).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:30).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:76).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:77).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:38; DRB1*14:39; DRB1*14:40; DRB1*14:44; DRB1*14:45 AND DRB1*14:80).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:51; DRB1*14:52; DRB1*14:62; DRB1*14:64; DRB1*14:68; DRB1*14:69; DRB1*14:70; DRB1*14:71; DRB1*14:72; DRB1*14:73; DRB1*14:79; DRB1*14:81 AND DRB1*14:83).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:24).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:84).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELE DRB1*14:35).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*14:28).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*14:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELES DRB1*14:09 AND DRB1*14:25).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-122 (ALLELE DRB1*14:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-119 (ALLELE DRB1*14:31).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-122 (ALLELE DRB1*14:33).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-116 (ALLELE DRB1*14:20).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 42-131 (ALLELE DRB1*14:24).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-120 (ALLELE DRB1*14:16).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*15:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DRB1*15:01; DRB1*15:02 AND DRB1*15:03).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELES DRB1*15:03 AND DRB1*15:04).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE DRB1*15:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 11-266 (ALLELE DRB1*15:02).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*15:01).

************

PROTEIN SEQUENCE OF 30-228.

************

X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 30-227.

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*16:01).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*16:02).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*16:03).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB1*16:01).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*16:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-216 (ALLELE DRB1*16:04).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:08).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:09).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:11).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:05).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:10).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:12).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-119 (ALLELE DRB1*16:01).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 39-120 (ALLELE DRB1*16:07).

************

SUBCELLULAR LOCATION, AND MUTAGENESIS OF 23-ARG--ARG-25.

************

X-RAY CRYSTALLOGRAPHY (2.82 ANGSTROMS) OF 1-69 IN COMPLEX WITH A SMALL INTERFERING RNA DUPLEX, AND SUBUNIT.

************

SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].

************

COFACTOR, SUBSTRATE SPECIFICITY, AND REACTION MECHANISM.

************

NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND REACTION MECHANISM.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH SUBSTRATE AND FMN, FUNCTION, COFACTOR, ACTIVE SITE, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CATALYTIC ACTIVITY, AND SUBUNIT.

************

US DOE Joint Genome Institute (JGI-PGF);

************

PROTEIN SEQUENCE OF 1-30, SUBUNIT, AND BIOTINYLATION.

************

PROTEIN SEQUENCE OF 1-30, AND SUBUNIT.

************

SEQUENCE REVISION TO 259.

************

X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) IN COMPLEX WITH ACETOACETYL-COA.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 38-73 AND 84-162.

************

PROTEIN SEQUENCE OF 37-64 AND 70-142.

************

3D-STRUCTURE MODELING, GLYCOSYLATION, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-90 AND 118-170.

************

PROTEIN SEQUENCE OF 36-68 AND 83-154.

************

PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 36-68 AND 83-154, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 103-164.

************

INTERACTION WITH AHK2.

************

PROTEIN SEQUENCE, SUBUNIT, AND ALLERGEN.

************

PROTEIN SEQUENCE OF 1-37, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 9-98.

************

PROTEIN SEQUENCE OF 90-120.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 162-173.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 39-141.

************

PROTEIN SEQUENCE OF 39-141.

************

STRUCTURE BY NMR OF 39-141, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE, AND PYROGLUTAMATE FORMATION AT GLN-32.

************

STRUCTURE BY NMR OF 1-106, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE, FUNCTION, TISSUE SPECIFICITY, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 23-56 AND 75-94, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 36-45 AND 75-84.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEOLYTIC PROCESSING OF PRECURSOR, BLOCKAGE OF N-TERMINUS, VARIANT THR-74, AND DEVELOPMENTAL STAGE.

************

PROTEIN SEQUENCE OF 157-190 AND 194-258.

************

PROTEIN SEQUENCE OF 36-76; 157-190 AND 194-258, AND PHOSPHORYLATION.

************

PROTEIN SEQUENCE OF 36-72; 87-153; 157-190 AND 194-258, BLOCKAGE OF N-TERMINUS, AND NOMENCLATURE.

************

SIMILARITY TO PROTEINASE INHIBITORS.

************

STRUCTURE BY NMR OF 36-156, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE OF 22-64.

************

PROTEIN SEQUENCE OF 82-96.

************

PROTEIN SEQUENCE, FUNCTION, SUBUNIT, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 21-40.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INDUCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE OF 2-254.

************

CRYSTALLIZATION, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (1.22 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-30.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-367.

************

VARIANTS VAL-79 AND LEU-286.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 227-358.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLN-94.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 49-102.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 167-205.

************

POSSIBLE INVOLVEMENT IN INSULIN-RESISTANT POLYCYSTIC OVARY SYNDROME.

************

VARIANTS AH2 LYS-142; PRO-245 AND ASN-253.

************

VARIANTS AH2 TRP-108 AND LEU-186.

************

VARIANT AH2 ASP-254.

************

VARIANT AH2 ARG-129.

************

VARIANT AH2 THR-82.

************

VARIANT AH2 ARG-173.

************

VARIANT AH2 ASP-15.

************

VARIANT AH2 PRO-205.

************

VARIANT AH2 ARG-259.

************

VARIANT AH2 SER-100.

************

VARIANT AH2 SER-236.

************

VARIANTS AH2.

************

VARIANTS AH2 ARG-129; GLN-222 AND MET-259.

************

VARIANT AH2 GLU-10.

************

VARIANTS AH2 LYS-142 AND THR-222.

************

VARIANT AH2 LEU-341, AND CHARACTERIZATION OF VARIANT AH2 LEU-341.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 109-373.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-42; LYS-60 AND LYS-362, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN CBAS1, AND VARIANT ALA-250.

************

VARIANTS CBAS1 SER-19 AND LYS-147, AND CHARACTERIZATION OF VARIANT CBAS1 LYS-147.

************

FUNCTION AS A 3BETA-HYDROXYSTEROL DEHYDROGENASE AND ISOMERASE, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, DISRUPTION PHENOTYPE, SUBCELLULAR LOCATION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 360-701 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-544, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-544 AND THR-626, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-550, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 263-601.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-553, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 528-537.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND 3).

************

SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-278, AND MASS SPECTROMETRY.

************

RIKEN structural genomics initiative (RSGI);

************

VARIANTS CRBM GLN-415; PRO-415; ARG-418; HIS-418; LEU-418; ARG-420 AND GLU-420.

************

VARIANT CRBM ARG-420.

************

VARIANT CRBM ARG-418.

************

PHOSPHORYLATION AT TYR-174; TYR-183 AND TYR-446.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-442, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113 AND SER-115, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343; SER-350 AND SER-362, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-362, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-361 AND SER-377, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-455 (ISOFORM 1), FUNCTION, INTERACTION WITH BTK, AND TISSUE SPECIFICITY.

************

INTERACTION WITH BTK, AND FUNCTION.

************

INTERACTION WITH MAPK8; MAPK9 AND MAPK10, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-347; LEU-349; LEU-434 AND LEU-436.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 16-22, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 33-458 (ISOFORM 2), AND FUNCTION.

************

INTERACTION WITH MAPK9 AND MAPK12, PHOSPHORYLATION AT SER-353 AND SER-423, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-353 AND SER-423.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND INDUCTION BY JASMONIC ACID.

************

NUCLEOTIDE SEQUENCE [MRNA], AND GENE FAMILY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, INDUCTION BY JASMONIC ACID, BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANTS VAL-190 AND GLU-473.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, CATALYTIC ACTIVITY, INDUCTION BY JASMONIC ACID, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE, AND STRUCTURE BY NMR.

************

PROTEIN SEQUENCE, FUNCTION, MASS SPECTROMETRY, D-AMINO ACID AT TRP-21, AND DISULFIDE BONDS.

************

STRUCTURE BY NMR OF 1-21.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION.

************

X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 2-146, AND SUBUNIT.

************

FUNCTION, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-124.

************

The Broad Institute Genome Sequencing Platform;

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 22-37, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 22-83.

************

FUNCTION, AND LETHAL DOSE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-215.

************

X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 2-286, SUBUNIT, AND IRON-BINDING SITES.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND VARIANT VAL-37.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-37.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-37.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-21, FUNCTION, COFACTOR, SUBSTRATE SPECIFICITY, ENZYME REGULATION, AND MUTAGENESIS OF HIS-52 AND HIS-96.

************

FUNCTION, ENZYME REGULATION, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF NATIVE PROTEIN AND COMPLEXES WITH SUBSTRATES OR INHIBITOR AND IRON, COFACTOR, KINETIC PARAMETERS, MUTAGENESIS OF ARG-47; ARG-99 AND GLU-110, SUBUNIT, AND REACTION MECHANISM.

************

PARTIAL NUCLEOTIDE SEQUENCE [MRNA] OF 44-236, AND PARTIAL PROTEIN SEQUENCE.

************

CATALYTIC ACTIVITY, AND PATHWAY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-176, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-175 IN COMPLEX WITH DIVALENT METAL IONS, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 2-42; 62-66 AND 120-134, FUNCTION AS A 3HAP MUTASE, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND REACTION MECHANISM.

************

PATHWAY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-7, FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INDUCTION.

************

CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, COFACTOR, AND ENZYME REGULATION.

************

INDUCTION.

************

FUNCTION IN 3-HYDROXYBENZOATE ASSIMILATION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, SUBSTRATE SPECIFICITY, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF ARG-169.

************

CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, INDUCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.

************

CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND COFACTOR.

************

PROTEIN SEQUENCE OF 37-47.

************

PROTEIN SEQUENCE OF 60-75; 297-310 AND 321-330, AND MASS SPECTROMETRY.

************

MUTAGENESIS.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-29.

************

IDENTIFICATION BY 2D-GEL.

************

STRUCTURE BY NMR.

************

STRUCTURE BY NMR, AND ZINC-BINDING SITES.

************

STRUCTURE BY NMR IN COMPLEX WITH 3-METHYLADENINE, AND ZINC-BINDING SITES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-12 AND 14-20.

************

CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS), AND MUTAGENESIS.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, ROLE IN RESISTANCE TO ALKYLATION DAMAGE, GENE NAME, INDUCTION, AND DISRUPTION PHENOTYPE.

************

NIEHS SNPs program;

************

NUCLEOTIDE SEQUENCE [MRNA] OF 28-298 (ISOFORMS 1/2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 69-298 (ISOFORMS 1/2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 230-298 (ISOFORMS 1/2).

************

INTERACTION WITH MBD1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-78, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 80-199.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 250-324.

************

FUNCTION AS A KETOSTEROID DEHYDROGENASE, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

FUNCTION AS A KETOSTEROID DEHYDROGENASE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN THE METABOLISM OF STEROIDS, AND SUBCELLULAR LOCATION.

************

FUNCTION AS A KETOSTEROID DEHYDROGENASE, CATALYTIC ACTIVITY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57, PROTEIN SEQUENCE OF 2-15, FUNCTION AS A KETOSTEROID DEHYDROGENASE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF GLU-138; GLU-234 AND GLU-268.

************

CBM31 DOMAIN.

************

X-RAY CRYSTALLOGRAPHY (0.86 ANGSTROMS) OF 23-349 IN COMPLEX WITH MAGNESIUM.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 23-41 AND 300-313, FUNCTION, AND CATALYTIC ACTIVITY.

************

PROTEIN SEQUENCE OF 23-38, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND CBM31 DOMAIN.

************

PROTEIN SEQUENCE OF 23-35, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 375-469, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [MRNA] OF 278-1698 (ISOFORMS 2 AND 3), AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-659 AND SER-1590, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-471; SER-474; SER-478; SER-566; SER-687; THR-689; SER-697; SER-1398; SER-1401; SER-1402 AND THR-1407, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND PROTEIN SEQUENCE OF 378-393.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 157-227, AND VARIANT ILE-214.

************

NUCLEOTIDE SEQUENCE OF 669-864 (ISOFORM 4), AND ALTERNATIVE SPLICING.

************

PROTEIN SEQUENCE OF 534-541; 693-701 AND 793-794, AND PHOSPHORYLATION AT SERINE RESIDUES.

************

PROTEIN SEQUENCE OF 648-714.

************

STRUCTURE OF CARBOHYDRATES.

************

PHOSPHORYLATION AT TYR-660 BY EGFR.

************

INTERACTION WITH DLG1.

************

INTERACTION WITH CALMODULIN.

************

INTERACTION WITH CENPJ.

************

CHARACTERIZATION OF C-TERMINAL DOMAIN.

************

SUBCELLULAR LOCATION, AND ALTERNATIVE SPLICING.

************

MUTAGENESIS OF THR-60 AND SER-712, AND PHOSPHORYLATION AT THR-60 AND SER-712.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-92, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-712, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188; SER-191; SER-555 AND SER-712, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 210-488.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING.

************

PROTEIN SEQUENCE OF 709-713, MASS SPECTROMETRY, AND CHARACTERIZATION OF CARBOXY-TERMINAL DOMAIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-223, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-541; SER-543 AND SER-556, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543 AND SER-668, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-550.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, INDUCTION, AND ENZYME ACTIVITY.

************

SUBSTRATE-BINDING DOMAINS.

************

GENE FAMILY ORGANIZATION.

************

INDUCTION BY WOUNDING.

************

GENE FAMILY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], TISSUE SPECIFICITY, INDUCTION, AND ENZYME ACTIVITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 498-556.

************

MUTAGENESIS OF LYS-211; GLU-401; CYS-403; ARG-449; LYS-457 AND LYS-540.

************

MUTAGENESIS OF MET-293 AND LYS-320.

************

GENE FAMILY ORGANIZATION, SUBSTRATE RECOGNITION SITES, AND MUTAGENESIS OF MET-293 AND LYS-320.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 140-562.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 284-561.

************

NUCLEOTIDE SEQUENCE [MRNA], AND GENE FAMILY ORGANIZATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 26-570.

************

FUNCTION, AND ENZYME ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, SUBCELLULAR LOCATION, AND INDUCTION.

************

FUNCTION, ENZYME ACTIVITY, SUBCELLULAR LOCATION, AND INDUCTION.

************

FUNCTION, SUBCELLULAR LOCATION, AND ENZYME ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH EIF4E1A.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-30; THR-42 AND THR-46, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH EIF4E, AND PHOSPHORYLATION.

************

PROTEIN SEQUENCE OF 2-13, AND ACETYLATION AT SER-2.

************

INTERACTION WITH EIF4E AND EIF4G.

************

PHOSPHORYLATION BY MTOR.

************

INTERACTION WITH RPTOR.

************

INTERACTION WITH RPTOR, AND PHOSPHORYLATION AT THR-37; THR-46; SER-65 AND THR-70 BY MTOR.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-46, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65; THR-70; SER-94 AND SER-101, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-112, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65 AND THR-68, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35; THR-36; THR-37; THR-41; THR-46; THR-50; THR-70; THR-82; SER-83; SER-94 AND SER-101, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37; THR-41; THR-46; THR-50; TYR-54; SER-65; THR-70; THR-77; SER-83 AND SER-94, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-10; TYR-34; THR-37; THR-41; SER-44; THR-45 AND THR-46, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37 AND THR-46, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR OF 4-118.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 36-70 IN COMPLEX WITH EIF4E AND MRNA CAP ANALOG.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 51-67 IN COMPLEX WITH EIF4E2 AND MRNA CAP ANALOG.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 51-64 IN COMPLEX WITH EIF4E AND MRNA CAP ANALOG.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, PHOSPHORYLATION, AND INTERACTION WITH EIF4E.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 18-33; 43-53; 62-80 AND 98-117, PHOSPHORYLATION, AND TISSUE SPECIFICITY.

************

FUNCTION, INTERACTION WITH EIF4E, PHOSPHORYLATION AT SER-64 BY MAPK1 AND MAPK3, AND MUTAGENESIS OF SER-64.

************

NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH EIF4E.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37; THR-41; SER-44 AND THR-45, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH EIF4E, MUTAGENESIS OF TYR-40 AND LEU-45, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CHARACTERIZATION, PHOSPHORYLATION, AND MUTAGENESIS OF TYR-30 AND 195-ARG-ARG-196.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-914 AND SER-920, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-74, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-120; SER-136; SER-138; SER-345; SER-564 AND SER-951, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-564, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-564; SER-587; SER-693 AND SER-951, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-486, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 428-983 (ISOFORM 2).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2), TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 4).

************

PROTEIN SEQUENCE OF 1-17; 146-171; 227-245; 304-313; 440-451; 511-525 AND 593-630, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-209 (ISOFORM 4).

************

PROTEIN SEQUENCE OF 112-122; 148-160; 227-245; 248-255; 288-298; 304-313; 440-451; 511-524 AND 593-625, AND MASS SPECTROMETRY.

************

FUNCTION, SUBUNIT, INHIBITION, AND MUTAGENESIS OF CYS-210 AND CYS-431.

************

FUNCTION, AND SUBUNIT.

************

FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

SUBUNIT, INTERACTION WITH BETA-1 INTEGRINS, AND MUTAGENESIS OF CYS-210 AND CYS-431.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

INTERACTION WITH FAM57A/CT120.

************

MASS SPECTROMETRY.

************

FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.

************

FUNCTION, SUBUNIT, INTERACTION WITH ICAM1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

GLYCOSYLATION AT ASN-365; ASN-381 AND ASN-424.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-381 AND ASN-424, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103 AND THR-106, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-147, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION AT SER-406; SER-408; SER-410; SER-527 AND SER-531.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381 AND ASN-506, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381; ASN-424 AND ASN-506, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 212-630, SUBUNIT, MUTAGENESIS OF CYS-210, SUBCELLULAR LOCATION, AND DISULFIDE BOND.

************

PROTEIN SEQUENCE OF 43-53; 163-171; 456-463 AND 488-496, AND MASS SPECTROMETRY.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INDUCTION, AND MUTAGENESIS OF CYS-103.

************

SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-160; ASN-166; ASN-249; ASN-259; ASN-385 AND ASN-399, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-166; ASN-259; ASN-385 AND ASN-399, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND SUBUNIT.

************

MUTAGENESIS OF CYS-110 AND CYS-332.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBUNIT.

************

SUBUNIT, AND TISSUE SPECIFICITY.

************

TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 82-88; 303-312 AND 369-383, FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, BLOCKED N-TERMINUS, AND SUBUNIT.

************

CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH SUBSTRATE ANALOG AND IN COMPLEX WITH PRODUCT, SUBUNIT, ACTIVE SITE, AND MUTAGENESIS OF GLU-73.

************

FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, PATHWAY, AND SUBUNIT.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-17; ARG-88; ARG-89; LYS-90; ARG-126 AND ARG-128.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-32.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), SUBUNIT, AND ACTIVE SITE.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF WILD-TYPE IN COMPLEX WITH INHIBITOR AND MUTANT ASN-17 IN COMPLEX WITH SUBSTRATE, SUBUNIT, AND ACTIVE SITE.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH VIRAL TOMATO SPOTTED WILT VIRUS NSM PROTEIN, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 6-247.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-34, FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS), SUBUNIT, AND REACTION MECHANISM.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).

************

STRUCTURE BY NMR, AND ACTIVE SITE.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 26-389 IN COMPLEX WITH NADP, SUBUNIT, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-179.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, INDUCTION BY HERBIVORY, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, INDUCTION BY UV TREATMENT, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], PROTEIN SEQUENCE OF 56-73, AND INDUCTION.

************

SEQUENCE REVISION TO 35.

************

CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF TYR-520.

************

X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEX WITH MAGNESIUM IONS AND SUBSTRATE, AND SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-9.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 200-365.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-334, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN PFMC.

************

VARIANTS SER-22 AND VAL-28.

************

VARIANTS LEU-16 AND ASP-273.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-23.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 136-353.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 192-352.

************

PALMITOYLATION, AND PHOSPHORYLATION.

************

VARIANT CYS-124.

************

VARIANT LEU-265.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 135-306.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-363.

************

VARIANT PHE-262.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 120-307.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ALA-96 AND ASN-196.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-588.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-588.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-242, NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 511-834, AND VARIANTS 29-GLU--PRO-32 DEL; GLN-46; VAL-49; GLU-51; GLU-52; GLY-54; THR-76; THR-86; GLN-91; ALA-96; THR-143; THR-146; VAL-171; ASP-182; TYR-184; ASN-196; HIS-198; GLY-213; LEU-531; ALA-536; 547-ALA--GLY-550 DELINS GLY-PRO-MET-GLY-PRO-LEU; VAL-571; LYS-585; MET-588; ARG-589; VAL-648; PRO-657; TRP-682; ILE-688; THR-692; THR-706; HIS-716; GLN-HIS-716 INS; 716-GLN-GLN-717 DEL; 716-GLN--GLN-718 DEL AND 717-GLN--GLN-719 DELINS HIS.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 9-464.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 105-218.

************

INTERACTION WITH MPDZ.

************

INTERACTION WITH INADL; MPP3; PRDX6; DLG4; DLG1; CASK; APBA1 AND MAGI2, AND MUTAGENESIS OF GLY-463; ASN-465; CYS-470 AND VAL-471.

************

VARIANTS ASN-25 AND TYR-452.

************

VARIANTS VAL-197; VAL-447 AND TYR-452.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 146-213.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 216-460.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND VARIANT VAL-61.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 229-617 (ISOFORM B).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-107 AND 152-617, AND VARIANTS VAL-14; ARG-40; VAL-61; LYS-76; TRP-79; ILE-90; GLU-301; HIS-309; GLY-310; ILE-460; SER-463; 478-ALA--GLY-481 DEL AND VAL-492.

************

INVOLVEMENT IN IMPULSIVE BEHAVIOR, TISSUE SPECIFICITY, POLYMORPHISM, AND VARIANTS GLU-45; LEU-173 AND TRP-388.

************

INVOLVEMENT IN IMPULSIVE BEHAVIOR.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3 AND 4), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND RNA EDITING OF POSITIONS 156; 158 AND 160.

************

INTERACTION WITH MPDZ, DOMAIN, MUTAGENESIS OF SER-456; SER-457 AND VAL-458, AND GLYCOSYLATION.

************

INTERACTION WITH ARRB2, AND MUTAGENESIS OF PRO-159.

************

VARIANT SER-23.

************

INTERACTION WITH MPDZ, AND MUTAGENESIS OF SER-458 AND SER-459.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE SPECIFICITY, AND PHARMACOLOGICAL CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).

************

FUNCTION, REGION, AND MUTAGENESIS OF ARG-432; ARG-436 AND ARG-440.

************

INTERACTION WITH RIC3.

************

SUBUNIT, AND MUTAGENESIS OF TRP-178.

************

VARIANT THR-33.

************

VARIANTS HIS-344; ARG-391 AND GLN-409.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.

************

FUNCTION, AND REGION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 22-483.

************

SUBUNIT, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT SER-129.

************

SUBUNIT.

************

SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-52; ASN-96; ASN-138; ASN-168 AND ASN-203, AND MUTAGENESIS OF ASN-52; ASN-96; ASN-138; ASN-168 AND ASN-203.

************

VARIANTS SER-129; ARG-156 AND ILE-183.

************

VARIANTS SER-129; THR-143 AND ILE-183.

************

VARIANT ARG-156.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANTS LYS-163 AND ALA-405.

************

VARIANT [LARGE SCALE ANALYSIS] MET-128.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBUNIT, SUBCELLULAR LOCATION, AND VARIANT GLY-171.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 4), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), SUBUNIT, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A); 5-HT4(B); 5-HT4(C) AND 5-HT4(D)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A) AND 5-HT4(B)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(A)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(B)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(E)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A); 5-HT4(B); 5-HT4(E) AND 5-HT4(G)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(E) AND 5-HT4(I)), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 10-388 (ISOFORM 5-HT4(F)).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 112-255.

************

MASS SPECTROMETRY, AND INTERACTION WITH GRK5.

************

VARIANT LEU-27.

************

SEQUENCE REVISION TO C-TERMINUS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A) AND 5-HT4(E)).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(F)).

************

INTERACTION WITH INADL; MAGI2; MPP3; NOS1; SEC23A; SLC9A3R1 AND SNX27.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 165-259.

************

VARIANT [LARGE SCALE ANALYSIS] CYS-262.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 215-280.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-125, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).

************

GLYCOSYLATION AT ASN-5 AND ASN-66.

************

VARIANTS LYS-92 AND LEU-279.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM A).

************

NUCLEOTIDE SEQUENCE (ISOFORM B).

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

MUTAGENESIS OF TYR-45; GLN-150; HIS-166; HIS-167; CYS-168; ASP-171; LYS-258; ARG-301; ASN-315 AND ASP-390, PROPOSED ENZYME MECHANISM, AND ACTIVE SITE.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, DISRUPTION PHENOTYPE, INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 312-610.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 325-601, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS VAL-201 AND CYS-205.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-248, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 46-85; 150-158; 220-243 AND 291-290, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), TISSUE SPECIFICITY, AND VARIANT P5N DEFICIENCY VAL-137.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, VARIANTS P5N DEFICIENCY PRO-181 AND ARG-280, AND CHARACTERIZATION OF VARIANTS P5N DEFICIENCY PRO-181 AND ARG-280.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 29-336 (ISOFORM 2).

************

PROTEIN SEQUENCE OF 83-95; 131-147; 226-240; 268-296 AND 311-329, INDUCTION, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 1-11, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION OF VARIANTS P5N DEFICIENCY VAL-137; PRO-181; SER-229 AND ARG-280, AND MUTAGENESIS OF ASP-88; PHE-89; ASP-90; GLU-135 AND PHE-233.

************

X-RAY CRYSTALLOGRAPHY (2.67 ANGSTROMS) OF 64-336 IN COMPLEX WITH PHOSPHATE AND MAGNESIUM IONS.

************

VARIANT P5N DEFICIENCY SER-229.

************

PROTEIN SEQUENCE OF 118-123, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) (ISOFORM 1) IN COMPLEXES WITH MAGNESIUM; PHOSPHATE; TRANSITION STATE ANALOG AND LEAD IONS.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-3.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-502, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-536 IN COMPLEX WITH ALLOSTERIC EFFECTOR AND MAGNESIUM IONS, AND SUBUNIT.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-527, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 15-40 AND 162-180.

************

PROTEIN SEQUENCE OF 26-38.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND GPI-ANCHOR AT SER-549.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-113.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 359-489, AND VARIANT ALA-376.

************

PROTEIN SEQUENCE OF 27-40.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-311; ASN-333 AND ASN-403, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-333, AND MASS SPECTROMETRY.

************

VARIANT CALJA TYR-358.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-313 AND ASN-335, AND MASS SPECTROMETRY.

************

FUNCTION, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 538-551, AND GPI-ANCHOR AT SER-551.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 3-22; 67-76; 88-92; 111-124; 134-147; 305-316; 325-337; 371-393; 397-410 AND 431-456.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE; PRODUCT AND COBALT IONS, SUBUNIT, CARBAMYLATION AT LYS-184, AND MUTAGENESIS OF ALA-59; LYS-184 AND MET-186.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-24, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE ATP SYNTHASE COMPLEX.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-14, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 151-163; 299-314 AND 399-414, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 21-55, FUNCTION, CATALYTIC ACTIVITY, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 21-31, FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 323-340, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE OF 88-103, AND CHARACTERIZATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-644 AND SER-659, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-157, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-157; SER-652; SER-667; SER-671 AND SER-675, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147; THR-157; THR-169; TYR-362; SER-644; SER-652 AND SER-656, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-158, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 41-47 AND 120-131.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.37 ANGSTROMS) IN COMPLEX WITH CITRATE, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 2-14.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 460-468.

************

PROBABLE FUNCTION.

************

PROTEIN SEQUENCE OF 37-48; 305-320 AND 447-456, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-125.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEXES WITH NADP AND SUBSTRATE, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, ACTIVE SITE, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-38; LYS-59; LYS-76; LYS-154 AND LYS-309, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 12-456.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE; PRODUCT; INHIBITORS AND NADP, SUBUNIT, AND ACTIVE SITE.

************

IDENTIFICATION OF PROBABLE FRAMESHIFTS.

************

IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107 AND SER-215, AND MASS SPECTROMETRY.

************

PRELIMINARY PROTEIN SEQUENCE OF 2-483.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEXES WITH NADP AND SUBSTRATE, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SUBSTRATE-BINDING SITE.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS), AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 242-325.

************

FUNCTION, AND CATALYTIC ACTIVITY.

************

The Citrobacter koseri Genome Sequencing Project;

************

IDENTIFICATION.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-287, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 41-72 AND 82-96, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 97-242.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-180, AND MASS SPECTROMETRY.

************

The Klebsiella pneumonia Genome Sequencing Project;

************

The Salmonella enterica serovar Arizonae Genome Sequencing Project;

************

The Salmonella enterica serovar Paratyphi B Genome Sequencing Project;

************

PROTEIN SEQUENCE OF 2-20.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 54-328.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PROTEIN SEQUENCE OF 125-140 (ISOFORM 1), AND PROTEIN SEQUENCE OF 126-132 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 61-92.

************

PROTEIN SEQUENCE OF 27-103.

************

FUNCTION, AND INTERACTION WITH PCSK2.

************

FUNCTION, AND DISRUPTION PHENOTYPE.

************

INHIBITION OF PCSK2 BY C-TERMINAL PEPTIDE.

************

SULFATION, CLEAVAGE BY FURIN-LIKE CONVERTASE, AND MUTAGENESIS OF ARG-177 AND ARG-178.

************

PROTEIN SEQUENCE OF 23-171.

************

PROTEIN SEQUENCE OF 23-103.

************

PROTEIN SEQUENCE OF 23-72.

************

PROTEOLYTIC PROCESSING.

************

DISULFIDE BOND.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

FUNCTION, CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND MUTAGENESIS OF LYS-2242.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2349-2408.

************

IDENTIFICATION OF FN-III REPEATS.

************

INTERACTION WITH DAB.

************

PROTEIN SEQUENCE OF 23-31; 77-105 AND 327-337, AND CHARACTERIZATION.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH SUBSTRATES, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 25-57; 135-150; 276-311 AND 383-417.

************

PROTEIN SEQUENCE OF 25-59 AND 283-311.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS B AND C).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 520-752.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P18), PARTIAL PROTEIN SEQUENCE, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P18), TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND VARIANT MET-124.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS P18/P21/P22/P26), AND ALTERNATIVE INITIATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM P18).

************

FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

MUTAGENESIS OF GLY-77; GLY-78; VAL-80; GLN-81; GLY-83; ILE-86; ASP-88; GLY-89; ALA-90; LEU-94; GLN-95; GLU-96; GLU-97 AND SER-98, FUNCTION, AND CATALYTIC ACTIVITY.

************

FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

CATALYTIC ACTIVITY, AND MUTAGENESIS OF PHE-68; TRP-158; ASP-160; LEU-191; ARG-192; GLU-193; VAL-194; ASP-195; THR-196; VAL-197; 192-ARG--VAL-197; 193-GLU--VAL-197; 194-VAL-VAL-197 AND 195-ASP--VAL-197.

************

CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.

************

STRUCTURE BY NMR OF 42-197, SUBUNIT, COFACTOR, AND SUBSTRATE BINDING SITE.

************

CRYSTALLIZATION, AND PRELIMINARY X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 42-197 IN COMPLEX WITH 8-OXO-DGMP, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

VARIANT MET-124.

************

DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

COMPLETE GENOME.

************

FUNCTION, INDUCTION, PHOSPHORYLATION, INTERACTION WITH A32, AND SUBUNIT.

************

FUNCTION, AND MUTAGENESIS OF 55-ALA--ALA-57.

************

PROTEOLYTIC PROCESSING, INDUCTION, AND MUTAGENESIS OF 55-ALA--ALA-57.

************

PHOSPHORYLATION, INDUCTION, AND MUTAGENESIS OF SER-21; SER-29; SER-40; SER-60; SER-68 AND SER-69.

************

FUNCTION, INDUCTION, SUBCELLULAR LOCATION, AND ABSENCE OF PHOSPHORYLATION.

************

PROTEIN SEQUENCE OF 1-9.

************

PHOSPHORYLATION, AND INTERACTION WITH A17.

************

DISULFIDE BONDS, PHOSPHORYLATION AT SER-85, TOPOLOGY, AND MUTAGENESIS OF SER-12; SER-25; SER-34; SER-36; SER-38; SER-47; SER-65; CYS-71; SER-77; SER-85 AND SER-88.

************

IDENTIFICATION OF IN COMPLEX WITH A30; G7; F10; D2; D3 AND J1, FUNCTION, INDUCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT VAL-227.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-50, AND MASS SPECTROMETRY.

************

INTERACTION WITH SPG21.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-300.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 5), AND ASSOCIATION OF VARIANT ALA-300 WITH SUSCEPTIBILITY TO IBD10.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 55-607 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 513-607.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287; SER-290 AND SER-304, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND MASS SPECTROMETRY.

************

ASSOCIATION OF VARIANT ALA-300 WITH SUSCEPTIBILITY TO IBD10.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INTERACTION WITH ATG5.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289, AND MASS SPECTROMETRY.

************

INTERACTION WITH RAB33B.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 297-619.

************

MYRISTOYLATION AT GLY-2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLY-2.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-275.

************

IDENTIFICATION IN A COMPLEX WITH A21; A28; G3; G9; H2; J5 AND L5.

************

FUNCTION, DISULFIDE BONDS, INDUCTION, AND TOPOLOGY.

************

INTERACTION WITH G9.

************

INTERACTION WITH A27.

************

INTERACTION WITH A14, CLEAVAGE AT GLY-185, AND PHOSPHORYLATION BY F10 KINASE.

************

PHOSPHORYLATION AT TYR-203.

************

TOPOLOGY, AND ABSENCE OF GLYCOSYLATION.

************

DISULFIDE BONDS.

************

SUBCELLULAR LOCATION, AND TOPOLOGY.

************

POST-TRANSLATIONAL MODIFICATIONS, AND MUTAGENESIS OF GLY-16; GLY-18 AND GLY-185.

************

PHOSPHORYLATION AT TYR-203, AND MUTAGENESIS OF TYR-203.

************

IDENTIFICATION IN A COMPLEX WITH A25; A26 AND A27.

************

INTERACTION WITH D13.

************

SIMILARITY TO HELICASES.

************

FUNCTION, DNA-BINDING, AND RNA-BINDING.

************

INTERACTION WITH G2, AND POSSIBLE IDENTIFICATION IN A COMPLEX WITH G2 AND H5.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 23-42 AND 73-91.

************

PROTEIN SEQUENCE OF 25-41.

************

PROTEIN SEQUENCE OF 374-380.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-38.

************

PROTEIN SEQUENCE OF 19-129.

************

PROTEIN SEQUENCE OF 129-201.

************

GLYCOSYLATION AT ASN-33; ASN-56; ASN-72; ASN-93 AND ASN-103.

************

GLYCOSYLATION AT ASN-33.

************

GLYCOSYLATION AT ASN-33; ASN-72 AND ASN-93, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-93, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72; ASN-93 AND ASN-103, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93 AND ASN-103, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-72, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

GLYCOSYLATION AT ASN-33, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 20-201, DOMAIN, AND DISULFIDE BONDS.

************

VARIANTS ARG-38 AND MET-174.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-25; ASN-34; ASN-76 AND ASN-94, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-94 AND ASN-104, AND MASS SPECTROMETRY.

************

PYROGLUTAMATE FORMATION AT GLN-19, GLYCOSYLATION AT ASN-33 AND ASN-93, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72 AND ASN-93, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-93 AND ASN-103, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 19-201 OF VARIANT ARG-167 IN COMPLEXES WITH DISOPYRAMIDE; AMITRIPTYLINE AND CHLORPROMAZINE, FUNCTION, DISULFIDE BONDS, AND DOMAIN.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 70-207.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-76, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 25-44 AND 75-93.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 211-413.

************

FUNCTION, SUBCELLULAR LOCATION, AND REGION RCL.

************

GENE FAMILY, AND NOMENCLATURE.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-64 AND ASN-101, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 25-43 AND 381-412.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 12-413.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-101 AND ASN-265, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 203-412.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-265, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-64, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 17-47.

************

PROTEIN SEQUENCE OF 352-376.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 22-37 AND 127-146.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF MET-382.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION OF VARIANT Z.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-237 AND ASP-400.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-172; ALA-237 AND LYS-366.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-237.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67; 196-255 AND 387-418.

************

PRELIMINARY PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 25-418 (ISOFORM 1), VARIANTS ABERRANT FORM 190-GLY--ARG-198 AND VAL-288, AND FUNCTION.

************

PROTEIN SEQUENCE OF 25-39, AND FUNCTION.

************

PROTEIN SEQUENCE OF 30-48 AND 248-257 (ISOFORMS 1/2/3), GLYCOSYLATION AT ASN-70; ASN-107 AND ASN-271, STRUCTURE OF CARBOHYDRATES, CYSTEINE-BINDING, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 47-66.

************

PROTEIN SEQUENCE OF 50-63 AND 161-178 (ISOFORMS 1/2/3), AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 292-418 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 350-418 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 375-414, IDENTIFICATION OF SPAAT, FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 387-418 (ISOFORM 1).

************

GLYCOSYLATION AT ASN-70 AND ASN-271.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

GLYCOSYLATION AT ASN-70 AND ASN-271, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 25-418.

************

X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 45-418.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 48-418 IN COMPLEX WITH BOVINE TRYPSIN.

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 44-418.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-418.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-418.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-418 OF VARIANT PITTSBURGH ARG-382.

************

CHARACTERIZATION OF VARIANT M2.

************

VARIANT M3 ASP-400.

************

VARIANT F CYS-247.

************

VARIANT M-HEERLEN LEU-393.

************

VARIANT M-MALTON PHE-75 DEL.

************

VARIANT M-MINERAL SPRINGS GLU-91.

************

VARIANT M-NICHINAN PHE-75 DEL.

************

VARIANT M-PROCIDA PRO-65.

************

VARIANT P-DUARTE VAL-280.

************

INVOLVEMENT OF VARIANT PITTSBURGH ARG-382 IN BLEEDING DIATHESIS.

************

INVOLVEMENT IN A1ATD, AND VARIANT S-IIYAMA PHE-77.

************

VARIANT V-MUNICH ALA-26.

************

INVOLVEMENT IN A1ATD, AND VARIANT W-BETHESDA THR-360.

************

VARIANT Z-AUGSBURG LYS-366.

************

INVOLVEMENT IN A1ATD, AND VARIANTS Z-WREXHAM LEU-4 AND Q0-NEWPORT SER-139.

************

VARIANTS P-CARDIFF VAL-280; I CYS-63 AND M-MALTON PHE-75 DEL.

************

VARIANT QO-LUDWIGSHAFEN ASN-116.

************

VARIANTS.

************

VARIANT Z-BRISTOL MET-109.

************

VARIANTS Y-BARCELONA VAL-280 AND HIS-415.

************

VARIANT SAO TOME HIS-386.

************

VARIANT BASQUE ARG-305 DEL.

************

GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-44 AND 77-96, FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-411, PROTEIN SEQUENCE OF 25-57, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 44-57; 148-172; 174-181; 187-192; 278-287 AND 301-328, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 188-389.

************

PROTEIN SEQUENCE OF 25-55.

************

PROTEIN SEQUENCE OF 22-36, INTERACTION WITH CRISP3, AND GLYCOSYLATION.

************

PROTEIN SEQUENCE OF 1-15, INTERACTION WITH CRISP3, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-52.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-52.

************

PROTEIN SEQUENCE OF 22-495, DISULFIDE BONDS, GLYCOSYLATION AT ASN-44; ASN-179; ASN-363 AND ASN-371, AND VARIANT ARG-52.

************

INTERACTION WITH CRISP3.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-44 AND ASN-179, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-44; ASN-179; ASN-363 AND ASN-371, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-44, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-89 AND ASN-485, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, INTERACTION WITH CRISP3, GLYCOSYLATION, AND VARIANTS ASN-5 AND ARG-7.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 219-513 (ISOFORM 2), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND INTERACTION WITH APOBEC1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INTERACTION WITH APOBEC1, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).

************

INTERACTION WITH SYNCRIP.

************

GENE STRUCTURE, AND ALTERNATIVE SPLICING.

************

RNA-BINDING DOMAIN, AND MUTAGENESIS OF PHE-59; PHE-100; PHE-139; PHE-183; TYR-234 AND PHE-270.

************

NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH TNPO2.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 295-594 (ISOFORM 3), NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 295-409 (ISOFORM 1), AND TISSUE SPECIFICITY.

************

PARTIAL PROTEIN SEQUENCE, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF HIS-37; HIS-73; HIS-108; HIS-164; HIS-180 AND THR-258.

************

PROTEIN SEQUENCE OF 27-64, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION ON RAT LIVER.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-306.

************

IMMUNIZATION WITH RECOMBINANT PROTEIN.

************

PROTEIN SEQUENCE OF 23-60, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-143.

************

PROTEIN SEQUENCE OF 673-723.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1253-1477.

************

PROTEIN SEQUENCE OF 27-55, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-35, AND FUNCTION.

************

FUNCTION, AND TOXIC DOSE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-117 AND 279-320, NUCLEOTIDE SEQUENCE [MRNA] OF 55-320, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-54; 724-743; 901-930 AND 1245-1269, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 1287-1294 AND 1321-1327, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1362-1495.

************

PROTEIN SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-297, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH PROTEIN E9.

************

FUNCTION, AND INTERACTION WITH PROTEIN UDG/D4.

************

INTERACTION WITH D5.

************

IDENTIFICATION IN A COMPLEX WITH UDG/D4 AND THE DNA POLYMERASE.

************

IDENTIFICATION IN A COMPLEX WITH A16; A28; G3; G9; H2; J5 AND L5.

************

FUNCTION, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], INTERACTION WITH E10, INTERACTION WITH G4, AND FUNCTION.

************

FUNCTION, SUBUNIT, AND MUTAGENESIS OF CYS-17 AND CYS-21.

************

INTERACTION WITH HOST LAMININ.

************

INTERACTION WITH A17.

************

SUBCELLULAR LOCATION, INTERACTION WITH A27, AND MUTAGENESIS OF CYS-441 AND CYS-442.

************

INTERACTION WITH PROTEIN A25.

************

SUBUNIT, AND MUTAGENESIS OF LEU-51 AND LEU-54.

************

INTERACTION WITH A17 AND A26.

************

CHARACTERIZATION, AND DISULFIDE BONDS.

************

IDENTIFICATION IN A COMPLEX WITH A16; A21; G3; G9; H2; J5 AND L5.

************

INTERACTION WITH PROTEIN H2, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASN-29; ARG-59; SER-105; LEU-113; LYS-153 AND ASP-214.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASN-29; ARG-59; LEU-113 AND LYS-153.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-27; ARG-59; GLU-104; ASP-108; LEU-113; LYS-153 AND VAL-171.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-59; LEU-113 AND LYS-153.

************

NUCLEOTIDE SEQUENCE [MRNA], DISULFIDE BOND, AND GLYCOSYLATION AT ASN-127; ASN-249; ASN-296; ASN-310 AND ASN-317.

************

PROTEIN SEQUENCE OF 23-45 AND 374-410.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-491 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 28-58.

************

PROTEIN SEQUENCE OF 28-52.

************

PROTEIN SEQUENCE OF 40-491.

************

PROTEIN SEQUENCE OF 40-43.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 218-491.

************

PROTEIN SEQUENCE OF 481-491, AND SULFATION.

************

ACTIVE SITES.

************

FUNCTION IN MEMBRANE-ANCHORED SERINE PROTEASE TMPRSS7 INHIBITION, AND HETERODIMER WITH TMPRSS7.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-126; ASN-295 AND ASN-309, AND MASS SPECTROMETRY.

************

VARIANT APLID GLU-176 DEL.

************

VARIANT APLID MET-411, AND VARIANTS VAL-27; TRP-33 AND LYS-434.

************

PROTEIN SEQUENCE OF 28-33.

************

PROTEIN SEQUENCE OF 36-347.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-186, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-186; ASN-269 AND ASN-325, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-79 AND ASN-186, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) IN COMPLEX WITH 5-OXOPROLINE AND NITRATE, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, ACTIVE SITE, AND MUTAGENESIS OF GLU-82.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS), AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1375-1504, PARTIAL PROTEIN SEQUENCE, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-1440.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASP-639 AND VAL-1000.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-639.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-639 AND VAL-1000.

************

PROTEIN SEQUENCE OF 24-1474, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE OF 273-286 AND 426-436, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE OF 672-747.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 672-746, AND VARIANT TYR-972.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 832-1474.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1208-1474.

************

INHIBITORY SITE.

************

GLYCOSYLATION AT ASN-991.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-869 AND ASN-1424, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-55; ASN-247; ASN-396; ASN-410; ASN-869; ASN-991 AND ASN-1424, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-396; ASN-991 AND ASN-1424, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR OF 1337-1474.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 126-227, AND DOMAIN STRUCTURE.

************

VARIANT VAL-1000.

************

NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-164.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 178-227 AND 420-526.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLU-850 AND ARG-1229.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 25-44 AND 1240-1259.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-161.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-157; ASN-405; ASN-412; ASN-1003; ASN-1385 AND ASN-1443, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-157; ASN-568; ASN-881; ASN-1003; ASN-1385 AND ASN-1443, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-644, AND MASS SPECTROMETRY.

************

INTERACTION WITH PROTEIN G7.

************

PHOSPHORYLATION.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 27-311, DISULFIDE BONDS, METAL-BINDING SITES, AND ACTIVE SITES.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND LETHAL DOSE.

************

NUCLEOTIDE SEQUENC [LARGE SCALE GENOMIC DNA].

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 24-289.

************

POSSIBLE FUNCTION.

************

INTERACTION WITH A11.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 11-47.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

SEQUENCE REVISION TO 15-60 AND 427-429.

************

FUNCTION, SUBCELLULAR LOCATION, ZINC-BINDING, AND MUTAGENESIS OF CYS-178; CYS-202 AND HIS-267.

************

INTERACTION WITH PROTEIN A36.

************

INTERACTION WITH B5.

************

DOMAIN.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 90-185.

************

INTERACTION WITH PROTEINS A36 AND B5.

************

NUCLEOTIDE SEQUENCE, FUNCTION, AND TISSUE SPECIFICITY.

************

SEQUENCE REVISION TO N-TERMINUS AND C-TERMINUS.

************

NUCLEOTIDE SEQUENCE OF 144-889.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-912.

************

INTERACTION WITH HOST NCK, MUTAGENESIS OF TYR-112 AND TYR-132, AND PHOSPHORYLATION AT TYR-112 AND TYR-132.

************

INTERACTION WITH PROTEIN A33.

************

INTERACTION WITH HOST KLC1.

************

INTERACTION WITH PROTEIN F12.

************

TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

DEVELOPMENTAL STAGE.

************

[LARGE SCALE GENOMIC DNA].

************

TOPOLOGY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-102.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 21-219.

************

SUBCELLULAR LOCATION, AND GLYCOSYLATION.

************

FUNCTION, AND INTERACTION WITH HOST MYD88; TRF4; TICAM2 AND MAL.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 112-252.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 49-361.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-37 AND LYS-183.

************

SeattleSNPs variation discovery resource;

************

VARIANTS VAL-37; LYS-183; ASP-187 AND LEU-251.

************

VARIANT PHE-80 DEL.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND MUTAGENESIS OF 199-ASP--ASP-201.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 6-686.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-249, AND MASS SPECTROMETRY.

************

INTERACTION OF BETA-APP40 WITH APOE.

************

PROTEOLYTIC PROCESSING BY GAMMA-SECRETASE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-83.

************

INTERACTION WITH APP-BP1, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP695).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM L-APP733).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP639), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM APP770).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-10.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-75.

************

PROTEIN SEQUENCE OF 18-50.

************

PROTEIN SEQUENCE OF 18-40.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 286-366.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 287-367.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 507-770.

************

PROTEIN SEQUENCE OF 523-555, AND DOMAIN COLLAGEN-BINDING.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 655-737, AND VARIANTS AD1 GLY-717; ILE-717 AND PHE-717.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 656-737.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 672-723, AND VARIANT AD1 ASN-678.

************

PROTEIN SEQUENCE OF 672-713.

************

PROTEIN SEQUENCE OF 672-704, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 672-701 AND 707-713.

************

PROTEIN SEQUENCE OF 672-701.

************

PROTEIN SEQUENCE OF 672-681.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 674-770.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 674-703.

************

PROTEIN SEQUENCE OF 609-713, AND GLYCOSYLATION AT SER-614; SER-623; SER-628; SER-679 AND SER-697.

************

PROTEIN SEQUENCE OF 691-698, AND CLEAVAGE BY THETA-SECRETASE.

************

PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).

************

PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).

************

CHARACTERIZATION OF L-APP733, AND MUTAGENESIS OF SER-656.

************

FUNCTION OF BETA-AMYLOID PEPTIDE AS LIPID PEROXIDATION INHIBITOR, AND MUTAGENESIS OF MET-706.

************

REVIEW ON FUNCTION OF BETA-AMYLOID AS ANTIOXIDANT.

************

IDENTITY OF APP WITH NEXIN-II.

************

PROTEASE-SPECIFICITY OF INHIBITOR DOMAIN.

************

EXTRACELLULAR ZINC-BINDING DOMAIN.

************

INTERACTION WITH G(O).

************

EXTRACELLULAR COPPER-BINDING DOMAIN, AND MUTAGENESIS OF HIS-137; MET-141; CYS-144; HIS-147 AND HIS-151.

************

N-TERMINAL HEPARIN-BINDING DOMAIN, AND MUTAGENESIS OF 99-LYS--ARG-102.

************

MUTAGENESIS OF VAL-717.

************

INTERACTION WITH APP-BP1.

************

INTERACTION WITH APBA1 AND APBB1, AND MUTAGENESIS OF TYR-728; TYR-757; ASN-759 AND TYR-762.

************

INTERACTION WITH APBB2.

************

HEPARIN-BINDING DOMAINS.

************

INTERACTION OF BETA-AMYLOID PEPTIDE WITH HADH2.

************

INTERACTION WITH APPBP2, AND MUTAGENESIS OF TYR-728.

************

BETA-AMYLOID ZINC-BINDING, AND MUTAGENESIS OF ARG-676; TYR-681 AND HIS-684.

************

IMPORTANCE OF MET-706 IN FREE RADICAL OXIDATIVE STRESS, AND MUTAGENESIS OF MET-706.

************

INTERACTION WITH APBA2.

************

ENDOCYTOSIS SIGNAL, AND MUTAGENESIS OF TYR-728; GLY-756; TYR-757; ASN-759; PRO-760 AND TYR-762.

************

IMPORTANCE OF CYS-144 IN COPPER REDUCTION, AND MUTAGENESIS OF CYS-144 AND 147-HIS--HIS-149.

************

INTERACTION OF BETA-AMYLOID WITH APOE.

************

INTERACTION OF BETA-APP42 WITH CHRNA7.

************

IDENTIFICATION OF GAMMA-CTFS BY MASS SPECTROMETRY, AND MUTAGENESIS OF ASP-739.

************

INTERACTION WITH FPRL1.

************

INTERACTION WITH BBP.

************

BETA-AMYLOID COPPER AND ZINC-BINDING.

************

INTERACTION WITH APBB1, FUNCTION, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH FBLN1.

************

INTERACTION WITH MAPT, AND FUNCTION.

************

INTERACTION WITH MAPK8IP1, AND MUTAGENESIS OF TYR-757.

************

COPPER-MEDIATED LIPID PEROXIDATION, AND MUTAGENESIS OF HIS-147 AND HIS-151.

************

REVIEW ON ZINC-BINDING.

************

SUBCELLULAR LOCATION, AND ASSOCIATION OF AMYLOID FIBRILS WITH GCP1.

************

INTERACTION WITH ANKS1B.

************

PHOSPHORYLATION AT THR-743.

************

PHOSPHORYLATION BY CASEIN KINASES, AND MUTAGENESIS OF SER-198 AND SER-206.

************

COPPER-BINDING, AND DISULFIDE BOND FORMATION.

************

CLEAVAGE BY CASPASES, AND MUTAGENESIS OF ASP-739.

************

PHOSPHORYLATION, AND MUTAGENESIS OF THR-743.

************

CHARACTERIZATION OF CASEIN KINASE PHOSPHORYLATION, AND MUTAGENESIS OF SER-198 AND SER-206.

************

PHOSPHORYLATION, INTERACTION WITH APBB1, AND MUTAGENESIS OF THR-743.

************

PHOSPHORYLATION BY MAPK10, AND MUTAGENESIS OF THR-743.

************

CLEAVAGE AT LEU-720.

************

PHOSPHORYLATION AT TYROSINE RESIDUES, INTERACTION WITH SHC1, AND MUTAGENESIS OF THR-743 AND TYR-757.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-542, AND MASS SPECTROMETRY.

************

SIGNAL SEQUENCE CLEAVAGE SITE, AND TOPOLOGY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-757 AND TYR-762, AND MASS SPECTROMETRY.

************

INTERACTION WITH APBB1.

************

INTERACTION WITH ITM2C.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-757, AND MASS SPECTROMETRY.

************

FUNCTION, CLEAVAGE, AND INTERACTION WITH TNFRSF21.

************

FUNCTION, AND INTERACTION WITH AGER.

************

GLYCOSYLATION AT THR-633; THR-651; THR-652; SER-656; THR-663 AND SER-667 PROTEOLYTIC PROCESSING, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

INTERACTION WITH S100A9.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 287-344.

************

STRUCTURE BY NMR OF 289-344.

************

STRUCTURE BY NMR OF 672-699.

************

STRUCTURE BY NMR OF 672-711.

************

STRUCTURE BY NMR OF 696-706.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF KUNITZ DOMAIN IN COMPLEX WITH CHYMOTRYPSIN; TRYPSIN AND BASIC PANCREATIC TRYPSIN INHIBITOR.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 28-123.

************

STRUCTURE OF CAA-APP VARIANTS.

************

STRUCTURE BY NMR OF 681-706.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 346-551, PARTIAL PROTEIN SEQUENCE, MASS SPECTROMETRY, AND MUTAGENESIS OF ARG-499 AND LYS-503.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 672-711 IN COMPLEX WITH IDE.

************

X-RAY CRYSTALLOGRAPHY (0.85 ANGSTROMS) OF 133-189, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 133-189 IN COMPLEXES WITH COPPER IONS, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 672-679 IN COMPLEX WITH IGG.

************

X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 672-678 IN COMPLEXES WITH ANTIBODY FAB FRAGMENTS.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 18-190, PARTIAL PROTEIN SEQUENCE, MASS SPECTROMETRY, SUBUNIT, AND DISULFIDE BONDS.

************

REVIEW ON VARIANTS.

************

VARIANT CAA-APP GLN-693.

************

VARIANT AD1 ILE-717.

************

VARIANT AD1 GLY-717.

************

VARIANT AD1 PHE-717.

************

VARIANT AD1 GLY-693.

************

VARIANT AD1 GLY-692.

************

VARIANT AD1 670-ASN-LEU-671.

************

VARIANT VAL-713.

************

VARIANT AD1 THR-713.

************

VARIANTS AD1 ILE-717 AND PHE-717.

************

VARIANT ASP-665.

************

VARIANT AD1 VAL-716.

************

VARIANT AD1 GLY-692, AND CHARACTERIZATION OF PHENOTYPE.

************

VARIANT AD1 MET-715, AND CHARACTERIZATION OF VARIANT AD1 MET-715.

************

VARIANT AD1 PRO-723.

************

VARIANT AD1 LEU-717.

************

VARIANT AD1 ILE-714, CHARACTERIZATION OF VARIANT AD1 ILE-714, AND MUTAGENESIS OF VAL-717.

************

VARIANT CAA-APP ASN-694.

************

CHARACTERIZATION OF VARIANT AD1 GLY-692.

************

VARIANT AD1 ALA-714.

************

VARIANT CAA-APP VAL-705.

************

VARIANT AD1 ILE-714.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS APP695 AND APP770).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 281-380, AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 289-364.

************

TISSUE SPECIFICITY OF ALTERNATIVE SPLICED FORMS.

************

INTERACTION WITH KNS2.

************

PHOSPHORYLATION AT TYR-757.

************

C-TERMINAL PROTEIN-PROTEIN INTERACTION, AND MUTAGENESIS OF TYR-728; THR-743; TYR-757; ASN-759 AND TYR-762.

************

INTERACTION WITH DAB2, AND MUTAGENESIS OF GLY-756; TYR-757; ASN-759; PRO-760 AND TYR-762.

************

INTERACTION WITH MAPK8IP1, AND PHOSPHORYLATION.

************

INTERACTION OF CTF PEPTIDES WITH NUMB.

************

PROTEOLYTIC PROCESSING BY GAMMA SECRETASE, AND INTERACTION WITH APBB1.

************

SUBCELLULAR LOCATION, AND FUNCTION.

************

INTERACTION WITH CPEB1.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-136.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 667-723.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP770).

************

PROTEIN SEQUENCE OF 18-44.

************

PROTEIN SEQUENCE OF 18-32.

************

PROTEIN SEQUENCE OF 720-730, AND MASS SPECTROMETRY.

************

ALTERNATIVE SPLICING.

************

TISSUE SPECIFICITY OF APPICAN.

************

TISSUE SPECIFICITY OF ISOFORMS.

************

INTERACTION WITH DDB1, AND MUTAGENESIS OF TYR-757; ASN-759 AND TYR-762.

************

INTERACTION WITH GNAO1, AND MUTAGENESIS OF 732-HIS-HIS-733.

************

COPPER-BINDING.

************

CHARACTERISTICS OF APPICAN, AND MUTAGENESIS OF SER-656.

************

BETA-AMYLOID METAL-BINDING.

************

BETA-AMYLOID ZINC-BINDING.

************

IMPORTANCE OF GLY-704 IN FREE RADICAL PROPAGATION, AND MUTAGENESIS OF GLY-704.

************

PHOSPHORYLATION AT SER-730.

************

PHOSPHORYLATION, INDUCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-743.

************

STRUCTURE OF CARBOHYDRATE IN APPICAN.

************

INTERACTION WITH P4A/A10, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH HOST TRAF6 AND IRAK2.

************

X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 37-190.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 626-944.

************

NUCLEOTIDE SEQUENCE OF 7-111.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-86; THR-133 AND SER-134, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 20-55.

************

STRUCTURE BY NMR OF 20-55, AND DISULFIDE BOND.

************

Drosophila 12 genomes consortium;

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-386.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 143-330.

************

IDENTIFICATION AS A DRUG TARGET [LARGE SCALE ANALYSIS].

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 43-338, AND DISULFIDE BOND.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 41-70.

************

DOMAIN FIBRONECTIN BINDING.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-325.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 41-325, AND DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 47-328.

************

X-RAY CRYSTALLOGRAPHY (2.02 ANGSTROMS) OF 47-340 IN COMPLEX WITH SUBSTRATE ANALOG.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3-31.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 5-31.

************

FUNCTION, INDUCTION, AND SUBCELLULAR LOCATION.

************

VARIANT [LARGE SCALE ANALYSIS] LYS-170.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-107.

************

POSSIBLE INTERACTION WITH DRD4.

************

3D-STRUCTURE MODELING OF TRANSMEMBRANE DOMAINS.

************

INTERACTION WITH USP4, UBIQUITINATION, AND DEUBIQUITINATION BY USP4.

************

X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 2-316 IN COMPLEX WITH ANTAGONIST, TOPOLOGY, AND DISULFIDE BONDS.

************

VARIANT VAL-50.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 53-213.

************

SEQUENCE REVISION TO 183.

************

FUNCTION, AND 3D-STRUCTURE MODELING.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-248.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 166-272 (ISOFORM 1).

************

VARIANT [LARGE SCALE ANALYSIS] THR-105.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 111-239.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND CHARACTERIZATION.

************

PHOSPHORYLATION AT THR-307; THR-318 AND THR-319, AND MUTAGENESIS OF 302-CYS--CYS-305; THR-307; THR-318 AND THR-319.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASP-112.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 170-530.

************

PROTEIN SEQUENCE OF 103-122.

************

NUCLEOTIDE SEQUENCE, AND PROTEIN SEQUENCE OF 1-31 AND 104-129.

************

PROTEIN SEQUENCE OF 1-20; 103-131; 188-200; 258-265 AND 316-323.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT ILE-281.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-281.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-281.

************

PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78 AND ASN-282, AND MASS SPECTROMETRY.

************

VARIANT ILE-281.

************

FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND GLYCOSYLATION.

************

PROTEIN SEQUENCE, ENZYME ACTIVITY, SUBCELLULAR LOCATION, MEMBRANE TOPOLOGY, DISULFIDE BOND, ACTIVE SITE, AND PROBABLE GLYCOSYLATION AT ASN-77 AND ASN-281.

************

TOPOLOGY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-3.

************

SUBCELLULAR LOCATION, MEMBRANE TOPOLOGY, AND MUTAGENESIS OF LYS-3; ASP-24 AND 27-GLU-GLU-28.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 187-226, FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS AAAS LYS-15; ARG-160 AND PRO-263.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 210-546 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33 AND SER-495, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION AS A VIRAL RECEPTOR.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 14-541, AND ALTERNATIVE INITIATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-535, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-532, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-212, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503 AND SER-535, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 60-248, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 17-464.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEXES WITH COENZYME A; RIBOSTAMYCIN; KANAMYCIN AND TOBRAMYCIN, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 42-478, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-312, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEXES WITH COENZYME A AND SUBSTRATE, FUNCTION, CATALYTIC ACTIVITY, REACTION MECHANISM, SUBUNIT, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH INHIBITOR, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-18, FUNCTION, AND CATALYTIC ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEXES WITH ATP; ZINC AND SUBSTRATE ANALOG, FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, COFACTOR, KINETIC PARAMETERS, AND SUBUNIT.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, COFACTOR, KINETIC PARAMETERS, AND SUBUNIT.

************

FUNCTION AS A CARRIER PROTEIN, PHOSPHOPANTETHEINYLATION, PTM, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 12-672 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 48-672 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-524, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 87-94; 236-242; 258-267; 370-377; 533-539; 558-567; 583-588 AND 647-671, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS BOCHUM-1 PRO-78 AND BONN-1 ALA-252.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT THR-9.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-46, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 17-423 (ISOFORM 1), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 22-86 AND 130-423 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 24-34.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 36-45.

************

PROTEIN SEQUENCE OF 41-60.

************

PROTEIN SEQUENCE OF 48-68 (ISOFORMS 1/2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 87-129 (ISOFORMS 1/2), AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 205-423.

************

ACTIVE SITE.

************

GLYCOSYLATION AT ASN-93 AND ASN-106.

************

INTERACTION WITH DNAJC1.

************

REGION RCL.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-93; ASN-106; ASN-127; ASN-186 AND ASN-271, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93; ASN-106; ASN-127 AND ASN-271, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 24-423.

************

X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370 AND ARG-372.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370; ARG-372 AND ARG-374.

************

X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 26-423.

************

VARIANT ISEHARA-1 VAL-401.

************

VARIANT BONN-1 ALA-252.

************

VARIANT VAL-401.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 35-53; 212-214 AND 230-249.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND COFACTOR.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH 2-OXOGLUTARATE, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, SUBUNIT, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE AND KYRUNENINE, CATALYTIC ACTIVITY, COFACTOR, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE, SUBUNIT, AND COFACTOR.

************

NUCLEOTIDE SEQUENCE [MRNA], HOMODIMERIZATION, AND PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INDUCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 19-727.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 321-727.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-295.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 64-721, TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-556.

************

TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-550.

************

INVOLVEMENT IN THE AAEAB EFFLUX SYSTEM.

************

TOPOLOGY [LARGE SCALE ANALYSIS].

************

REGULATION.

************

PROTEIN SEQUENCE, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-132.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-310 AND SER-311, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INTERACTION WITH AP1G1 AND AP2A1.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 27-43 AND 802-821.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 685-696; 1181-1188 AND 1291-1298, FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 1289-1298, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

The bovine genome sequencing and analysis consortium;

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH CLATHRIN, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLN-509.

************

FUNCTION, AND MUTAGENESIS OF LYS-74 AND ASP-176.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-606; SER-670 AND SER-676, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-620, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389 AND THR-606, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-637, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-327; THR-389; THR-441; THR-606; SER-637; SER-670; SER-676 AND SER-731, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-221; THR-222; TYR-234; SER-235; THR-389; THR-606; SER-618; THR-620; SER-623; SER-624 AND SER-637, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH NUMB, AND MUTAGENESIS OF LYS-74 AND ASP-176.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-606; THR-620; SER-623 AND SER-624, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-18; SER-20; SER-21; THR-354; THR-389; THR-441; THR-448; THR-606; SER-618; THR-620; SER-623; SER-624; SER-637; THR-640; SER-642; SER-650; SER-652; SER-668; SER-670; THR-672; THR-674; SER-676; SER-678; THR-681; SER-682; TYR-687; SER-690 AND SER-731, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389; THR-606; SER-637 AND THR-653, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH EPS15 AND NOTCH1, AND MUTAGENESIS OF LYS-74 AND 777-ASP--PHE-779.

************

VARIANTS [LARGE SCALE ANALYSIS] VAL-59; HIS-533; ALA-603; MET-694; THR-725; ARG-771 AND ASP-835.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 417-959 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; THR-604; THR-618; SER-621; SER-635; SER-650; SER-729; SER-935 AND SER-936, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-635; THR-638 AND SER-650, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-635, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-354, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-604; THR-618; SER-622 AND SER-635, AND MASS SPECTROMETRY.

************

INTERACTION WITH NOTCH1.

************

Porcine genome sequencing project;

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-54.

************

FUNCTION, AND INTERACTION WITH ALPHA-ADAPTIN.

************

INTERACTION WITH FNIP1.

************

INTERACTION WITH FNIP2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-4; SER-5; SER-6 AND SER-108, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-19; SER-40 AND SER-108, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-19; SER-24; SER-25; SER-40; SER-96; SER-101; SER-108; THR-148; SER-174; SER-177; SER-180; SER-181 AND SER-252, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96 AND SER-108, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION BY ULK1.

************

INTERACTION WITH PRKAA1 AND PRKAG1, AND MUTAGENESIS OF GLY-2.

************

REVIEW ON FUNCTION.

************

NUCLEOTIDE SEQUENCE OF 15-120, AND PROTEIN SEQUENCE OF 1-21; 23-86 AND 92-122.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 36-159, AND PROTEIN SEQUENCE OF 36-72; 79-83 AND 90-159.

************

PARTIAL PROTEIN SEQUENCE, MYRISTOYLATION AT GLY-2, AND PHOSPHORYLATION AT SER-24; SER-25; SER-108 AND SER-182.

************

MUTAGENESIS, MYRISTOYLATION AT GLY-2, AND PHOSPHORYLATION AT SER-24; SER-25; SER-108 AND SER-182.

************

PHOSPHORYLATION AT SER-96; SER-101 AND SER-108.

************

X-RAY CRYSTALLOGRAPHY (1.49 ANGSTROMS) OF 68-162 IN COMPLEX WITH BETA-CYCLODEXTRIN, DOMAIN GLYCOGEN-BINDING, AND MUTAGENESIS OF TRP-100; LYS-126; LEU-146 AND ASN-150.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-184, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; SER-108 AND SER-184, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; THR-40 AND SER-184, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; SER-108; SER-182; SER-183 AND SER-184, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION BY ULK1 AND ULK2.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 187-272 IN COMPLEX WITH PRKAA1 AND PRKAG1.

************

X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 187-272 IN COMPLEX WITH PRKAA1 AND PRKAG1, AND MUTAGENESIS OF HIS-235.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PHOSPHORYLATION AT SER-183.

************

PHOSPHORYLATION BY ULK1 AND ULK2, AND PHOSPHORYLATION AT SER-38; THR-39; SER-68 AND SER-173.

************

DOMAIN CBS, AMP-BINDING, AND ATP-BINDING.

************

INTERACTION WITH FNIP1, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

DOMAIN AMPK PSEUDOSUBSTRATE.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-264, AND MASS SPECTROMETRY.

************

INTERACTION WITH PRKAA1 AND PRKAB1, DOMAIN CBS, ADP-BINDING, MUTAGENESIS OF ASP-90; ASP-245 AND ASP-317, AND FUNCTION.

************

PROTEIN SEQUENCE OF 48-58; 101-113; 153-169; 177-208; 225-231; 240-253 AND 300-329.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 8-330.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 48-330, AND PARTIAL PROTEIN SEQUENCE.

************

PHOSPHORYLATION BY ULK1 AND ULK2, AND PHOSPHORYLATION AT SER-260; THR-262 AND SER-269.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEX WITH PRKAA1 AND PRKAB2, FUNCTION, DOMAIN CBS, AMP-BINDING, AND ATP-BINDING.

************

X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) IN COMPLEX WITH PRKAA1 AND PRKAB2, FUNCTION, DOMAIN CBS, AND ADP-BINDING.

************

DOMAIN CBS, AMP-BINDING, ATP-BINDING, CHARACTERIZATION OF VARIANTS WPWS GLN-302; ARG-383 AND ASN-400, CHARACTERIZATION OF VARIANT WPWS GLY-531, AND FUNCTION.

************

DOMAIN AMPK PSEUDOSUBSTRATE, AND MUTAGENESIS OF VAL-387.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-157; SER-162 AND THR-167, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71; SER-143 AND SER-196, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129; SER-130; SER-143; SER-162; SER-164; THR-165 AND SER-196, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65; SER-71; SER-86; SER-131; SER-134; SER-135; SER-138; THR-142; SER-143; THR-156; SER-157; SER-160; SER-162; SER-164; SER-195; SER-196 AND SER-219, AND MASS SPECTROMETRY.

************

VARIANT WPWS GLY-531.

************

VARIANTS CMH6 LEU-350 INS AND ARG-383.

************

VARIANT WPWS GLN-302.

************

VARIANTS CMH6 GLN-302; ASN-400 AND ILE-488.

************

VARIANT GSDH GLN-531, AND CHARACTERIZATION OF VARIANT GSDH GLN-531.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-196, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65; SER-71; SER-73; SER-90; SER-138; SER-158; SER-161 AND SER-162, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3 AND 4), AND VARIANTS SER-127; SER-153; TRP-262; TYR-358 AND MET-373.

************

DOMAIN CBS, AMP-BINDING, ATP-BINDING, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT RN(-) GLN-250.

************

NUCLEOTIDE SEQUENCE (ISOFORM 2).

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 3-334.

************

X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 3-334.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, AND INTERACTION WITH SNF1.

************

PROTEIN SEQUENCE OF 30-34 AND 316-322.

************

FUNCTION, AND INTERACTION WITH SNF1.

************

FUNCTION OF THE AMPK COMPLEX.

************

INTERACTION WITH SNF1; SIP1; SIP2 AND GAL83.

************

INTERACTION WITH SNIF1, AND FUNCTION OF THE AMPK COMPLEX.

************

IDENTIFICATION IN THE AMPK COMPLEX, AND FUNCTION OF THE AMPK COMPLEX.

************

IDENTIFICATION IN THE AMPK COMPLEX.

************

FUNCTION, AND MUTAGENESIS OF VAL-63; CYS-136; GLY-145; ARG-146; THR-166; ASN-177; ASN-251 AND HIS-293.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 179-322, AND MUTAGENESIS OF LEU-242; ARG-291 AND HIS-293.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 7-321 IN COMPLEX WITH SNF1 AND SIP2.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 2-322, ADP-BINDING, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND TISSUE SPECIFICITY.

************

FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

TOPOLOGY.

************

DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

BIOPHYSICOCHEMICAL PROPERTIES.

************

FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 473-557.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 107-652.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-248, AND MASS SPECTROMETRY.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, AND TISSUE SPECIFICITY.

************

TISSUE SPECIFICITY, SUBCELLULAR LOCATION, REGULATION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.

************

TISSUE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

SEQUENCE REVISION TO 68 AND C-TERMINUS.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-559 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-559 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 9-559 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 36-209 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 303-559 (ISOFORMS 1/2).

************

DOMAIN AIS.

************

FUNCTION IN PHOSPHORYLATION OF EP300.

************

ENZYME REGULATION.

************

FUNCTION IN PHOSPHORYLATION OF CFTR.

************

FUNCTION IN PHOSPHORYLATION OF TSC2.

************

PHOSPHORYLATION AT THR-183, AND ENZYME REGULATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-496, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-442, AND MASS SPECTROMETRY.

************

DOMAIN AIS, AND MUTAGENESIS OF VAL-307.

************

FUNCTION IN PHOSPHORYLATION OF FOXO3.

************

FUNCTION IN CELL POLARITY.

************

FUNCTION IN PHOSPHORYLATION OF HDAC5.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-382, AND MASS SPECTROMETRY.

************

FUNCTION IN PHOSPHORYLATION OF RPTOR.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; SER-486; THR-490; SER-496; SER-508; SER-523 AND SER-527, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; THR-382; SER-486; THR-490 AND SER-496, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-32; THR-183; SER-184; SER-187; THR-355; SER-356; SER-397; TYR-441; SER-467; SER-476; SER-486; THR-488; THR-490; SER-496; SER-502; SER-506; SER-508; SER-516; SER-520; THR-522; SER-523; SER-524 AND SER-527, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-382 AND THR-490, AND MASS SPECTROMETRY.

************

FUNCTION IN PHOSPHORYLATION OF KLC1.

************

FUNCTION IN PHOSPHORYLATION OF ULK1.

************

INTERACTION WITH PRKAB1 AND PRKAG1, AND ENZYME REGULATION.

************

VARIANT [LARGE SCALE ANALYSIS] ARG-16.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-559.

************

ENZYME REGULATION, AND PHOSPHORYLATION AT THR-183.

************

FUNCTION IN PHOSPHORYLATION OF LIPE, AND MUTAGENESIS OF ASP-168.

************

FUNCTION IN PHOSPHORYLATION OF CRTC2.

************

FUNCTION IN PHOSPHORYLATION OF CRTC2, AND PHOSPHORYLATION AT THR-183.

************

FUNCTION IN PHOSPHORYLATION OF TBC1D4.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-184 AND SER-508, AND MASS SPECTROMETRY.

************

UBIQUITINATION.

************

FUNCTION IN PHOSPHORYLATION OF CRY1, AND SUBCELLULAR LOCATION.

************

FUNCTION IN PHOSPHORYLATION OF CTNNB1.

************

FUNCTION IN PHOSPHORYLATION OF H2B.

************

FUNCTION IN PHOSPHORYLATION OF SREBF1 AND SREBF2, AND ENZYME REGULATION.

************

FUNCTION IN PHOSPHORYLATION OF ULK1, AND MUTAGENESIS OF ASP-168.

************

PROTEIN SEQUENCE OF 1-22; 73-87; 100-157; 222-240 AND 344-361, AND FUNCTION.

************

PROTEIN SEQUENCE OF 1-22; 73-88; 100-132; 144-156; 209-216; 221-255; 256-270; 271-290; 291-300; 301-323; 324-342; 343-367 AND 368-385.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 23-243.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-559, AND PROTEIN SEQUENCE OF 24-40; 90-115; 129-140; 150-160; 166-182; 236-257; 272-276; 286-305; 326-341; 350-367; 375-384; 409-426; 437-446; 458-475 AND 507-517.

************

CATALYTIC ACTIVITY, AND FUNCTION IN PHOSPHORYLATION OF HMGCR.

************

CATALYTIC ACTIVITY, AND FUNCTION IN PHOSPHORYLATION OF ACACA AND ACACB.

************

FUNCTION IN PHOSPHORYLATION OF NOS3.

************

FUNCTION IN PHOSPHORYLATION OF PFKFB2.

************

FUNCTION IN PHOSPHORYLATION OF IRS1.

************

FUNCTION IN PHOSPHORYLATION OF MLXIPL.

************

FUNCTION IN PHOSPHORYLATION OF PFKFB3.

************

FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION AT THR-183.

************

FUNCTION IN PHOSPHORYLATION OF HNF4A.

************

PHOSPHORYLATION AT THR-269 AND SER-496, MUTAGENESIS OF THR-183; THR-269 AND SER-496, AND MASS SPECTROMETRY.

************

FUNCTION IN PHOSPHORYLATION OF EEF2K.

************

FUNCTION IN PHOSPHORYLATION OF SLC12A1.

************

PHOSPHORYLATION BY ULK1 AND ULK, AND PHOSPHORYLATION AT SER-360; THR-368; SER-397; SER-486 AND THR-488.

************

FUNCTION IN PHOSPHORYLATION OF MAPT.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 405-557 IN COMPLEX WITH PRKAB2 AND PRKAG1.

************

X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 13-559 IN COMPLEX WITH PRKAB2 AND PRKAG1, AND MUTAGENESIS OF 386-ARG--GLU-391.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, ENZYME REGULATION, DISRUPTION PHENOTYPE, AND PHOSPHORYLATION AT THR-243.

************

IDENTIFICATION IN AMPK COMPLEX.

************

PHOSPHORYLATION AT THR-172, AND ENZYME REGULATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173 AND SER-176, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-176 AND SER-377, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377 AND SER-500, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-69, AND MASS SPECTROMETRY.

************

ENZYME REGULATION BY SALICYLATE.

************

X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279.

************

X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN COMPLEX WITH COMPOUND C, AND ENZYME REGULATION.

************

VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523.

************

VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 15-552.

************

FUNCTION IN PHOSPHORYLATION OF GYS1.

************

FUNCTION IN PHOSPHORYLATION OF CRTC2, AND PHOSPHORYLATION AT THR-172.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173 AND SER-500, AND MASS SPECTROMETRY.

************

FUNCTION IN PHOSPHORYLATION OF PPARGC1A.

************

FUNCTION IN PHOSPHORYLATION OF CRY1.

************

FUNCTION IN PHOSPHORYLATION OF H2B, AND MUTAGENESIS OF ASP-157.

************

FUNCTION IN PHOSPHORYLATION OF HDAC5, AND MUTAGENESIS OF LYS-45.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 16-144.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), AND PARTIAL PROTEIN SEQUENCE.

************

FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION AT THR-172.

************

PHOSPHORYLATION AT THR-258 AND SER-491, AND MASS SPECTROMETRY.

************

MUTAGENESIS OF ASP-12.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND MUTAGENESIS OF ASP-13.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 228-384.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-160, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 77-355.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-331, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DEVELOPMENTAL STAGE, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-150.

************

CATALYTIC ACTIVITY, AND MUTAGENESIS OF ALA-149 AND SER-150.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-409, AND MASS SPECTROMETRY.

************

FUNCTION AS TRNA(ALA) EDITING PROTEIN.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM LONG), AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 529-1064 (ISOFORM LONG).

************

ALTERNATIVE INITIATION.

************

SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

ENZYME REGULATION, SUBUNIT, PHOSPHORYLATION AT THR-238 AND SER-458, AND MUTAGENESIS OF THR-238; SER-407; SER-458 AND 551-ASN--ARG-554.

************

TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND INVOLVEMENT IN HYPLYS.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-707, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 150-311.

************

MUTAGENESIS OF HIS-36.

************

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5), INTERACTION WITH AMY1 AND AKAP1, AND PHOSPHORYLATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT PRO-207.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 7 AND 8), AND VARIANT PRO-207.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT PRO-207.

************

ALTERNATIVE SPLICING, INTERACTION WITH AMY1, AND TISSUE SPECIFICITY (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-579 AND SER-587, AND MASS SPECTROMETRY.

************

ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND 3).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2-418.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 327-405.

************

PROTEIN SEQUENCE OF 2-412.

************

GENE STRUCTURE.

************

X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) IN COMPLEX WITH 2-OXOGLUTARATE.

************

X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH PYRODOXAL PHOSPHATE AND MALEIC ACID, COFACTOR, PYRIDOXAL PHOSPHATE AT LYS-258, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 2-413, AND ACETYLATION AT THR-2.

************

PROTEIN SEQUENCE OF 2-413.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-71, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN ASTQTL1, VARIANT ASN-389 DEL, AND CHARACTERIZATION OF VARIANT ASN-389 DEL.

************

PROTEIN SEQUENCE OF 2-55; 61-81; 87-97; 101-166; 208-236; 260-276; 306-318 AND 347-411, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-66, AND MASS SPECTROMETRY.

************

COFACTOR.

************

X-RAY CRYSTALLOGRAPHY (1.74 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE AND 2-METHYLASPARTATE, COFACTOR, PYRIDOXAL PHOSPHATE AT LYS-259, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 2-31.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-39.

************

PROTEIN SEQUENCE OF 21-32; 34-42; 101-122; 217-236; 268-276 AND 388-396, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-234.

************

PROTEIN SEQUENCE OF 2-418.

************

PROTEIN SEQUENCE OF 2-418, ACETYLATION AT SER-2, AND ENZYME ACTIVITY.

************

CRYSTALLIZATION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

ENZYME ACTIVITY, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) IN COMPLEX WITH PYRODOXAL PHOSPHATE AND MALEIC ACID, COFACTOR, PYRIDOXAL PHOSPHATE AT LYS-255, AND SUBUNIT.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-28 AND SER-32, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH POLR2J AND RB1, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 361-560.

************

FUNCTION, PHOSPHORYLATION AT THE G1/S TRANSITION, AND INTERACTION WITH RB1; RBL1 AND RBL2.

************

IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].

************

FUNCTION, AND INTERACTION WITH SP1.

************

INTERACTION WITH MAPT.

************

FUNCTION, AND INTERACTION WITH PAWR.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; SER-320 AND SER-321, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; SER-316; SER-320 AND SER-321, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316; SER-320 AND SER-321, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316; SER-320 AND SER-321, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24 (ISOFORMS 1/2), NUCLEOTIDE SEQUENCE [MRNA] OF 1-265 (ISOFORM 2), AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-288, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH DAPK3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, AND INTERACTION WITH TSG101.

************

PROTEIN SEQUENCE OF 30-41.

************

PYRIDOXAL PHOSPHATE AT LYS-279.

************

SUCCINYLATION AT LYS-309.

************

PROTEIN SEQUENCE OF 23-423.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEXES WITH PYRIDOXAL PHOSPHATE, PYRIDOXAL PHOSPHATE AT LYS-272, COFACTOR, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-423 IN COMPLEXES WITH PYRIDOXAL PHOSPHATE; L-ASPARTATE AND L-GLUTAMATE, COFACTOR, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-423 IN COMPLEX WITH ERYTHRO-BETA-HYDROXYASPARTATE, AND COFACTOR.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 23-423 IN COMPLEXES WITH PYRIDOXAL PHOSPHATE AND SUBSTRATE ANALOGS, COFACTOR, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLY-346.

************

PROTEIN SEQUENCE OF 30-430, AND VARIANT GLY-346.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-401, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-96, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-73; LYS-90; LYS-150; LYS-159; LYS-234; LYS-296; LYS-396 AND LYS-404, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 60-81; 91-122; 126-139; 171-180; 186-200; 280-296; 310-345; 356-363 AND 397-404, AND MASS SPECTROMETRY.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-96, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-94; LYS-159; LYS-185; LYS-296; LYS-345 AND LYS-363, AND MASS SPECTROMETRY.

************

CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 30-430 IN COMPLEX WITH SYNTHETIC INHIBITOR, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 30-430 IN COMPLEX WITH L-KYNURENINE; OXALOACETATE AND PYRIDOXAL PHOSPHATE, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, AND COFACTOR.

************

PROTEIN SEQUENCE OF 30-430.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 256-399.

************

PROTEIN SEQUENCE OF 30-42, CATALYTIC ACTIVITY, AND FUNCTION.

************

PROTEIN SEQUENCE OF 60-68; 91-122; 126-147; 171-180; 186-200; 280-296; 310-337; 356-363 AND 397-404, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 279-329.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ENZYME ACTIVITY.

************

SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-24 AND 387-392.

************

PROTEIN SEQUENCE OF 1-12.

************

MUTAGENESIS OF TYR-65.

************

MUTAGENESIS OF HIS-133.

************

CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-280 AND ARG-374.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT ALA-246.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), AND MUTAGENESIS OF ARG-374.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF MUTANT.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF MUTANTS ALA-183/PHE-214; ALA-183/LEU-280; ALA-183/LEU-374 AND ALA-183/LEU-280/LEU-374 IN COMPLEXES WITH PYRIDOXAL PHOSPHATE, COFACTOR, AND PYRIDOXAL PHOSPHATE AT LYS-246.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE AND SADTA, AND PYRIDOXAL PHOSPHATE AT LYS-246.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-74.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-64.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-39 AND 297-327.

************

PROTEIN SEQUENCE OF 2-402, AND METHYLATION AT LYS-203 AND LYS-385.

************

PROTEIN SEQUENCE OF 2-23.

************

PROTEIN SEQUENCE OF 240-251.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH MALEIC ACID AND PYRIDOXAL PHOSPHATE, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEXES WITH PYRIDOXAL PHOSPHATE AND ASPARTATE, COFACTOR, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 48-53, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 48-64, FUNCTION, COFACTOR, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

CATALYTIC ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 48-182 IN COMPLEX WITH AAUB AND AZURIN, FUNCTION, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 48-182 IN COMPLEX WITH AAUB AND SUBSTRATE, FUNCTION, COFACTOR, SUBUNIT, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 48-182 IN COMPLEX WITH AAUB AND SUBSTRATE, FUNCTION, COFACTOR, SUBUNIT, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, MASS SPECTROMETRY, AND PYROGLUTAMATE FORMATION AT GLN-26.

************

FUNCTION, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND BLOCKAGE OF THE N-TERMINUS.

************

INTERACTION WITH AZURIN.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 26-390 IN COMPLEX WITH AAUA AND AZURIN, SUBUNIT, AND DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 26-390 IN COMPLEX WITH AAUA AND SUBSTRATE, SUBUNIT, AND DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (1.20 ANGSTROMS) OF 26-390 IN COMPLEX WITH AAUA AND SUBSTRATE, FUNCTION, SUBUNIT, AND DISULFIDE BOND.

************

FUNCTION IN ARGININE UPTAKE, AND SUBCELLULAR LOCATION.

************

CHARACTERIZATION, BIOPHYSICOCHEMICAL PROPERTIES, MASS SPECTROMETRY, AND MUTAGENESIS OF THR-52.

************

FUNCTION AS PYRUVOYL-DEPENDENT ARGININE DECARBOXYLASE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-555, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 22-28; 29-40; 953-958 AND 1247-1254, AND INTERACTION WITH NPA.

************

SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].

************

PHOSPHORYLATION, IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND SUBCELLULAR LOCATION.

************

FUNCTION, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, DISRUPTION PHENOTYPE, INDUCTION BY LIGHT AND ABA, REPRESSION BY CYTOKININ, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.

************

FUNCTION, DISRUPTION PHENOTYPE, INDUCTION BY SALT; ABSCISIC ACID AND WOUNDING, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4).

************

VARIANT [LARGE SCALE ANALYSIS] VAL-282.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF GLY-171.

************

FUNCTION, DISRUPTION PHENOTYPE, AND INDUCTION BY SALT AND ABSCISIC ACID.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-661, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 187-391.

************

GENE REANNOTATION.

************

INDUCTION BY SALT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 139-264.

************

FUNCTION, MUTAGENESIS OF PHE-94, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

PARTIAL NUCLEOTIDE SEQUENCE, PROTEIN SEQUENCE OF 2-13; 39-73; 103-116; 245-287; 561-575 AND 599-609, FUNCTION, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-93; SER-321 AND SER-326, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-326; THR-328 AND SER-331, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321 AND SER-326, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-93; THR-150; SER-321 AND SER-326, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-894; SER-897 AND SER-922, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-634, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 612-1228.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-527.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 523-536 AND 941-947, FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INTERACTION WITH NPA, AND INDUCTION.

************

PROTEIN SEQUENCE OF 36-54; 956-963 AND 1111-1122, AND INTERACTION WITH NPA.

************

FUNCTION, AND INTERACTION WITH FKBP42/TWD1.

************

FUNCTION, AND INDUCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-628 AND SER-647, AND MASS SPECTROMETRY.

************

FUNCTION, BIOTECHNOLOGY, AND SUBCELLULAR LOCATION.

************

INDUCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1561-1882.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 238-249, FUNCTION, AND INTERACTION WITH NPA.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH FKBP42.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 820-1622.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1390-1486.

************

SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH PAS1; CALMODULIN AND FKBP42/TWD1.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, DISRUPTION PHENOTYPE, DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], MUTAGENESIS OF SER-810 AND ARG-1035, FUNCTION, DEVELOPMENTAL STAGE, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 108-595.

************

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND SUBCELLULAR LOCATION.

************

UBIQUITINATION [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH RAP1A; PFN1; VASP AND ENAH.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-526, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; SER-526 AND SER-531, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH ENAH; VASP AND RAP1A.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-282.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 66-670, TISSUE SPECIFICITY, AND INTERACTION WITH APBB1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55 AND SER-507, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1234-1408.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1237-1408.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-657 AND SER-660, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, INDUCTION BY IRON DEPRIVATION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DISRUPTION PHENOTYPE, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

FUNCTION, DISRUPTION PHENOTYPE, AND INDUCTION BY CADMIUM AND LEAD.

************

NUCLEOTIDE SEQUENCE [MRNA], GENE FAMILY, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF GLU-261, LACK OF INDUCTION BY ALUMINUM, FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 556-737.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 380-634.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 354-634.

************

IDENTIFICATION, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] OF 11-1273.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 21-1273.

************

PROTEIN SEQUENCE OF 64-73 AND 198-207, AND INTERACTION WITH NPA.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-649, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, TISSUE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1174-1295.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1182-1491, AND INDUCTION.

************

FUNCTION, SUBCELLULAR LOCATION, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

INTERACTION WITH FKBP42/TWD1.

************

PROTEIN SEQUENCE OF 45-57, N-ACETYLATION, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].

************

INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 478-755.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1173-1453.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 844-1469.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-40; THR-43; SER-45; SER-494; SER-841 AND SER-844, AND MASS SPECTROMETRY.

************

FUNCTION, MUTAGENESIS OF GLY-354 AND GLY-915, DISRUPTION PHENOTYPE, INDUCTION, AND SUBCELLULAR LOCATION.

************

FUNCTION, DISRUPTION PHENOTYPE, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-494 AND SER-825, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40 AND SER-45, AND MASS SPECTROMETRY.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INDUCTION BY CADMIUM AND LEAD.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40; SER-45 AND SER-825, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40 AND SER-825, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-928.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION.

************

FUNCTION, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88; SER-90 AND SER-93, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-93, AND MASS SPECTROMETRY.

************

FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.

************

FUNCTION, TISSUE SPECIFICITY, INDUCTION, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-962, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], IDENTIFICATION, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 25-31; 317-333 AND 1202-1218, FUNCTION, INDUCTION, INTERACTION WITH NPA, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642; SER-646 AND SER-647, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642 AND SER-671, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1272-1516, AND INDUCTION.

************

TISSUE SPECIFICITY, SUBCELLULAR LOCATION, ENZYME REGULATION, FUNCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1438-1514.

************

FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND ENZYME REGULATION.

************

FUNCTION, AND GENE FAMILY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 496-649.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-745, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 1-1441.

************

IDENTIFICATION, FUNCTION, INTERACTION WITH NAP6, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

INTERACTION WITH NAP6, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 79-1453 (ISOFORM 2), AND TISSUE SPECIFICITY.

************

IDENTIFICATION, FUNCTION, SUBCELLULAR LOCATION, INDUCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-1095.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 971-1365.

************

PROTEIN SEQUENCE OF 1066-1133.

************

PROTEIN SEQUENCE OF 1066-1106.

************

PROTEIN SEQUENCE OF 1066-1075.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], MUTAGENESIS OF ALA-45; ARG-145; GLY-162 AND SER-264, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INDUCTION, AND FUNCTION.

************

IDENTIFICATION, AND MUTAGENESIS OF ALA-236.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, INDUCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF GLY-28; SER-176 AND SER-264.

************

DOMAIN TEA.

************

PROTEIN SEQUENCE OF 20-53.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.

************

IDENTIFICATION, FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

FUNCTION, DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

INDUCTION BY PHYTOCHROME B.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND LACK OF INDUCTION.

************

IDENTIFICATION, AND LACK OF INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND INDUCTION.

************

IDENTIFICATION, FUNCTION, MUTAGENESIS OF CYS-411, ENZYME REGULATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

FUNCTION, INDUCTION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, IDENTIFICATION IN ABAP1-TCP24 COMPLEX, INTERACTION WITH ORC1A; ORC1B; CDT1A; CDT1B, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-737.

************

DOMAIN BTB.

************

PROTEIN SEQUENCE OF 24-155.

************

PROTEIN SEQUENCE OF 24-63.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-51.

************

PROTEIN SEQUENCE OF 24-141.

************

FUNCTION, ATPASE ACTIVITY, SUBUNIT, DOMAIN, PHOSPHORYLATION BY PKNF, AND MUTAGENESIS OF ARG-33; SER-47; ASN-69; ARG-234; SER-248; ASN-270 AND GLU-479.

************

FUNCTION, SUBUNIT, INTERACTION WITH PKNF, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF SER-47 AND SER-248.

************

ENZYME REGULATION, PHOSPHORYLATION AT THR-152 AND THR-210, AND MUTAGENESIS OF SER-47; THR-152; THR-210 AND SER-248.

************

REVISION OF GENE MODEL.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1043-1478.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-839; SER-843 AND SER-863, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 19-27; 31-35; 53-60; 112-123; 129-137 AND 192-198, AND FUNCTION.

************

PROTEIN SEQUENCE OF 53-60; 112-121 AND 129-137.

************

GENE FAMILY ORGANIZATION, AND TISSUE SPECIFICITY.

************

REVIEW ON APOBEC FAMILIES.

************

FUNCTION IN HOST DEFENSE.

************

FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, MUTAGENESIS OF HIS-70; GLU-72 AND CYS-106, AND TISSUE SPECIFICITY.

************

FUNCTION, CATALYTIC ACTIVITY, INDUCTION, AND ALTERNATIVE SPLICING (ISOFORMS 1 AND 2).

************

FUNCTION IN FOREIGN DNA CLEARANCE, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND INDUCTION.

************

FUNCTION IN DNA DEMETHYLATION.

************

FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-28; HIS-29; LYS-30; ASN-57; LYS-60; ARG-69; GLU-72; TRP-98; ARG-128; TYR-130; ASP-131; ASP-133 AND TYR-136.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LYS-146, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.

************

GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, RNA-BINDING, ZINC-BINDING, AND INTERACTION WITH APOBEC3G.

************

FUNCTION IN HIV-1 INFECTIVITY.

************

FUNCTION IN RETROTRANSPOSITION.

************

INTERACTION WITH HUMAN FOAMY VIRUS PROTEIN BET.

************

FUNCTION IN HIV-1 INFECTIVITY, AND TISSUE SPECIFICITY.

************

FUNCTION IN RETROTRANSPOSITION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN DNA C TO U EDITING, AND SPECIES-SPECIFIC RESTRICTION TO HIV-1 INFECTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN HIV-1 INFECTION INHIBITION.

************

SeattleSNPs program for genomic applications;

************

GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, SUBUNIT, RNA-BINDING, AND ZINC-BINDING.

************

TISSUE SPECIFICITY, AND FUNCTION IN HIV-1 INFECTION INHIBITION.

************

SUBCELLULAR LOCATION, FUNCTION IN DNA C TO U EDITING, AND MUTAGENESIS OF GLU-67; HIS-81; GLU-85; CYS-97; CYS-100; CYS-221; HIS-257; GLU-259; CYS-288; CYS-291 AND GLU-323.

************

FUNCTION IN DNA C TO U EDITING, AND MLV INFECTION INHIBITION.

************

CATALYTIC ACTIVITY, FUNCTION IN DNA C TO U EDITING, AND MUTAGENESIS OF HIS-81; CYS-97; CYS-100; HIS-257; CYS-288 AND CYS-291.

************

FUNCTION IN DNA C TO U EDITING, AND INTERACTION WITH VIF.

************

FUNCTION IN DNA C TO U EDITING, INFECTION REGULATION OF HIV-1, AND MUTAGENESIS OF GLU-67; CYS-100; GLU-259 AND CYS-291.

************

INTERACTION WITH VIF, PROTEASOME MEDIATED DEGRADATION, AND TRANSLATION INHIBITION.

************

INTERACTION WITH VIF, AND UBIQUITINATION.

************

FUNCTION IN DNA C TO U EDITING, AND UBIQUITINATION.

************

REVIEW ON APOBEC FAMILY.

************

MUTAGENESIS OF ASP-128.

************

FUNCTION IN HBV INHIBITION.

************

FUNCTION IN HOST DEFENSE, AND MUTAGENESIS OF GLU-217 AND PRO-247.

************

STRUCTURE BY NMR OF 198-384 IN COMPLEX WITH ZINC, CATALYTIC ACTIVITY, FUNCTION, AND MUTAGENESIS OF ARG-213; ARG-215; GLU-259; TRP-285; ARG-313 AND ARG-320.

************

X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 197-380 IN COMPLEX WITH ZINC, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-213; ARG-215; ASN-244; TRP-285 AND TYR-315.

************

STRUCTURE BY NMR OF 193-384 IN COMPLEX WITH ZINC, AND CATALYTIC ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (1.38 ANGSTROMS) OF 191-380.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-380.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-378, FUNCTION IN DNA C TO U EDITING, AND SPECIES-SPECIFIC RESTRICTION TO HIV-1 INFECTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLU-140, AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS ASN-15 DEL; LEU-18; ARG-105; GLU-140 AND ASP-178.

************

FUNCTION, AND CHARACTERIZATION OF VARIANTS ASN-15 DEL AND ARG-105.

************

FUNCTION, CHARACTERIZATION OF ALLELE A3H-VAR, AND MUTAGENESIS OF GLU-56.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 207-348, AND SUBCELLULAR LOCATION.

************

INDUCTION, SUBCELLULAR LOCATION, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 898-1620.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1415-1620 (ISOFORMS 1/2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1433-1620 (ISOFORMS 1/2).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 174-828.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT ARG-1587.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-1587.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-1587.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 21-2261, AND VARIANTS THR-1555; ARG-1587; PRO-1648 AND PRO-2168.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 21-2261, AND VARIANTS THR-1555; ARG-1587; PRO-1648 AND PRO-2168.

************

PHOSPHORYLATION AT SER-1042 AND SER-2054.

************

REPRESSION BY ZNF202.

************

INDUCTION BY LPS.

************

INTERACTION WITH MEGF10.

************

PALMITOYLATION AT CYS-3; CYS-23; CYS-1110 AND CYS-1111, AND SUBCELLULAR LOCATION.

************

DISULFIDE BONDS, AND SUBCELLULAR LOCATION.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-98 AND ASN-244, AND MASS SPECTROMETRY.

************

VARIANTS HDLD2 THR-1091 AND 1893-GLU-ASP-1894 DEL.

************

VARIANTS HDLD1 ARG-597 AND ARG-1477, AND VARIANT HDLD2 LEU-693 DEL.

************

VARIANTS HDLD1 SER-590; SER-935 AND VAL-937, AND VARIANTS ALA-399 AND MET-883.

************

VARIANTS HDLD1 ARG-597; ILE-929 AND ARG-1477, AND VARIANTS HDLD2 LEU-693 DEL; THR-1091; 1893-GLU-ASP-1894 DEL AND LEU-2150.

************

VARIANTS HDLD1 ASN-1289 AND HIS-1800.

************

VARIANT HDLD1 ASP-1046, VARIANT HDLD2 CYS-230, AND VARIANTS LYS-219; ILE-825; MET-883 AND ARG-1587.

************

VARIANT HDLD1 TRP-587, AND VARIANT PRO-2168.

************

VARIANTS LYS-219; MET-883 AND ASP-1172.

************

VARIANT HDLD1 LEU-1506.

************

VARIANTS HDLD1 ASN-1289 AND TRP-2081, AND VARIANT LYS-219.

************

VARIANTS LYS-219; ALA-399; MET-771; PRO-774; ASN-776; ILE-825; MET-883; ASP-1172; ARG-1587 AND CYS-1731.

************

VARIANT HDLD2 LEU-85.

************

VARIANTS HDLD2 TYR-1099 AND SER-2009.

************

VARIANT HDLD1 THR-255, AND VARIANT ATHEROSCLEROSIS ASP-1611.

************

VARIANT HDLD1 LEU-590.

************

VARIANTS HDLD1 HIS-935 AND SER-935.

************

VARIANT HDLD1 TRP-1680.

************

VARIANT HDLD1 GLN-1851.

************

VARIANTS ILE-825 AND MET-883, AND ASSOCIATION OF VARIANTS ILE-825 AND MET-883 WITH HIGHER PLASMA HDL CHOLESTEROL.

************

VARIANTS LYS-219; MET-771; ILE-825; MET-883; ASP-1172; PHE-1181 AND ARG-1587.

************

VARIANT LYS-219.

************

VARIANTS HDLD1 LEU-590; ARG-840 AND CYS-1068, AND VARIANTS MET-771; SER-2163 AND ILE-2244.

************

VARIANTS HDLD1 LYS-284; CYS-482; HIS-1800; SER-1901 AND HIS-2196.

************

VARIANTS HDLD1 PHE-1379 AND ASP-1704, AND CHARACTERIZATION OF VARIANTS HDLD1 PHE-1379 AND ASP-1704.

************

VARIANT HDLD1 HIS-1800, AND VARIANTS LYS-219; CYS-364; MET-771; PRO-774; ASN-776; ILE-825; MET-883; SER-1065; ASP-1172; VAL-1216 AND ARG-1587.

************

VARIANT HDLD1 HIS-1800, AND VARIANTS ALA-248; GLN-401; TRP-496; SER-590; GLN-638; SER-774; GLY-815; PHE-1181; THR-1341; GLY-1376; GLN-1615; THR-1670; GLN-1680 AND GLU-2243.

************

VARIANT SCOTT SYNDROME GLN-1925, AND CHARACTERIZATION OF VARIANT SCOTT SYNDROME GLN-1925.

************

VARIANT ASN-776, AND ASSOCIATION OF VARIANT ASN-776 WITH INCREASED RISK OF ISCHEMIC HEART DISEASE.

************

VARIANT HDLD2 TRP-1897.

************

VARIANTS [LARGE SCALE ANALYSIS] ASP-210; TYR-917; THR-1407 AND THR-2109.

************

INDUCTION BY LIPOPOLYSACCHARIDE.

************

DOWN-REGULATION BY ENDOTOXIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1141 AND SER-1147, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-489, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 3), AND VARIANT PRO-583.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND VARIANT PRO-583.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 651-2435 (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 665-2435 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1327 AND SER-1331, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-2412, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 964-2434.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND GLYCOSYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1265 AND TYR-1268, AND MASS SPECTROMETRY.

************

VARIANTS SMDP3 PRO-101; ASP-568; PRO-1553 AND PRO-1591.

************

VARIANTS [LARGE SCALE ANALYSIS] MET-290; ASP-801 AND GLN-1069.

************

NUCLEOTIDE SEQUENCE [MRNA], VARIANTS STGD1, AND VARIANTS HIS-846; GLN-943 AND ASP-1817.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS STGD1 TRP-18 AND CYS-212, AND VARIANT ASP-1817.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS STGD1.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-943.

************

MEMBRANE TOPOLOGY, AND GLYCOSYLATION AT ASN-98; ASN-415; ASN-444; ASN-504; ASN-1469; ASN-1529; ASN-1588 AND ASN-1662.

************

VARIANTS ARMD2, AND VARIANTS.

************

VARIANTS STGD1 TRP-18; CYS-212; HIS-636; MET-1019; VAL-1038; CYS-1108; TRP-1640; SER-1977 AND HIS-2107, AND VARIANTS FFM PRO-11; PRO-541; VAL-1038; GLU-1091; CYS-1508; PHE-1970 AND ARG-1971.

************

VARIANTS STGD1.

************

VARIANTS STGD1, AND VARIANTS.

************

VARIANT STGD1 TYR-54, AND VARIANT ALA-863.

************

VARIANTS STGD1 VAL-60; ARG-206; ASN-300; PRO-541; ALA-849; PRO-974; VAL-1038; CYS-1108; LEU-1408; ARG-1488; ASP-1652; PRO-1729; GLU-1961; TRP-2038; TRP-2077; HIS-2107; ARG-2128 AND TYR-2150.

************

VARIANTS GLU-1961 AND ASN-2177.

************

VARIANTS STGD1 GLU-60; THR-60; GLU-65; LEU-68; ARG-72; CYS-212; SER-230; SER-247; VAL-328; LYS-471; PRO-541; GLN-572; ARG-607; LYS-635; CYS-653; TYR-764; ARG-765; ALA-901; ILE-959; LYS-1036; VAL-1038; PRO-1063; ASP-1087; CYS-1097; CYS-1108; LEU-1380; LYS-1399; PRO-1430; VAL-1440; HIS-1443; LEU-1486; TYR-1488; MET-1537; PRO-1689; LEU-1705; THR-1733; ARG-1748; PRO-1763; LYS-1885; HIS-1898; GLU-1961; ARG-1975; SER-1977; GLY-2077; TRP-2077 AND VAL-2241, AND VARIANTS GLN-152; HIS-212; ARG-423; ILE-552; ARG-914; GLN-943; THR-1562; ILE-1868; MET-1921; LEU-1948; PHE-1970; ALA-2059; ASN-2177 AND VAL-2216.

************

VARIANTS CORD3 GLU-65; CYS-212; PRO-541; ALA-863; GLY-863 DEL; VAL-1038; LYS-1122; TYR-1490 AND ASP-1598.

************

VARIANTS STGD1 ASP-340; GLN-572; ALA-863; SER-965; VAL-1038; ALA-1780 AND HIS-1898, AND VARIANT GLN-943.

************

VARIANTS STGD1 CYS-212; ASP-767; ILE-897; VAL-1038; LYS-1087; LYS-1399; GLN-1640 AND GLU-1961, AND VARIANT HIS-212.

************

CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLY-966; LYS-969; GLY-1975 AND LYS-1978.

************

VARIANT STGD1 ASN-972, AND VARIANTS GLN-943; ILE-1868 AND LEU-1948.

************

VARIANTS RETINAL TOXICITY CYS-1129; ARG-1201 AND HIS-2107, AND VARIANTS HIS-212; ARG-423; ILE-1868 AND ILE-2255.

************

VARIANTS FFM GLY-339; ALA-863; TRP-943; ARG-991; VAL-1038; CYS-1108; ARG-1488; THR-1562; GLN-1640; PHE-2027; GLN-2030 AND CYS-2106, AND VARIANTS HIS-212; ARG-423; GLN-943; THR-1148; ILE-1868 AND ILE-2255.

************

VARIANTS STGD1 SER-686; TRP-1055; ASP-1799; ASP-1805; PRO-1940 AND HIS-2107, VARIANTS FFM MET-1253 AND PRO-1940, VARIANTS CORD3 CYS-212 AND ARG-2060, AND VARIANTS GLN-943; LEU-1948 AND ILE-2255.

************

VARIANTS STGD1 13-LYS--TRP-15 DEL; TYR-54; LYS-58; VAL-60; GLU-65; GLU-77; HIS-190; PRO-244; ARG-309; CYS-525; CYS-537; PRO-541; PRO-549; ARG-550; GLN-602; ARG-607; MET-643; ASP-767; PRO-797; ARG-821; THR-824; ALA-863; ALA-935; TRP-943; ALA-989; VAL-1038; CYS-1108; LEU-1108; LYS-1122; ARG-1201; GLN-1300; LEU-1380; PRO-1388; ARG-1408; LEU-1486; ARG-1488; TYR-1490; MET-1526; ASN-1532; THR-1562; TRP-1640; LEU-1776; THR-1846; GLU-1961; SER-1977; PHE-2027; GLN-2030; PRO-2035; LEU-2050; CYS-2107; HIS-2107; TRP-2139; ARG-2150 AND TYR-2150, VARIANTS CORD3 GLN-1640 AND ASP-2146, AND VARIANTS HIS-212; ARG-423; GLN-943; THR-1637; ILE-1868 AND LEU-1948.

************

VARIANT ARG-423.

************

VARIANT [LARGE SCALE ANALYSIS] MET-224.

************

VARIANTS ARMD2 GLU-762; LEU-1129; CYS-1724; SER-1977; ASN-2047 AND TYR-2137, AND VARIANT ILE-552.

************

VARIANTS STGD1 VAL-156; CYS-212; LYS-380; ARG-550; PRO-572; TRP-602; ARG-607; CYS-653; ASP-767; ILE-897; ALA-901; MET-931; SER-965; MET-1019; HIS-1108; LEU-1129; LEU-1380; ILE-1433; LEU-1486; TYR-1490; GLN-1640; TRP-1640; ARG-1748; ASP-1799; PRO-1940; GLU-1961; SER-1977; PHE-2027; ARG-2060; HIS-2107; TYR-2150 AND VAL-2241.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT SER-832, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, AND VARIANTS THR-178; ARG-484 AND SER-832.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1187-1642 (ISOFORM 1), AND VARIANT SER-832.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 906-1642 (ISOFORM 1), AND VARIANT VAL-960.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, GLYCOSYLATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1589.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1034-1642.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORM 2), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND VARIANTS ILE-282; ILE-875 AND SER-1322.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 801-1617 (ISOFORM 1), AND VARIANT SER-1322.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-940, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS GLN-1349; ALA-1527 AND SER-2045, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-1527.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS GLN-1349; ALA-1527 AND SER-2045.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS GLY-188; ALA-1527 AND SER-2045, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 195-352 (ISOFORMS 1/2).

************

VARIANTS GLY-188; ALA-319; ARG-395; HIS-463; THR-718; GLN-1349; ARG-1686 AND SER-2045.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1920-2159.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, TISSUE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-84, AND MASS SPECTROMETRY.

************

VARIANT SER-331.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 68-845, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS HIS-353 AND THR-1306, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORMS 2; 3 AND 4), FUNCTION, INDUCTION, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-856 (ISOFORM 1), AND VARIANT HIS-353.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-949, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 654-1623.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS SER-203; VAL-287 AND THR-916.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), VARIANTS SER-203 AND VAL-287, ALTERNATIVE SPLICING (ISOFORMS 2; 3 AND 4), TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND VARIANTS SER-203 AND VAL-287.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-307, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-568, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-112; THR-115 AND THR-118, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT THR-777.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT THR-777.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 221-2595, AND VARIANT THR-777.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2400-2595.

************

REVIEW ON VARIANTS, AND INVOLVEMENT IN ARCI.

************

VARIANTS LI2 SER-1380; GLU-1381; HIS-1514; LYS-1539 AND SER-1651.

************

VARIANT HI ASN-2365.

************

VARIANT HI ASN-387.

************

VARIANT HI ARG-1179.

************

VARIANTS NCIE PRO-345 AND THR-1494.

************

VARIANT NCIE ASP-1136.

************

VARIANT [LARGE SCALE ANALYSIS] VAL-476.

************

VARIANTS NCIE SER-1235; HIS-1514; LEU-1798 AND LYS-1980.

************

VARIANT NCIE VAL-1559.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORM 3), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4659-5058 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2933-5058 (ISOFORM 1), AND VARIANT PHE-3851.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4798-5034 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2887-5034 (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORM 2), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, TISSUE SPECIFICITY, AND VARIANT LYS-525.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANTS GLU-115 AND LYS-525, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LYS-525.

************

VARIANT [LARGE SCALE ANALYSIS] VAL-230.

************

VARIANT [LARGE SCALE ANALYSIS] THR-435.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-229.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 112-842 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 332-842 (ISOFORM 1).

************

FUNCTION, DEVELOPMENTAL STAGE, INDUCTION BY CELLULAR PORPHYRINS, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH HEMIN.

************

SUBCELLULAR LOCATION, TISSUE SPECIFICITY, VARIANTS MCOPCB7 THR-57 AND VAL-811, AND CHARACTERIZATION OF VARIANTS MCOPCB7 THR-57 AND VAL-811.

************

INVOLVEMENT IN LANGEREIS BLOOD GROUP SYSTEM.

************

STRUCTURE BY NMR OF 558-842 IN COMPLEX WITH ADP.

************

VARIANT [LARGE SCALE ANALYSIS] GLY-69.

************

PROTEIN SEQUENCE OF 764-771, AND MASS SPECTROMETRY.

************

FUNCTION, DEVELOPMENTAL STAGE, INDUCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLY-315 AND ILE-346.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASAT MET-400.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASAT LYS-433.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-752 (ISOFORM 1).

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-216 AND LYS-251, AND MASS SPECTROMETRY.

************

VARIANT ASAT LEU-411, AND VARIANTS GLY-315 AND ILE-346.

************

VARIANT ASAT ASP-208.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 59-752.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-350, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND MUTAGENESIS.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND SHORT).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).

************

SUBCELLULAR LOCATION, AND TRANSIT PEPTIDE.

************

VARIANT ILE-152.

************

VARIANTS [LARGE SCALE ANALYSIS] THR-165 AND GLY-690.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5).

************

SUBCELLULAR LOCATION, AND DOMAIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-530, AND MASS SPECTROMETRY.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF 136-LYS-LYS-137.

************

VARIANT MET-121.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 414-762 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-545.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 510-738.

************

TRANSIT PEPTIDE, AND SUBUNIT.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-265, AND MASS SPECTROMETRY.

************

VARIANT SER-150.

************

VARIANT [LARGE SCALE ANALYSIS] THR-471.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS PFIC2 GLY-297; GLU-461; GLY-482; ARG-982; CYS-1153 AND GLN-1268.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-444.

************

GLYCOSYLATION AT ASN-109; ASN-116; ASN-122 AND ASN-125.

************

VARIANTS PFIC2 VAL-238 AND SER-336.

************

VARIANT ALA-444.

************

VARIANTS PFIC2 LEU-284 AND ASP-1004.

************

VARIANTS BRIC2 GLY-186; GLY-297; THR-570; PRO-923; PRO-926; CYS-1050 AND HIS-1128.

************

VARIANTS GLN-415; ALA-444; SER-591 AND VAL-677.

************

VARIANTS BRIC2 GLY-297 AND THR-432, AND CHARACTERIZATION OF VARIANTS BRIC2 GLY-297 AND THR-432.

************

VARIANTS VAL-206; ALA-284; LYS-299; ALA-444; GLY-616; ALA-619; VAL-677; HIS-698; VAL-865 AND GLN-958.

************

VARIANTS ALA-444 AND VAL-677.

************

VARIANTS ALA-284; ALA-444; TYR-676; VAL-677; HIS-698 AND ARG-855, BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANTS ALA-444; TYR-676; VAL-677 AND ARG-855.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 463-635.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-692; SER-696; SER-703 AND SER-709, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-692, AND MASS SPECTROMETRY.

************

INTERACTION WITH HAX1.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 613-1460, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 6-1328, AND NOMENCLATURE.

************

GLYCOSYLATION AT ASN-10.

************

TOPOLOGY, AND GLYCOSYLATION AT ASN-10.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND VARIANT SER-1369.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT SER-1369.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-1369.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1187-1581, AND VARIANT SER-1369.

************

VARIANT HHF1 VAL-716.

************

VARIANT SER-1369.

************

VARIANT HHF1 PHE-1387 DEL, AND VARIANTS GLY-1360; SER-1369 AND ILE-1572.

************

CHARACTERIZATION OF VARIANT HHF1 ARG-1478.

************

VARIANTS GLN-275; MET-560; ASN-810; CYS-834 AND SER-1369.

************

VARIANTS ASN-673 AND SER-1369.

************

CHARACTERIZATION OF VARIANTS HHF1 GLN-125; SER-188; LEU-591; MET-1138; GLN-1214; SER-1381; PHE-1387 DEL AND HIS-1393.

************

VARIANTS HHF1 GLN-74; GLN-125; SER-188; ASP-406; LEU-591; MET-1138; GLN-1214; ARG-1378; SER-1381; PHE-1387 DEL AND HIS-1393.

************

VARIANTS HHF1 PRO-1352; CYS-1420 AND TRP-1493.

************

VARIANT HHF1 ASP-187.

************

VARIANTS SER-1369 AND ILE-1572.

************

VARIANTS HHF1 GLY-841; CYS-1420 AND TRP-1493.

************

CHARACTERIZATION OF VARIANTS HHF1 CYS-1420 AND GLN-1436, AND VARIANT SER-1369.

************

CHARACTERIZATION OF VARIANT HHF1 LYS-1506.

************

CHARACTERIZATION OF VARIANT HHF1 PHE-1387 DEL.

************

CHARACTERIZATION OF VARIANT HHF1 PRO-1543.

************

VARIANTS HHF1 ASP-187; THR-1457; LYS-1506; ASP-1550 AND VAL-1551.

************

VARIANT HHF1 SER-1385 DEL, AND CHARACTERIZATION OF VARIANT HHF1 SER-1385 DEL.

************

VARIANT LIH HIS-1352, AND CHARACTERIZATION OF VARIANT LIH HIS-1352.

************

VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418 AND TRP-1493, AND CHARACTERIZATION OF VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418 AND TRP-1493.

************

VARIANTS HHF1 GLN-1384 AND LYS-1486, AND VARIANT SER-1369.

************

VARIANTS HHF1 SER-27; TRP-74; SER-188; GLN-495; LYS-501; SER-686; TRP-1214; GLN-1214; ASN-1336; PHE-1387 DEL; HIS-1471 AND ASN-1471.

************

VARIANT PNDM LEU-132, AND CHARACTERIZATION OF VARIANT PNDM LEU-132.

************

VARIANTS HHF1 TRP-74; ARG-111; SER-188; ARG-233; ASN-310; ARG-551; THR-719; PRO-1130; ARG-1147; LYS-1295 AND PRO-1450, AND VARIANTS SER-1369 AND ILE-1572.

************

VARIANTS HHF1 ARG-7; ASP-21; SER-27; TRP-74; LYS-501; PRO-503; SER-686; TRP-1214; TRP-1214; GLN-1349; ARG-1378; PHE-1387 DEL; ARG-1400 AND GLN-1493.

************

VARIANTS PNDM ARG-213 AND VAL-1424, VARIANTS TNDM2 ARG-435; VAL-582; TYR-1023; GLN-1182 AND CYS-1379, CHARACTERIZATION OF VARIANT PNDM VAL-1424, AND CHARACTERIZATION OF VARIANT TNDM2 TYR-1023.

************

VARIANT PNDM ALA-86.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM C).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS SUR2A AND SUR2B), AND REVIEW.

************

POSSIBLE FUNCTION IN REGULATION OF SLEEP DURATION.

************

VARIANT CMD1O THR-1513.

************

VARIANT ATFB12 ILE-1547, AND CHARACTERIZATION OF VARIANT ATFB12 ILE-1547.

************

VARIANTS HTOCD VAL-478; TYR-1043; GLN-1154 AND TRP-1154.

************

VARIANTS HTOCD TYR-60; GLU-207; CYS-380; LEU-432; PRO-1020; SER-1039; TYR-1054; HIS-1116; CYS-1116; GLN-1154 AND TRP-1154, AND CHARACTERIZATION OF VARIANTS HTOCD LEU-432; HIS-1116 AND GLN-1154.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SUR2A AND SUR2B).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SUR2A AND SUR2C).

************

PROTEIN SEQUENCE OF 493-498, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SUR2A).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SUR2B).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS GLU-317 AND ARG-1344.

************

FUNCTION IN CYCLIC NUCLEOTIDE EFFLUX.

************

VARIANT ARG-180, CHARACTERIZATION OF VARIANT ARG-180, AND FUNCTION IN SECRETION OF EARWAX.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-1265, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 682-1350, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), INDUCTION, AND TISSUE SPECIFICITY.

************

SUBUNIT, AND CHARACTERIZATION OF VARIANTS X-ALD HIS-389; GLN-401; ARG-484 AND GLN-591.

************

FUNCTION, AND CHARACTERIZATION OF VARIANTS X-ALD SER-512 AND LEU-606.

************

INTERACTION WITH PEX19.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-733, AND MASS SPECTROMETRY.

************

VARIANT X-ALD LYS-291.

************

VARIANTS X-ALD SER-148; ASP-174; ARG-266; GLN-401; TRP-418 AND PHE-515.

************

VARIANTS X-ALD TRP-518; LEU-606; CYS-617 AND HIS-617.

************

VARIANTS X-ALD.

************

VARIANTS X-ALD HIS-104; GLU-178; LEU-560 AND GLY-528 DEL.

************

VARIANT X-ALD ARG-679.

************

VARIANTS X-ALD LEU-108 AND SER-143.

************

VARIANTS X-ALD GLN-401; TRP-418; LEU-543 AND ARG-556.

************

VARIANTS X-ALD LEU-98; ASP-99; GLU-217; GLN-518; ASP-608; ILE-633 AND PRO-660, AND VARIANT THR-13.

************

VARIANT X-ALD VAL-GLY-GLN-300 INS.

************

INVOLVEMENT IN CONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME.

************

VARIANTS X-ALD TRP-88; CYS-152; CYS-181; SER-343; PRO-503; ARG-514 AND HIS-554.

************

VARIANTS X-ALD GLN-401; PRO-516; LEU-560; PRO-606 AND GLN-660.

************

VARIANTS X-ALD LEU-139 DEL; ARG-198; ARG-266; GLU-266; TRP-401; GLN-518; PHE-523; CYS-540; LEU-560; PRO-606; HIS-617; THR-626; PRO-632; ARG-633; LYS-640 AND ASP-677.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 362-736.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND CHARACTERIZATION.

************

VARIANT [LARGE SCALE ANALYSIS] LYS-244.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-58, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-17.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH PEX19.

************

FUNCTION, AND MUTAGENESIS OF GLY-478 AND SER-572.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-145, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-260 AND LYS-399, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 271-647.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-260, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-424, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-15 AND 283-296.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS THR-304 AND LYS-368.

************

VARIANTS THR-304 AND LYS-368.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND INTERACTION WITH RNASEL.

************

INDUCTION BY EMCV, AND FUNCTION.

************

INDUCTION BY HIV-1, AND FUNCTION.

************

INTERACTION WITH HIV-1 VIF AND GAG PROTEINS.

************

INTERACTION WITH HIV-2 AND SIV GAG PROTEINS.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-121; LYS-191; LYS-210; LYS-349 AND LYS-431, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 160-845 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-108 AND SER-109, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105; THR-108 AND SER-109, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105; THR-108; SER-109; SER-140 AND SER-228, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-228, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-140 AND SER-228, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-573 AND LYS-582, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-595, AND MASS SPECTROMETRY.

************

INTERACTION WITH EIF2S1, ASSOCIATION WITH RIBOSOMES, PHOSPHORYLATION AT SER-109 AND SER-140, MASS SPECTROMETRY, AND MUTAGENESIS OF SER-109 AND SER-140.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-109, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24; SER-105; THR-108; SER-109; SER-140; SER-166 AND SER-228, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-109 AND SER-228, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22; SER-24; THR-108; SER-109 AND SER-140, AND MASS SPECTROMETRY.

************

FUNCTION, ATP-BINDING, ASSOCIATION WITH RIBOSOMES, MUTAGENESIS OF LYS-342; GLN-367; GLY-454; GLU-477; HIS-506; LYS-664; GLN-695; GLY-745; GLU-768 AND HIS-797, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-108; SER-109; SER-140; SER-166 AND SER-228, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103; SER-107 AND SER-138, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107; SER-138 AND SER-194, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138 AND SER-194, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103; SER-107 AND SER-194, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-839, FUNCTION, ASSOCIATION WITH RIBOSOMES, AND INTERACTION WITH EIF2.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 74-623.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-349, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-304, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 376-628.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT LEU-503.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-283, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 589-709.

************

FUNCTION, AND INTERACTION WITH OAS1B.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-678 (ISOFORMS 1 AND 4).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND REPRESSION BY ZNF202.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2; 3; 4; 5; 6 AND 7).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), AND VARIANT LEU-668.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 33-678.

************

INDUCTION, AND PROBABLE FUNCTION.

************

SUBCELLULAR LOCATION, AND MISCELLANEOUS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-578.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS GLU-166 AND SER-208, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND VARIANTS GLU-166 AND SER-208.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LYS-141.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PRO-316.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 294-655 (ISOFORM 1).

************

SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-596, AND MUTAGENESIS OF ASN-418; ASN-557 AND ASN-596.

************

MUTAGENESIS OF ARG-482.

************

MUTAGENESIS OF LYS-86, SUBCELLULAR LOCATION, AND HOMODIMERIZATION.

************

SUBUNIT, AND DISULFIDE BONDS.

************

INVOLVEMENT IN UAQTL1 AND GOUT.

************

INVOLVEMENT IN UAQTL1, ASSOCIATION OF VARIANT LYS-141 WITH GOUT, AND CHARACTERIZATION OF VARIANT LYS-141.

************

INVOLVEMENT IN UAQTL1, AND ASSOCIATION OF VARIANT LYS-141 WITH GOUT.

************

INVOLVEMENT IN JR, AND VARIANT MET-12.

************

INVOLVEMENT IN JR.

************

VARIANTS MET-12 AND LYS-141.

************

VARIANTS LEU-431 AND LEU-489.

************

VARIANTS MET-12; LYS-141; LEU-206 AND TYR-590.

************

CHARACTERIZATION OF VARIANTS MET-12; LYS-141 AND ASN-620.

************

VARIANTS MET-12; LEU-13; LYS-141; GLN-160; ARG-354; LEU-431; ASN-441 AND LEU-489.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 511-657.

************

NUCLEOTIDE SEQUENCE [MRNA], GLYCOSYLATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 506-657.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-646.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLU-604.

************

NUCLEOTIDE SEQUENCE [MRNA], VARIANTS STSL HIS-389; HIS-419 AND PRO-419, AND VARIANT GLU-604.

************

VARIANTS STSL GLN-146; HIS-389; PRO-419; HIS-419 AND SER-550, AND VARIANT GLU-604.

************

VARIANT STSL LYS-437, AND VARIANTS VAL-523; TYR-600; GLU-604 AND VAL-622.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 2.

************

NUCLEOTIDE SEQUENCE, TISSUE SPECIFICITY, AND VARIANT CYS-583.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 15-1534, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS STSL THR-231; GLN-263; ARG-574 AND ARG-596, AND VARIANT CYS-54.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), VARIANTS STSL HIS-184; THR-231; GLN-263; HIS-405; PRO-501; SER-543; PHE-570 DEL; PRO-572; ARG-574; GLU-574 AND ARG-596, AND VARIANTS HIS-19; CYS-54; LYS-238; VAL-259; LYS-400; ARG-575 AND ALA-632.

************

VARIANTS HIS-19; CYS-54; LYS-400; ALA-632 AND PHE-641.

************

VARIANTS CYS-54 AND LYS-400.

************

VARIANT HIS-19, AND ASSOCIATION WITH GBD4.

************

SEQUENCE REVISION TO 3-4.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 3), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], DISRUPTION PHENOTYPE, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 100-158.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 152-398 (ISOFORM 1).

************

INVOLVEMENT IN PHARC.

************

FUNCTION, SUBCELLULAR LOCATION, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 16-89.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ABD-A1), FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS ABD-A1 AND ABD-A2).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ABD-A1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 210-343.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS M AND R).

************

NUCLEOTIDE SEQUENCE (ISOFORM R), AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM M), AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM M).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORMS M AND R).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 387-447.

************

ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, SUBUNIT, INDUCTION, AND KINETIC PARAMETERS.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF APOENZYME AND IN COMPLEX WITH NAD AND SUBSTRATE ANALOG, FUNCTION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-80.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND VARIANT ILE-80.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-80.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 16-147.

************

INTERACTION WITH HNRPAB.

************

FUNCTION IN NF1 EDITING.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND MUTAGENESIS.

************

INTERACTION WITH A1CF.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-136.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 41-224, SUBUNIT, COFACTOR, ACTIVE SITE, AND ZINC-BINDING SITES.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANTS ARG-34; 37-ILE-ASP-38; 112-VAL-LEU-113; 134-ILE-ARG-135; ASN-139; LYS-181; 233-VAL-HIS-LEU-235; GLY-258; ILE-306 AND HIS-404.

************

NUCLEOTIDE SEQUENCE (ISOFORM 4), AND VARIANTS.

************

DNA C TO U EDITING ACTIVITY, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-271 AND GLU-331.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 30-75.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 128-154 AND 535-555, AND MUTAGENESIS OF HIS-57 AND CYS-71.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PHOSPHORYLATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 585-731.

************

PHOSPHORYLATION AT SER-720, AND MUTAGENESIS OF SER-720.

************

DNA-BINDING.

************

IDENTIFICATION IN THE GGR COMPLEX, AND FUNCTION.

************

FUNCTION, AND DOMAIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-467, AND MASS SPECTROMETRY.

************

FUNCTION OF THE GGR COMPLEX.

************

SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-625, AND INTERACTION WITH PSE1.

************

DNA-BINDING, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-467 AND SER-720, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-189; SER-193 AND SER-618, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-189; SER-193; SER-258; SER-302; SER-304; SER-467; SER-554; SER-618 AND SER-720, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 397.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 44-72.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 27-56.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 26-43.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 26-43 AND 482-494, SUBCELLULAR LOCATION, INDUCTION, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 26-35 AND 63-77.

************

SEQUENCE REVISION TO 114.

************

TRANSCRIPTIONAL REGULATION.

************

PROTEIN SEQUENCE OF 2-51, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-23.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 18-27.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 18-27 AND 421-432, SUBCELLULAR LOCATION, INDUCTION, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND BIOTECHNOLOGY.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 19-499 IN COMPLEX WITH SUBSTRATE, DOMAIN, ACTIVE SITE, DISULFIDE BONDS, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, GLYCOSYLATION AT ASN-202, AND MUTAGENESIS OF 176-CYS-CYS-177; THR-204; GLU-221 AND ASP-297.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 19-499 OF THE ALA-221 MUTANT IN COMPLEX WITH SUBSTRATE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 19-30; 221-234; 285-304 AND 312-324.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, INDUCTION, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], INDUCTION, SUBCELLULAR LOCATION, AND FUNCTION.

************

PROTEIN SEQUENCE OF 1-10, FUNCTION AS A PABA-GLU HYDROLASE, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND COFACTOR.

************

FUNCTION AS A PABA-GLU HYDROLASE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], DISRUPTION PHENOTYPE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND SEQUENCE REVISION TO 504.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 452-508.

************

FUNCTION AS A TRANSPORT PROTEIN, AND ENZYME REGULATION.

************

FUNCTION AS A TRANSPORT PROTEIN.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-334.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT GLU-137.

************

IDENTIFICATION, AND DEVELOPMENTAL STAGE.

************

FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND VARIANTS CDS LYS-7; PRO-130 AND LYS-260.

************

FUNCTION, AND CHARACTERIZATION OF VARIANTS CDS PRO-130 AND LYS-260.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS CDS PRO-130 AND LYS-260.

************

VARIANT ARG-82.

************

VARIANT CDS GLY-115.

************

INTERACTION WITH PLIN, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, TISSUE SPECIFICITY, AND INTERACTION WITH PLIN AND PNPLA2.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH PLIN AND ADRP, SUBCELLULAR LOCATION, INDUCTION, AND MUTAGENESIS OF GLU-9; GLN-132 AND GLU-262.

************

PROTEIN SEQUENCE OF 245-254, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 73-306.

************

IDENTIFICATION BY MASS SPECTROMETRY, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 7-315 (ISOFORM 2).

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-87, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS), INTERACTION WITH TAF1, AND SUBCELLULAR LOCATION.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS), FUNCTION, ACTIVE SITE, SUBCELLULAR LOCATION, INTERACTION WITH TAF1, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 2-12 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 418-426, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), PHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH EPS8 AND ABL1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORMS 3; 7; 8 AND 9), AND INTERACTION WITH SPTA1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND INTERACTION WITH ABL1; NAP1 AND NCK1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND INTERACTION WITH NCF1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 11).

************

PROTEIN SEQUENCE OF 2-17.

************

PROTEIN SEQUENCE OF 2-17; 139-154; 229-237 AND 451-477, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH SOS1; SOS2 AND GRB2.

************

ALTERNATIVE SPLICING (ISOFORMS 2 AND 10), AND CHROMOSOMAL TRANSLOCATION WITH MLL.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-333, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-213, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183, AND MASS SPECTROMETRY.

************

FUNCTION, AND PHOSPHORYLATION AT TYR-213.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183 AND SER-216, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), ALTERNATIVE SPLICING (ISOFORM 2), AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 5).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 70-360 (ISOFORM 4), FUNCTION, PHOSPHORYLATION, TISSUE SPECIFICITY, AND INTERACTION WITH ABL1 AND V-ABL.

************

FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH EPS8 AND SOS1.

************

FUNCTION, AND INTERACTION WITH ENAH.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH STX1A; SNAP25; VAMP2 AND WASF1.

************

COMPONENT OF WAVE2 COMPLEX.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-428, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183 AND SER-222, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183 AND TYR-213, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH ABL1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND INTERACTION WITH ABL2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.29 ANGSTROMS) OF 1-164, AND SUBUNIT.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-395, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2-719.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 48-302, AND VARIANTS LEU-225; GLU-231 AND THR-248.

************

INTERACTION WITH APRR1; AIP2; AIP3 AND AIP4.

************

INTERACTION WITH ABI5.

************

INTERACTION WITH BZIP10 AND BZIP25, AND DEVELOPMENTAL STAGE.

************

INTERACTION WITH AIP2, SUBCELLULAR LOCATION, AND UBIQUITINATION.

************

INTERACTION WITH SCAR3.

************

FUNCTION, AND INTERACTION WITH BZIP10; BZIP25 AND BZIP53.

************

INDUCTION BY EMF1 AND EMF2.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT SER-209.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS GLN-44 AND SER-209.

************

FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH TARSH.

************

FUNCTION, AND MUTAGENESIS OF GLU-69.

************

FUNCTION, AND INDUCTION BY IMBIBITION AND GLUCOSE.

************

INDUCTION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

INTERACTION WITH SCAR2 AND SCAR3.

************

FUNCTION, AND INDUCTION BY TREHALOSE.

************

NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, TISSUE SPECIFICITY, DNA-BINDING, AND HETERODIMERIZATION.

************

INTERACTION WITH ABI3, AND HOMODIMERIZATION.

************

FUNCTION, INDUCTION, AND PHOSPHORYLATION.

************

FUNCTION, AND DEVELOPMENTAL STAGE.

************

FUNCTION, AND DNA-BINDING.

************

FUNCTION, SUBCELLULAR LOCATION, DNA-BINDING, PHOSPHORYLATION, AND MASS SPECTROMETRY.

************

FUNCTION, AND PHOSPHORYLATION.

************

PROTEIN DEGRADATION, AND INTERACTION WITH AFP1.

************

PROTEIN DEGRADATION.

************

FUNCTION, AND INTERACTION WITH ABI3.

************

PROTEIN DEGRADATION, AND INTERACTION WITH KEG.

************

PHOSPHORYLATION BY SRK2D AND SRK2I.

************

INTERACTION WITH AFP1; AFP2; AFP3 AND AFP4.

************

SUMOYLATION AT LYS-391, AND MUTAGENESIS OF LYS-391.

************

IDENTIFICATION IN THE WAVE COMPLEX, INTERACTION WITH SCRA, AND FUNCTION.

************

IDENTIFICATION IN THE WAVE COMPLEX, DISRUPTION PHENOTYPE, AND FUNCTION.

************

EFFECT ON PHAGES.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INTERACTION WITH SCAR2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-143, AND VARIANT ASN-135.

************

INDUCTION [LARGE SCALE ANALYSIS].

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 150-706.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA), ALTERNATIVE SPLICING, AND VARIANT PRO-140.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS IA AND IB).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 27-40, AND SUBCELLULAR COMPONENT.

************

NUCLEOTIDE SEQUENCE OF 360-426.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 825-845.

************

MYRISTOYLATION (ISOFORM IB).

************

DOMAIN, AND DNA-BINDING.

************

INTERACTION WITH RIN1, AND FUNCTION.

************

FUNCTION, AND INTERACTION WITH RAD51.

************

INTERACTION WITH INPPL1.

************

FUNCTION, ENZYME REGULATION, AND INTERACTION WITH TP73.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185; TYR-226; TYR-253; TYR-257; TYR-264; TYR-393; THR-394 AND TYR-469, AND MASS SPECTROMETRY.

************

INTERACTION WITH SORBS1.

************

FUNCTION, AND INTERACTION WITH RAD52.

************

FUNCTION, AND INTERACTION WITH RAD9A.

************

INTERACTION WITH BCR.

************

INTERACTION WITH YWHAB; YWHAE; YWHAG; YWHAH; SFN AND YWHAZ, PHOSPHORYLATION AT THR-735, MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-735.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; SER-683; SER-805; SER-809 AND SER-949, AND MASS SPECTROMETRY.

************

ACETYLATION AT LYS-711, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION, INTERACTION WITH HCK, LAN AND FYN, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH PSMA7.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH WASF3.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION AT SER-618 AND SER-619, AND INTERACTION WITH ABI2 AND CRK.

************

FUNCTION, AND ENZYME REGULATION.

************

PHOSPHORYLATION AT TYR-70, AND INTERACTION WITH ABI1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; TYR-185; TYR-393; SER-569; THR-613; SER-620; SER-659; SER-683; SER-718; THR-781; SER-805; SER-809; THR-814; THR-844; THR-852; SER-917; SER-919; SER-936 AND SER-977, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; THR-844; THR-852 AND SER-917, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-805; SER-809; THR-852 AND SER-855, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-392; TYR-393 AND SER-569, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50 AND SER-569, AND MASS SPECTROMETRY.

************

INTERACTION WITH MYLK AND CTTN.

************

REVIEW ON FUNCTION, AND DOMAIN.

************

STRUCTURE BY NMR OF SH2 DOMAIN.

************

3D-STRUCTURE MODELING OF SH3 DOMAIN.

************

STRUCTURE BY NMR OF SH3 DOMAIN.

************

X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 64-121.

************

STRUCTURE BY NMR OF 62-122 IN COMPLEX WITH CRK.

************

X-RAY CRYSTALLOGRAPHY (3.42 ANGSTROMS) OF 27-512, MYRISTOYLATION (ISOFORM IB), ENZYME REGULATION, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 229-513 OF MUTANT PRO-396 IN COMPLEX WITH INHIBITOR VX-680, FUNCTION, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-512, MASS SPECTROMETRY, MYRISTOYLATION OF N-TERMINUS (ISOFORM IB), PHOSPHORYLATION AT SER-50, AUTOINHIBITION MECHANISM, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 229-512 IN COMPLEXES WITH ATP-PEPTIDE CONJUGATE, AND CONFORMATION CHANGES DURING ACTIVATION.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 229-500 IN COMPLEXES WITH IMANITIB AND WITH THE INHIBITORS NVP-AEG082; NVP-AFN941; NVP-AFG210 AND PD180970.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 64-121 OF MUTANT ALA-114 IN COMPLEX WITH PROLINE-RICH PEPTIDE.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 60-121 IN COMPLEX WITH PROLINE-RICH PEPTIDE P41.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 121-232 IN COMPLEX WITH ANTIBODY MIMIC HA4, FUNCTION, AND CATALYTIC ACTIVITY.

************

VARIANTS GLY-47; LYS-166; VAL-706; LEU-810 AND LEU-972.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM I).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-187 (ISOFORMS I; II; III AND IV).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 85-182.

************

PHOSPHORYLATION AT THR-547 AND SER-569.

************

DNA-BINDING, DOMAIN, AND PHOSPHORYLATION.

************

FUNCTION, ENZYME REGULATION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-446, AND MUTAGENESIS OF SER-446.

************

IDENTIFICATION IN A TRIMOLECULAR COMPLEX WITH CDK5 AND CABLES1, AND INTERACTION WITH CABLES1.

************

INTERACTION WITH PSTPIP1.

************

INTERACTION WITH CRK, AND FUNCTION.

************

INTERACTION WITH ZDHHC16.

************

FUNCTION, ENZYME REGULATION, INTERACTION WITH CRK, AUTOPHOSPHORYLATION AT TYR-226 AND TYR-393, AND MUTAGENESIS OF TYR-226; LYS-271 AND TYR-393.

************

FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION.

************

FUNCTION IN REGULATION OF CELL MIGRATION, PHOSPHORYLATION, AND INTERACTION WITH ITGB1; HCK AND FGR.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 61-121.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 229-515 IN COMPLEX WITH INHIBITOR STI-571, CATALYTIC ACTIVITY, ENZYME REGULATION, PHOSPHORYLATION AT TYR-393, AND ACTIVATION LOOP.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 229-515, MYRISTOYLATION (ISOFORM IV), AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 229-515 OF WILD-TYPE AND MUTANT ILE-315 IN COMPLEX WITH INHIBITOR PPY-A.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 229-515 OF MUTANT ILE-315 IN COMPLEX WITH INHIBITOR AP24534, CATALYTIC ACTIVITY, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.22 ANGSTROMS) OF 115-401 IN COMPLEXES WITH INHIBITORS AP24283 AND AP24163.

************

X-RAY CRYSTALLOGRAPHY (1.74 ANGSTROMS) OF 115-401 IN COMPLEX WITH INHIBITORS IMATINIB AND GNF-2, CATALYTIC ACTIVITY, ENZYME REGULATION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF PRO-112; TYR-128; TYR-139; SER-229; THR-315; CYS-464; PRO-465; PHE-497; GLU-505 AND VAL-506.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS IA AND IB).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4; 5; 6 AND 7).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 343-469.

************

AUTOPHOSPHORYLATION AT TYR-272; TYR-439; TYR-568 AND TYR-683, AND ENZYME REGULATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-310; TYR-439; THR-440 AND TYR-515, AND MASS SPECTROMETRY.

************

INTERACTION WITH RIN1, FUNCTION, AND ENZYME REGULATION.

************

FUNCTION, PHOSPHORYLATION AT TYR-261, AND UBIQUITINATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203 AND SER-631, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-439, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631; SER-783; SER-817 AND SER-936, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817 AND SER-820, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-116; SER-203; TYR-231; SER-275; SER-602; SER-620; SER-631; SER-671; TYR-718; SER-820; THR-864; SER-915 AND SER-936, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-633; SER-655; SER-817; SER-820; SER-915 AND SER-936, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-783; SER-817; THR-818; SER-819; SER-820; SER-936 AND THR-938, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96; SER-620; SER-631; TYR-683; TYR-718; SER-781; THR-784; THR-815; SER-817; SER-819; SER-820 AND SER-936, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817; SER-820 AND SER-936, AND MASS SPECTROMETRY.

************

VARIANTS [LARGE SCALE ANALYSIS] HIS-78; GLN-99; ILE-519; SER-769; ARG-930 AND ARG-996, AND VARIANT [LARGE SCALE ANALYSIS] THR-12 (ISOFORM 4).

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DOMAIN, SUBCELLULAR LOCATION, AND ACTIN-BINDING.

************

NUCLEOTIDE SEQUENCE [MRNA], CAP DOMAIN, FUNCTION, ENZYME REGULATION, INTERACTION WITH CRK, AUTOPHOSPHORYLATION AT TYR-272; TYR-439; TYR-568 AND TYR-684, AND MUTAGENESIS OF TYR-272; LYS-317; TYR-439; TYR-568 AND TYR-684.

************

DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-936, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-632, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-621, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-357; TYR-373; SER-435; TYR-439 AND TYR-461, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-431; SER-452; SER-655 AND SER-706, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-396; TYR-406 AND TYR-410, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-461, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-473, AND MASS SPECTROMETRY.

************

INTERACTION WITH ABRA.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452 AND SER-458, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-431, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-431; SER-435; SER-455; SER-458; SER-587; SER-640; SER-655 AND SER-706, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-429; SER-431; SER-435; TYR-439; SER-450; THR-451; SER-458 AND SER-655, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; TYR-373; SER-426; SER-431; THR-433 AND SER-435, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.

************

FUNCTION, DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND 3).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-475 AND SER-479, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-475, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-475 AND SER-671, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-475 AND SER-494, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-440, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-475 AND SER-502, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-397; SER-411 AND SER-496, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7), FUNCTION, TISSUE SPECIFICITY, AND INTERACTION WITH ABRA AND F-ACTIN.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 34-611 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 390-572 (ISOFORM 5).

************

VARIANTS [LARGE SCALE ANALYSIS] ARG-227 AND MET-274.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 4 AND 5).

************

SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH F-ACTIN AND ABRA.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289; SER-294; SER-296 AND SER-477, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, TISSUE SPECIFICITY, AND INTERACTION WITH F-ACTIN AND ABRA.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 117-683 (ISOFORM 3).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394; SER-503 AND SER-504, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-372; SER-373 AND SER-388, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503 AND SER-504, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-282, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277; SER-280; SER-373 AND SER-502, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEX WITH CARBOHYDRATE, SEQUENCE REVISION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CATALYTIC ACTIVITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 61-1620.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 357-631.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1497, AND MASS SPECTROMETRY.

************

ERRATUM, AND SEQUENCE REVISION TO 588-746.

************

NUCLEOTIDE SEQUENCE OF 233-327.

************

DISRUPTION PHENOTYPE, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 20-38, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 20-32 AND 125-139.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 33-37, SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLU-215.

************

SEQUENCE REVISION TO 172 AND C-TERMINUS.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 31-323, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF HIS-43; ASP-44; TRP-104; PHE-124; ASP-163; PHE-181; TRP-182 AND GLU-215.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 34-68.

************

UBIQUITINATION BY RMA2.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT ASP-645.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS PHE-332 AND ASP-645.

************

PROTEIN SEQUENCE OF 20-39, AND CHARACTERIZATION.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 22-751 ALONE AND IN COMPLEX WITH IHIBITORS, GLYCOSYLATION AT ASN-110; ASN-538 AND ASN-745, COFACTOR, ACTIVE SITE, CALCIUM-BINDING SITES, COPPER-BINDING SITES, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE, AND VARIANT GLY-13.

************

PRELIMINARY DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH AUXIN AND ZINC ION, GLYCOSYLATION, MUTAGENESIS OF 199-ASP-GLU-200, AND DISULFIDE BOND.

************

PROTEIN SEQUENCE, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 1-20.

************

PROTEIN SEQUENCE OF 21-39, AND TOPAQUINONE AT TYR-28.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 40-141.

************

GLYCAN STRUCTURE, AND MASS SPECTROMETRY.

************

INTERACTION WITH ABP1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-460, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-13 AND 97-112, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.

************

INTERACTION WITH SRV2.

************

INTERACTION WITH RVS167.

************

FUNCTION, INTERACTION WITH ACTIN AND ARP2/3 COMPLEX, AND MUTAGENESIS OF 201-ASP--TRP-203 AND 437-ASP--TRP-439.

************

INTERACTION WITH SLA1, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-165; SER-169; THR-181 AND SER-183, AND MASS SPECTROMETRY.

************

INTERACTION WITH APP1; PRK1; SCP1 AND YIR003W.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-165 AND SER-169, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-181; SER-183; SER-365 AND SER-481, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-165; SER-169; THR-181; SER-183 AND SER-389, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-157; THR-165; SER-167; SER-169; THR-181; SER-183; SER-365; SER-458; SER-478 AND SER-481, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-157; THR-165; SER-169; THR-181; SER-183; SER-223; TYR-225; SER-282; SER-291; THR-293; SER-313; SER-365; SER-389; SER-458; SER-475; SER-478; SER-481 AND SER-515, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF SH3 DOMAIN, MUTAGENESIS OF TRP-569, AND INTERACTION WITH ARK1 AND PRK1.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF ADF DOMAIN, MUTAGENESIS OF LYS-21; ARG-24; LYS-80; LYS-94; ARG-96; ASP-122; ASP-125 AND LYS-134, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 154-171; 302-308; 312-328; 377-384 AND 419-431, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-331; GLY-332 AND ARG-333.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-297; SER-298 AND SER-302, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, FUNCTION, SUBUNIT, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

ACTIN-BINDING, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 364-372; 537-548; 850-862; 1040-1052 AND 1356-1371, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-16.

************

STRUCTURE BY NMR OF 1-81.

************

PROTEIN SEQUENCE OF 1-251.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-251.

************

PROTEIN SEQUENCE OF 262-528.

************

MUTAGENESIS OF ASN-200.

************

X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH ACTIN, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

INTERACTION WITH ABLIM1; ABLIM2 AND ABLIM3.

************

PROTEIN SEQUENCE OF 260-527.

************

CHARACTERIZATION, AND MUTAGENESIS OF CYS-56.

************

ABRB-REGULATED GENES.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, TISSUE SPECIFICITY, MUTAGENESIS OF ARG-585, AND DISRUPTION PHENOTYPE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-474; SER-837; SER-846; SER-868; SER-889 AND SER-896, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 436-597.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-407 (ISOFORM 1).

************

INTERACTION WITH IGHMBP2.

************

INTERACTION WITH ESF1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 440-839.

************

SUBCELLULAR LOCATION, INTERACTION WITH ARABIDOPSIS THALIANA RCH2; ASK7/ASK-ETA AND ASK6/ASK-ZETA, MUTAGENESIS OF GLY-2; PRO-44; ALA-45; SER-49 AND PRO-50, MYRISTOYLATION, AND PHOSPHORYLATION BY ARABIDOPSIS THALIANA ASK7/ASK-ETA.

************

SUBCELLULAR LOCATION, INTERACTION WITH ARABIDOPSIS THALIANA ASK7/ASK-ETA, MUTAGENESIS OF ARG-44; LEU-45; ARG-49 AND ARG-50, AND PHOSPHORYLATION BY ARABIDOPSIS THALIANA ASK7/ASK-ETA.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20, AND MASS SPECTROMETRY.

************

PRELIMINARY NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND PARTIAL PROTEIN SEQUENCE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND CALMODULIN-BINDING DOMAIN.

************

PHOSPHORYLATION AT SER-45 BY CPK1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-557 AND THR-559, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-396; SER-399; SER-557 AND THR-559, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394; SER-396; SER-557 AND THR-559, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90; SER-171; SER-266; SER-396; SER-404; SER-407; SER-557 AND THR-559, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND CALMODULIN-BINDING DOMAIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-22; SER-27; SER-29 AND THR-31, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-22; SER-27 AND SER-29, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [MRNA] OF 1-366 (ISOFORMS 2 AND 3), AND NUCLEOTIDE SEQUENCE [MRNA] OF 1-120 (ISOFORM 4).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-2271.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-113 (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [MRNA] OF 1-93 (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-47 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 1-18; 39-45; 77-86; 99-111; 121-132; 153-170; 218-224; 267-276; 278-288; 323-335; 568-579; 589-615; 646-657; 748-755; 818-838; 985-992; 997-1008; 1083-1096; 1147-1169; 1192-1199; 1233-1247; 1283-1294; 1317-1325; 1327-1334; 1372-1385; 1401-1420; 1508-1514; 1553-1564; 1668-1687; 1714-1731; 1750-1759; 1782-1798; 1824-1833; 1838-1856; 1905-1916; 1922-1929; 1978-2009; 2063-2072; 2104-2111; 2115-2127; 2139-2161; 2200-2209; 2213-2218; 2221-2229 AND 2261-2293, ACETYLATION AT MET-1, PHOSPHORYLATION AT SER-80, AND MASS SPECTROMETRY.

************

INTERACTION WITH BRCA1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-29, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25; SER-29; SER-48; SER-50; SER-53; SER-56; THR-58 AND SER-60, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION AT SER-1263, AND MUTAGENESIS OF SER-78; SER-344; SER-432; SER-1201; SER-1263; SER-1585; SER-1952 AND SER-2211.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1042; SER-2099 AND TYR-2108, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1844, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN ACACAD.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50 AND SER-488, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-25; SER-29 AND SER-48, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25; SER-29 AND SER-80, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-23; SER-29 AND SER-80, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25 AND SER-29, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1334 AND LYS-1580, AND MASS SPECTROMETRY.

************

FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, ENZYME REGULATION, AND INTERACTION WITH MID1IP1.

************

VARIANT [LARGE SCALE ANALYSIS] GLN-1687.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-119 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-38; 1221-1348 AND 1681-1891.

************

PROTEIN SEQUENCE OF 298-306 AND 2267-2275, INTERACTION WITH BRCA1, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-79, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-29 AND SER-79, AND MASS SPECTROMETRY.

************

FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, ENZYME REGULATION, INTERACTION WITH MID1IP1, PHOSPHORYLATION AT SER-79, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-33.

************

PROTEIN SEQUENCE OF 76-85 AND 1198-1201, AND PHOSPHORYLATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1167-1200 (ISOFORMS 1 AND 2), AND PHOSPHORYLATION AT SER-1200.

************

PARTIAL PROTEIN SEQUENCE, AND MASS SPECTROMETRY.

************

BIOTIN-BINDING SITE.

************

PHOSPHORYLATION AT SER-79; SER-1200 AND SER-1215.

************

PHOSPHORYLATION BY AMPK.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-144 (ISOFORM 2), TISSUE SPECIFICITY, AND INDUCTION BY LACTATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-93 (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND VARIANT ILE-2141.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT ILE-2141.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1324-2109.

************

CATALYTIC ACTIVITY, SUBUNIT, ENZYME REGULATION, AND INTERACTION WITH MID1IP1.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 217-775.

************

VARIANT [LARGE SCALE ANALYSIS] LEU-193.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 493-820.

************

PROTEIN SEQUENCE OF 1-18; 99-111; 121-132; 153-163; 278-288; 300-311; 336-350; 589-607; 742-755; 826-845; 1083-1096; 1147-1155; 1157-1169; 1233-1239; 1275-1286; 1319-1326; 1349-1362; 1365-1377; 1387-1397; 1653-1678; 1701-1708; 1727-1737; 1759-1775; 1801-1810; 1815-1833; 1882-1891; 1899-1906; 1955-1986; 2040-2049; 2067-2080; 2092-2104; 2177-2186; 2190-2195; 2199-2206 AND 2209-2226, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 14-161; 636-871; 998-1098 AND 1380-1547.

************

INTERACTION WITH SAD1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1179 AND SER-1181, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2015-2022.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1157, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1148, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; THR-233; SER-430; THR-1114; THR-1145; SER-1148; SER-1157; SER-1159; SER-1162; TYR-1163 AND SER-1169, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1429-2233 IN COMPLEX WITH COA, MUTAGENESIS OF LEU-1705; ARG-1731; TYR-1738 AND ARG-1954, AND HOMODIMERIZATION.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 13-566 IN COMPLEX WITH SORAPHEN, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1482-2218 IN COMPLEXES WITH THE INHIBITORS HALOXYFOP OR DICLOFOP, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROBABLE FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.

************

IDENTIFICATION IN ARC COMPLEX, AND PROTEIN SEQUENCE OF 50-61; 70-80 AND 345-355.

************

X-RAY CRYSTALLOGRAPHY (1.77 ANGSTROMS) OF 24-415 IN COMPLEX WITH FAD AND PRODUCT, AND SUBUNIT.

************

VARIANT IBDD GLN-302, AND FUNCTION.

************

VARIANTS IBDD ILE-128 AND ILE-203.

************

VARIANTS IBDD TYR-134; ARG-137; THR-152; GLN-302; THR-320; CYS-334 AND ARG-385, AND CHARACTERIZATION OF VARIANTS IBDD ARG-137; GLN-302 AND THR-320.

************

INVOLVEMENT IN ACAD9 DEFICIENCY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-41 AND LYS-608, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-333.

************

VARIANTS THR-303 AND GLN-333.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-201.

************

PROTEIN SEQUENCE OF 52-61 AND 255-267, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 218-235, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-342, AND VARIANT ACADMD GLU-329.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-212; LYS-279 AND LYS-301, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH FAD AND OCTANOYL-COENZYME A, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-421 IN COMPLEXES WITH FAD AND THE ETFA-ETFB HETERODIMER, MUTAGENESIS OF LEU-86; LEU-98; LEU-100; ILE-108; GLU-237 AND GLU-384, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEXES WITH FAD AND THE ETFA-ETFB HETERODIMER, MUTAGENESIS OF TRP-191; GLU-237 AND GLU-384, AND SUBUNIT.

************

REVIEW ON VARIANTS ACADMD.

************

VARIANT ACADMD GLU-329.

************

VARIANTS ACADMD ILE-149; ARG-244; ARG-267 AND THR-375.

************

VARIANT ACADMD GLU-329 FREQUENCY.

************

VARIANTS ACADMD THR-326 AND ARG-336.

************

VARIANT ACADMD 115-GLY-CYS-116 DEL.

************

VARIANT ACADMD ARG-195.

************

VARIANTS ACADMD TYR-116; ALA-193 AND CYS-352.

************

CHARACTERIZATION OF VARIANT ACADMD ALA-193.

************

VARIANTS ACADMD LEU-206 AND GLU-329.

************

VARIANTS ACADMD HIS-67; THR-78; ILE-121 AND ARG-310.

************

VARIANT ACADMD LEU-245.

************

VARIANTS ACADMD THR-281 AND GLU-329.

************

VARIANT [LARGE SCALE ANALYSIS] ARG-132.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 134-193.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEXES WITH FAD AND SUBSTRATE.

************

PROTEIN SEQUENCE OF 11-81.

************

PROTEIN SEQUENCE OF 25-34.

************

VARIANTS ACADSD.

************

VARIANTS ACADSD CYS-92; ARG-177 AND CYS-383, AND VARIANTS TRP-171 AND SER-209.

************

VARIANTS ACADSD SER-90; GLU-104 DEL; VAL-192; TRP-325; LEU-353 AND TRP-380, AND VARIANTS TRP-171 AND SER-209.

************

X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 25-412 IN COMPLEX WITH ACETOACETYL-COA AND FAD, AND HOMOTETRAMERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-239 AND LYS-331, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 69-655 IN COMPLEX WITH MYRISTOYL-COA, FUNCTION, SUBUNIT, COFACTOR, AND ACTIVE SITE.

************

VARIANTS ACADVLD GLU-130 DEL; LYS-299 DEL; GLN-382 AND TRP-613.

************

VARIANT ACADVLD HIS-450.

************

VARIANTS ACADVLD.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 84-656.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 339-656.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-240 AND LYS-277, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-332, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 355-367, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

PROTEIN SEQUENCE OF 173-243, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

FUNCTION, ENZYME REGULATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF ARG-448.

************

FUNCTION, PHOSPHORYLATION AT SER-554, AND MUTAGENESIS OF SER-554 AND SER-724.

************

INTERACTION WITH PHOSPHOLIPIDS, AND MUTAGENESIS OF LYS-274.

************

FUNCTION, INTERACTION WITH GULP AND ARF6, AND MUTAGENESIS OF ARG-448.

************

FUNCTION, AND INTERACTION WITH CLTC.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-485, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-274, AND MASS SPECTROMETRY.

************

VARIANTS [LARGE SCALE ANALYSIS] ARG-114 AND GLN-129.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 583-740.

************

FUNCTION, INTERACTION WITH CLTC AND SLC2A4, AND MUTAGENESIS OF ARG-448.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF ARG-442.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-742 AND TYR-750, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-775, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-521, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-379 AND SER-384, AND MASS SPECTROMETRY.

************

IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] ALA-400.

************

VARIANT SPG42 ARG-113.

************

VARIANT CCHLND PRO-110, AND CHARACTERIZATION OF VARIANT CCHLND PRO-110.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 252-534.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-296, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-127 AND THR-131, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-196; SER-200; SER-215; SER-256; SER-388; THR-400; SER-418; SER-428 AND SER-437, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193; SER-194; SER-196 AND SER-200, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-196 AND SER-200, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-181, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-163; SER-184; SER-185; SER-187; SER-191 AND SER-418, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 202-212, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-69, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-633.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-633 AND VAL-673.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-633.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-135; TYR-138 AND TYR-139, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME ACTIVITY, TISSUE SPECIFICITY, AND MUTAGENESIS OF GLY-281 AND LYS-287.

************

ENZYME ACTIVITY, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-655, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND VARIANT ALA-143.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND VARIANT ALA-143.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-143.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ALA-143.

************

ENZYME ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF HIS-511.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

SUBCELLULAR LOCATION, AND SIGNAL-ANCHOR.

************

FUNCTION, AND MUTAGENESIS OF TYR-126; LYS-130; ARG-150; LYS-152 AND TYR-171.

************

FUNCTION, DISRUPTION PHENOTYPE, AND INDUCTION BY LEAD.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, MUTAGENESIS OF TYR-136; LYS-140; LYS-162 AND TYR-181, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH EBP.

************

FUNCTION, AND MUTAGENESIS OF ALA-142; GLY-145; PRO-152; TRP-163; TRP-166 AND ALA-177.

************

FUNCTION, AND INDUCTION BY LEAD.

************

INTERACTION WITH HIPP26.

************

PROTEIN SEQUENCE OF 2-87.

************

FUNCTION, MUTAGENESIS OF PHE-260; LYS-264; ARG-284; LYS-286 AND TYR-305, AND SUBCELLULAR LOCATION.

************

FUNCTION, MUTAGENESIS OF GLY-24; LEU-25; SER-28; LEU-45; TYR-48; GLN-52; LYS-74 AND PHE-93, AND TISSUE SPECIFICITY.

************

SUBCELLULAR LOCATION, INDUCTION BY ETHYLENE; JASMONATE AND BOTRYTIS CINEREA, TISSUE SPECIFICITY, AND INTERACTION WITH EBP.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501; SER-503; SER-515 AND SER-520, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501; SER-515 AND SER-520, AND MASS SPECTROMETRY.

************

FUNCTION, MUTAGENESIS OF GLY-25; LEU-26; SER-29; LEU-46; TYR-49; GLN-53; LYS-75 AND PHE-94, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12, AND MASS SPECTROMETRY.

************

FUNCTION, DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INDUCTION BY COLD.

************

PROTEIN SEQUENCE OF 2-87, AND ACETYLATION AT SER-2.

************

STRUCTURE BY NMR IN COMPLEX WITH COENZYME A AND PALMITIC ACID.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), AND FUNCTION.

************

STRUCTURE BY NMR IN COMPLEX WITH PALMITOYL-COENZYME A.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, DEVELOPMENTAL STAGE, SYNTHESIS OF 18-52; 18-31 AND 32-52, AND DISRUPTION PHENOTYPE.

************

FUNCTION OF SDF-2.

************

FUNCTION OF SDF-2, AND INTERACTION WITH DHKA.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 4 AND 5), ALTERNATIVE SPLICING, AND ALTERNATIVE PROMOTER USAGE.

************

PROTEIN SEQUENCE OF 2-87 (ISOFORM 1), AND ACETYLATION AT SER-2.

************

PROTEIN SEQUENCE OF 2-14 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 26-30 AND 72-87.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-29, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-8; LYS-19; LYS-55 AND LYS-77, AND MASS SPECTROMETRY.

************

MALONYLATION AT LYS-55.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH ACYL-COENZYME A.

************

PROTEIN SEQUENCE OF 34-51, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-55, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-40 AND 59-88.

************

PROTEIN SEQUENCE OF 33-87.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-42.

************

PROTEIN SEQUENCE OF 18-51.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1246-2254.

************

FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF GLU-1588 AND GLY-1787.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1031 AND SER-1192, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], SUBUNIT, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-741, AND MASS SPECTROMETRY.

************

ENZYME REGULATION, ANTIBIOTIC RESISTANCE, AND MUTAGENESIS OF GLY-199.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND SEQUENCE REVISION TO 24.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 164-319.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20.

************

PROTEIN SEQUENCE OF 2-13.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], VARIANTS SER-313; LEU-452 AND GLU-631, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 51-875, PROTEIN SEQUENCE OF 51-62, AND ENZYME REGULATION.

************

ENZYME REGULATION, DISULFIDE BOND, AND MUTAGENESIS OF CYS-297 AND CYS-317.

************

SUBCELLULAR LOCATION, SUBUNIT, AND DEVELOPMENTAL STAGE.

************

CHARACTERIZATION OF ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36.

************

Genoscope;

************

The Vibrio harveyi Genome Sequencing Project;

************

SEQUENCE REVISION TO 107 AND 193.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 309-449.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-160.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH ATP.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS), SUBUNIT, AND MUTAGENESIS OF ARG-19; GLU-23; PHE-363 AND ARG-366.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND RNA EDITING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND RNA EDITING.

************

NUCLEOTIDE SEQUENCE [MRNA], AND RNA EDITING.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-91.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND SUBUNIT.

************

RNA EDITING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ABSENCE OF RNA EDITING.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-31.

************

SIMILARITY TO ZFPA.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, RNA-BINDING, SUGGESTED MECHANISM OF TRANSLATIONAL REGULATION, AND MUTAGENESIS OF CYS-27; CYS-30; CYS-46 AND CYS-49.

************

X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS), AND ZINC-FINGER.

************

SEQUENCE REVISION TO N-TERMINUS AND 80-94.

************

LACK OF ACTIVITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 220-590.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 12-590.

************

PROTEIN SEQUENCE OF 1-17, RNA EDITING, AND ENZYME REGULATION BY REDOX CONTROL.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND RNA EDITING.

************

ENZYME REGULATION BY REDOX CONTROL, DISULFIDE BOND, AND MUTAGENESIS OF CYS-230; CYS-233; CYS-249; CYS-252; CYS-442 AND CYS-466.

************

LEVEL OF PROTEIN EXPRESSION, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TRANSCRIPT ANALYSIS, AND TISSUE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS), AND ZINC-BINDING.

************

DETECTION IN CHLOROPLASTS, AND OVEREXPRESSION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 35-398, AND TISSUE SPECIFICITY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-16, AND MASS SPECTROMETRY.

************

INDUCTION BY LOW LIGHT.

************

INDUCTION BY ETHYLENE.

************

INDUCTION BY POTASSIUM DEPRIVATION.

************

FUNCTION, AND INDUCTION BY VERY-LONG-CHAIN FATTY ACIDS.

************

INDUCTION BY IRON DEFICIENCY.

************

INDUCTION BY NITRIC OXIDE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND DISRUPTION PHENOTYPE.

************

CHARACTERIZATION, AND PROTEIN SEQUENCE OF 115-134.

************

CHARACTERIZATION, AND PARTIAL PROTEIN SEQUENCE.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS), AND COFACTOR.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 21-315.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INDUCTION BY ETHYLENE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 230-320.

************

INDUCTION BY OZONE.

************

FUNCTION, INDUCTION BY VERY-LONG-CHAIN FATTY ACIDS, AND TISSUE SPECIFICITY.

************

GENE FAMILY, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

HOMODIMERIZATION.

************

GENE FAMILY, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-157.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 35-780 (ISOFORM 1), AND VARIANT HIS-157.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-563 (ISOFORM 3), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 343-780 (ISOFORM 1), AND VARIANT HIS-157.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-324, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-166, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-323, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-12.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-21.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-107, AND PROTEIN SEQUENCE OF 2-20.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-12 AND 560-564.

************

ELECTRON MICROSCOPY OF ALPHA-EPSILON COMPLEX.

************

GENE NAME, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-26.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CHARACTERIZATION, AND MUTAGENESIS OF CYS-278; CYS-280 AND HIS-394.

************

CRYSTALLIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], DEVELOPMENTAL STAGE, AND INDUCTION.

************

SEQUENCE REVISION TO 329.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-26.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.

************

CHARACTERIZATION OF PARTIAL REACTIONS IN THE ACDS COMPLEX.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-16.

************

PROTEIN SEQUENCE OF 2-30.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND BLOCKAGE OF N-TERMINUS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-19.

************

CHARACTERIZATION OF PARTIAL REACTIONS IN THE ACDS COMPLEX, AND CATALYTIC ACTIVITY.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND COMPLEX WITH BPHI.

************

MUTAGENESIS OF ILE-195, AND ALDEHYDE CHANNELING MECHANISM.

************

CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, ACTIVE SITE, REACTION MECHANISM, AND MUTAGENESIS OF CYS-131; ASN-170; ILE-171; ILE-195 AND ASP-208.

************

INTERACTION WITH MHPF, AND FUNCTION.

************

PROTEIN SEQUENCE OF 1-6, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, ENZYME REGULATION, SUBUNIT, INTERACTION WITH DMPG, AND PH DEPENDENCE.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH DMPG AND NAD, SUBUNIT, AND REACTION MECHANISM.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE SPECIFICITY, SUBUNIT, COMPLEX WITH TTHB246, AND ALDEHYDE CHANNELING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 6-432, AND VARIANTS LYS-13 AND VAL-316.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-284, AND MASS SPECTROMETRY.

************

VARIANT SBCADD PHE-255.

************

PROTEIN SEQUENCE OF 348-355, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 51-59.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-50.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, PATHWAY, COFACTOR, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) IN COMPLEX WITH FAD AND SUBSTRATE, AND MUTAGENESIS OF ALA-80; VAL-88 AND VAL-366.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MOTIF, SUBCELLULAR LOCATION, INTERACTION WITH POT1 AND TINF2, FUNCTION, AND VARIANT ALA-518.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 65-544, AND ALTERNATIVE SPLICING (ISOFORM 1).

************

MASS SPECTROMETRY, AND INTERACTION WITH POT1 AND TINF2.

************

IDENTIFICATION IN THE SHELTERIN COMPLEX.

************

FUNCTION OF THE SHELTERIN COMPLEX.

************

FUNCTION IN SHELTERIN COMPLEX ASSEMBLY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-422 AND SER-425, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-422; SER-424; SER-425 AND SER-435, AND MASS SPECTROMETRY.

************

INTERACTION WITH OBFC1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-111, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 90-250, FUNCTION, SUBUNIT, AND IDENTIFICATION IN A COMPLEX WITH POT1 AND SINGLE-STRANDED TELOMERIC DNA.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, FUNCTION, AND INVOLVEMENT IN ACD.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-74 AND ASN-486, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, FUNCTION, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, GLYCOSYLATION, FUNCTION, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-638.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-805 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 679-689, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH ITGB1.

************

BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND COFACTOR.

************

FUNCTION, INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN, GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-90, AND MASS SPECTROMETRY.

************

INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN, AND MUTAGENESIS.

************

PROTEOLYTIC CLEAVAGE.

************

INTERACTION WITH HCOV-NL63 SPIKE GLYCOPROTEIN.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-546, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 19-615, X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 19-615 IN COMPLEX WITH MLN-4760, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-53; ASN-90; ASN-103; ASN-322; ASN-432 AND ASN-546.

************

INTERACTION WITH SARS-COV S PROTEIN.

************

TISSUE SPECIFICITY, INDUCTION, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH SARS-COV S PROTEIN.

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 19-613, ZINC-BINDING SITES, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [MRNA], AND LACK OF INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN.

************

ENZYME REGULATION, GLYCOSYLATION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

IDENTIFICATION, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-701, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-80 AND SER-122, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-80, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428 AND THR-501, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-709, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; SER-253; SER-564 AND SER-709, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE OF 1-455.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 50-152.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-11, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 293-434.

************

MUTAGENESIS OF CYS-195.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-20, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, PATHWAY, AND SUBUNIT.

************

PROTEASOME SUBSTRATE, PUPYLATION AT LYS-334, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 110-138; 144-156; 245-260; 318-325; 393-404; 414-426 AND 468-480.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 365-434.

************

CHARACTERIZATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PHOSPHORYLATION, AND INDUCTION.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

MUTAGENESIS OF THR-53.

************

MUTAGENESIS OF LYS-216 AND MET-220.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-55.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 552-578.

************

REVIEW, AND MUTAGENESIS OF LYS-336.

************

MUTAGENESIS OF ASP-371; ASN-377; ASP-403 AND GLU-439.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TOPOLOGY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-215.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.

************

BIOPHYSICOCHEMICAL PROPERTIES, GLYCOSYLATION, SUBCELLULAR LOCATION, AND ENZYME REGULATION.

************

PARTIAL GENE STRUCTURE.

************

PROTEIN SEQUENCE OF 31-613 (ISOFORM H).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM S).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 512-606 (ISOFORMS S AND T), SUBUNIT, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 206-220; 253-272; 321-340; 347-372 AND 503-511.

************

PROTEOLYTIC PROCESSING, GPI-ANCHOR, AND PROTEIN SEQUENCE OF 40-43.

************

GPI-ANCHOR.

************

GLYCOSYLATION AT ASN-126; ASN-174; ASN-331 AND ASN-531, ABSENCE OF GLYCOSYLATION AT ASN-569, INTERCHAIN AT CYS-615, AND MUTAGENESIS OF ASN-126; ASN-174; CYS-328; ASN-331; ASN-531; ASN-569 AND CYS-615.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 41-623 IN COMPLEX WITH INHIBITOR.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS H AND T).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM T).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS H; R AND T).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM T).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 521-614.

************

PROTEIN SEQUENCE OF 256-273; 306-326; 396-422; 465-480 AND 528-551, FUNCTION, AND TISSUE SPECIFICITY.

************

FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-611.

************

FUNCTION, AND MUTAGENESIS OF ASP-206; SER-234; GLU-365; ASP-435 AND HIS-478.

************

3D-STRUCTURE MODELING OF 35-574.

************

X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 32-614 IN COMPLEX WITH FASCICULIN-2, AND GLYCOSYLATION AT ASN-381 AND ASN-495.

************

X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 575-614 IN COMPLEX WITH COLQ.

************

VARIANT BLOOD GROUP YT(B) ASN-353.

************

INTERACTION WITH PRIMA1.

************

X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF COMPLEX WITH FASCICULIN.

************

X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 34-573 IN COMPLEX WITH INHIBITOR.

************

PROTEIN SEQUENCE OF 1-44 AND 53-181.

************

PROTEIN SEQUENCE OF 45-52.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS H AND R).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-586.

************

PROTEIN SEQUENCE OF 22-45 AND 214-237.

************

PROTEIN SEQUENCE OF 100-108.

************

PROTEIN SEQUENCE OF 552-558.

************

STRUCTURE OF THE GPI-ANCHOR.

************

GPI-ANCHOR AT SER-564.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 22-558, ACTIVE SITE, GLYCOSYLATION AT ASN-437, DISULFIDE BONDS, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 22-556 IN COMPLEX WITH SUBSTRATE ANALOGS.

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 22-558 IN COMPLEX WITH FASCICULIN.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 22-558 IN COMPLEX WITH THE INHIBITOR HUPERZINE A.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 22-558.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 22-558.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 22-564 IN COMPLEX WITH GALANTHAMINE.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 22-564 IN COMPLEX WITH THE SYNTHETIC INHIBITOR ARICEPT, AND GLYCOSYLATION AT ASN-80; ASN-437; ASN-478 AND ASN-554.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 22-564 IN COMPLEX WITH THE SYNTHETIC INHIBITOR HUPRINE.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-556 IN COMPLEX WITH THE SYNTHETIC INHIBITOR RIVASTIGMINE.

************

X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 22-564 IN COMPLEX WITH THE SYNTHETIC INHIBITOR CPT-11.

************

X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 22-558 IN COMPLEXES WITH SUBSTRATE AND SUBSTRATE ANALOGS, GLYCOSYLATION AT ASN-80 AND ASN-437, ACTIVE SITE, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 22-558 IN COMPLEX WITH SOMAN, ACTIVE SITE, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 23-556 IN COMPLEX WITH GALANTHAMINE DERIVATIVES.

************

PROTEIN SEQUENCE OF 25-47.

************

SUBUNITS INTERACTION.

************

SUBUNITS INTERACTION, AND SEQUENCE REVISION TO 421.

************

PROTEIN SEQUENCE OF 2-11, FUNCTION, AND MUTAGENESIS OF ARG-72; LYS-83; SER-118 AND TRP-122.

************

PROTEIN SEQUENCE OF 29-50.

************

NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.

************

CLEAVAGE SITE, GLYCOSYLATION, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

TISSUE SPECIFICITY, FUNCTION, AND DISRUPTION PHENOTYPE.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 14-615, X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 14-615 IN COMPLEX WITH CAPTOPRIL, AND X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 14-615 IN COMPLEX WITH LISINOPRIL.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC-1).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-261; TRP-561 AND SER-1286.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1239 (ISOFORM SOMATIC-1).

************

PROTEIN SEQUENCE OF 30-46.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1114-1306 (ISOFORM SOMATIC-2), AND ALTERNATIVE SPLICING.

************

ZINC-BINDING.

************

GLYCOSYLATION AT ASN-38; ASN-54; ASN-111; ASN-146; ASN-509; ASN-695; ASN-714; ASN-760; ASN-942 AND ASN-1191, AND MASS SPECTROMETRY.

************

CLEAVAGE SITE, AND MASS SPECTROMETRY.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANT LEU-1228.

************

PHOSPHORYLATION AT SER-1299, AND MUTAGENESIS OF SER-1299.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND CLEAVAGE SITE.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-509; ASN-695 AND ASN-714, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-716, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-111; ASN-445 AND ASN-714, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 642-1230, AND X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 642-1230 IN COMPLEX WITH LISINOPRIL.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 642-1230 IN COMPLEX WITH ENALAPRILAT, AND X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 642-1230 IN COMPLEX WITH CAPTOPRIL.

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 30-641 IN COMPLEX WITH LISINOPRIL; ZINC AND CHLORIDE IONS, AND GLYCOSYLATION AT ASN-54; ASN-74; ASN-146; ASN-318 AND ASN-509.

************

INVOLVEMENT IN DIABETIC NEPHROPATHY SUSCEPTIBILITY.

************

VARIANTS THR-1018; VAL-1051; GLN-1279; SER-1286 AND PRO-1296.

************

VARIANT LEU-1228, AND ASSOCIATION WITH BENIGN SERUM INCREASE OF ANGIOTENSIN-CONVERTING ENZYME.

************

INVOLVEMENT IN SUSCEPTIBILITY TO ISCHSTR.

************

INVOLVEMENT IN SUSCEPTIBILITY TO ICH.

************

INVOLVEMENT IN RTD, AND VARIANT ARG-354.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC), AND PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA].

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-332 (ISOFORM SOMATIC), AND PARTIAL PROTEIN SEQUENCE.

************

PROTEIN SEQUENCE OF 35-54.

************

FUNCTION, ENZYME REGULATION, AND MUTAGENESIS OF HIS-993; GLU-994 AND HIS-997.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-151, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1305, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-88, AND ALTERNATIVE SPLICING.

************

PROTEIN SEQUENCE OF 34-44 AND 755-758.

************

PROTEIN SEQUENCE OF 34-55.

************

PROTEIN SEQUENCE OF 34-55, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE OF 646-746.

************

PROTEIN SEQUENCE OF 727-733 AND 809-815.

************

PROTEIN SEQUENCE OF 1237-1259, AND CLEAVAGE SITE.

************

MUTAGENESIS OF LYS-727 AND TYR-809, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC), AND VARIANT LYS-207.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 12-1313 (ISOFORM SOMATIC), AND VARIANT LYS-207.

************

NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, ENZYME REGULATION, AND TISSUE SPECIFICITY.

************

FUNCTION PREDICTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71; SER-74; SER-78; SER-165 AND SER-288, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44 AND THR-49, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44; THR-49; SER-61; SER-62; SER-71; SER-74; SER-78 AND SER-165, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-49; SER-61; SER-62; SER-71; SER-74; SER-78; SER-165 AND SER-288, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1320-1519.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1321-1520.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-383, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-52.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-53.

************

SUBCELLULAR LOCATION, FUNCTION, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-75.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 73-224.

************

IDENTIFICATION, AND NOMENCLATURE.

************

INDUCTION BY HYPOXIA.

************

DISCUSSION OF SEQUENCE.

************

INDUCTION BY NITRIC OXIDE (NO), BY HYPOXIA, IN MOUSE MODEL, AND DORMANCY REGULON.

************

INDUCTION BY CARBON MONOXIDE (CO).

************

INDUCTION BY CARBON MONOXIDE (CO), AND DORMANCY REGULON.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH CHRNA9, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH CHRNA9, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, AND INTERACTION WITH CHRNA9.

************

PROTEIN SEQUENCE, D-AMINO ACID AT PHE-2, CHARACTERIZATION, AND SYNTHESIS.

************

PROTEIN SEQUENCE OF 17-34.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B), AND FUNCTION.

************

PROTEIN SEQUENCE OF 82-91 AND 350-359, SUBCELLULAR LOCATION, AND ANTIGENICITY.

************

PROTEIN SEQUENCE, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 174-521.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND BLOCKED N-TERMINUS.

************

PROTEIN SEQUENCE OF 174-181, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND MUTAGENESIS OF ILE-314.

************

INTERACTION WITH DES-2, AND FUNCTION.

************

INTERACTION WITH DES-2 AND RIC-3.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-37, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH DEG-3, AND FUNCTION.

************

INTERACTION WITH DEG-3 AND RIC-3.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-519 (ISOFORM A).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-65.

************

RNA EDITING OF POSITION 278.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND FUNCTION.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-136, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-109, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-125.

************

VARIANT ENFL4 ASN-279, AND CHARACTERIZATION OF VARIANT ENFL4 ASN-279.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 81-496.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT LEU-23 DEL.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-23 DEL.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT LEU-23 DEL.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 7-495 (ISOFORMS 1/2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 32-505 (ISOFORMS 1/2).

************

INVOLVEMENT IN SQTL3 AND LUNG CANCER.

************

MUTAGENESIS OF GLU-289, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-627.

************

VARIANT ENFL1 PHE-280.

************

VARIANT ENFL1 LEU-280.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-529.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-27.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 118-357.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-4-1), AND NUCLEOTIDE SEQUENCE [MRNA] OF 5-630 (ISOFORM ALPHA-4-2).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-4-2).

************

PROTEIN SEQUENCE OF 31-47.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-398.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-398.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-102, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-18.

************

PROTEIN SEQUENCE OF 24-47.

************

MUTAGENESIS OF LEU-270.

************

MUTAGENESIS TO CONVERT ION SELECTIVITY FROM CATIONIC TO ANIONIC.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 17-502 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 24-502 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 118-129.

************

SEQUENCE REVISION TO 363.

************

INTERACTION WITH RIC3, AND MUTAGENESIS OF LEU-433; LYS-435; VAL-440; ASN-445; ARG-446; PHE-447 AND ARG-448.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH CHRNA10, TISSUE SPECIFICITY, AND VARIANT SER-442.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-442.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 7-476, FUNCTION, AND TISSUE SPECIFICITY.

************

INTERACTION WITH CHRNA10, AND TISSUE SPECIFICITY.

************

FUNCTION, AND INTERACTION WITH CHRNA10.

************

NUCLEOTIDE SEQUENCE OF 1-12.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 180-227 AND 260-333.

************

PROTEIN SEQUENCE OF 21-44.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 2).

************

PROTEIN SEQUENCE OF 21-482 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 78-113.

************

VARIANT SCCMS SER-198.

************

VARIANT SCCMS LYS-262.

************

VARIANTS SCCMS SER-198; MET-201; ILE-299 AND ILE-314.

************

VARIANT SCCMS PHE-294, AND CHARACTERIZATION OF VARIANT SCCMS PHE-294.

************

VARIANTS FCCMS VAL-278 AND ILE-330, AND CHARACTERIZATION OF VARIANTS FCCMS VAL-278 AND ILE-330.

************

VARIANT FCCMS LEU-177, AND CHARACTERIZATION OF VARIANT FCCMS LEU-177.

************

VARIANT FCCMS LEU-301, AND CHARACTERIZATION OF VARIANT FCCMS LEU-301.

************

VARIANT SCCMS TRP-463, AND CHARACTERIZATION OF VARIANT SCCMS TRP-463.

************

VARIANT MUPSL LEU-254.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 13-457.

************

X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 21-231 IN COMPLEX WITH ALPHA-BUNGAROTOXIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-161.

************

PROTEIN SEQUENCE OF 25-127; 336-421 AND 429-450, AND GLYCOSYLATION AT ASN-165.

************

PROTEIN SEQUENCE OF 29-41; 82-88; 132-149; 338-354 AND 363-411.

************

PROTEIN SEQUENCE OF 104-131.

************

PROTEIN SEQUENCE OF 234-266; 287-319 AND 423-453.

************

PROTEIN SEQUENCE OF 126-145 AND 192-198, GLYCOSYLATION AT ASN-165, AND DISULFIDE BOND.

************

STRUCTURE BY NMR OF 209-220.

************

STRUCTURE BY NMR OF 91-100.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-335 AND 341-411.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-79.

************

STRUCTURE BY ELECTRON MICROSCOPY (4.0 ANGSTROMS) OF 235-461.

************

STRUCTURE BY NMR OF 206-228 IN COMPLEX WITH ALPHA-BUNGAROTOXIN.

************

MUTAGENESIS OF LYS-278, AND SUBUNIT.

************

STRUCTURE BY NMR OF 231-486.

************

VARIANT ENFL3 LEU-287.

************

VARIANT ENFL3 MET-287.

************

VARIANT HIS-397.

************

SEQUENCE REVISION TO 331.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 36-458.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-136; GLY-140 AND VAL-467.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 48-498.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 120-395, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM SHORT).

************

VARIANT SCCMS MET-285.

************

VARIANT SCCMS MET-289.

************

VARIANT CMS-ACHRD 449-GLU--GLU-451 DEL, AND CHARACTERIZATION OF VARIANT CMS-ACHRD 449-GLU--GLU-451 DEL.

************

PROTEIN SEQUENCE OF 25-78.

************

PROTEIN SEQUENCE OF 126-147, GLYCOSYLATION AT ASN-165, AND DISULFIDE BOND.

************

PHOSPHORYLATION AT TYR-379.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 30-41; 206-216 AND 285-294.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-14.

************

VARIANT SCCMS GLU-288.

************

VARIANT SCCMS PHE-289, AND CHARACTERIZATION OF VARIANT SCCMS PHE-289.

************

VARIANT FCCMS LYS-80, AND CHARACTERIZATION OF VARIANT FCCMS LYS-80.

************

VARIANT FCCMS GLN-271, AND CHARACTERIZATION OF VARIANT FCCMS GLN-271.

************

VARIANT [LARGE SCALE ANALYSIS] GLU-398.

************

VARIANT MUPSL LEU-95.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-70.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-17.

************

NUCLEOTIDE SEQUENCE OF 1-17.

************

STRUCTURE BY NMR OF 276-298.

************

PROTEIN SEQUENCE OF 125-134 AND 139-145, GLYCOSYLATION AT ASN-164, AND DISULFIDE BOND.

************

PHOSPHORYLATION AT TYR-393.

************

VARIANT SCCMS PHE-289.

************

VARIANT SCCMS PRO-284, AND CHARACTERIZATION OF VARIANT SCCMS PRO-284.

************

VARIANTS FCCMS ARG-13; LEU-141 AND LEU-163, AND CHARACTERIZATION OF VARIANTS FCCMS ARG-13; LEU-141 AND LEU-163.

************

VARIANTS CMS-ACHRD LEU-167; LEU-265 AND TRP-331, AND CHARACTERIZATION OF VARIANTS CMS-ACHRD LEU-167; LEU-265 AND TRP-331.

************

VARIANT FCCMS PRO-431, AND CHARACTERIZATION OF VARIANT FCCMS PRO-431.

************

VARIANTS SCCMS PRO-98 AND PHE-241.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 202-305.

************

ERRATUM, AND RETRACTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-12.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-285, AND MASS SPECTROMETRY.

************

VARIANT MUPSE CYS-239, AND VARIANT MUPSL CYS-239.

************

VARIANT MUPSE GLY-107, AND VARIANT MUPSL GLY-107.

************

NUCLEOTIDE SEQUENCE OF 1-57.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 115-170 (ISOFORMS LONG AND SHORT).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 203-306.

************

PROTEIN SEQUENCE OF 123-147, AND DISULFIDE BOND.

************

PHOSPHORYLATION AT TYR-381.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 20-30, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 20-229.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), PARTIAL PROTEIN SEQUENCE, FUNCTION, MUTAGENESIS OF ASP-1093, AND VARIANT PRO-447.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT PRO-447.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-447.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 56-1341 (ISOFORM 1), AND VARIANT PRO-447.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 798-813.

************

IDENTIFICATION IN A MRNA SPLICING-DEPENDENT EXON JUNCTION COMPLEX, HETERODIMERIZATION, IDENTIFICATION IN A HETEROTRIMERIC COMPLEX, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-240; SER-243; SER-365; SER-386; SER-388; THR-414; SER-657; SER-661; SER-676; THR-682 AND SER-1004, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386; SER-388 AND SER-710, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-240; SER-243; SER-328; SER-365; SER-384; SER-386; THR-393; THR-408; SER-410; SER-490; SER-655; SER-657; SER-710; SER-729; SER-1004; SER-1176; SER-1178 AND SER-1284, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-254; THR-682 AND SER-1004, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-710; SER-714; SER-729 AND SER-1004, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-208; SER-216; SER-228; SER-229; THR-254; SER-256; SER-384; SER-386; SER-388; SER-425; SER-561; SER-710; SER-729; SER-814; SER-815; THR-830; SER-838; THR-976; THR-978; SER-981; SER-983; SER-1176; SER-1178 AND SER-1180, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-5, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-254; SER-365; SER-657 AND SER-661, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-657, AND MASS SPECTROMETRY.

************

FUNCTION, PHOSPHORYLATION AT SER-1180 BY SRPK2, INTERACTION WITH SRPK2, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-424; SER-425; SER-434; SER-453; SER-895; SER-898 AND SER-1004, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-710, AND MASS SPECTROMETRY.

************

METHYLATION AT LYS-654, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-166; SER-169; SER-216; SER-240; SER-243; THR-254; THR-269; SER-295; SER-328; SER-365; SER-384; SER-386; SER-388; THR-393; SER-410; THR-414; SER-425; SER-434; SER-453; SER-490; TYR-512; SER-561; SER-655; SER-657; THR-682; SER-710; SER-714; THR-720; SER-838 AND SER-1004, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-254; THR-408; SER-410; THR-414; SER-655; SER-657; SER-664; SER-675; SER-676; THR-682; SER-825; SER-838; THR-840 AND SER-1004, AND MASS SPECTROMETRY.

************

INTERACTION WITH API5.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-240; SER-243; THR-254; THR-269; SER-328; SER-365; SER-400; THR-408; SER-410; THR-414; SER-478; SER-490; SER-838; SER-987; SER-990 AND SER-1004, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-717, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] GLN-1160.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-284 (ISOFORM 1), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1190 (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 57-806 (ISOFORM 4).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387 AND SER-391, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391 AND THR-840, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391; SER-477; SER-479 AND SER-491, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389; SER-391; SER-479 AND SER-1003, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-295; SER-389; SER-391; SER-729; SER-825; SER-1326; SER-1328 AND THR-1329, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-710 AND SER-1003, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-479; SER-491 AND SER-1003, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), CATALYTIC ACTIVITY, AND INTERACTION WITH CDC42.

************

FUNCTION, INTERACTION WITH SNX9 AND EGFR, IDENTIFICATION IN A COMPLEX WITH SNX9 AND CLATHRIN HEAVY CHAIN, AND MUTAGENESIS OF LYS-158.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-725.

************

INTERACTION WITH CSPG4.

************

FUNCTION AS MCF2 KINASE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-827; TYR-859 AND TYR-860, AND MASS SPECTROMETRY.

************

AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND MUTAGENESIS OF LYS-158 AND LEU-487.

************

INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION.

************

FUNCTION AS WAS KINASE, AND INTERACTION WITH WASL.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-859 AND TYR-860, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-518, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149 AND TYR-827, AND MASS SPECTROMETRY.

************

FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK.

************

FUNCTION, AND AUTOPHOSPHORYLATION AT TYR-284.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-518 AND TYR-859, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284; TYR-518; TYR-859 AND TYR-860, AND MASS SPECTROMETRY.

************

INTERACTION WITH AR.

************

INTERACTION WITH NPHP1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101; SER-785 AND SER-881, AND MASS SPECTROMETRY.

************

INTERACTION WITH NEDD4, AND UBIQUITINATION.

************

FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-860, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101; TYR-284; THR-517; TYR-518; SER-724; SER-728; SER-785; TYR-827 AND THR-925, AND MASS SPECTROMETRY.

************

SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN SAM-LIKE.

************

FUNCTION AS AR KINASE, AND ENZYME REGULATION.

************

FUNCTION, INTERACTION WITH AKT1, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT LYS-346, PHOSPHORYLATION AT TYR-284, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ENZYME REGULATION.

************

PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC.

************

SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518; TYR-827; TYR-859 AND TYR-872.

************

REVIEW ON TUMOR GROWTH.

************

STRUCTURE BY NMR OF 448-489.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION AT TYR-284.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH INHIBITOR, AND CATALYTIC ACTIVITY.

************

VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409; SER-507; LEU-725; GLN-748 AND HIS-1038.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-158; TRP-424 AND HIS-464.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 121-1055 (ISOFORM 3).

************

INTERACTION WITH CDC42, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, INTERACTION WITH EGFR, SUBCELLULAR LOCATION, DOMAIN EBD AND UBA, AND MUTAGENESIS OF TYR-650.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-533 AND TYR-874, AND MASS SPECTROMETRY.

************

INTERACTION WITH NEDD4 AND NEDD4L, UBIQUITINATION, INDUCTION, AND DOMAIN SAM-LIKE AND UBA.

************

FUNCTION, INTERACTION WITH AKT1, AND SUBCELLULAR LOCATION.

************

SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284 AND TYR-533.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-184, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-143, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-155, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 9-408.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 48-114.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 207-314.

************

PROTEIN SEQUENCE OF 1-12, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, PATHWAY, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 293-615.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-359, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), MUTAGENESIS OF GLU-123, FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.

************

TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

FUNCTION, AND INDUCTION BY THERMOSPERMINE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND IDENTIFICATION IN BAF COMPLEX.

************

PROTEIN SEQUENCE OF 2-24; 63-76; 113-130; 195-207 AND 380-389, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 35-60; 63-76; 113-130; 154-164; 195-207; 304-315 AND 380-389, IDENTIFICATION IN NUA4 COMPLEX, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN NUA4 COMPLEX, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN NUA4-LIKE COMPLEX.

************

IDENTIFICATION IN THE BAF53 COMPLEX WITH RUVBL1; SMARCA2 AND TRRAP.

************

IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE WINAC COMPLEX, AND FUNCTION.

************

REVIEW ON NUA4 COMPLEX.

************

FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN NUA4 COMPLEX, AND IDENTIFICATION IN A NUA4-RELATED SRCAP-CONTAINING COMPLEX.

************

IDENTIFICATION IN THE INO80 COMPLEX, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-233, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND ASSOCIATION WITH THE INO80 COMPLEX.

************

IDENTIFICATION IN THE BAF COMPLEX, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

IDENTIFICATION IN THE INO80 COMPLEX, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN THE INO80 COMPLEX.

************

FUNCTION, FUNCTION OF THE NBAF AND NPBAF COMPLEXES, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE NPBAF COMPLEX, INTERACTION WITH PHF10, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

PROTEIN SEQUENCE OF 64-76, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH SMARCA2, AND INDUCTION.

************

FUNCTION, IDENTIFICATION IN THE BRAIN BAF53 COMPLEX WITH ACTB; ARID1A; SMARCA2; SMARCA4; SMARCB1; SMARCC1; SMARCC2; SMARCD2 AND SMARCE1, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

FUNCTION OF THE NBAF AND NPBAF COMPLEXES, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE NBAF COMPLEX, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, DISRUPTION PHENOTYPE, AND IDENTIFICATION IN THE NBAF COMPLEX.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-45 AND MET-340.

************

X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 1-65 IN COMPLEX WITH ENAH AND TES, SUBUNIT, AND MUTAGENESIS OF ALA-31 AND ALA-41.

************

INTERACTION WITH TES AND ENAH, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-175.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ASP-175.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455, AND MASS SPECTROMETRY.

************

ISGYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-131 AND TYR-682, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455 AND SER-481, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455; SER-481 AND SER-1100, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-260; SER-442; THR-445; THR-447; THR-453; SER-455; SER-478; SER-481; THR-639; SER-663; TYR-682; SER-839; SER-922; SER-979 AND SER-1100, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481 AND TYR-682, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-86; LYS-546; LYS-554; LYS-948; LYS-962; LYS-968; LYS-978 AND LYS-1077, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-425 AND 487-820 IN COMPLEX WITH CITRATE, AND CITRATE-BINDING SITES.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-672, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 250-1100, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 418-459, AND PHOSPHORYLATION.

************

PHOSPHORYLATION AT SER-454.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-454, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING (ISOFORMS B AND C).

************

NUCLEOTIDE SEQUENCE (ISOFORM A).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 45-805 (ISOFORM B), AND FUNCTION.

************

INTERACTION WITH GPRASP2.

************

PROTEIN SEQUENCE OF 63-124.

************

MUTAGENESIS OF CYSTEINE RESIDUES.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-202, AND MASS SPECTROMETRY.

************

FUNCTION, MASS SPECTROMETRY, INDUCTION, AND INTERACTION WITH CDH1; BMH1 AND BMH2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; THR-41; SER-48; THR-161; SER-188 AND SER-202, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-161; SER-186 AND THR-189, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126; THR-161; SER-188 AND SER-202, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 247-373.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 27-466.

************

INTERACTION WITH ARRB1 AND ARRB2.

************

INDUCTION, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN SUSCEPTIBILITY TO ALCOHOLISM AND MAJOR DEPRESSIVE DISORDER.

************

INTERACTION WITH GNB2L1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232 AND SER-234, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 327-467.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B), FUNCTION, AND DEVELOPMENTAL STAGE.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-28 AND ASN-33, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-384.

************

INVOLVEMENT IN EGBRS.

************

STRUCTURE BY NMR OF 271-289, MUTAGENESIS OF GLU-276; PHE-280 AND VAL-281, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 314-439.

************

SEQUENCE REVISION TO 184.

************

PROTEIN SEQUENCE OF 104-166.

************

MUTAGENESIS OF TYR-148; THR-231; THR-234; TYR-506; TYR-529 AND TYR-533.

************

MUTAGENESIS OF THR-234 AND TYR-506.

************

SEQUENCE REVISION TO 258 AND 261-266.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 235-355.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-526.

************

PROTEIN SEQUENCE OF 66-128.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) IN COMPLEX WITH DHAP, FUNCTION, SUBUNIT, AND ZINC-BINDING SITES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-194, TISSUE SPECIFICITY, AND INDUCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-7 AND THR-116, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-20 AND 136-152, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 24-86, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MASS SPECTROMETRY, AND AMIDATION.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-159, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-159 AND ASN-653, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-63, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MASS SPECTROMETRY, AND AMIDATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-128.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-407, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 60-426.

************

NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-335.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ASP-202.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 339-543.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 18-259.

************

IDENTIFICATION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, ENZYME REGULATION, AND FUNCTION.

************

VARIANT HIS-190.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 161-174 AND 352-364.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS), FUNCTION, MASS SPECTROMETRY, MUTAGENESIS OF ASP-65, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH SUBSTRATE ANALOG, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF ASN-50; HIS-56; ASP-65 AND SER-83, AND SUBUNIT.

************

INTERACTION WITH PCTP, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, SUBUNIT, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-206.

************

X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 35-247, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF GLY-160; ASP-167 AND THR-183.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 92-248 (ISOFORM 2).

************

PROTEIN SEQUENCE OF 44-52 AND 472-485.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 54-257, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PATHWAY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-32.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-23.

************

CHARACTERIZATION, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH GEX-3.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-28.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 74-889, RNA-BINDING, AND PARTIAL PROTEIN SEQUENCE.

************

SIMILARITY TO ACONITASES AND IPM ISOMERASES.

************

FUNCTION AS AN ACONITASE.

************

FUNCTION, AND MUTAGENESIS OF CYS-300; CYS-437; CYS-503; CYS-506; ARG-536; ARG-541; ARG-699; SER-778 AND ARG-780.

************

UBIQUITINATION, AND INTERACTION WITH FBXL5.

************

INTERACTION WITH FRATAXIN(81-210).

************

X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEX WITH IRON-SULFUR CLUSTER, AND COFACTOR.

************

PROTEIN SEQUENCE OF 133-146 AND 624-638.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH TARGET MRNA, AND FUNCTION.

************

PROTEIN SEQUENCE OF 114-134 AND 277-293, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND MEMBRANE TOPOLOGY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-60.

************

SEQUENCE REVISION TO 11-25 AND C-TERMINUS.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-224.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-224.

************

PROTEIN SEQUENCE [LARGE SCALE ANALYSIS] OF 2-27.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-239.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-198; THR-199 AND SER-203, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-19.

************

CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MAGNETIC CIRCULAR DICHROISM, AND EPR SPECTROSCOPY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-131, PROTEIN SEQUENCE OF 1-11, AND CHARACTERIZATION.

************

PROTEIN SEQUENCE OF 1-15, CATALYTIC ACTIVITY AS 2-METHYLISOCITRATE LYASE, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 568-663, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MAGNETIC CIRCULAR DICHROISM, AND EPR SPECTROSCOPY.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH IRON-SULFUR AND ACONITATE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-141.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45, AND PROTEIN SEQUENCE OF 2-8.

************

PRELIMINARY PROTEIN SEQUENCE OF 28-780.

************

PROTEIN SEQUENCE OF 118-139 AND 439-457, AND CHARACTERIZATION OF IRON-SULFUR CLUSTERS.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 29-779 IN COMPLEX WITH IRON-SULFUR AND NITROISOCITRATE, AND REACTION MECHANISM.

************

PROTEIN SEQUENCE OF 377-393 AND 412-422, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 3-19.

************

PROTEIN SEQUENCE OF 69-84; 234-245; 313-323; 379-395; 412-424; 430-437; 507-520; 565-573; 608-628; 634-648 AND 657-671, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 69-83; 96-107; 371-396 AND 524-534.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-50; LYS-573 AND LYS-605, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] ASN-697.

************

VARIANT ICRD ARG-112, AND CHARACTERIZATION OF VARIANT ICRD ARG-112.

************

PROTEIN SEQUENCE OF 32-56; 59-84; 96-138; 143-160; 234-245; 251-258; 313-323; 371-395; 402-409; 412-424; 430-457; 466-474; 480-517; 522-587; 592-605; 608-628; 634-648; 657-671; 694-739 AND 744-767, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-144, AND MASS SPECTROMETRY.

************

PUPYLATION AT LYS-394, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 29-781 IN COMPLEX WITH IRON-SULFUR.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 29-779 OF MUTANT ALA-669 IN COMPLEX WITH IRON-SULFUR; CITRATE AND ISOCITRATE, AND REACTION MECHANISM.

************

PROTEIN SEQUENCE OF 32-44; 59-84; 96-138; 143-160; 234-245; 251-302; 313-323; 371-395; 402-409; 412-424; 430-458; 466-474; 480-517; 522-587; 592-628; 634-648; 657-679 AND 694-767, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 626-888.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-556, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-409, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-351, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-587.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-10.

************

NUCLEOTIDE SEQUENCE [MRNA], BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 2-12; 25-35 AND 223-233, CLEAVAGE OF INITIATOR METHIONINE, LACK OF N-TERMINAL ACETYLATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, INDUCTION, AND TISSUE SPECIFICITY.

************

ACTIVE SITES, MUTAGENESIS OF SER-232; ASP-324 AND HIS-358, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 13-34; 85-107; 187-198; 312-324 AND 374-338.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 106-122.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-475.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 35-483 (ISOFORM 1), FUNCTION, AND VARIANT ARG-475.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-104, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CHARACTERIZATION, INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 147-166 AND 168-178.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-197.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND TISSUE SPECIFICITY.

************

BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND INDUCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-56, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, PROBABLE ABSENCE OF CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 63-419 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH HIV-1 NEF, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-52 AND LYS-318, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INDUCTION.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-103; LYS-157; LYS-250 AND LYS-407, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] HIS-305.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 22-41, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH NYAP1; NYAP2 AND MYO16.

************

NUCLEOTIDE SEQUENCE [MRNA], DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND CHARACTERIZATION.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-659 OF MUTANT LEU-155.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-544 AND SER-551, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT MET-312, AND INVOLVEMENT IN PSEUDO-NALD.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-312.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT MET-312.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT MET-312.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND MASS SPECTROMETRY.

************

FUNCTION, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-255; LYS-267; LYS-437; LYS-500; LYS-504 AND LYS-651, AND MASS SPECTROMETRY.

************

TISSUE SPECIFICITY, AND REVERSAL OF ACOX1 NULL PHENOTYPE IN MOUSE.

************

VARIANTS PSEUDO-NALD CYS-178 AND VAL-278.

************

VARIANTS PSEUDO-NALD VAL-64 DEL; CYS-178; LEU-184; VAL-231; VAL-278; ARG-309 AND PRO-310, AND FUNCTION.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-267 AND LYS-643, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-310 AND SER-649, AND MASS SPECTROMETRY.

************

TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND CHARACTERIZATION.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH A C12-FATTY ACID, SUBUNIT, AND ACTIVE SITE.

************

X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS), SUBUNIT, AND ACTIVE SITE.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 46-81, FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 8-14; 271-282; 337-346; 450-468 AND 656-664.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-417, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-667, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 27-33; 74-83; 128-137; 265-270; 328-336; 454-464 AND 656-667, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-281, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH NAD AND ACYL-COA.

************

SEQUENCE REVISION TO 367; 381 AND 385.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 208-709.

************

SEQUENCE REVISION TO 265.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 162-547 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, AND TARGETING SIGNAL.

************

CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS) OF APOENZYME AND IN COMPLEX WITH SUBSTRATE AND IRON, AND COFACTOR.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-327.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-6 AND SER-11, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, SYNTHESIS, FUNCTION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 24-308, AND PROTEIN SEQUENCE OF 93-100.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 109-274.

************

PROTEIN SEQUENCE OF 60-131.

************

PROTEIN SEQUENCE OF 57-138.

************

STRUCTURE BY NMR OF 57-138 IN COMPLEX WITH PHOSPHOPANTETHEINE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 39-134.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 90-97.

************

PROTEIN SEQUENCE OF 50-73.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 23-132.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 19-53; 62-72; 75-130; 134-154 AND 312-381, MASS SPECTROMETRY, AND ALLERGEN.

************

Honeybee genome sequencing consortium;

************

NUCLEOTIDE SEQUENCE [MRNA] OF 16-388, AND ALLERGEN.

************

PROTEIN SEQUENCE OF 194-213.

************

PRELIMINARY NUCLEOTIDE SEQUENCE OF 102-732.

************

PARTIAL PROTEIN SEQUENCE, MASS SPECTROMETRY, AND ACETYLATION AT MET-1.

************

ACTIVE SITES SER-587 AND HIS-707.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-187, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-185 AND SER-187, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND ACETYLATION AT MET-1.

************

PROTEIN SEQUENCE, ACETYLATION AT MET-1, MASS SPECTROMETRY, AND ACTIVE SITE SER-587.

************

BLOCKAGE OF N-TERMINUS, AND FUNCTION.

************

IDENTIFICATION, AND PHOSPHOPANTETHEINYLATION.

************

FUNCTION IN BACILLAENE BIOSYNTHESIS.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 69-156, PROTEIN SEQUENCE OF 69-90, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE [LARGE SCALE ANALYSIS] OF 69-83.

************

MASS SPECTROMETRY, AND IDENTIFICATION IN THE NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-92, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 89-97 AND 138-151, AND MASS SPECTROMETRY.

************

PUPYLATION AT LYS-79, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 47-71.

************

PROTEIN SEQUENCE OF 47-105.

************

MUTAGENESIS OF ILE-2; ILE-5 AND GLN-113, X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF NATIVE PROTEIN AND COMPLEXES WITH COENZYME A AND WITH HOLO-(ACYL-CARRIER-PROTEIN), AND SUBUNIT.

************

PROTEIN SEQUENCE OF 2-26, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF N-TERMINUS, AND MUTAGENESIS OF GLY-5.

************

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR METHIONINE.

************

IDENTIFICATION, AND DISRUPTION PHENOTYPE.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF COMPLEX WITH 3'-5'-ADP.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-28; 30-41 AND 69-75, CHARACTERIZATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-51.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 47-83.

************

PROTEIN SEQUENCE OF 2-26.

************

PROTEIN SEQUENCE OF 2-77.

************

PROTEIN SEQUENCE OF 15-77, AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-14.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF HOLO-(ACYL-CARRIER-PROTEIN) IN COMPLEX WITH HOLO-(ACYL-CARRIER-PROTEIN) SYNTHASE.

************

PROTEIN SEQUENCE OF 2-78.

************

PROTEIN SEQUENCE OF 2-21.

************

PROTEIN SEQUENCE OF 10-19 AND 63-78, AND INTERACTION WITH MUKB.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 76-78.

************

MUTAGENESIS OF SER-37.

************

PROTEIN SEQUENCE OF 2-79.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 34-78.

************

PROTEIN SEQUENCE OF 2-70.

************

PROTEIN SEQUENCE OF 2-47.

************

PROTEIN SEQUENCE OF 1-46.

************

PROTEIN SEQUENCE OF 1-61, AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 21-45.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 8-20, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 21-68, MASS SPECTROMETRY, AND LETHAL DOSE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-160, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INDUCTION, AND MUTAGENESIS OF CYS-94.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INDUCTION, AND MUTAGENESIS OF CYS-70.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 39-78, MASS SPECTROMETRY, AND LETHAL DOSE.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.

************

FUNCTION, DISRUPTION PHENOTYPE, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-540, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

FUNCTION, DISRUPTION PHENOTYPE, MUTAGENESIS OF LYS-540, AND SUBCELLULAR LOCATION.

************

GENE FAMILY, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-540, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

FUNCTION, MUTAGENESIS OF CYS-221, AND SUBCELLULAR LOCATION.

************

FUNCTION, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION BY ALE2.

************

HOMODIMERIZATION, AND MUTAGENESIS OF ALA-433; GLY-438 AND ALA-452.

************

FUNCTION, AND INDUCTION BY CLE40.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-101, AND MASS SPECTROMETRY.

************

PROTEOLYTIC PROCESSING, AND INTERACTION WITH ACRB.

************

HOMOTRIMERIZATION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH PROACROSIN, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

INTERACTION WITH ACRA.

************

X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS), AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (3.48 ANGSTROMS) IN COMPLEXES WITH SUBSTRATES, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH SUBSTRATE, SUBUNIT, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), SUBUNIT, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS), FUNCTION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 998-1037.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96.

************

OPERON STRUCTURE, AND INDUCTION.

************

PRELIMINARY NUCLEOTIDE SEQUENCE [GENOMIC DNA].

************

DISCUSSION OF PUBMED:1628652.

************

ENZYME REGULATION, AND HETERODIMER WITH SERPINA5.

************

PROPEPTIDE, AND ACTIVATION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 41-66, ENZYME REGULATION, GLYCOSYLATION, AND MASS SPECTROMETRY.

************

ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 17-39.

************

PROTEIN SEQUENCE OF 25-91.

************

PROTEIN SEQUENCE OF 17-32 AND 40-53.

************

PROTEIN SEQUENCE OF 17-40.

************

PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-19 AND ASN-208.

************

NUCLEOTIDE SEQUENCE [MRNA], AND X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 18-329.

************

PROTEIN SEQUENCE OF 2-144, CHARACTERIZATION, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-13, AND INDUCTION BY NITRIC OXIDE (NO).

************

FUNCTION AS A CHAPERONE, INDUCTION IN STATIONARY PHASE, AND INDUCTION BY HYPOXIA.

************

IDENTIFICATION BY MASS SPECTROMETRY, MULTIPLE FORMS, AND INDUCTION BY HYPOXIA.

************

INDUCTION BY HOST IMMUNITY.

************

INDUCTION BY ANAEROBISIS, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

DISRUPTION PHENOTYPE, AND PROBABLE OPERON STRUCTURE.

************

BIOTECHNOLOGY.

************

PUPYLATION AT LYS-64; LYS-85; LYS-114 AND LYS-132, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-59.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 72-713 IN COMPLEX WITH AMP.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 299-577, AND VARIANT LEU-513.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 32-577 IN COMPLEXES WITH ATP; COENZYME A; IBUPROFEN AND MAGNESIUM.

************

VARIANT LEU-513.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 152-163 AND 483-491, FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.

************

SUBCELLULAR LOCATION, COFACTOR, TISSUE SPECIFICITY, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 169-689 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 336-689 (ISOFORM 1).

************

ACETYLATION AT LYS-642, MUTAGENESIS OF LYS-642, FUNCTION, ENZYME REGULATION, PROTEIN SEQUENCE OF N-TERMINUS, MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-396, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 638-649 IN COMPLEX WITH SIRT3.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH SIRT3, ENZYME REGULATION, MASS SPECTROMETRY, AND ACETYLATION AT LYS-635.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-581.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-506, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620 AND SER-679, AND MASS SPECTROMETRY.

************

3D-STRUCTURE MODELING, AND MUTAGENESIS OF ASP-188; ASP-189; ASP-236; ASP-333; GLN-369; ARG-370 AND ARG-372.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 6-20.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 768-781.

************

REVIEW ON DOMAIN ARCHITECTURE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN SPORULATION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-605, AND MUTAGENESIS OF GLY-263; GLY-266; LYS-269 AND GLU-414.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBSTRATE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS A AND B).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 299-652.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.

************

FUNCTION, CATALYTIC ACTIVITY, AND DISRUPTION PHENOTYPE.

************

ACETYLATION OF CHEY.

************

INVOLVEMENT IN CHEMOTAXIS.

************

INTERACTION WITH COBB, AND DEACETYLATION.

************

AUTOACETYLATION AT LYS-609.

************

DEACETYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30 AND SER-267, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-418, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-267, AND MASS SPECTROMETRY.

************

FUNCTION, AUTOACETYLATION AT LYS-617, MUTAGENESIS OF LYS-617, BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.

************

FUNCTION, ACETYLATION AT LYS-617, AND MUTAGENESIS OF LYS-617.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 31-667.

************

ACETYLATION AT LYS-609, DEACETYLATION BY SIR2 HOMOLOG, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS), AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.42 ANGSTROMS) OF WILD-TYPE AND MUTANTS IN COMPLEX WITH SUBSTRATE ANALOGS AND MAGNESIUM IONS, FUNCTION, MUTAGENESIS OF ARG-194; ALA-357; GLY-524; ARG-526; ARG-584 AND LYS-609, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 97-662.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-596, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-8, AND PROTEIN SEQUENCE OF 2-19.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 29-53, AND PROTEIN SEQUENCE OF 30-63.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-296, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-439, AND MASS SPECTROMETRY.

************

VARIANTS CMAMMA ARG-198; LEU-243; ILE-358; LYS-359; THR-462; 465-GLN--GLY-470 DEL; GLN-471; TRP-471; SER-480 AND TRP-558, FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT ASP-1030.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT VAL-747.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 96-1098.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-164, AND VARIANTS VAL-61 AND ARG-93.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), POSSIBLE FUNCTION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-645 (ISOFORM 1).

************

COMMENT ON PUBMED:12712191 RESULTS.

************

PROTEIN SEQUENCE OF 1-8; 12-19; 341-349; 377-386; 562-572; 633-640 AND 655-675, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 395-698 (ISOFORM 2).

************

PROTEIN SEQUENCE OF 1-8; 358-369; 389-396; 563-573; 617-627 AND 634-641, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-544, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-19; 82-91 AND 628-641, ACETYLATION AT MET-1 AND LYS-633, NITRATION AT TYR-9 AND TYR-86, PHOSPHORYLATION AT TYR-85, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-551.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT SER-551.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-593, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-683 AND THR-688, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-89, AND MASS SPECTROMETRY.

************

VARIANT MRX63 SER-570.

************

VARIANT [LARGE SCALE ANALYSIS] CYS-133.

************

PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2).

************

FUNCTION, SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

VARIANTS [LARGE SCALE ANALYSIS] ARG-388 AND ASP-466.

************

FUNCTION, SUBCELLULAR LOCATION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND CHROMOSOMAL TRANSLOCATION WITH ETV6.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), NUCLEOTIDE SEQUENCE [MRNA] OF 253-374 (ISOFORM 5), AND ALTERNATIVE SPLICING (ISOFORM 8).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 8).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 491-503; 544-551; 573-579 AND 633-636.

************

Amgen EST program;

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 35-53 AND 324-333, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 32-35, VARIANT ALA-372, FUNCTION, COFACTOR, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 249-254, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], DEVELOPMENTAL STAGE, INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND LACK OF INVOLVEMENT IN HEREDITARY HYPERTENSION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASN-367.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-43, AND MASS SPECTROMETRY.

************

VARIANT ASN-367.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 374-479.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 330-474.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-547, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

VARIANTS HIS-159; ARG-352; ARG-360 AND MET-533, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, TISSUE SPECIFICITY, INDUCTION BY HERBIVORY; WOUNDING AND ELICITORS, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 133-590.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND IDENTIFICATION OF GENE CLUSTER.

************

PROTEIN SEQUENCE OF 30-63; 97-114; 149-178; 198-211; 240-255 AND 292-337, AND MASS SPECTROMETRY.

************

GENE FAMILY ORGANIZATION, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-41.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 320-374.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-86.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 2-376 IN COMPLEX WITH GELSOLIN AND ATP.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ACT8 AND ACT12).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-260 (ACT15).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-68 (ACT2; ACT5; ACT7; ACT14 AND ACT16).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-9 (ACT8).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-9 (ACT4).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-8 (ACT6 AND ACT8).

************

PROTEIN SEQUENCE OF 2-376.

************

PROTEIN SEQUENCE OF 120-133.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 289-376 (ACT2; ACT5; ACT8 AND ACT15).

************

PHOSPHORYLATION AT TYR-54.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH GELSOLIN AND ATP.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH GELSOLIN AND ATP.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-376 (ACT1).

************

NUCLEOTIDE SEQUENCE [MRNA] (ACT4).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-84 AND 324-376.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 366-376.

************

OXIDATION AT MET-45 AND MET-48, AND MUTAGENESIS OF MET-45 AND MET-48.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-7.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-63.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-160 AND 229-376.

************

OXIDATION AT MET-45 AND MET-48.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-43.

************

SEQUENCE REVISION TO 319.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH NADPH.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH NADPH, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-43.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

IDENTIFICATION IN THE TIP60 COMPLEX, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 302-376, AND MUTAGENESIS OF 357-TRP--PHE-376.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 318-377.

************

PROTEIN SEQUENCE OF 3-377, AND METHYLATION AT HIS-75.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 260-377.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-330.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 331-377.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-296, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-325, AND MASS SPECTROMETRY.

************

VARIANTS AAT6 THR-117; GLN-118; HIS-135; CYS-149; ALA-154; CYS-258; HIS-258; GLY-292 AND ASN-353.

************

VARIANTS AAT6 HIS-39; THR-117; GLN-118; CYS-149; ALA-154; GLN-185; GLN-212; HIS-258; CYS-258; ASN-326 AND ASN-353.

************

VARIANTS AAT6 CYS-145; CYS-149 AND GLN-212, AND PREDISPOSITION TO A VARIETY OF VASCULAR DISEASES.

************

VARIANT MSMDYS HIS-179.

************

VARIANT MYMY5 HIS-179.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 30-59.

************

PROTEIN SEQUENCE OF 21-41; 53-63; 71-86; 98-115; 186-193; 241-256 AND 318-328, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ARDB).

************

PHOSPHORYLATION AT THR-203 AND THR-204 BY AFK.

************

PHOSPHORYLATION AT THR-202 BY AFK.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 285-377.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 336-377.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 85-187, AND INTERACTION WITH PFN1 AND PFDN1.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 84-186, INTERACTION WITH PFN1 AND PFDN1, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 2-375.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 77-228 AND 345-375.

************

X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF COMPLEX WITH PROFILIN.

************

X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF COMPLEX WITH PROFILIN.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-189.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 23-206.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 282-341.

************

PROTEIN SEQUENCE OF 2-37; 85-113; 178-191; 197-206; 239-254; 291-326 AND 360-372, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ASP-2, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 7-22 AND 225-237.

************

PROTEIN SEQUENCE OF 2-28.

************

PROTEIN SEQUENCE OF 2-18; 29-37; 40-50; 85-95; 148-177; 184-191; 197-206; 292-312 AND 316-326, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ASP-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 19-62; 85-113; 184-191; 197-206; 216-254; 291-312; 316-326 AND 360-372, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 252-375.

************

IDENTIFICATION IN A COMPLEX WITH RAN; XPO6 AND PFN1, AND INTERACTION WITH XPO6.

************

INTERACTION WITH EMD.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-166; TYR-218 AND TYR-294, AND MASS SPECTROMETRY.

************

INTERACTION WITH GCSAM.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-53; TYR-91; TYR-198 AND TYR-294, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN A MRNP GRANULE COMPLEX, IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-318, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-53; TYR-91; TYR-169 AND TYR-198, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-169; TYR-198; TYR-218 AND TYR-294, AND MASS SPECTROMETRY.

************

INTERACTION WITH ERBB2.

************

VARIANT DYTJ TRP-183, AND CHARACTERIZATION OF VARIANT DYTJ TRP-183.

************

IDENTIFICATION IN THE MLL5-L COMPLEX.

************

VARIANTS BRWS1 ASP-12; VAL-65; CYS-196 AND HIS-196.

************

PROTEIN SEQUENCE OF 19-39; 51-61; 85-113; 148-177; 184-191; 197-206; 216-254; 257-284; 291-326 AND 360-372, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 27-375.

************

ACETYLATION.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-218, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 19-39; 51-62; 85-113; 184-191; 197-206; 239-254; 292-312; 316-326; 329-335 AND 360-372, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 68-376.

************

VARIANTS CMD1R HIS-314 AND GLY-363.

************

VARIANT CMH11 SER-297.

************

VARIANTS CMH11 LYS-101; ALA-166 AND PRO-333.

************

VARIANTS CMH11 CYS-168 AND LEU-307.

************

VARIANT ASD5 VAL-125, AND CHARACTERIZATION OF VARIANT ASD5 VAL-125.

************

VARIANTS CMH11 TYR-90 AND CYS-97.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-377.

************

PROTEIN SEQUENCE OF 71-97 AND 241-256, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-314.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 315-376.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-4.

************

PROTEIN SEQUENCE OF 2-375, AND METHYLATION AT HIS-73.

************

PROTEIN SEQUENCE OF 2-37; 85-113; 178-191; 197-206; 239-254; 291-326 AND 360-372, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLU-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-18; 29-37; 40-50; 85-113; 148-177; 184-191; 197-206; 239-254; 292-312 AND 316-326, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLU-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-116; 119-210; 216-254 AND 291-372, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLU-2, METHYLATION AT HIS-73, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 29-39; 85-113; 239-254 AND 292-312, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 144-375.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-198 AND TYR-294, AND MASS SPECTROMETRY.

************

VARIANTS DFNA20 ILE-89; MET-118; LEU-264 AND ALA-332.

************

VARIANT DFNA20 ILE-278.

************

VARIANT DFNA20 ALA-370, AND CHARACTERIZATION OF VARIANT DFNA20 ALA-370.

************

VARIANT DFNA20 VAL-122.

************

VARIANTS DFNA20 ASN-118 AND LYS-241.

************

VARIANTS BRWS2 ILE-120; VAL-135; PHE-155; LYS-203; TRP-254 AND TRP-256.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 8-375.

************

PROTEIN SEQUENCE OF 29-39.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-169, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 4-19 AND 228-231.

************

PROTEIN SEQUENCE OF 29-37; 51-62 AND 85-95, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-293.

************

INTERACTION WITH FALP.

************

REVIEW ON GCCD1 VARIANTS.

************

VARIANT GCCD1 ILE-74.

************

VARIANT GCCD1 ARG-120.

************

VARIANTS GCCD1 ASN-107 AND PHE-251.

************

VARIANTS GCCD1 ASN-103 AND TRP-137.

************

VARIANTS GCCD1 ILE-74; TRP-137 AND CYS-254.

************

VARIANT PRO-137.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH ADP, BIOPHYSICOCHEMICAL PROPERTIES, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-3.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-37 AND ALA-51.

************

VARIANTS [LARGE SCALE ANALYSIS] ASP-42 AND THR-332.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 38-893 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 62-769 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 297-892 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 1-21.

************

PROTEIN SEQUENCE OF 134-146.

************

PROTEIN SEQUENCE OF 566-577; 727-738 AND 835-863, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH TTID.

************

INTERACTION WITH MYOZ2.

************

PHOSPHORYLATION AT TYR-12.

************

INTERACTION WITH LPP.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-50, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-140, AND MASS SPECTROMETRY.

************

INTERACTION WITH DDN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-193, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-246, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-95; LYS-195 AND LYS-676, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 30-253.

************

INTERACTION WITH PSD, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH PDLIM2.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 662-867 (ISOFORM 2).

************

INTERACTION WITH LDB3.

************

INTERACTION WITH MYOZ1.

************

INTERACTION WITH MYOZ1 AND MYOZ2.

************

INTERACTION WITH MYOZ1, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH MYOZ3.

************

INTERACTION WITH XIRP2.

************

INTERACTION WITH DST, AND SUBCELLULAR LOCATION.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 391-637.

************

STRUCTURE BY NMR OF 823-894 IN COMPLEX WITH A TITIN Z-REPEAT.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 274-746.

************

VARIANT CMD1AA ARG-9, AND VARIANT VAL-604.

************

INTERACTION WITH ADAM12.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-237, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLN-523; ARG-628 AND ARG-776.

************

TISSUE SPECIFICITY, AND POLYMORPHISM.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 26-273.

************

VARIANT GLN-523, AND POLYMORPHISM.

************

PROTEIN SEQUENCE OF 294-316.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-911.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-170.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-218.

************

INTERACTION WITH BAIAP1.

************

IDENTIFICATION IN THE CART COMPLEX.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-265, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-378, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-114; LYS-214; LYS-417; LYS-592 AND LYS-625, AND MASS SPECTROMETRY.

************

VARIANTS FSGS1 GLU-255; ILE-259 AND PRO-262.

************

PROTEIN SEQUENCE OF 85-96 AND 311-319, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN A COMPLEX WITH CASK; IQGAP1; MAGI2; NPHS1; SPTAN1 AND SPTBN1, IDENTIFICATION BY MASS SPECTROMETRY, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 91-504, PROTEIN SEQUENCE OF 126-139; 275-285; 293-309; 313-328; 397-405 AND 481-487, AND DEVELOPMENTAL STAGE.

************

FUNCTION, SUBUNIT, AND DISRUPTION PHENOTYPE.

************

FUNCTION, AND MUTAGENESIS OF ASP-742; ASP-744; ASP-746; GLU-753; ASP-778; ASP-780; SER-786 AND GLU-789.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 265-502.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], DEVELOPMENTAL STAGE, INDUCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 70-380, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

PROTEIN SEQUENCE OF 127-346.

************

PROTEIN SEQUENCE OF 127-136, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS), AND SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-13.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 70-380.

************

PROTEIN SEQUENCE OF 127-131, AND ALLERGEN.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ADULT MUSCLE).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORMS LONG AND ADULT MUSCLE).

************

NUCLEOTIDE SEQUENCE OF 229-286 (ISOFORM NON-MUSCLE), AND ALTERNATIVE SPLICING.

************

AMINO-ACID COMPOSITION, AND LETHAL DOSE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 48-77.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 35-83; 104-111; 155-160; 187-193 AND 196-212, AND FUNCTION.

************

PROTEIN SEQUENCE, LETHAL DOSE, HEMOLYTIC ACTIVITY, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND TOXIC DOSE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 9-176.

************

MUTAGENESIS OF GLU-16.

************

PROTEIN SEQUENCE OF 36-214, AND CIRCULAR DICHROISM ANALYSIS.

************

PROTEIN SEQUENCE OF 36-80; 168-197 AND 200-214.

************

PROTEIN SEQUENCE OF 105-118 AND 168-183.

************

SPHINGOMYELIN-BINDING.

************

MUTAGENESIS, SITE ARG-179 AND SER-195, AND DOMAINS N-TERMINAL AND TRP-RICH.

************

MUTAGENESIS OF TRP-80; 151-TRP-TRP-152 AND TRP-184, AND SITE INVOLVED IN THE INITIAL CONTACT WITH THE MEMBRANE.

************

TWO STEPS FOR PORE FORMATION, AND SITE INVOLVED IN THE INITIAL CONTACT WITH THE MEMBRANE.

************

TOPOLOGY OF N-TERMINAL REGION IN TWO STEPS OF PORE FORMATION.

************

SPHINGOMYELIN-BINDING, MUTAGENESIS OF TRP-147 AND TYR-148, SITES INVOLVED IN THE INITIAL BINDING TO THE LIPID MEMBRANE, AND HYDROPHOBIC INTERACTION.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 40-214.

************

STRUCTURE BY NMR OF 36-214.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 24-33; 84-100; 101-114; 136-168 AND 169-189, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 187-207.

************

AMINO-ACID COMPOSITION, AND FUNCTION.

************

PROTEIN SEQUENCE, LETHAL DOSE, HEMOLYTIC ACTIVITIES, AND FUNCTION.

************

PROTEIN SEQUENCE, SEQUENCE REVISION, AND MASS SPECTROMETRY.

************

MUTAGENESIS OF LYS-19; PHE-106 AND TYR-111.

************

REGION IMPORTANT FOR HEMOLYTIC ACTIVITY.

************

PORE FORMATION, AND ALPHA-HELICAL STRUCTURE.

************

X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS), PHOSPHOCHOLINE-BINDING SITES, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-175, AND HEMOLYTIC ACTIVITY.

************

PROTEIN SEQUENCE OF 1-30, AND FUNCTION.

************

PROTEIN SEQUENCE OF 1-30, AND LETHAL DOSE.

************

PROTEIN SEQUENCE OF 1-8.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 48-96, AND LETHAL DOSE.

************

PROTEIN SEQUENCE OF 1-15, NUCLEOTIDE SEQUENCE [MRNA] OF 13-179, FUNCTION, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 2-106, AND CRYSTALLIZATION.

************

X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], MASS SPECTROMETRY, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 7-147, PROTEIN SEQUENCE OF 1-15, LETHAL DOSE, HEMOLYTIC ACTIVITY, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 3-377.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH ATP.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS NEM3 TYR-42; PRO-96; SER-117; VAL-134; ASP-184; CYS-185; HIS-258; VAL-261; LEU-265; LYS-282; GLY-288 AND PHE-372, AND VARIANTS MPCETM ARG-17 AND LEU-165.

************

INTERACTION WITH USP25.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-63, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-55 AND TYR-93, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-63; LYS-70; LYS-193; LYS-328 AND LYS-330, AND MASS SPECTROMETRY.

************

MALONYLATION AT LYS-63.

************

VARIANTS NEM3 SER-117; MET-138; GLY-185; CYS-270 AND LEU-359.

************

VARIANTS NEM3 VAL-134 AND ARG-271.

************

VARIANTS NEM3 LEU-37; LEU-40; TYR-42; ARG-43; ASN-66; LEU-75; ARG-75; LEU-77; ALA-79; LYS-85; ALA-136; ASP-148; GLY-181; ASP-184; GLY-185; SER-199; GLY-226; VAL-229; ILE-229; ARG-248; ASP-253; CYS-270; HIS-281; LYS-282; GLY-288 AND GLN-375.

************

VARIANTS CFTD PRO-223; VAL-294 AND SER-334.

************

VARIANTS NEM3 ILE-68; LYS-74; SER-117; MET-138; LEU-165; MET-165; GLY-185; CYS-270 AND LEU-359.

************

VARIANTS NEM3 TYR-3 AND ALA-336.

************

VARIANTS NEM3 ASP-270 AND GLU-375.

************

VARIANT NEM3 MET-165.

************

VARIANT NEM3 GLU-338.

************

CHARACTERIZATION OF VARIANT CFTD VAL-294.

************

CHARACTERIZATION OF VARIANT NEM3 MET-165.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-93, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-55; TYR-93 AND TYR-242, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 5; 7; 14 AND 75-81.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 74-147; 194-283 AND 311-377.

************

X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 3-377 IN COMPLEX WITH ATP.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 7-377 ADP-RIBOSYLATED BY SPVB.

************

NUCLEOTIDE SEQUENCE OF 353-377.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH PFN3.

************

PROTEIN SEQUENCE OF 22-40; 46-62; 110-117; 218-228; 230-235; 243-262; 93-310 AND 362-370, FUNCTION, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 239-255, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 201-215 AND 239-255, AND MASS SPECTROMETRY.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-4, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-22; 239-255 AND 330-336, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 97-118; 201-215 AND 239-255, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE OF 83-245.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 96-376.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-341.

************

PROTEIN SEQUENCE, AND ALLERGEN.

************

NUCLEOTIDE SEQUENCE OF 1-137.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 18-343.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 67-229.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF GLY-273.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND SER-324, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 4-58.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-57.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-358.

************

ACETYLATION AT MET-1, AND PROTEIN SEQUENCE OF N-TERMINUS.

************

PROTEIN SEQUENCE OF 19-25.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199; SER-201; SER-323 AND SER-324, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION IN A ACTIVIN RECEPTOR COMPLEX, ACTIVIN-BINDING, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2 AND 3), AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 5).

************

INTERACTION WITH ACVR2B, PHOSPHORYLATION BY ACVR2B, DOMAIN GS, AND MUTAGENESIS OF THR-206.

************

SUBUNIT, AND FUNCTION.

************

INTERACTION WITH SMAD2; SMAD3 AND SMAD7, AND FUNCTION.

************

INTERACTION WITH IGSF1, AND ENZYME REGULATION.

************

PHOSPHORYLATION, AND INTERACTION WITH SMAD7.

************

INTERACTION WITH TDGF1, AND ENZYME REGULATION.

************

PHOSPHORYLATION AT TYR-380.

************

MUTAGENESIS OF LEU-40; ILE-70; VAL-73; LEU-75 AND PRO-77, AND ACTIVIN-BINDING.

************

INTERACTION WITH FKBP1A AND SMAD7, AND UBIQUITINATION.

************

FUNCTION, AND AUTOPHOSPHORYLATION.

************

INVOLVEMENT IN SYSTEMIC SCLEROSIS.

************

VARIANT [LARGE SCALE ANALYSIS] LEU-146, AND VARIANT [LARGE SCALE ANALYSIS] HIS-478 (ISOFORM 3).

************

FUNCTION, AND INTERACTION WITH TDP2.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-222.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, AND MUTAGENESIS OF THR-194 AND LYS-222.

************

VARIANTS [LARGE SCALE ANALYSIS] THR-195; ARG-216; ARG-267; VAL-355 AND VAL-482.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF THR-194 AND LYS-222.

************

PROTEIN SEQUENCE OF 139-159, FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INTERACTION WITH ACVR2A; ACTIVIN AB AND B.

************

FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF THR-194.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HHT2 CYS-50; GLN-67; ILE-333; TRP-374 AND THR-424.

************

VARIANTS HHT2 SER-232 DEL; ARG-376 AND GLN-411.

************

VARIANTS HHT2 TYR-51; TRP-77 AND ASP-96.

************

VARIANTS HHT2 GLY-48-49-ALA DELINS EP; CYS-50; SER-232 DEL; ILE-333; TYR-344 AND ASP-407.

************

VARIANTS HHT2 TRP-374 AND ASN-398.

************

VARIANTS HHT2 ASP-254 DEL; TRP-411 AND TRP-484.

************

VARIANTS HHT2 ALA-179; ASP-211; TYR-344; TRP-374; GLN-374; SER-399; GLN-411 AND THR-487, AND CHARACTERIZATION OF VARIANTS HHT2 CYS-50; GLN-67; TRP-77; ALA-179; ASP-211; SER-232 DEL; ASP-254 DEL; ILE-333; TYR-344; GLN-374; LEU-378; GLN-411 AND THR-487.

************

French Rendu-Osler network;

************

VARIANTS HHT2 TRP-67; TRP-374; LYS-379; ASP-407; TRP-411; VAL-425 AND PHE-425 DEL.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND SER-501, AND MASS SPECTROMETRY.

************

INTERACTION WITH FCHO1.

************

VARIANT FOP HIS-206.

************

VARIANTS [LARGE SCALE ANALYSIS] GLY-15; PHE-41; GLN-47 AND SER-115.

************

VARIANTS FOP 197-PRO-PHE-198 DELINS LEU; HIS-206; GLU-207; ARG-328; TRP-328; GLU-328; ASP-356 AND PRO-375.

************

VARIANTS FOP ILE-202 AND GLU-328.

************

DEVELOPMENTAL STAGE, AND FUNCTION.

************

PARTIAL NUCLEOTIDE SEQUENCE, AND PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 547-561; 944-979; 1928-1944; 2396-2419 AND 3102-3118, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], IDENTIFICATION, AND BLOCKAGE OF N-TERMINUS.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-14, AND IDENTIFICATION.

************

PROTEIN SEQUENCE OF 89-100; 116-126; 169-190 AND 368-378, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 161-178, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH ZINC IONS, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, ACTIVE SITE, AND MUTAGENESIS OF HIS-80; ASP-113; GLU-147; GLU-148; GLU-175; HIS-206 AND HIS-373.

************

VARIANT ACY1D CYS-353.

************

VARIANTS ACY1D ASP-233 AND CYS-353, AND TISSUE SPECIFICITY.

************

VARIANT [LARGE SCALE ANALYSIS] ASP-381.

************

VARIANTS ACY1D TRP-197; CYS-353 AND HIS-393.

************

VARIANTS ACY1D GLN-378; TRP-378 AND CYS-386, AND CHARACTERIZATION OF VARIANTS ACY1D TRP-197; ASP-233; CYS-353; TRP-378 AND CYS-386.

************

INTERACTION WITH SPHK1.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT CAND ALA-285.

************

CHARACTERIZATION, CHARACTERIZATION OF VARIANT CAND ALA-285, AND MUTAGENESIS OF GLU-285.

************

CATALYTIC ACTIVITY, ZINC-BINDING SITES, ACTIVE SITE, AND MUTAGENESIS OF GLU-178.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEXES WITH ZINC IONS; PHOSPHATE AND N-PHOSPHONOMETHYL-L-ASPARTATE, COFACTOR, SUBUNIT, AND MUTAGENESIS OF ARG-71; TYR-164; ARG-168; GLU-178 AND TYR-288.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT, AND COFACTOR.

************

VARIANTS CAND ALA-285 AND GLU-305.

************

VARIANTS CAND 176-GLY-ILE-177 DEL; ARG-274; SER-295 AND GLU-305.

************

VARIANT CAND ARG-152.

************

VARIANTS CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152; CYS-168; ALA-285 AND GLU-305, VARIANT GLY-310, AND CHARACTERIZATION OF VARIANTS CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152 AND CYS-168.

************

VARIANT CAND THR-143.

************

VARIANT CAND CYS-231.

************

VARIANTS CAND THR-16; ARG-27; HIS-183; PHE-186; ARG-195; ARG-274; SER-280; LEU-280; THR-287; SER-295 AND GLU-305.

************

VARIANTS CAND PRO-21; THR-57; HIS-168 AND THR-181.

************

VARIANTS CAND GLY-24; ALA-68; TRP-152; ARG-244 AND VAL-249.

************

VARIANTS CAND TYR-114 AND VAL-249.

************

PROTEIN SEQUENCE OF 172-187 AND 200-212, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 43-55; 132-143 AND 172-187, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT, AND COFACTOR.

************

INTERACTION WITH HCV CORE PROTEIN, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION AS AN ACYLTRANSFERASE, SUBCELLULAR LOCATION, PATHWAY, AND SUBSTRATE SPECIFICITY.

************

FUNCTION AS AN ACYLTRANSFERASE, AND PATHWAY.

************

PROTEIN SEQUENCE OF 2-101 (ISOFORM ACY2), AND ACETYLATION AT SER-2.

************

PROTEIN SEQUENCE OF 2-101 (ISOFORM ACY2), PROTEIN SEQUENCE OF 4-101 (ISOFORM ACY1), AND ACETYLATION OF N-TERMINUS.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4-101 (ISOFORM ACY1).

************

PROTEIN SEQUENCE OF 2-99.

************

PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] OF 10-86.

************

X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS).

************

STRUCTURE BY NMR OF 2-99.

************

PROTEIN SEQUENCE OF 2-101 (ISOFORM ACYA), PROTEIN SEQUENCE OF 4-101 (ISOFORM ACYB), AND ACETYLATION OF N-TERMINUS.

************

PROTEIN SEQUENCE OF 2-103.

************

CATALYTIC ACTIVITY, MASS SPECTROMETRY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS), AND ACTIVE SITE.

************

STRUCTURE BY NMR OF ALPHA HELICES.

************

STRUCTURE BY NMR OF BETA-STRUCTURES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 22-99.

************

PROTEIN SEQUENCE OF 2-97.

************

PROTEIN SEQUENCE OF 44-56, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVE SITE.

************

CATALYTIC ACTIVITY, MASS SPECTROMETRY, DISULFIDE BOND, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF CYS-5.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS), MASS SPECTROMETRY, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

X-RAY CRYSTALLOGRAPHY (1.27 ANGSTROMS), STRUCTURE BY NMR, MASS SPECTROMETRY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 214-233, FUNCTION, AND MUTAGENESIS OF GLU-384.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 216-237.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 109-748.

************

IDENTIFICATION IN A COMPLEX WITH EFNA5 AND EPHA3, AND FUNCTION IN EFNA5-EPHA3 SIGNALING.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-278, AND MASS SPECTROMETRY.

************

FUNCTION IN CLEAVAGE OF FASLG.

************

FUNCTION IN CLEAVAGE OF ITM2B.

************

FUNCTION IN CLEAVAGE OF JAM3.

************

FUNCTION IN CLEAVAGE OF CORIN.

************

VARIANT TYR-176.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 252-749.

************

INTERACTION WITH EPHA2.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-279, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 476-637, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 106-769 (ISOFORMS LONG AND SHORT).

************

VARIANT [LARGE SCALE ANALYSIS] ARG-693.

************

INTERACTION WITH LGI1 AND LGI4.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT ARG-48.

************

SEQUENCE REVISION TO 36.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT ARG-48.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-48.

************

INTERACTION WITH SYNDECANS.

************

INTERACTION WITH SH3PXD2A.

************

INTERACTION WITH FST3.

************

VARIANTS [LARGE SCALE ANALYSIS] HIS-301; GLU-479 AND PHE-792.

************

VARIANTS GLU-712 AND SER-893.

************

INTERACTION WITH ALPHA-ACTININ-2.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT THR-191.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10), FUNCTION, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8; 9; 10), AND VARIANT THR-191.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 4 AND 10), ALTERNATIVE SPLICING, AND INTERACTION WITH GRB2; MAPK1; MAPK3; NCK1; PTK6; SH3PXD2A AND SRC.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8 AND 9), AND VARIANT THR-191.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT THR-191.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 11).

************

INTERACTION WITH INTEGRIN ALPHAV-BETA3.

************

INTERACTION WITH INTEGRIN ALPHAV-BETA3 AND INTEGRIN ALPHA5-BETA1.

************

PHOSPHORYLATION AT TYR-715 AND TYR-735, AND INTERACTION WITH GRB2; LCK AND HCK.

************

FUNCTION, AND MUTAGENESIS OF 484-ARG-GLY-485.

************

INTERACTION WITH HCK; ITSN1; ITSN2; LYN; NCF1; NEPHROCYSTIN; SH3PXD2A; SNX33; SNX9 AND SRC.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND PROTEOLYTIC PROCESSING.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 207-694 (ISOFORMS 1/2/3), FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

INTERACTION WITH ENDOPHILIN I AND SNX9.

************

FUNCTION, INTERACTION WITH INTEGRIN ALPHAV-BETA3 AND ALPHA9-BETA1, AND MUTAGENESIS OF ARG-482; ASP-489; LEU-490; PRO-491; GLU-492 AND PHE-493.

************

FUNCTION, DEVELOPMENTAL STAGE, AND INDUCTION.

************

TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-732 (ISOFORM B).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND PARTIAL PROTEIN SEQUENCE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B).

************

PHOSPHORYLATION AT THR-735.

************

INTERACTION WITH MUC1, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-379; SER-382 AND SER-791, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-791, AND MASS SPECTROMETRY.

************

ROLE IN PROTEOLYTICAL RELEASE OF JAM3.

************

PHOSPHORYLATION AT THR-735, AND INTERACTION WITH MAPK14.

************

INVOLVEMENT IN NISBD.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 219-473.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS LONG AND SHORT).

************

FUNCTION IN PROCESSING OF GROWTH HORMONE RECEPTOR.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-794, AND MASS SPECTROMETRY.

************

VARIANTS SER-170; GLY-284; ILE-344; LYS-362 AND LEU-536.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 405-453.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), AND VARIANT SER-4.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 99-955 (ISOFORM A).

************

VARIANTS [LARGE SCALE ANALYSIS] GLN-133 AND THR-298.

************

VARIANT [LARGE SCALE ANALYSIS] GLN-609.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 429-578.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ARG-347.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-347.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), VARIANT ARG-347, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6; 7; 8 AND 9).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 52-400 (ISOFORMS 1/2/3/4), TISSUE SPECIFICITY, AND VARIANT ARG-347.

************

SUBCELLULAR LOCATION, SUBUNIT, FUNCTION, AND MUTAGENESIS OF LYS-334; LYS-335; ARG-342; ARG-348 AND LYS-349.

************

VARIANT ARG-347.

************

VARIANT [LARGE SCALE ANALYSIS] TRP-40.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 197-280.

************

SUBCELLULAR LOCATION, SUBUNIT, FUNCTION, AND MUTAGENESIS OF 368-ARG--ARG-380.

************

MUTAGENESIS OF ALA-293.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 238-276.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-263 AND SER-266, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-253.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 190-350.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-62.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-19.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 181-722.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND VARIANT ARG-81.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 40-906 (ISOFORM 1), AND VARIANT ARG-81.

************

FUNCTION, INTERACTION WITH YWHAZ, AND MUTAGENESIS OF SER-834 AND SER-857.

************

FUNCTION, INTERACTION WITH YWHAB, AND MUTAGENESIS OF SER-834 AND SER-857.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-834; SER-869 AND SER-870, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.36 ANGSTROMS) OF 233-736, GLYCOSYLATION AT ASN-519; ASN-634 AND ASN-675, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 17 AND 20).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 619-904 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 709-904 (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20 AND 21), TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

FUNCTION, INTERACTION WITH LGI1, AND MUTAGENESIS OF ASP-509.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-832; SER-864 AND SER-866, AND MASS SPECTROMETRY.

************

INTERACTION WITH LIGI1 AND LGI4.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 464-511.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), INTERACTION WITH INTEGRIN ALPHA-V/BETA-3, AND MUTAGENESIS OF GLU-566.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-707, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM DELTA).

************

NUCLEOTIDE SEQUENCE OF 666-829 (ISOFORMS ALPHA; BETA AND GAMMA), AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT MET-765.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-765.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-765.

************

VARIANTS GLU-65; GLU-134; GLU-450; PHE-482 AND ASP-502.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), CHARACTERIZATION, AND MUTAGENESIS OF GLU-343.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).

************

INVOLVEMENT IN CUTANEOUS MELANOMA, VARIANTS PHE-72; MET-89; LYS-111; PHE-112; PHE-115; ASN-131; LYS-176; PHE-234; PHE-257; GLU-305; ASN-345; ASP-403; ASP-434; LYS-503 AND TYR-533, AND CHARACTERIZATION OF VARIANTS LYS-111; PHE-112; PHE-115; PHE-257; ASP-434 AND LYS-503.

************

VARIANTS [LARGE SCALE ANALYSIS] LEU-31 AND ILE-205.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 171-210.

************

SEQUENCE REVISION TO 333-365.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 77-209.

************

MUTAGENESIS OF PHE-412.

************

MUTAGENESIS OF ASPARTIC ACID AND SERINE RESIDUES.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-297; SER-298 AND SER-299, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR OF 118-149, AND PROBABLE MEMBRANE TOPOLOGY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 212-232.

************

MUTAGENESIS OF CYS-442.

************

SEQUENCE REVISION TO 121.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 301-GLU--GLU-303 DEL.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT 301-GLU--GLU-303 DEL.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-389.

************

SEQUENCE REVISION TO 148 AND 255.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 6-453.

************

SEQUENCE REVISION TO 60; 75; 110; 143; 326-332; 365 AND 432.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 322-GLY--PRO-325 DEL.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-223.

************

PROTEIN SEQUENCE, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND GLYCOSYLATION.

************

INTERACTION WITH GCN5.

************

IDENTIFICATION IN THE ADA/GCN5 COMPLEX.

************

IDENTIFICATION IN THE SAGA COMPLEX, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN A SAGA COMPLEX WITH SPT7; HFI1; SPT8; GCN5; SPT20; SPT2; ADA3 AND TRA1.

************

FUNCTION IN HISTONE ACETYLATION AT THE SAGA COMPLEX, AND FUNCTION IN HISTONE ACETYLATION AT THE ADA COMPLEX.

************

IDENTIFICATION IN THE ADA COMPLEX, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN THE SLIK COMPLEX.

************

IDENTIFICATION IN THE SALSA COMPLEX.

************

3D-STRUCTURE MODELING OF THE SAGA COMPLEX.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), AND VARIANT PRO-359.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT PRO-359.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-467.

************

PROTEIN SEQUENCE OF 17-31.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-754 (ISOFORM 1), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND INVOLVEMENT IN ASTHMA.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-269, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN SUSCEPTIBILITY TO ASTHMA.

************

X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 204-410 IN COMPLEX WITH METALLOPROTEASE INHIBITOR MARIMASTAT, AND X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 204-410.

************

VARIANT VAL-305.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 113-797 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 562-570 AND 780-797, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION AS A TRANSCRIPTIONAL ACTIVATOR, ROLE IN RESISTANCE TO ALKYLATION DAMAGE, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, ROLE IN RESISTANCE TO ALKYLATION DAMAGE, AND INDUCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-227 AND TYR-230, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), RNA-BINDING, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 174-619 (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 438-619 (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 539-619 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT GLU-44.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-44.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 92-355 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 383-735.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 17-735.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6 AND 7), FUNCTION, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING.

************

TISSUE SPECIFICITY, PROTEOLYTIC PROCESSING, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 4).

************

NUCLEOTIDE SEQUENCE [MRNA], DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 167-754.

************

TISSUE SPECIFICITY, INVOLVEMENT IN CUTANEOUS MELANOMA, VARIANTS SER-14; CYS-31; SER-36; TYR-106; PRO-173; ALA-180; TYR-243; GLU-302; ILE-359; GLU-533; LEU-593; LYS-639 AND ASN-703, AND CHARACTERIZATION OF VARIANTS TYR-243; ILE-359; LYS-639 AND ASN-703.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 26-38.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 196-403 IN COMPLEX WITH INHIBITOR AND ZINC IONS.

************

PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA].

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-758 AND THR-761, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-815, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN CORD9.

************

3D-STRUCTURE MODELING OF 208-404.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 426-575.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 432-478.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF ARG-149 AND ARG-273.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF CYS-21; CYS-24; ARG-149 AND ARG-273, AND VARIANT SER-241.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-241.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-241.

************

INTERACTION WITH PRKCA; PRKCI; PRKCZ AND PRKD1, AND PHOSPHORYLATION AT SER-87 AND THR-276.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-272, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH PTDINS(4,5)P2; PTDINS(3,4,5)P3 AND INS(1,3,4,5)P4, TISSUE SPECIFICITY, AND MUTAGENESIS OF ARG-151 AND ARG-275.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS A; C; D; E; F AND G), FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND RNA EDITING OF POSITION 437.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 59-83; 92-114; 422-445 AND 515-539.

************

CHARACTERIZATION, AND MUTAGENESIS OF HIS-300; SER-367; ARG-419; HIS-615; HIS-616 AND HIS-617.

************

X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 9-587, COFACTOR, ACTIVE SITE, AND MUTAGENESIS OF ARG-352; ARG-447; TYR-508; HIS-544; HIS-545 AND HIS-546.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-102; LYS-169 AND LYS-347, AND MASS SPECTROMETRY.

************

VARIANT RCDP3 HIS-419.

************

VARIANTS RCDP3 ILE-309 AND PRO-469.

************

VARIANTS RCDP3 GLN-182; LYS-471 AND MET-568, AND CHARACTERIZATION OF VARIANTS RCDP3 GLN-182; LYS-471 AND MET-568.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-52 AND SER-57, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME ACTIVITY, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, TISSUE SPECIFICITY, AND VARIANT ASN-167.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, AND ENZYME ACTIVITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-167, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] CYS-332.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 87-349.

************

PROTEIN SEQUENCE OF 2-357, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 2-356 IN COMPLEX WITH ZINC IONS AND TRANSITION STATE ANALOG 6-HYDROXY-1,6-DIHYDROPURINE RIBOSIDE.

************

X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-356 IN COMPLEX WITH INHIBITOR AND ZINC IONS.

************

X-RAY CRYSTALLOGRAPHY (3.03 ANGSTROMS) OF 1-357 IN COMPLEX WITH ZINC IONS AND DPP4, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 2-356 IN COMPLEX WITH INHIBITOR.

************

X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 2-356 IN COMPLEX WITH INHIBITOR.

************

X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 2-356 IN COMPLEX WITH INHIBITOR.

************

X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 2-362 IN COMPLEX WITH DPP4 AND A HIV-1 TAT PEPTIDE.

************

X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 2-356 IN COMPLEX WITH INHIBITOR AND ZINC IONS.

************

X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 2-357 IN COMPLEX WITH EHNA.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 287-354.

************

STRUCTURE BY NMR OF 1-129.

************

STRUCTURE BY NMR OF 1-92 IN COMPLEX WITH ZINC IONS.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 175-354.

************

STRUCTURE BY NMR OF 1-92 IN COMPLEX WITH ZINC IONS, AND INTERACTION WITH DNA.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 9-139 IN COMPLEX WITH DNA AND ZINC IONS, STRUCTURE BY NMR OF 9-139, MASS SPECTROMETRY, AND ACTIVE SITE.

************

STRUCTURE BY NMR OF 1-146 IN COMPLEX WITH ZINC IONS, MASS SPECTROMETRY, AND ACTIVE SITE CYS-38.

************

PROTEIN SEQUENCE OF 2-11, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 141-363.

************

INTERACTION WITH DPP4, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH DPP4.

************

INTERACTION WITH APP4.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-54 AND LYS-232, AND MASS SPECTROMETRY.

************

VARIANTS ADASCID TRP-76; PRO-107; GLN-149; CYS-211; THR-215 AND LEU-274.

************

VARIANT ADA*2 ASN-8.

************

VARIANTS ADASCID.

************

VARIANT ADASCID GLN-101.

************

VARIANTS ADASCID TRP-101; HIS-211 AND VAL-329.

************

VARIANT ADASCID GLN-297.

************

VARIANTS ADASCID CYS-156 AND LEU-291.

************

VARIANTS ADASCID LEU-101; HIS-156; MET-177; ARG-216 AND LEU-291.

************

VARIANT ADASCID ARG-20.

************

VARIANTS ARG-80 AND GLN-142.

************

VARIANTS ADASCID ASP-15; ASP-83 AND ASP-179.

************

VARIANTS MET-152 AND ILE-233.

************

VARIANTS ADASCID CYS-74; MET-129; GLU-140; TRP-149 AND PRO-199.

************

EFFECT OF VARIANT ADA*2 ASN-8 ON SLEEP.

************

VARIANT [LARGE SCALE ANALYSIS] GLN-142.

************

MUTAGENESIS OF GLU-217, CIRCULAR DICHROISM, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, ACTIVE SITE, AND PROPOSED ENZYME MECHANISM.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH ZINC IONS AND TRANSITION STATE ANALOG 6-HYDROXYL-1,6-DIHYDROPURINE RIBONUCLEOTIDE, COFACTOR, AND PROPOSED ENZYME MECHANISM.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 4-352 OF MUTANTS GLU-295 AND ALA-296 IN COMPLEXES WITH ZINC IONS; 6-HYDROXYL-1,6-DIHYDROPURINE RIBONUCLEOTIDE AND PURINE RIBOSIDE, CIRCULAR DICHROISM, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-295 AND ASP-296.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF MUTANTS ALA-238 AND GLU-238 IN COMPLEXES WITH ZINC IONS; 6-HYDROXYL-1,6-DIHYDROPURINE RIBONUCLEOTIDE AND PURINE RIBOSIDE, AND MUTAGENESIS OF HIS-238.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH ZINC IONS AND INHIBITOR, COFACTOR, AND ACTIVE SITE.

************

INDUCTION, AND DISRUPTION PHENOTYPE.

************

MEMBRANE LOCALIZATION, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-423.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-93 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-441, AND MASS SPECTROMETRY.

************

VARIANTS [LARGE SCALE ANALYSIS] PRO-307; LEU-418; LEU-622 AND LEU-626.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 262-648.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.

************

VARIANT [LARGE SCALE ANALYSIS] THR-341.

************

VARIANTS COQ10D4 TRP-213; VAL-272; ASP-272 AND LYS-551.

************

VARIANTS COQ10D4 CYS-514; SER-549 AND THR-584 DEL.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 250-547 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-166 (ISOFORM 1).

************

VARIANTS [LARGE SCALE ANALYSIS] CYS-78; ARG-174; MET-318; ARG-352 AND MET-462.

************

VARIANT [LARGE SCALE ANALYSIS] SER-17.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT PHE-195.

************

PROTEIN SEQUENCE OF 7-18; 36-51; 60-70 AND 130-136, AND MASS SPECTROMETRY.

************

3D-STRUCTURE MODELING OF 295-450; 861-936 AND 950-1045.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 281-1119.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 100-1050.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 434-1307.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 205-1091.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 616-1091.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 948-1017.

************

PHOSPHORYLATION BY RAF1, INTERACTION WITH RAF1, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF 871-1090.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 870-1081 OF COMPLEX WITH G(S)-ALPHA.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 870-1081 OF COMPLEX WITH G(S)-ALPHA.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PRO-107.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 212-1144.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 984-1060.

************

PROTEIN SEQUENCE OF 355-366, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 445-661 OF COMPLEX WITH G(S)-ALPHA.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 445-661 OF COMPLEX WITH G(S)-ALPHA.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 368-1261 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 560-664 (ISOFORM 1).

************

VARIANT FDFM THR-726.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH AKAP5; ADCY6; PDE4C AND PKD2.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 164-1262.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1040-1103.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54 AND SER-576, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-576, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-1165.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH AKAP5; ADCY5; PDE4C AND PKD2.

************

PHOSPHORYLATION AT SER-554; SER-660 AND THR-917, AND MUTAGENESIS OF SER-311; SER-554; SER-660 AND THR-917.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 577-1251.

************

VARIANT [LARGE SCALE ANALYSIS] LEU-881.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT MET-772.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT MET-772.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-365, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-354; SER-357 AND SER-1259, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1106-1193.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-610 AND SER-613, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-608; SER-610 AND SER-613, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-697.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, INVOLVEMENT IN HCA2, AND VARIANT VAL-697.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANT VAL-697.

************

TISSUE SPECIFICITY, ENZYME REGULATION, SUBCELLULAR LOCATION, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-809 AND SER-810, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 60-67; 254-262 AND 402-409, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-25.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-30.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 207-244.

************

CATALYTIC MECHANISM, AND MUTAGENESIS OF LYS-115 AND LYS-116.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 6), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-70, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 780.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1000-1232.

************

SUBUNIT, AND FUNCTION IN E.COLI.

************

FUNCTION AS AN EXONUCLEASE AND HELICASE, COFACTOR, AND ATP-DEPENDENCE.

************

RECRUITS RECA TO DNA DOUBLE-STRAND BREAKS.

************

FUNCTION, AND MUTAGENESIS OF LYS-36 AND ASP-1172.

************

SUBUNIT, AND DNA-BINDING.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 24-36; 41-47; 516-569 AND 722-729, AND VARIANT CYS-586.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 531-737 (ISOFORMS 1/3).

************

PHOSPHORYLATION AT SER-59; SER-408; SER-436; SER-481; SER-716 AND SER-726, AND PARTIAL PROTEIN SEQUENCE.

************

PHOSPHORYLATION AT THR-445 AND THR-480, AND MUTAGENESIS OF THR-445 AND THR-480.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-358 AND SER-465, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-355 AND SER-358, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-707; SER-710 AND SER-716, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-353; SER-355; SER-358 AND SER-465, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12 AND SER-358, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; THR-331; SER-334; SER-358; SER-431; SER-436 AND SER-465, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-355; SER-358; SER-464; SER-465 AND SER-726, AND MASS SPECTROMETRY.

************

VARIANT TRP-460.

************

VARIANTS TRP-460 AND CYS-586.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, FUNCTION IN E.COLI, OPERON STRUCTURE, AND DISRUPTION PHENOTYPE.

************

RECOGNITION OF CHI SEQUENCES.

************

EXONUCLEASE ACTIVITY, AND MUTAGENESIS OF 1144-ASP--LYS-1146.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-610, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12 AND SER-586, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-355; THR-358; SER-586; THR-610 AND THR-614, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-358; SER-483 AND THR-610, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 426-735.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-610 AND THR-614, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 844.

************

FUNCTION AS AN EXONUCLEASE AND HELICASE, MAGNESIUM COFACTOR, AND ATP-DEPENDENCE.

************

FUNCTION, AND MUTAGENESIS OF ASP-961.

************

COFACTOR, SUBUNIT, DNA-BINDING, AND MUTAGENESIS OF CYS-801; CYS-1121; CYS-1124 AND CYS-1130.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4; 5; 6 AND 7), TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 8).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 332-726 (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 462-559 (ISOFORM 2), AND ALTERNATIVE SPLICING.

************

PHOSPHORYLATION AT THR-55; SER-703 AND SER-713, AND PARTIAL PROTEIN SEQUENCE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-592; SER-596; SER-600; SER-604; SER-693; SER-697 AND SER-699, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, FUNCTION IN E.COLI, AND OPERON STRUCTURE.

************

EXONUCLEASE ACTIVITY, AND MUTAGENESIS OF ASP-910 AND 910-ASP--LYS-912.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-561 (ISOFORM 2), AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION AT SER-594 AND SER-602, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-602 AND THR-687, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-532 AND SER-535, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-594, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 532-725 (ISOFORM 1).

************

SUMOYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-673; SER-677 AND SER-693, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-681, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42 AND SER-681, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42; SER-423; SER-442; SER-673; SER-677; SER-681 AND SER-693, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-12, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-402; SER-423; SER-673; SER-677 AND SER-681, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-673 AND SER-681, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-402; SER-677 AND SER-681, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBUNIT, AND INTERACTION WITH ADD1.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-237, AND MASS SPECTROMETRY.

************

INDUCTION, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CATALYTIC ACTIVITY, AND COFACTOR.

************

SEQUENCE REVISION TO 262-265.

************

CATALYTIC ACTIVITY, COFACTOR, AND SUBUNIT.

************

CATALYTIC ACTIVITY, COFACTOR, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 167-204.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-198.

************

FUNCTION, DISRUPTION PHENOTYPE, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

New York structural genomix research consortium (NYSGXRC);

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND MUTAGENESIS OF ARG-150.

************

FUNCTION, INTERACTION WITH SAF1, UBIQUITINATION, AND MUTAGENESIS OF ILE-69; ASN-72; ASP-219; GLU-237 AND LYS-329.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-612.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

IDENTIFICATION OF PROBABLE INITIATION SITE.

************

PROTEIN SEQUENCE OF 56-64, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], TISSUE SPECIFICITY, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-137.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 78-140.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 12-141.

************

PROTEIN SEQUENCE, FUNCTION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, FUNCTION, TISSUE SPECIFICITY, MASS SPECTROMETRY, AND SYNTHESIS.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 848-1131.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-1637.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-754 (ISOFORM 1), AND VARIANT THR-310.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 697-964.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-375.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.

************

X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) IN COMPLEX WITH NAD AND ZINC IONS.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH NAD AND ZINC IONS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-48; LYS-57 AND CYS-370.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HIS-48.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT HIS-48.

************

PARTIAL NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-57.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-86.

************

VARIANT HIS-48.

************

VARIANT CYS-370.

************

X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS).

************

ASSOCIATION OF VARIANT HIS-48 WITH LOWER RISK OF ALCOHOLISM.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GAMMA-2 GLN-272 AND VAL-350.

************

PROTEIN SEQUENCE OF 2-374.

************

PARTIAL PROTEIN SEQUENCE, AND ACETYLATION AT SER-2.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-101 AND LYS-106.

************

MUTANT R006.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-229, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 111-349.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 104-313.

************

PROTEIN SEQUENCE OF 2-17 AND 360-376.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-187; VAL-189 AND LEU-236.

************

X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) IN COMPLEX WITH ZINC IONS, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (1.77 ANGSTROMS) IN COMPLEX WITH ZINC IONS.

************

X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) IN COMPLEX WITH ZINC, COFACTOR, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-30.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS.

************

PROTEIN SEQUENCE OF 1-45.

************

PROTEIN SEQUENCE OF 34-54.

************

PROTEIN SEQUENCE OF 1-37; 188-197; 247-263 AND 324-336.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 74-304.

************

NUCLEOTIDE SEQUENCE (ALLELE ADH1-F).

************

NUCLEOTIDE SEQUENCE (ALLELE ADH1-CM).

************

NUCLEOTIDE SEQUENCE OF 212-379.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 8-51.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 224-375.

************

PROTEIN SEQUENCE OF 1-5.

************

ACETYLATION AT SER-2.

************

PROTEIN SEQUENCE OF 1-13, AND ACETYLATION AT SER-1.

************

PARTIAL PROTEIN SEQUENCE, AND ACETYLATION AT SER-1.

************

PROTEIN SEQUENCE OF 2-348, ACETYLATION AT SER-2, AND VARIANT ILE-236.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 214-333.

************

PROTEIN SEQUENCE OF 62-76; 320-332 AND 337-348.

************

PROTEIN SEQUENCE OF 9-17; 40-48 AND 304-310.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-290 AND SER-316, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-15; SER-213 AND THR-223, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316 AND THR-325, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40.

************

PROTEIN SEQUENCE OF 1-31.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-28; THR-92; LEU-112; THR-115; ILE-136; LEU-146; PRO-147; GLN-226 AND LEU-236.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-28 AND SER-71.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-28; TYR-98; THR-115; ILE-136 AND LEU-236.

************

SEQUENCE REVISION TO 380-383.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 336-383.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 377-395 AND 860-870.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-40.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 252-380.

************

PROTEIN SEQUENCE OF 193-207 AND 227-234.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-290, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-290; SER-294 AND THR-302, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-288; SER-290 AND SER-316, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-50.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-310, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS VAL-309 AND ILE-374.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ZINC-BINDING, MUTAGENESIS OF PRO-48; ASN-52 AND SER-183, AND TISSUE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF WILD-TYPE IN COMPLEX WITH NADH AND INHIBITOR AND OF MUTANT HIS-48 IN COMPLEX WITH NADH.

************

PROTEIN SEQUENCE OF 1-13, AND ACETYLATION AT THR-1.

************

PARTIAL PROTEIN SEQUENCE, AND ACETYLATION AT THR-1.

************

BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, COFACTOR, AND ENZYME REGULATION.

************

INDUCTION, AND IDENTIFICATION OF PROBABLE INITIATION SITE.

************

EXPRESSION LEVEL IN BREWING STRAINS.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-305, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252 AND THR-305, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122; SER-131; SER-210 AND SER-359, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 13-386 (ISOFORM 1), AND ZINC-BINDING SITES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 13-386 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 13-386.

************

PROTEIN SEQUENCE OF 24-33; 53-58; 74-92; 97-123; 147-154 AND 181-186.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 239-311 (ISOFORM 1).

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 14-386.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 14-386 IN COMPLEX WITH NAD AND ZINC IONS.

************

CHARACTERIZATION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-373.

************

SEQUENCE REVISION TO 226.

************

FUNCTION, INDUCTION, OPERON STRUCTURE, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE OF N-TERMINUS.

************

SEQUENCE REVISION TO 58.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-14, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

GENE DUPLICATION, AND DISRUPTION PHENOTYPE.

************

PUPYLATION AT LYS-210, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

PUPYLATION AT LYS-209, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-11.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-7, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 849-891.

************

ANTIOXIDANT ROLE OF ADHE.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-358, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, AND ACETYLATION AT ALA-1.

************

PARTIAL PROTEIN SEQUENCE, AND ACETYLATION AT ALA-1.

************

PROTEIN SEQUENCE OF 1-35, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 87-118.

************

SEQUENCE REVISION TO 74.

************

FUNCTIONS TO ACTIVATE THE ADHA-YRAA OPERON, DNA-BINDING, INDUCTION, MUTAGENESIS OF CYS-52, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-77.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 26-40.

************

FUNCTION AS AN ADH SYNTHASE.

************

FUNCTION AS A FBP ALDOLASE, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH SUBSTRATE ANALOGS, REACTION MECHANISM, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND ENZYME ACTIVITY.

************

PROTEIN SEQUENCE OF 2-374, AND ACETYLATION AT SER-2.

************

PROTEIN SEQUENCE OF 2-7, AND ACETYLATION AT SER-2.

************

PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS OF ARG-115.

************

MUTAGENESIS OF ARG-115.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-366, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).

************

PROTEIN SEQUENCE OF 234-248, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, AND ACETYLATION AT SER-1.

************

PROTEIN SEQUENCE OF 2-7, AND ACETYLATION AT ALA-2.

************

3D-STRUCTURE MODELING.

************

PROTEIN SEQUENCE OF 1-21, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) IN COMPLEX WITH NADP AND ZINC, SUBUNIT, AND COFACTOR.

************

X-RAY CRYSTALLOGRAPHY (1.97 ANGSTROMS) IN COMPLEX WITH ZINC.

************

X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH ZINC, SUBUNIT, COFACTOR, FUNCTION, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 50-145.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 32-166.

************

PHYLOGENETIC RELATIONSHIP TO OTHER DROSOPHILA ADH.

************

X-RAY CRYSTALLOGRAPHY (1.92 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH NAD AND PRODUCT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE ADH-S).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE ADH-NB).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES ADH-S AND ADH-F).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES ADH-JA-F AND ADH-AF-S).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE ADH-N4).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE ADH-F-CHD).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE ADH-71K).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE ADH-F).

************

NUCLEOTIDE SEQUENCE [MRNA] (ALLELE ADH-S).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES ADH-H3; ADH-H12; ADH-H13; ADH-H18; ADH-H21; ADH-K15; ADH-K30; ADH-K35; ADH-K37 AND ADH-K82).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE ADH-S).

************

PROTEIN SEQUENCE OF 2-256 (ALLELE ADH-F').

************

PROTEIN SEQUENCE OF 2-256 (ALLELES ADH-F; ADH-S; ADH-UF AND ADH-N11), AND ACETYLATION AT SER-2.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 52-256 (ALLELE ADH-NLA248).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 141-256 (ALLELE ADH-F).

************

PROTEIN SEQUENCE OF 208-225 (ALLELE ADH-F-CHD).

************

MUTAGENESIS OF TYR-153.

************

MUTAGENESIS OF TYR-153 AND LYS-157.

************

MUTAGENESIS OF GLY-130; GLY-133; TYR-153; LYS-157 AND GLY-184.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH NAD AND SUBSTRATE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-82 AND LYS-185.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 12-248.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 32-220.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ADH1 AND ADH2).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 12-248 (ADH1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 12-248 (ADH1).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 130-165.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-57; ALA-77; PRO-138; PRO-194; ALA-213 AND THR-225.

************

PROTEIN SEQUENCE, AND CHARACTERIZATION.

************

IDENTIFICATION AS A TYPE-A DEHYDROGENASE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 343-350.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-205 AND THR-250, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) IN COMPLEX WITH NADP AND ZINC.

************

X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 153-295 IN COMPLEX WITH ZINC, FUNCTION, SUBUNIT, COFACTOR, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-78.

************

PROTEIN SEQUENCE OF 1-7.

************

X-RAY CRYSTALLOGRAPHY (3.61 ANGSTROMS), SUBUNIT, SUBSTRATE-BINDING SITES, MUTAGENESIS OF TYR-87; TYR-93 AND TYR-365, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS), SUBUNIT, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 18-26; 194-197; 203-208 AND 221-228, GLYCOSYLATION, AND STRUCTURE OF CARBOHYDRATES.

************

PROTEIN SEQUENCE OF 18-26, PARTIAL PROTEIN SEQUENCE, HYDROXYLATION AT LYS-28; PRO-39; PRO-42; PRO-48; LYS-60; LYS-63; LYS-72; PRO-86 AND LYS-96, GLYCOSYLATION AT LYS-28; LYS-60; LYS-63 AND LYS-96, ABSENCE OF HYDROXYLATION AT PRO-57; PRO-66; PRO-71; PRO-90 AND PRO-99, ABSENCE OF GLYCOSYLATION AT ASN-225, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 19-33.

************

PROTEIN SEQUENCE OF N-TERMINUS, AND PARTIAL PROTEIN SEQUENCE.

************

SUBUNIT, DISULFIDE BOND, MUTAGENESIS OF CYS-36, AND CHARACTERIZATION OF VARIANTS ARG-84; SER-90; CYS-112 AND THR-164.

************

SUBUNIT, HYDROXYLATION AT PRO-44; PRO-47; PRO-53; LYS-65; LYS-68; PRO-71; PRO-76; LYS-77; PRO-91; PRO-95 AND LYS-101, GLYCOSYLATION AT LYS-65; LYS-68; LYS-77 AND LYS-101, DISULFIDE BOND, LACK OF HYDROXYLATION AT PRO-62; PRO-86 AND PRO-104, LACK OF GLYCOSYLATION AT ASN-230, MUTAGENESIS OF LYS-33; CYS-36; LYS-65; LYS-68; LYS-77 AND LYS-101, AND MASS SPECTROMETRY.

************

GLYCOSYLATION AT THR-21 AND THR-22, SUBUNIT, MASS SPECTROMETRY, AND MUTAGENESIS OF THR-20; THR-21 AND THR-22.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 104-244, AND SUBUNIT.

************

VARIANT ADPND CYS-112.

************

VARIANTS ARG-84; MET-117; THR-164; SER-221 AND PRO-241.

************

VARIANTS CYS-112; THR-164; SER-221 AND PRO-241, AND ASSOCIATION WITH LOW PLASMA ADIPONECTIN CONCENTRATION AND DIABETES MELLITUS TYPE 2.

************

VARIANTS ARG-84; SER-90 AND HIS-111.

************

PROTEIN SEQUENCE OF 18-25, HYDROXYLATION AT LYS-68; LYS-71; LYS-80; PRO-94 AND LYS-104, GLYCOSYLATION AT LYS-68; LYS-71; LYS-80 AND LYS-104, GLYCAN STRUCTURE, ABSENCE OF HYDROXYLATION AT PRO-79; PRO-98 AND PRO-107, ABSENCE OF GLYCOSYLATION AT ASN-233, AND MASS SPECTROMETRY.

************

SUBUNIT, AND MUTAGENESIS OF LYS-68; LYS-71; LYS-80 AND LYS-104.

************

SUBUNIT, INTERACTION WITH CTRP9, AND MUTAGENESIS OF CYS-39.

************

GLYCOSYLATION AT THR-23 AND THR-24, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 111-247.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH SSX2 AND SSX3, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-578.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293 AND SER-325, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-339; SER-341; SER-540 AND THR-565, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312; SER-536 AND SER-540, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH AFIDIN AND ALPHA-ACTININ, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AFIDIN AND ALPHA-ACTININ.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND CHARACTERIZATION.

************

INTERACTION WITH TOMATO GOLDEN MOSAIC VIRUS AL2 AND BEET CURLY TOP VIRUS L2.

************

INTERACTION WITH TOMATO GOLDEN MOSAIC VIRUS AL2 AND BEET CURLY TOP VIRUS L2, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND PROTEIN SEQUENCE OF 94-133; 175-200 AND 272-289.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), AND ALTERNATIVE SPLICING.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF SHORT ISOFORM.

************

PHOSPHORYLATION AT TYR-77.

************

VARIANTS HMAKD GLU-30; ALA-235 AND GLU-318, AND CHARACTERIZATION OF VARIANTS HMAKD GLU-30; ALA-235 AND GLU-318.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), TISSUE SPECIFICITY, AND MUTAGENESIS OF SER-48; SER-85; SER-272 AND SER-328.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 84-361, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 17-361, AND CHARACTERIZATION.

************

PROTEIN SEQUENCE OF 88-110 AND 119-148, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF ARG-4; ARG-6; ARG-7 AND LYS-8.

************

INTERACTION WITH SNL1.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 192-791.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 456-499.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-331.

************

NUCLEOTIDE SEQUENCE [MRNA], VARIANT PHE-57, AMIDATION AT TYR-77, DISULFIDE BOND, SYNTHESIS OF 26-77, TISSUE SPECIFICITY, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND IDENTIFICATION OF AM 11-26.

************

PROTEIN SEQUENCE OF 95-146, AMIDATION AT TYR-146, AND DISULFIDE BOND.

************

STRUCTURE BY NMR OF 22-41, AND AMIDATION AT ARG-41.

************

PROTEIN SEQUENCE OF 22-41.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-89, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 420-596, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 30-1102.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 98-1102.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-953 AND SER-955, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-413, AND MASS SPECTROMETRY.

************

CHARACTERIZATION OF NAP PEPTIDE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-409; SER-709; SER-736; SER-876; SER-878; SER-953 AND SER-955, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-921; SER-970 AND SER-982, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-736 AND SER-955, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1035 AND LYS-1042, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND SYNTHESIS OF 74-81.

************

STRUCTURE BY NMR, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INDUCTION, AND MUTAGENESIS OF ASP-320 AND ASP-425.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH CRY1 AND PHYB.

************

INTERACTION WITH SKP1A; SKP1B; SKP1D; SKP1K AND SKP1S.

************

INTERACTION WITH SKP1A; SKP1B; SKP1D; SKP1K; SKP1N; ADO2; APRR1 AND APRR5.

************

FUNCTION, MUTAGENESIS OF LEU-200 AND LEU-213, AND IDENTIFICATION IN A SCF(ADO1) COMPLEX.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.

************

INTERACTION WITH SKP1A; SKP1B; SKP1C; SKP1D; SKP1E; SKP1K; SKP1N; SKP1TA; SKP1TB; ADO1; AD03; APRR1 AND APRR5, SELF-ASSOCIATION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH DI19 AND COL1, AND SUBCELLULAR LOCATION.

************

FUNCTION, INDUCTION, FMN-BINDING AT CYS-91, AND MUTAGENESIS OF CYS-91.

************

INTERACTION WITH SKP1A; SKP1B; SKP1K; SKP1N AND ADO2.

************

INTERACTION WITH SKP1A/ASK1; SKP1B/ASK2; ASK3; ASK11; ASK12 AND ASK13.

************

PROTEIN SEQUENCE OF 2-16, FUNCTION, COFACTOR, SUBUNIT, ENZYME REGULATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 43-48; 187-218 AND 538-573.

************

NUCLEOTIDE SEQUENCE OF 561-746, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 857-884; 891-943 AND 1272-1293, AND CATALYTIC ACTIVITY.

************

PROTEIN SEQUENCE OF 203-231 AND 574-597.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 106-177.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 468-588; 627-723; 980-1162 AND 1235-1289.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 378-570.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 159-1122.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1301-1520.

************

SEQUENCE REVISION TO 29.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-677, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-659; THR-678 AND SER-702, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 94-1122.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-185.

************

FUNCTION, DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, AND INDUCTION.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-89, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).

************

CHARACTERIZATION, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 99-309.

************

PROTEIN SEQUENCE OF 235-246, AND MASS SPECTROMETRY.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, COFACTOR, MASS SPECTROMETRY, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-258, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 14-309 IN COMPLEXES WITH COENZYME A; MAGNESIUM IONS AND FASN, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, AND MUTAGENESIS OF ARG-47; ARG-86; HIS-111; GLN-112; ASP-129; GLU-181 AND LYS-185.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-15, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 98-209.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF APOPROTEIN AND COMPLEXES WITH ADP-RIBOSE AND GADOLINIUM IONS, COFACTOR, CATALYTIC ACTIVITY, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS), IN COMPLEX WITH AMPCPR AND MAGNESIUM IONS, COFACTOR, AND CATALYTIC MECHANISM.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-47.

************

PROTEIN SEQUENCE OF 147-165, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-217 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA], IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, COFACTOR, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND TOPOLOGY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-259, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-193; SER-212; SER-230; THR-259; SER-301; SER-322; SER-323; THR-327; SER-400; SER-401; SER-475; THR-1248 AND SER-1250, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR OF ZINC-FINGERS.

************

STRUCTURE BY NMR OF 131-159.

************

STRUCTURE BY NMR OF 102-161.

************

MUTAGENESIS, AND PHOSPHORYLATION AT SER-230.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-159.

************

LACK OF CELLULOSE PRODUCTION IN K12 STRAINS.

************

REGULATION BY CSGD.

************

INDUCTION, RPOS-DEPENDENCE, AND REGULATION CASCADE.

************

INDUCTION, AND RPOS-DEPENDENCE.

************

FUNCTION, PROBABLE ENZYME ACTIVITY, AND MUTAGENESIS OF 291-ASP-GLU-292.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 90-367.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-49 AND GLY-389.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-389.

************

INTERACTION WITH GOPC AND DLG4, MUTAGENESIS OF GLU-474; SER-475; LYS-476 AND VAL-477, AND SUBCELLULAR LOCATION.

************

VARIANT GLY-389.

************

VARIANT GLY-49.

************

STRUCTURE BY NMR OF 345-359.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 33-367 IN COMPLEX WITH THE ANTAGONIST CYANOPINDOLOL, DISULFIDE BONDS, FUNCTION, AND TOPOLOGY.

************

PROTEIN SEQUENCE OF 303-307, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 101-468.

************

INTERACTION WITH MAGI3, AND MUTAGENESIS OF VAL-466.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 90-435.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 253-377.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-27.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16 AND GLN-27.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ARG-16 AND GLN-27.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-27.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16; GLN-27; MET-34 AND ILE-164.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-27; LEU-159; PHE-159 AND ARG-375.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-16 AND GLN-27.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-27.

************

MUTAGENESIS OF ASP-79.

************

PALMITOYLATION AT CYS-341, AND MUTAGENESIS OF CYS-341.

************

MUTAGENESIS OF TYR-141; TYR-350; TYR-354 AND TYR-366, AND PHOSPHORYLATION AT TYR-141.

************

INTERACTION WITH ARRB1.

************

INTERACTION WITH SLC9A3R1.

************

INTERACTION WITH SRC AND ARRB1.

************

EFFECT OF PALMITOYLATION, PHOSPHORYLATION AT SER-345 AND SER-346, AND MUTAGENESIS OF 345-SER-SER-346.

************

INTERACTION WITH GPRASP1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-246, AND MASS SPECTROMETRY.

************

UBIQUITINATION, DEUBIQUITINATION BY USP20 AND USP33, AND INTERACTION WITH USP20 AND USP33.

************

INTERACTION WITH EGLN3 AND VHL, SUBCELLULAR LOCATION, INDUCTION, UBIQUITINATION, HYDROXYLATION AT PRO-382 AND PRO-395, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 1-365 IN COMPLEX WITH CARAZOLOL, AND TOPOLOGY.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-365 IN COMPLEX WITH CARAZOLOL AND CHOLESTEROL, DISULFIDE BONDS, TOPOLOGY, AND PALMITOYLATION AT CYS-341.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-365 IN COMPLEX WITH TIMOLOL AND CHOLESTEROL, DISULFIDE BONDS, TOPOLOGY, AND PALMITOYLATION AT CYS-341.

************

VARIANTS ARG-16 AND GLN-27, AND CHARACTERIZATION.

************

VARIANT ARG-16, AND ASSOCIATION OF GLY-16 WITH NOCTURNAL ASTHMA.

************

MUTAGENESIS TO CONFIRM GLYCOSYLATION SITES.

************

MUTAGENESIS OF SER-204 AND SER-207.

************

MUTAGENESIS OF ASP-79 AND ASP-113.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 144-252, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 4-106.

************

NUCLEOTIDE SEQUENCE OF 156-298.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 392-408.

************

VARIANT ARG-64.

************

VARIANTS ARG-64 AND MET-265.

************

NUCLEOTIDE SEQUENCE OF 378-400.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2-105, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-52; VAL-270; VAL-322 AND GLN-376.

************

REGULATION BY CSGD, INDUCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-283 (ISOFORM 2).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND MASS SPECTROMETRY.

************

INTERACTION WITH PHG2, AND FUNCTION.

************

INTERACTION WITH 26S PROTEASOME, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; SER-185; SER-217; SER-218 AND SER-219, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; THR-196; THR-205; SER-207; SER-217; SER-219 AND THR-367, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH PSMD1 AND UCHL5, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-405, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH UCHL5, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH 26S PROTEASOME, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH PSMD1 AND UCHL5, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-34, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH UBIQUITIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-211; THR-217; SER-220 AND SER-405, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-213 AND THR-217, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-21, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, AND LACK OF GLYCOSYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-213, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR OF 22-130, X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-150, FUNCTION, PH DOMAIN, AND INTERACTION WITH UBIQUITIN; UCHL5 AND PSMD1.

************

PROTEIN SEQUENCE OF 33-62; 254-276 AND 487-492.

************

PROTEIN SEQUENCE OF 33-51 AND 298-320.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 33-492 IN COMPLEX WITH FAD.

************

X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 33-492 IN COMPLEX WITH NADP.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-492 IN COMPLEX WITH FDX1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SHORT AND LONG), AND VARIANT GLN-123.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 34-54.

************

IDENTIFICATION, AND SUBCELLULAR LOCATION.

************

FUNCTION, AND SPECIFICITY.

************

PROTEIN SEQUENCE OF 364-375, AND DOMAIN FUNCTION.

************

PROTEIN SEQUENCE OF 129-137 AND 243-247, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DEVELOPMENTAL STAGE, AND INDUCTION.

************

X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 345-715, AND MUTAGENESIS OF PHE-455.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-102 AND TYR-599, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-381.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-190.

************

PROTEIN SEQUENCE OF 2-298, AND ACETYLATION AT SER-2.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 208-298.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH INHIBITOR.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-37.

************

PROTEIN SEQUENCE OF 2-31; 34-43; 64-92; 141-147; 189-199 AND 273-296, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLY-2, AND MASS SPECTROMETRY.

************

INTERACTION WITH HIV-1 VPR.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-96, AND MASS SPECTROMETRY.

************

VARIANTS PEOA2 PRO-114 AND MET-289.

************

VARIANT PEOA2 PRO-98.

************

VARIANT PEOA2 GLY-104.

************

VARIANT PEO MET-289.

************

VARIANT HYPERTROPHIC CARDIOMYOPATHY ASP-123.

************

VARIANT PEOA2 ASP-90.

************

VARIANTS PEOA2 PRO-98 AND PRO-114.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 59-387.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 70-387.

************

PROTEIN SEQUENCE OF 81-92, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN A COMPLEX WITH ARL2 AND ARL2BP, INTERACTION WITH ARL2BP, AND TISSUE SPECIFICITY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-10, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-195, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-126 AND SER-127, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-31; 34-43; 73-80 AND 273-280, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLY-2, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 265-309.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-111.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-111.

************

PROTEIN SEQUENCE OF 2-31; 34-43; 64-92; 141-147; 189-199 AND 273-296, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-23; 32-43; 50-60; 64-92; 81-92; 97-106; 112-138; 172-199; 207-235; 245-259 AND 281-295, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, METHYLATION AT LYS-52, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 46-297.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191 AND TYR-195, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-23; LYS-105; LYS-163 AND LYS-199, AND MASS SPECTROMETRY.

************

FUNCTION, AND IDENTIFICATION IN MMXD COMPLEX.

************

MALONYLATION AT LYS-23; LYS-92; LYS-96 AND LYS-147.

************

PROTEIN SEQUENCE OF 2-31; 34-43; 64-72; 81-92; 97-106 AND 189-199, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-23; LYS-92; LYS-155; LYS-163; LYS-166 AND LYS-199, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-31; 34-43; 73-80 AND 273-280, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.

************

MUTAGENESIS, AND TOPOLOGY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-39 AND SER-42, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 3-9; 35-43; 65-80 AND 274-280, IDENTIFICATION IN A COMPLEX WITH ARL2 AND ARL2BP, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-242.

************

PROTEIN SEQUENCE OF 2-10, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 36-298.

************

FUNCTION IN APOPTOSIS.

************

INTERACTION WITH INFLUENZA A VIRUS PB1-F2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-148, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-23; LYS-96; LYS-105; LYS-268 AND LYS-272, AND MASS SPECTROMETRY.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, AND INDUCTION.

************

PROTEIN SEQUENCE OF 57-76; 144-154; 191-201 AND 267-282, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-305.

************

PROTEIN SEQUENCE OF 59-172 (ISOFORM 1).

************

PROTEIN SEQUENCE OF 171-185.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 59-186 IN COMPLEX WITH ADRENODOXIN REDUCTASE.

************

STRUCTURE BY NMR OF 59-186.

************

X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 63-166.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-143.

************

CYCLIC VOLTAMMETRY.

************

PROTEIN SEQUENCE OF 59-175.

************

PROTEIN SEQUENCE OF 59-76.

************

PROTEIN SEQUENCE OF 1-127.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 7-128.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-47, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, AND INDUCTION.

************

IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, COMPOSITION OF A SPB COMPLEX, AND INTERACTION WITH SSP1; NUD1; CNM67 AND MPC54.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SPO21; NUD1 AND CNM67.

************

FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND INTERACTION WITH CNM67; SPO21 AND NUD1.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLU-1133.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 314-1158 (ISOFORM 1), AND TISSUE SPECIFICITY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528 AND ASN-922, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND DEVELOPMENTAL STAGE.

************

FUNCTION, DNA-BINDING, AND INTERACTION WITH GNG5.

************

ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.

************

FUNCTION, INTERACTION WITH MAPK1 AND MAPK3, AND DEVELOPMENTAL STAGE.

************

FUNCTION, DISRUPTION PHENOTYPE, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

DNA-BINDING, MUTAGENESIS OF THR-1003, AND PHOSPHORYLATION.

************

SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND INDUCTION.

************

FUNCTION, DNA-BINDING, AND INTERACTION WITH CALMODULIN.

************

FUNCTION, INTERACTION WITH NFKBIA, AND SUBCELLULAR LOCATION.

************

DISRUPTION PHENOTYPE, AND INTERACTION WITH PTEN.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 61-517 (ISOFORM 1).

************

IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH EED; EZH2; RBBP4; RBBP7 AND SUZ12.

************

FUNCTION, SELF-ASSOCIATION, AND INTERACTION WITH EED; EZH2; RBBP4 AND SUZ12.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-24, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND SER-27, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206; SER-210 AND SER-211, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-24, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 164-503 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 178-504 (ISOFORM 1), FUNCTION, DNA-BINDING, TISSUE SPECIFICITY, AND MUTAGENESIS OF 315-HIS-SER-316.

************

IDENTIFICATION IN THE PRC2/EED-EZH1 COMPLEX.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 35-270, AND VARIANT ALA-39.

************

CATALYTIC ACTIVITY, COFACTOR, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, AND PROBABLE ROLE IN MUREIN PEPTIDE METABOLISM.

************

PROBABLE FUNCTION IN PEPTIDOGLYCAN DEGRADATION, AND REVIEW.

************

X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEX WITH MAGNESIUM, COFACTOR, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEX WITH SUBSTRATE AND MAGNESIUM, COFACTOR, ACTIVE SITES, AND REACTION MECHANISM.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

FUNCTION IN PEPTIDOGLYCAN RECYCLING, AND REVIEW.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS), AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF APOENZYME AND IN COMPLEXES WITH SUBSTRATE AND MAGNESIUM, FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

PROTEIN SEQUENCE, FUNCTION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLY-987.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 725-1216 (ISOFORM 3), AND VARIANT GLY-987.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-197 AND THR-205, AND MASS SPECTROMETRY.

************

VARIANTS [LARGE SCALE ANALYSIS] THR-244 AND TRP-1174.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 22-27; 108-121; 159-179; 210-227 AND 270-279, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASP-140.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-140.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 106-325 (ISOFORM 1), AND VARIANT ASP-140.

************

FUNCTION, SUBCELLULAR LOCATION, INDUCTION, NUCLEAR LOCALIZATION SIGNAL, NUCLEOLAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF ASP-114; GLU-116 AND ASP-258.

************

The Genolevures Consortium;

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 22-75, FUNCTION, AND MASS SPECTROMETRY.

************

PRELIMINARY PROTEIN SEQUENCE OF 22-71, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-500, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-108.

************

FUNCTION, MRNA-BINDING, AND MUTAGENESIS OF LEU-413.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-34.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 35-454.

************

PROTEIN SEQUENCE OF 158-182.

************

PROTEIN SEQUENCE OF 8-196.

************

MUTAGENESIS OF PRO-196.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 7-196 IN COMPLEX WITH CALCIUM IONS.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 9-185 (AEQUORIN 2 AND 3).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-50.

************

IMPORTANCE OF HIS-155 FOR OLIGOMERIZATION.

************

MUTAGENESIS OF TYR-244.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-103.

************

PROTEIN SEQUENCE OF 1-10, FUNCTION, SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

MUTAGENESIS OF HIS-103; GLU-128; GLY-163; ASP-164; SER-165; GLY-167; ASP-262; ASP-266 AND HIS-292.

************

FUNCTION, AND INTERACTION WITH MALT.

************

FUNCTION, DIMERIZATION, AND INTERACTION WITH MELA.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 13-197 (ISOFORMS 1 AND 2).

************

FUNCTION, AND INTERACTION WITH RELA.

************

FUNCTION, AND OLIGOMERIZATION.

************

INTERACTION WITH PHF12.

************

UBIQUITINATION BY XIAP/BIRC4.

************

OLIGOMERIZATION, AND INTERACTION WITH TCF7.

************

PROTEIN SEQUENCE, MASS SPECTROMETRY, AND LETHAL DOSE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TOXICITY.

************

SECRETION VIA TYPE III SECRETION PATHWAY.

************

SELF-ASSOCIATION, SUBCELLULAR LOCATION, AND DNA-BINDING.

************

INTERACTION WITH SS18.

************

INTERACTION WITH YEATS4.

************

TRANSACTIVATION DOMAIN.

************

INTERACTION WITH DOT1L.

************

FUNCTION, SELF-ASSOCIATION, AND INTERACTION WITH FSTL3.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-406, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696; SER-700 AND SER-702, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-436, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-705, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 211-226, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH MLL/HRX.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-1093.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 648-1093.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-378, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-451, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH CTTN, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343 AND SER-351, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343; SER-353 AND SER-359, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-413, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-383 AND TYR-413, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH SRC, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MUTAGENESIS OF TYR-4, AND PHOSPHORYLATION.

************

PHOSPHORYLATION, INTERACTION WITH LCK, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-668 AND THR-669, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-56 AND TYR-413, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-345, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], CHROMOSOMAL REARRANGEMENT, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, MASS SPECTROMETRY, FUNCTION, AND TOXIN TARGET.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 51-81, AND FUNCTION.

************

PROTEIN SEQUENCE OF 51-81, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 51-81, MASS SPECTROMETRY, FUNCTION, AND TOXIN TARGET.

************

INTERACTION WITH BCOR.

************

INTERACTION WITH CBX8.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294; SER-412; SER-419; SER-429 AND SER-483, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-288; SER-294; SER-412; SER-419; SER-429 AND SER-483, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-288, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-412; SER-419 AND SER-429, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-569, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH CBX8.

************

IDENTIFICATION IN THE SWR1 COMPLEX, FUNCTION OF THE SWR1 COMPLEX, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, AND IDENTIFICATION IN THE NUA4 COMPLEX.

************

INTERACTION WITH SWC4.

************

FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE NUA4 COMPLEX, AND MASS SPECTROMETRY.

************

FUNCTION, IDENTIFICATION IN THE SWR1 COMPLEX, IDENTIFICATION IN THE NUA4 COMPLEX, AND MASS SPECTROMETRY.

************

IDENTIFICATION IN THE NUA4 COMPLEX, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHROMOSOMAL TRANSLOCATION WITH MLL/HRX.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND 3).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 13-1824 (ISOFORM 6).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 335-1824 (ISOFORM 5).

************

INTERACTION WITH PVRL3.

************

REVIEW ON INTERACTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1172 AND SER-1173, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1182 AND SER-1201, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1698, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-94, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1182, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1230, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1696, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-1107; SER-1182; THR-1232; SER-1721; SER-1779 AND SER-1799.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-1172; SER-1173; SER-1182; THR-1330; SER-1512 AND SER-1721, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-1083; SER-1182; SER-1721 AND SER-1799.

************

STRUCTURE BY NMR OF 1003-1094 IN COMPLEX WITH NRXN1 AND BCR.

************

STRUCTURE BY NMR OF 1001-1095.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-320 (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 36-900 (ISOFORM 3).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107; SER-1182 AND SER-1275, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107 AND SER-1182, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PARTIAL PROTEIN SEQUENCE, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH F-ACTIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1282, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-557; SER-1179; SER-1180; SER-1189; THR-1337 AND THR-1341, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-152.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-69; 105-207 AND 560-599.

************

PROTEIN SEQUENCE OF 22-45, GLYCOSYLATION, TISSUE SPECIFICITY, AND FUNCTION.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-402, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-402 AND ASN-488, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-402, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-109; ASN-383 AND ASN-402, STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-153 AND ASN-402, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH SRC AND FYN.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.

************

SUBCELLULAR LOCATION, INTERACTION WITH SRC, AND PHOSPHORYLATION.

************

SH3-BINDING MOTIF, INTERACTION WITH SRC, AND MUTAGENESIS OF PRO-71.

************

SH2-BINDING MOTIF, INTERACTION WITH SRC, PHOSPHORYLATION BY SRC, AND MUTAGENESIS OF TYR-93; TYR-94; TYR-451 AND TYR-453.

************

SELF-ASSOCIATION, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH F-ACTIN.

************

INTERACTION WITH F-ACTIN, AND INTERACTION WITH PRKCA; PRKCB; PRKCG AND PRKCI.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SRC, PHOSPHORYLATION BY SRC, AND MUTAGENESIS OF PRO-71; PRO-77; TYR-93; TYR-94; TYR-125; TYR-451 AND TYR-453.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 93-730, AND VARIANT MET-518.

************

TISSUE SPECIFICITY, AND KNOCKDOWN IN MDA-MB-231 CELLS.

************

TISSUE SPECIFICITY, AND POSSIBLE FUNCTION IN PROSTATE CANCER PROGRESSION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-282; SER-336; THR-337; THR-341; SER-342 AND SER-343, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-665 AND SER-668, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-668, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277; SER-278; SER-282; SER-283; THR-663; SER-664; SER-665; SER-668; SER-679; THR-686 AND SER-687, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; SER-668 AND SER-687, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-669, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-547, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, PHOSPHORYLATION, INTERACTION WITH SRC, AND TISSUE SPECIFICITY.

************

LEUCINE-RICH REPEATS.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INTERACTION WITH IAA7.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INTERACTION WITH CUL1; IAA7; IAA12 AND SKP1A/ASK1.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 6-400.

************

CHROMOSOMAL TRANSLOCATION WITH MLL/HRX.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588 AND THR-766, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199; SER-206; SER-212; SER-588; SER-750; THR-755 AND THR-1209, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206; SER-212; THR-220; SER-750 AND THR-755, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206; SER-212; SER-216; SER-245; SER-588; THR-697; SER-750 AND THR-1209, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206 AND SER-750, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-681, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] LYS-1204.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 526-896.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 348-421 (ISOFORM 1).

************

FUNCTION, SUBCELLULAR LOCATION, AND INVOLVEMENT IN MRFRAXE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-517, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN MRFRAXE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASN-358.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-358.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 689-1226.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-310 AND SER-316, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-393; SER-755 AND SER-881, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-229.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM D).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1374-1673 (ISOFORMS A/D).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-420; SER-450; SER-452; SER-821; SER-822; SER-871; SER-873; SER-1362 AND THR-1364, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CHROMOSOMAL TRANSLOCATION WITH MLL, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 111-122, IDENTIFICATION IN PTEF-B COMPLEX, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 788-1163 (ISOFORM 2).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387; SER-388; SER-389; SER-392; SER-549; SER-703 AND SER-706, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-499, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-674, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32; SER-124; SER-212; SER-222; SER-487; SER-514; THR-528; SER-549; SER-599; SER-694; SER-703; SER-706; SER-814; SER-836; SER-1043; SER-1055 AND SER-1058, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387; SER-388; SER-389; SER-392; SER-694; SER-703; SER-706; TYR-712; SER-1043; SER-1055; SER-1058 AND SER-1062, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-487; SER-491; SER-703; SER-706; SER-1043; SER-1055; SER-1058 AND SER-1062, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31; SER-32; SER-178; SER-210; SER-549; SER-617; TYR-668; SER-671; SER-694; SER-703; SER-706; SER-814; SER-836; SER-1043; SER-1055 AND SER-1058, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1058, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-79, AND MASS SPECTROMETRY.

************

VARIANT THR-757.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-481.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-789 (ISOFORM 1).

************

INTERACTION WITH SPG7.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-306 AND LYS-543, AND MASS SPECTROMETRY.

************

VARIANT SCA28 LYS-700.

************

VARIANTS SCA28 ILE-654; VAL-666; ARG-666; THR-666; ARG-671 AND GLU-671.

************

VARIANTS SCA28 THR-432; LYS-691; GLU-694 AND GLN-702, AND TISSUE SPECIFICITY.

************

VARIANT SPAX5 CYS-616, AND CHARACTERIZATION OF VARIANT SPAX5 CYS-616.

************

PROTEIN SEQUENCE OF 173-181; 283-296 AND 632-650, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-307 AND LYS-542, AND MASS SPECTROMETRY.

************

FUNCTION, AND VARIANT PAR GLY-389.

************

IDENTIFICATION IN THE M-AAA PROTEASE COMPLEX, FUNCTION OF THE M-AAA PROTEASE COMPLEX, AND SUBCELLULAR LOCATION.

************

FUNCTION OF THE M-AAA PROTEASE COMPLEX, AND MUTAGENESIS OF GLU-559.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-157.

************

SUBCELLULAR LOCATION, INTERACTION WITH CNM67, AND INDUCTION.

************

FUNCTION, INTERACTION WITH ARF3, INDUCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 38-LYS--PRO-41.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 42-49; 225-234; 410-420; 442-454; 471-481; 493-507; 545-574; 629-642; 644-656 AND 659-668, FUNCTION, SUBUNIT, ATP-BINDING SITE, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 42-49; 225-234; 410-420; 442-454; 471-481; 493-507; 545-574; 629-642; 644-656 AND 659-668.

************

SUBUNIT, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 2-343 IN COMPLEX WITH AMP.

************

NUCLEOTIDE SEQUENCE OF 1-406.

************

PROTEIN SEQUENCE, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INDUCTION, MASS SPECTROMETRY, AND SYNTHESIS.

************

FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, INDUCTION, INTERACTION WITH ABI5/DPBF1, AND DISRUPTION PHENOTYPE.

************

GENE FAMILY, NOMENCLATURE, SUBUNIT, INTERACTION WITH ABI5/DPBF1; DPBF2; AREB3/DPBF3; ABF1; ABF3/DPBF5 AND ABF4/AREB2, INDUCTION, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE, FUNCTION, SUBUNIT, DISULFIDE BONDS, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

GENE FAMILY, NOMENCLATURE, FUNCTION, SUBUNIT, INTERACTION WITH ABI5/DPBF1; DPBF2; AREB3/DPBF3; EEL/DPBF4; ABF1; ABF3/DPBF5 AND ABF4/AREB2, INDUCTION, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

GENE FAMILY, NOMENCLATURE, SUBUNIT, INTERACTION WITH ABI5/DPBF1; DPBF2; AREB3/DPBF3; EEL/DPBF4; ABF1; ABF3/DPBF5 AND ABF4/AREB2, INDUCTION, AND DISRUPTION PHENOTYPE.

************

GENE FAMILY, NOMENCLATURE, SUBUNIT, INTERACTION WITH ABI5/DPBF1; AREB3/DPBF3; EEL/DPBF4; ABF1 AND ABF3/DPBF5, INDUCTION, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE OF 21-128.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 35-94.

************

PROTEIN SEQUENCE OF 44-94, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE, FUNCTION, RESISTANCE TO HEAT AND PROTEOLYSIS, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 35-53; 57-69; 79-84 AND 88-92, FUNCTION, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-472 AND SER-526, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 6-21; 44-53 AND 148-167, SUBUNIT, INTERACTION WITH A-FACTOR, AND VARIANTS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], DNA-BINDING, INTERACTION WITH A-FACTOR, AND MUTAGENESIS OF VAL-41; TRP-119; GLU-135; PRO-138; LYS-147; ILE-149; GLY-155; SER-160; ASP-163; ASP-168 AND PRO-187.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH A-FACTOR.

************

INTERACTION WITH A-FACTOR.

************

DNA-BINDING, AND INTERACTION WITH A-FACTOR.

************

MUTANT HO1.

************

FUNCTION, INDUCTION, AND INTERACTION WITH SKP1A/ASK1.

************

INTERACTION WITH SKP1A/ASK1.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-25, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, MASS SPECTROMETRY, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2-333 IN COMPLEX WITH NADP, AND MUTAGENESIS OF SER-10; ALA-13; SER-33; LYS-94; ASP-176; HIS-180 AND GLY-206.

************

NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND INDUCTION BY 1-MCP.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND MUTAGENESIS OF ASP-326 AND ASP-330.

************

POTASSIUM-BINDING, AND MUTAGENESIS OF ASP-484; SER-485; SER-487 AND SER-488.

************

SEQUENCE REVISION TO 239-240.

************

INTERACTION WITH KBPA, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-44.

************

AUTPOPHOSPHORYLATION AT SER-71 AND THR-168, MASS SPECTROMETRY, AND MUTAGENESIS OF SER-71; SER-128; THR-168 AND THR-170.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF ASP-52.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 751-993.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND PHOSPHORYLATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE OF 283-690.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-193, AND MASS SPECTROMETRY.

************

FUNCTION AS A ARABINOFURANOSYLTRANSFERASE, AND ENZYME REGULATION.

************

FUNCTION AS A ARABINOFURANOSYLTRANSFERASE, ENZYME REGULATION, SUBCELLULAR LOCATION, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), SUBCELLULAR LOCATION, AND INTERACTION WITH GGA1; GGA3; AP1G1 AND AP1G2.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 347-937 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-617, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-517 AND THR-522, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORMS 1 AND 2).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 149-473.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-366 AND SER-387, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND VARIANT GLY-84.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-84.

************

VARIANT VAL-446, CHARACTERIZATION OF VARIANT VAL-446, AND POSSIBLE PROTECTIVE ROLE IN SUSCEPTIBILITY TO ACQUIRED LONG QT SYNDROME.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH KCNH1, AND TISSUE SPECIFICITY.

************

FUNCTION, INTERACTION WITH KCNH2, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 24-79 AND 81-100.

************

SEQUENCE REVISION, AND IDENTIFICATION OF FRAMESHIFT.

************

The Broad Institute Genome Sequencing Center for Infectious Disease;

************

PROTEIN SEQUENCE OF 21-46.

************

LACK OF FUNCTION IN CEMENT GLAND FORMATION.

************

SEQUENCE REVISION TO 824.

************

PRELIMINARY PROTEIN SEQUENCE OF 53-78.

************

PROTEIN SEQUENCE OF 53-63.

************

GENE NAME.

************

SUBCELLULAR LOCATION, AND FUNCTION IN AGGREGATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-82.

************

GPI-ANCHOR, GLYCOSYLATION, AND SUBCELLULAR LOCATION.

************

REPEATS.

************

SUBUNIT, AND MUTAGENESIS OF CYS-25 AND CYS-68.

************

INTERACTION WITH SAG1.

************

PROTEIN SEQUENCE, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.

************

SEQUENCE REVISION TO 145.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 32-59.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND CATALYTIC ACTIVITY.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND KINETIC PARAMETERS.

************

X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 27-662 IN COMPLEX WITH CALCIUM, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, ACTIVE SITE, MUTAGENESIS OF ASP-415 AND GLU-470, CATALYTIC MECHANISM, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PHYLOGENETIC STUDY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 16-34; 215-231 AND 373-378.

************

PROTEIN SEQUENCE OF 48-57 AND 172-178.

************

PROTEIN SEQUENCE OF 1-20, COFACTOR, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 31-429, AND PARTIAL PROTEIN SEQUENCE.

************

RNA EDITING OF POSITION 396.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-215, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (3.45 ANGSTROMS) OF 32-422 IN COMPLEX WITH PRODUCT, HOMODIMERIZATION, AND GLYCOSYLATION AT ASN-139; ASN-192 AND ASN-215.

************

REVIEW ON FD VARIANTS.

************

VARIANT FD SER-40.

************

VARIANT FD VAL-296.

************

VARIANT FD GLN-301.

************

VARIANT FD TRP-356.

************

VARIANTS FD GLN-66; CYS-112; GLU-279; GLN-301 AND ARG-328.

************

VARIANTS FD SER-34; GLY-56; ARG-162; GLN-227; VAL-264; VAL-266; PHE-297; TYR-313; ALA-328 AND ARG-404 DEL.

************

VARIANTS FD SER-34; SER-215; ALA-269; LYS-327 AND ARG-361.

************

VARIANTS FD ARG-35; LEU-49; VAL-165 AND GLU-316.

************

VARIANTS FD.

************

VARIANTS FD GLN-66; CYS-112; VAL-156; VAL-166; ALA-260; GLU-279; ILE-296; GLN-301; LYS-320; ARG-328 AND SER-373.

************

VARIANTS FD TYR-142; VAL-156 AND VAL-166.

************

VARIANTS FD PRO-32; SER-34; ASP-85; THR-156 AND GLN-301.

************

VARIANTS FD PRO-20 AND ILE-296.

************

VARIANTS FD VAL-42; SER-49; TYR-56; HIS-92; GLY-93; THR-205; CYS-236; GLY-287; HIS-298 AND ARG-340.

************

VARIANT FD PHE-383 DEL.

************

VARIANTS FD ARG-52; CYS-162; ARG-265 AND 316-VAL--ASP-322 DEL.

************

VARIANTS FD ARG-52; GLU-128; THR-205; THR-284; LYS-298 AND GLU-358 DEL.

************

VARIANT FD ASN-231.

************

VARIANTS FD PRO-20; SER-40; GLN-66; VAL-72; CYS-112; TYR-142; VAL-156; VAL-166; ASN-242; ALA-260; ASP-261; GLU-279; ILE-296; GLN-301; LYS-320; ARG-328; GLU-358 DEL AND SER-373.

************

VARIANTS FD VAL-31; 45-ARG-SER-46; ARG-46; CYS-86; PRO-89; THR-91; TYR-92; TYR-94; VAL-97; THR-100; LEU-113; SER-134; ARG-138; THR-143; ARG-148; VAL-163; VAL-170; TYR-202; 205-PRO--TYR-207 DEL; ASP-216; SER-263; CYS-287; SER-298 AND ARG-404 DEL.

************

VARIANT FD THR-65.

************

VARIANT FD LYS-358.

************

VARIANT FD VAL-72.

************

VARIANTS FD SER-40; SER-215; ASP-224; TYR-313 AND TRP-THR-SER-247 INS.

************

VARIANTS FD TRP-202; GLY-223; ASP-224; GLN-301 AND LYS-327.

************

VARIANT FD LYS-341.

************

CHARACTERIZATION OF VARIANTS FD GLU-279 AND GLN-301.

************

VARIANTS FD VAL-42; CYS-112; ARG-142; ARG-148; VAL-165; ASP-183; SER-215; CYS-235; LEU-236; HIS-244; LEU-259; ILE-267; PHE-289; GLU-321; GLU-358 DEL AND TYR-378.

************

VARIANT FD ASN-266.

************

VARIANTS FD LEU-40; SER-95; CYS-112; HIS-112; ASN-148; ARG-172; VAL-187; SER-224; ARG-226; GLN-227; THR-230; HIS-266; GLN-301 AND TYR-320.

************

VARIANT FD ASP-373.

************

VARIANTS FD TYR-46; GLY-47; PRO-49; SER-94; SER-95; CYS-112; SER-113; THR-143; SER-215; ARG-258; ARG-259; ILE-267; HIS-279; HIS-280; HIS-298; TYR-313; HIS-363; ASP-377; ALA-409 AND THR-409.

************

VARIANT FD PRO-143.

************

VARIANT FD ALA-410.

************

CHARACTERIZATION OF VARIANT FD THR-65.

************

VARIANT FD SER-272.

************

VARIANTS FD VAL-31; LEU-42; ARG-43; ASN-93; CYS-112; HIS-112; SER-112; SER-134; VAL-135; ASP-171; PHE-201; SER-215; GLU-234; ASP-261; TYR-264; VAL-264; GLY-276; PRO-285; PHE-300; ALA-328; VAL-328; LYS-338; ALA-358; GLU-358 DEL; ARG-404 DEL AND SER-414.

************

VARIANT FD THR-143.

************

VARIANTS FD 12-CYS--LEU-14 DEL; PRO-46; GLN-66; ASN-93; VAL-120; THR-219; GLN-356 AND CYS-360, AND CHARACTERIZATION OF VARIANTS FD 12-CYS--LEU-14 DEL; PRO-46; GLN-66; ASN-93; VAL-120; THR-219; GLN-356 AND CYS-360.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-186, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 56-95, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 101-284.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 56-417 IN COMPLEX WITH D-GALACTOSE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 409-451.

************

MUTAGENESIS OF ASP-367 AND ASP-425, AND CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT ILE-671, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT ILE-671.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ILE-671.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 429-857 (ISOFORM 1), AND VARIANT ILE-671.

************

CHARACTERIZATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF CYS-647 AND ARG-652.

************

INTERACTION WITH THE AP-3 COMPLEX.

************

SUBUNIT, TISSUE SPECIFICITY, PHOSPHORYLATION, AND INTERACTION WITH GUCY1A3 AND GUCY1B3.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-836, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND MASS SPECTROMETRY.

************

VARIANTS GLY-82; ILE-671; GLY-798 AND THR-854.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2), AND VARIANT VAL-1124.

************

SEQUENCE REVISION TO 389; 768-769; 1124; 1137 AND 1147 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION.

************

TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INTERACTION WITH AKT1, AND FUNCTION.

************

TISSUE SPECIFICITY, INTERACTION WITH AKT1, AND FUNCTION.

************

TISSUE SPECIFICITY, INTERACTION WITH THE AP-1 COMPLEX, AND FUNCTION.

************

PHOSPHORYLATION BY FYN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-635 AND SER-638, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 402-577.

************

STRUCTURE BY NMR OF 674-914.

************

VARIANTS ALA-455; GLY-518; ILE-568; VAL-651; VAL-767; ASP-939; MET-947 AND PRO-1022, AND SUBCELLULAR LOCATION.

************

VARIANTS [LARGE SCALE ANALYSIS] ALA-339 AND TYR-816.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 138-1186 (ISOFORM 2).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149 AND SER-262, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-632; SER-802; SER-859 AND SER-921, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INTERACTION WITH HOMER1 AND HOMER2, AND MUTAGENESIS OF PRO-187.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-754, GTP-BINDING, TISSUE SPECIFICITY, INTERACTION WITH EPB41L1, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF SER-414.

************

FUNCTION, AND INTERACTION WITH PLCG1.

************

SUBCELLULAR LOCATION, INTERACTION WITH NF2, AND MUTAGENESIS OF PRO-187.

************

FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-679 AND LYS-687.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 45-855 (ISOFORM 3).

************

TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INTERACTION WITH PML, ENZYME REGULATION, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-443, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-324; THR-326 AND SER-336, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, MUTAGENESIS OF SER-140 AND 368-LYS-ARG-369, ENZYME REGULATION, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLU-661.

************

VARIANT HIS-567.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 31-61.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PUTATIVE FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-30, FUNCTION, SUBUNIT, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-15, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

IDENTIFICATION, FUNCTION, CATALYTIC ACTIVITY, AND DISRUPTION PHENOTYPE.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF CYS-33, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-192 AND SER-196, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INDUCTION BY AUXIN, SUBUNIT, SUBCELLULAR LOCATION, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 419-827.

************

INTERACTION WITH DRP1A.

************

FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF ASP-518 AND CYS-519.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-445, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 7-483.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-169; SER-188 AND SER-189, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH ARF1, ENZYME REGULATION, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173 AND SER-191, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175 AND SER-318, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-169 AND SER-307, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 16-1182, FUNCTION, DEVELOPMENTAL STAGE, AND MUTAGENESIS OF SER-862.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-180; SER-183; THR-195 AND SER-197, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), INTERACTION WITH HIV-1 REV AND HTLV-1 REX, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH HIV-1 REV.

************

SUBCELLULAR LOCATION, INTERACTION WITH EPS15, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-177 AND SER-181, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-177, AND MASS SPECTROMETRY.

************

INTERACTION WITH EPS15R.

************

FUNCTION, DEVELOPMENTAL STAGE, SUBCELLULAR LOCATION, INTERACTION WITH EPS15, AND DISRUPTION PHENOTYPE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-177; SER-179 AND SER-181, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 355-373, GLYCOSYLATION AT SER-367, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 75-481.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-173, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 247-479 (ISOFORM 1).

************

PROTEIN SEQUENCE, SUBUNIT, MASS SPECTROMETRY, GLYCOSYLATION, AND CIRCULAR DICHROISM ANALYSIS.

************

PROTEIN SEQUENCE OF 1-12, GLYCOSYLATION, AND FUNCTION.

************

PARTIAL PROTEIN SEQUENCE, FUNCTION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 1-22.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS), SUBUNIT, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS), SUBUNIT, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 24-41.

************

PROTEIN SEQUENCE OF 24-53, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 24-146, SUBUNIT, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 24-146, SUBUNIT, AND DISULFIDE BONDS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DISEASE, INTERACTION WITH TNFSF12, VARIANT THR-698, AND VARIANT KTS LYS-133.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 370-714 (ISOFORM 1).

************

ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7 AND SER-11, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-664, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 21-278 AND 281-543, FUNCTION, AND MUTAGENESIS OF PRO-219.

************

IMMUNOMODULATORY ROLE.

************

SUBUNIT, AND 3D-STRUCTURE MODELING.

************

PROTEIN SEQUENCE OF 303-564.

************

PROTEIN SEQUENCE OF 303-337.

************

X-RAY CRYSTALLOGRAPHY (2.63 ANGSTROMS) OF 25-286 AND 303-564 IN COMPLEX WITH GALACTOSE, AND DISULFIDE BONDS.

************

PARTIAL PROTEIN SEQUENCE, AND GLYCOSYLATION AT ASN-133.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 22-32 AND 115-128, MASS SPECTROMETRY, AND GLYCOSYLATION AT ASN-132.

************

PROTEIN SEQUENCE OF 27-197.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 27-197, AND PYROGLUTAMATE FORMATION AT GLN-27.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH N-ACETYLNEURAMINYL-LACTOSE.

************

PROTEIN SEQUENCE OF 28-198.

************

SEQUENCE REVISION TO 68; 136; 161 AND 177.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH SUBSTRATES.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-227.

************

PRELIMINARY PROTEIN SEQUENCE OF 123-157.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 24-112.

************

PRELIMINARY PROTEIN SEQUENCE OF 24-54.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 24-112 IN COMPLEX WITH TRI-ACETYLCHITOTRIOSE AND TETRA-ACETYLCHITOTETRAOSE, FUNCTION, INTERACTION WITH HUMAN TCR AND MHC, AND DISULFIDE BONDS.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 24-112, SUBUNIT, ZINC BINDING, AND DISULFIDE BONDS.

************

PROTEIN SEQUENCE OF 24-32, AND FUNCTION.

************

FUNCTION, COFACTOR, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-6, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN MTDPS10.

************

INVOLVEMENT IN CATC5.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

INTERACTION WITH AGL15 AND AGL16.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 7-221.

************

INTERACTION WITH AGL16.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 7-268.

************

FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.

************

TISSUE SPECIFICITY, AND GENE FAMILY.

************

INTERACTION WITH AGL15; SVP; AGL24; AP1; AGL6; AG; AGL1; AGL11; AGL5; AGL16; SOC1 AND AGL21.

************

FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION BY AUXIN.

************

FUNCTION, DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION AS TRANSCRIPTION FACTOR.

************

FUNCTION AS TRANSCRIPTION ACTIVATOR.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND GENE FAMILY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 24-240 (ISOFORM 1), AND TISSUE SPECIFICITY.

************

INTERACTION WITH AGL15; AGL16; AGL24; AP1; AGL6; AG; AGL1; AGL11; AGL5; SEP3; SEP1; AGL63; AGL14; SOC1 AND AGL21.

************

REPRESSION BY MIR824.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 8-227.

************

INTERACTION WITH SOC1 AND AGL21.

************

FUNCTION, DISRUPTION PHENOTYPE, INDUCTION BY VERNALIZATION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH AGL15; AGL16 AND AGL19.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH IMK3, AND PHOSPHORYLATION BY IMK3.

************

FUNCTION, TISSUE SPECIFICITY, AND INDUCTION BY VERNALIZATION.

************

FUNCTION, DEVELOPMENTAL STAGE, AND INDUCTION BY AP1 AND LFY.

************

FUNCTION, AND INTERACTION WITH AP1; SEU AND LUG.

************

INDUCTION BY AP1.

************

FUNCTION, AND INDUCTION BY SOC1.

************

FUNCTION, INTERACTION WITH SOC1, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND REPRESSION BY VERNALIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, AND GENE FAMILY.

************

INDUCTION BY ELF7 AND ELF8.

************

INTERACTION WITH AGL39; AGL97 AND AGL74.

************

INDUCTION BY HUA2.

************

REPRESSION BY VIL1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-149 (ISOFORM 1/2), AND FUNCTION.

************

INTERACTION WITH AGL62.

************

NUCLEOTIDE SEQUENCE OF 1-141.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 68-246 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 39-264, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH AGL80.

************

FUNCTION, INTERACTION WITH AGL80; AGL86; PHE1 AND PHE2, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH AGL80, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

INTERACTION WITH AGL36; PHE1; PHE2; AGL80; AGL86; AGL90; AGL92 AND AGL97.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, MUTANT FEM111, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH AGL61.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-116, AND MASS SPECTROMETRY.

************

INTERACTION WITH AGL27 AND AGL62.

************

CHARACTERIZATION, SUBUNIT, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

MUTAGENESIS OF GLY-10; GLY-12 AND SER-13, AND KINETIC PARAMETERS.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF COMPLEX WITH NAD(+) AND MALTOSE.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN GLYCOSYLATION, PATHWAY, AND GENE NAME.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-26, FUNCTION, CHARACTERIZATION, COFACTORS, SUBSTRATE SPECIFICITY, KINETIC PARAMETERS, INDUCTION, SUBUNIT, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-25, FUNCTION, AND INDUCTION.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, PATHWAY, AND GENE NAME.

************

MUTAGENESIS OF ASP-110; ASP-112; ASP-133; GLY-137; SER-138; ARG-139; ASP-173; GLN-175; CYS-176; GLY-177; PHE-178; LYS-179; ASP-195 AND ASP-201.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN GLYCOSYLATION, PATHWAY, SUBCELLULAR LOCATION, DISRUPTION PHENOTYPE, AND GENE NAME.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN GLYCOSYLATION, AND GENE NAME.

************

FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN GLYCOSYLATION, PATHWAY, DISRUPTION PHENOTYPE, AND GENE NAME.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, PATHWAY, AND GENE NAME.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND GENE NAME.

************

FUNCTION AS A METHYLTRANSFERASE, PATHWAY, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 26-252 AND 267-985, AND GLYCOSYLATION AT THR-36; ASN-124; ASN-143; ASN-218; ASN-347; ASN-422; ASN-506; ASN-534; SER-545; SER-550; THR-559; SER-560; THR-561; SER-562; THR-571; ASN-601; ASN-623; ASN-835; ASN-881; SER-895; ASN-899; ASN-957 AND ASN-970.

************

ACTIVE SITE, AND PROTEIN SEQUENCE OF 464-472.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 36-49 AND 613-634.

************

PROTEIN SEQUENCE OF 34-43.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-36; 175-194; 375-395 AND 427-451, AND MUTAGENESIS OF ASP-218; ASP-287; ASP-355; ASP-481; GLU-484; ASP-647; ASP-676; GLU-714 AND ASP-877.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-20 AND 552-561, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND INTERACTION WITH MGLA.

************

ROLE IN A-TYPE GLIDING MOTILITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 183-556.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-68, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS, AND VARIANT ASN-466.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 392-542.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND MASS SPECTROMETRY.

************

VARIANT ASN-466.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-49 AND SER-51, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-67, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-65 AND SER-67, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77 AND SER-82, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 23-62.

************

PROTEIN SEQUENCE OF 24-54 AND 66-108.

************

PYROGLUTAMATE FORMATION AT GLU-24 AND GLU-52.

************

CHARACTERIZATION, PROTEIN SEQUENCE OF 24-33, AND AMIDATION AT PHE-33.

************

MASS SPECTROMETRY, AND PROTEOLYTIC PROCESSING.

************

ISOFORM AGNO-1B.

************

MUTAGENESIS OF SER-53; SER-93; THR-97; PRO-136; THR-137; 141-THR-THR-142 AND PRO-147.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VP1.

************

SUBCELLULAR LOCATION AND ISOFORM AGNO-2A AND AGNO-2B.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-10.

************

IDENTIFICATION OF PROTEIN.

************

SUBCELLULAR LOCATION, FUNCTION, AND PHOSPHORYLATION.

************

INTERACTION WITH LARGE T ANTIGEN.

************

INTERACTION WITH HOST YBX1.

************

INTERACTION WITH HOST TP53, AND FUNCTION.

************

INTERACTION WITH HOST FEZ1.

************

INTERACTION WITH HUMAN CBX5, AND SUBCELLULAR LOCATION.

************

MUTAGENESIS OF SER-7; SER-11 AND THR-21.

************

INTERACTION WITH SMALL T ANTIGEN AND HOST PP2A.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTATION OF 8-ARG-LYS-9.

************

PRELIMINARY CHARACTERIZATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 517-883.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 693-883.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-346 (ISOFORM 2).

************

FUNCTION, AND INTERACTION WITH CUCUMBER MOSAIC VIRUS PROTEIN 2B.

************

INTERACTION WITH TURNIP YELLOWS VIRUS PROTEIN P0.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1001, AND MASS SPECTROMETRY.

************

INTERACTION WITH TURNIP CRINKLE VIRUS CAPSID PROTEIN P38.

************

INTERACTION WITH SDE3.

************

ASSOCIATION WITH MIRNA.

************

FUNCTION, INTERACTION WITH DICER1; MOV10; PRMT5 AND TNRC6B, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH DDX6 AND EIF2C2.

************

ASSOCIATION WITH POLYSOMES AND MNRP, AND INTERACTION WITH DDB1; DDX5; DHX30; DHX36; DDX47; ELAVL1; HNRNPF; IGF2BP1; ILF3; MATR3; PABPC1; RBM4; SART3; UPF1 AND YBX1.

************

INTERACTION WITH IMP8.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH LIMD1; WTIP AND AJUBA.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 225-369, AND RNA-BINDING.

************

FUNCTION, COMPOSITION OF THE RDRC AND RITS COMPLEXES, INTERACTION WITH HRR1, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

FUNCTION, AND COMPOSITION OF THE RITS COMPLEX.

************

FUNCTION, RNA CLEAVAGE ACTIVITY, AND MUTAGENESIS OF ASP-580; ASP-651 AND HIS-788.

************

FUNCTION, INTERACTION WITH ARB1, COMPOSITION OF THE ARC COMPLEX, AND MUTAGENESIS OF PHE-276 AND ASP-580.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 444-1014.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 475-1014.

************

FUNCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH NERD.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 376-1214, AND VARIANTS ARG-714; PRO-740; ASN-783; ALA-835; THR-854 AND GLU-866.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 449-1214, AND VARIANTS ASN-783; ALA-835 AND THR-854.

************

PROTEIN SEQUENCE OF 506-515; 525-531; 554-557; 617-627; 662-674; 809-815 AND 1181-1188 (ISOFORM B), FUNCTION, AND INTERACTION WITH DCR-1.

************

INTERACTION WITH FMR1.

************

INTERACTION WITH CRICKET PARALYSIS VIRUS PROTEIN 1A.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 591-726.

************

STRUCTURE BY NMR OF 602-740.

************

STRUCTURE BY NMR OF 605-720.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 47-859 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 275-859 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 483-859 (ISOFORM 1).

************

INTERACTION WITH DICER1.

************

FUNCTION, AND INTERACTION WITH GEMIN4.

************

FUNCTION, ENZYME REGULATION, AND MUTAGENESIS OF LEU-140; ASP-597; GLN-633; HIS-634; ASP-669; HIS-682; PHE-704 AND THR-744.

************

FUNCTION, AND INTERACTION WITH DICER1 AND TARBP2.

************

FUNCTION, INTERACTION WITH DDX20; DICER1; GEMIN4; MOV10; PRMT5 AND TNRC6B, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH DICER1 AND TARBP2, AND MUTAGENESIS OF ASP-669.

************

MUTAGENESIS OF LYS-533; GLN-545 AND LYS-570.

************

INTERACTION WITH DICER1 AND TARBP2.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-597; ASP-669; GLU-673; GLU-683 AND HIS-807.

************

FUNCTION, INTERACTION WITH DCP1A AND XRN1, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH DDX6 AND EIF2C1, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH FXR1, AND SUBCELLULAR LOCATION.

************

FUNCTION, AND MUTAGENESIS OF PHE-470 AND PHE-505.

************

FUNCTION, ASSOCIATION WITH POLYSOMES AND MNRP, AND INTERACTION WITH DDB1; DDX5; DHX30; DHX36; DDX47; ELAVL1; HNRNPF; IGF2BP1; ILF3; MATR3; PABPC1; RBM4; SART3; UPF1 AND YBX1.

************

FUNCTION, AND INTERACTION WITH DHX9.

************

IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, INTERACTION WITH DICER1; EIF6; MOV10 AND TARBP2, AND ASSOCIATION WITH THE 60S RIBOSOME.

************

FUNCTION, AND MUTAGENESIS OF ASP-597.

************

FUNCTION, INTERACTION WITH DICER1; P4HA1; P4HB; TNRC6A AND TNRC6B, SUBCELLULAR LOCATION, HYDROXYLATION AT PRO-700, AND MUTAGENESIS OF PRO-700.

************

FUNCTION, INTERACTION WITH IMP8, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH RBM4.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 158-860.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-2, AND MASS SPECTROMETRY.

************

INTERACTION WITH TRIM71.

************

INTERACTION WITH EIF4B; IMP8; PRMT5 AND TNRC6B.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NRPE1.

************

FUNCTION, AND MUTAGENESIS OF ASP-660; ASP-742 AND HIS-874.

************

FUNCTION, AND INTERACTION WITH NRPE1.

************

FUNCTION, MUTAGENESIS OF GLU-641, AND DISRUPTION PHENOTYPE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-798, AND MASS SPECTROMETRY.

************

INTERACTION WITH EIF4B; IMP8; PRMT5; TNRC6A AND TNRC6B, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 144-861 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 317-896.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-464, AND MASS SPECTROMETRY.

************

FUNCTION, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF LYS-140; LYS-147; ASP-166 AND ASP-172.

************

X-RAY CRYSTALLOGRAPHY (1.0 ANGSTROMS) OF APOENZYME AND IN COMPLEX WITH 8-OXOGUANOSINE, AND DOMAIN.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, RNA-BINDING, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 22-37, TISSUE SPECIFICITY, MASS SPECTROMETRY, GLYCOSYLATION, AND GPI-ANCHOR.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2-136.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 28-38.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 28-37.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 29-38.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 23-35.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 27-37, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 43-63, TISSUE SPECIFICITY, AND GLYCOSYLATION.

************

SEQUENCE REVISION TO 191-192; 194-197; 316 AND C-TERMINUS.

************

CHARACTERIZATION, AND IDENTIFICATION OF FRAMESHIFT.

************

FUNCTION IN L-CYSTEINE UPTAKE.

************

INDUCTION BY SPS.

************

IDENTIFICATION OF FRAMESHIFT.

************

INDUCTION BY DAL81 AND STP1.

************

PALMITOYLATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-87, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 22-37.

************

GENE FAMILY, NOMENCLATURE, AND INDUCTION.

************

FUNCTION IN CARNITINE TRANSPORT.

************

PROTEIN SEQUENCE OF 22-40, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 108-130, AND PROTEIN SEQUENCE OF 22-37.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 21-33, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE, HYDROXYLATION AT PRO-5; PRO-7 AND PRO-12, GLYCOSYLATION AT PRO-5; PRO-7 AND PRO-12, AND STRUCTURE OF CARBOHYDRATE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 23-31.

************

PROTEIN SEQUENCE OF 23-34.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-413 IN COMPLEX WITH GLUCOSE 1-PHOSPHATE.

************

PROTEIN SEQUENCE OF 12-19; 71-94 AND 174-184, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-249.

************

PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BOND.

************

PYROGLUTAMATE FORMATION AT GLN-120.

************

TISSUE SPECIFICITY, DISULFIDE BOND, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 21-35.

************

INTERACTION WITH LYPD3 AND DAG1.

************

INTERACTION WITH MUC2, AND MUTAGENESIS OF CYS-81.

************

FUNCTION, DISRUPTION PHENOTYPE, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 22-36.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-114.

************

TOPOLOGY, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-221 (ISOFORMS 1 AND 6), GLYCOSYLATION, INTERACTION WITH LAMININ, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 94-2073 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1901-1913 (ISOFORMS 4 AND 5).

************

INTERDOMAIN DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 26-156 IN COMPLEX WITH LAMININ, AND DISULFIDE BOND.

************

STRUCTURE BY NMR OF 1870-2073 IN COMPLEX WITH CALCIUM IONS, X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 1870-2073 IN COMPLEX WITH CALCIUM IONS, AND DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 26-156, INTERACTION WITH LAMININ, AND DISULFIDE BOND.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-172, AND INTERACTION WITH LAMIN.

************

FUNCTION, VARIANT LGM ARG-1709, VARIANTS LEU-23; ASN-58; ILE-105; MET-267; SER-375; VAL-728; ARG-852; MET-984; PHE-1088; LYS-1118; ARG-1135; LEU-1240; ARG-1341; LEU-1451; THR-1514; HIS-1565; ILE-1666; GLN-1671; PRO-1698; HIS-1734; ASN-1785 AND VAL-2023, AND CHARACTERIZATION OF VARIANT LGM ARG-1709.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-135, AND MASS SPECTROMETRY.

************

FUNCTION IN NEUROMUSCULAR JUNCTION DEVELOPMENT, FUNCTION IN PHOSPHORYLATION OF MUSK, AND INTERACTION WITH LRP4.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-1779 AND 1799-1959.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1777-1801.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-67.

************

FUNCTION, AND INTERACTION WITH MC3R; MC4R AND MC5R.

************

FUNCTION AS INVERSE AGONIST FOR MC3R AND MC4R.

************

FUNCTION IN MC3R AND MC4R ENDOCYTOSIS.

************

STRUCTURE BY NMR OF 87-132, FUNCTION, CIRCULAR DICHROISM, DISULFIDE BONDS, AND MUTAGENESIS OF ARG-111.

************

STRUCTURE BY NMR OF 87-132, DOMAIN, AND DISULFIDE BONDS.

************

STRUCTURE BY NMR OF 87-120.

************

VARIANT THR-67, AND POSSIBLE ASSOCIATION WITH OBESITY.

************

CHARACTERIZATION OF VARIANT THR-67, SUBCELLULAR LOCATION, AND FUNCTION.

************

FUNCTION, AND INTERACTION WITH MELANOCORTIN RECEPTORS MC3R; MC4R AND MC5R.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2044-2410.

************

FUNCTION, AND MUTAGENESIS OF GLU-1526.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1643; SER-1644; SER-1651; THR-1653; SER-1738 AND SER-1812, AND MASS SPECTROMETRY.

************

FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

IDENTIFICATION AS POSSIBLE PSEUDOGENE.

************

PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-102; ILE-140 AND ILE-212.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASN-102; ILE-140; ILE-212 AND LEU-498.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-129, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 40-57.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 95-100; 246-251; 336-343; 352-357; 390-397 AND 492-499, FUNCTION, DOMAIN, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TRP-289.

************

INTERACTION WITH MAS1.

************

VARIANT RTD MET-282.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 53-291.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-132.

************

NUCLEOTIDE SEQUENCE OF 1-22.

************

NUCLEOTIDE SEQUENCE OF 1-16.

************

TISSUE SPECIFICITY, VARIANTS MRX88 VAL-21; GLN-324 AND VAL-337, AND VARIANT LYS-248.

************

INTERACTION WITH MTUS1, AND FUNCTION.

************

FUNCTION, INTERACTION WITH MTUS1, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE OF 84-259.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 84-259.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-383.

************

ENZYME ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, ENZYME REGULATION, AND MUTAGENESIS OF CYS-180; CYS-229; CYS-230 AND CYS-366.

************

ENZYME ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (1.53 ANGSTROMS) OF 2-383.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], INDUCTION, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

CATALYTIC ACTIVITY, AND INDUCTION.

************

FUNCTION, SUBUNIT, INDUCTION, TISSUE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES (ISOFORM 2).

************

X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) IN COMPLEX WITH PYRODOXAL PHOSPHATE AND GLYOXYLATE, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, DISRUPTION PHENOTYPE, FUNCTION, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA], AND DISRUPTION PHENOTYPE.

************

INDUCTION BY EMF1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B), FUNCTION, AND INTERACTION WITH AHR-1.

************

FUNCTION, INTERACTION WITH HIF-1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 129-350.

************

FUNCTION, INDUCTION, AND INTERACTION WITH HSP82.

************

FUNCTION, AND INTERACTION WITH HSP82.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-172, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35; SER-49; SER-159 AND SER-173, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 1-156 IN COMPLEX WITH HSP82, AND MUTAGENESIS OF ASP-53; ARG-59; LYS-60 AND LYS-62.

************

FUNCTION OF THE ADA COMPLEX.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-505, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-505 AND THR-510, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 818-1603, AND VARIANT THR-935.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1137-1603.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-829, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1549, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-846; SER-1399 AND SER-1403, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1399 AND SER-1403, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1457-1594.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-825, AND MASS SPECTROMETRY.

************

TISSUE SPECIFICITY, AND VARIANT JBTS3 ASP-443.

************

INTERACTION WITH NPHP1, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1123 AND SER-1127, AND MASS SPECTROMETRY.

************

VARIANT JBTS3 ASP-443.

************

International JSRD study group;

************

VARIANT JBTS3 GLY-1086.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-322.

************

INTERACTION WITH NPHP1, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH MKS1.

************

IDENTIFICATION IN THE TECTONIC-LIKE COMPLEX, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, INDUCTION, AND MUTAGENESIS OF HIS-508 AND ASP-1075.

************

INTERACTION WITH AHP2, AND MUTAGENESIS OF ASP-1075.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 519-1176.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1095-1176.

************

FUNCTION, DISRUPTION PHENOTYPE, AND DEVELOPMENTAL STAGE.

************

HOMODIMERIZATION, AND INTERACTION WITH AHK3; AHP1; AHP2; AHP3 AND AHP5.

************

FUNCTION, AND MUTAGENESIS OF THR-418 AND ILE-586.

************

INTERACTION WITH AT2S3; ATAF2; BETAA-AD; CYP20-2; DRP1A; HIR1; PI4KBETA1; AT1G69840; AT1G26270; AT4G12060; AHP3 AND AHP2.

************

FUNCTION, AND ACTIVATION BY CYTOKININS.

************

FUNCTION, AND MUTAGENESIS OF SER-713.

************

INTERACTION WITH AHP1; AHP2; AHP3; AHP5; AHK2 AND AHK4.

************

FUNCTION, MUTAGENESIS OF PRO-243 AND ASP-448, AND SUBCELLULAR LOCATION.

************

FUNCTION, AND MUTAGENESIS OF THR-281 AND VAL-449.

************

INTERACTION WITH AT5G43560.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, FUNCTION, AND MUTAGENESIS OF THR-301.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, ENZYME REGULATION, AND MUTAGENESIS OF HIS-482; GLY-490 AND ASP-996.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 722-983, AND VARIANT ASN-765.

************

FUNCTION, AND INTERACTION WITH AHP1; AHP2; AHP3 AND AHP5.

************

FUNCTION, ACTIVATION BY CYTOKININS, AND MUTAGENESIS OF THR-301.

************

FUNCTION, AND MUTAGENESIS OF GLY-490.

************

FUNCTION, DISRUPTION PHENOTYPE, INDUCTION, AND MUTAGENESIS OF GLY-493; THR-1008 AND ALA-1032.

************

FUNCTION, AND MUTAGENESIS OF THR-301 AND LEU-529.

************

FUNCTION, AUTOPHOSPHORYLATION AT HIS-482, MUTAGENESIS OF THR-301; HIS-482; PHE-708 AND ASP-996, DISRUPTION PHENOTYPE, AND DEVELOPMENTAL STAGE.

************

INTERACTION WITH AHP1; AHP2; AHP3; AHP5 AND AHK3.

************

FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF MET-459 AND GLY-490.

************

FUNCTION, AND MUTAGENESIS OF THR-301; GLY-435; PHE-436; MET-447; VAL-471 AND MET-494.

************

INTERACTION WITH AHP2; AMPD; WNK5 AND AT4G15630.

************

FUNCTION, DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.

************

FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, DISRUPTION PHENOTYPE, AND INDUCTION BY HYDROGEN PEROXIDE.

************

BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-108; TYR-194; ALA-206 AND GLY-207.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS), COFACTOR, SUBUNIT, AND ZINC-BINDING.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH L-HOMOSERINE LACTONE, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ZINC-BINDING, AND MUTAGENESIS OF HIS-104; HIS-106; ASP-108; HIS-109; ASP-191; TYR-194 AND HIS-235.

************

X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) IN COMPLEX WITH PRODUCT.

************

X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH ZINC, CATALYTIC ACTIVITY, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-8, FUNCTION, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-194.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-104; HIS-106; ASP-108; HIS-109 AND HIS-169.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND MUTAGENESIS OF HIS-106; ASP-108; HIS-109 AND HIS-169.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-631 (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2994-5795 (ISOFORMS 1/3).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4587-5795 (ISOFORMS 1/3), AND VARIANTS ALA-4664; ASP-5184 AND ALA-5397.

************

INTERACTION WITH DYSF.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280 AND SER-294, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-2500, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 114-1930 (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [MRNA] OF 4614-5890 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-5089, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5731, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5752, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-93; SER-511; SER-5552 AND SER-5731, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-93; THR-490; SER-511; SER-570; SER-793; SER-1068; SER-4684; THR-4766; SER-4812; SER-4903; SER-4960; SER-4986; SER-4993; THR-5009; SER-5077; SER-5099; SER-5110; SER-5332; THR-5415; SER-5448; SER-5552; SER-5555; SER-5731; SER-5749; SER-5752; SER-5763; SER-5769; SER-5780; SER-5782; SER-5784; SER-5793; THR-5794; SER-5830 AND SER-5841, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5841, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION AT SER-5749, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511; SER-559; SER-5448; SER-5731; SER-5752 AND SER-5782, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-490; SER-511; THR-4766; SER-5077; SER-5110; SER-5397; SER-5448; SER-5552; SER-5620; SER-5731; SER-5739; SER-5752; SER-5780; SER-5782; SER-5841; SER-5851; SER-5854 AND SER-5857, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-511; SER-5731 AND SER-5763, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-490; SER-511; SER-4986; SER-5099; SER-5110; SER-5552 AND SER-5731, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-177; SER-210; SER-216; THR-3716; SER-5731; SER-5749; SER-5752 AND SER-5763, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-715; TYR-836; TYR-964; TYR-1469; TYR-5089 AND TYR-5836, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511 AND SER-5752, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511; SER-570; SER-2397; SER-5448; SER-5731; SER-5749; SER-5752 AND SER-5763, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-4787, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 15-47.

************

PROTEIN SEQUENCE OF 9-47, AND CATALYTIC ACTIVITY.

************

CHARACTERIZATION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND MUTAGENESIS OF CYS-63; THR-65; GLY-84; HIS-85; GLY-95; GLY-104; CYS-118; CYS-129 AND CYS-199.

************

INTERACTION WITH ARR4; ARR9 AND ETR1.

************

INTERACTION.

************

INTERACTION WITH AHK4.

************

GENE FAMILY, NOMENCLATURE, AND FUNCTION.

************

FUNCTION, TISSUE SPECIFICITY, AND INTERACTION.

************

INTERACTION WITH AHK2; AHK3 AND AHK4.

************

PROTEIN SEQUENCE OF 2-8; 16-48; 80-102 AND 114-176, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 8-15; 33-41; 80-102 AND 125-176, AND CONJUGATION TO URM1.

************

PROTEIN SEQUENCE OF 16-41; 49-68; 82-96; 114-123 AND 142-150, POST-TRANSLATIONAL MODIFICATION, DISULFIDE BONDS, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 82-99.

************

CHARACTERIZATION, INDUCTION, AND SUBCELLULAR LOCATION.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION AT SER-2, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59 AND SER-171, AND MASS SPECTROMETRY.

************

3D-STRUCTURE MODELING, AND STRUCTURE BY NMR.

************

INTERACTION WITH AHK1; ETR1 AND CKI1.

************

INTERACTION WITH AHK2 AND AHK4, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH ARR9; ETR1 AND CKI1.

************

INTERACTION WITH AHK2, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH AHK2; AHK3 AND AHK4, AND MUTAGENESIS OF HIS-83.

************

PROTEIN SEQUENCE OF 1-41.

************

PROTEIN SEQUENCE OF 1-14.

************

PROTEIN SEQUENCE OF 2-28 AND 70-81.

************

PROTEIN SEQUENCE OF 2-11.

************

PROTEIN SEQUENCE OF 2-5.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-17; LYS-93; LYS-153; LYS-169 AND LYS-171, AND MASS SPECTROMETRY.

************

PUPYLATION AT LYS-41, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-16, LACK OF ACTION ON ISONIAZID, AND INDUCTION IN DRUG-RESISTANT BACTERIA.

************

FUNCTION, AND MUTAGENESIS OF CYS-61; CYS-174 AND CYS-176.

************

BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, FUNCTION AS ANTIOXIDANT, AND MUTAGENESIS OF CYS-61; CYS-174; CYS-176 AND 174-CYS--CYS-176.

************

MUTAGENESIS OF CYS-61; CYS-174 AND CYS-176.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF MUTANT SER-176, POSSIBLE CATALYTIC MECHANISM, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 2-25.

************

X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF MUTANT SER-47.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-20, AND INDUCTION BY OSMOTIC UPSHOCK.

************

INDUCTION BY METALS, AND REGULATION BY FUR AND PERR.

************

FUNCTION, AND REGULATION BY PERR.

************

FUNCTION, SUBUNIT, AND MUTAGENESIS OF CYS-130 AND CYS-133.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS), ACTIVE SITE, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), FUNCTION, SUBUNIT, AND MUTAGENESIS OF CYS-130 AND CYS-133.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF MUTANTS GLN-132 AND PHE-137, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF GLU-118; CYS-130; HIS-132; CYS-133 AND HIS-137.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-162.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-53 AND LYS-354, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 1-25.

************

DOMAIN, AND POSSIBLE FUNCTION.

************

FUNCTION, DNA-BINDING, AND INTERACTION WITH MCM1.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3), TISSUE SPECIFICITY, AND VARIANT PRO-114.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-189.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ALA-189.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-189.

************

TISSUE SPECIFICITY, AND FUNCTION.

************

POLYMORPHISM, AND ASSOCIATION WITH SUSCEPTIBILITY TO MALE INFERTILITY.

************

POLYMORPHISM, AND ASSOCIATION WITH SUSCEPTIBILITY TO ENDOMETRIOSIS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH ARNT, SUBCELLULAR LOCATION, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 92-701 (ISOFORM 3).

************

FUNCTION, AND INTERACTION WITH ANKRA2; HDAC4 AND HDAC5.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, AND INTERACTION WITH DAF-21.

************

INTERACTION WITH AHA-1.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-235; 388-461 AND 764-848.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 236-341, AND TISSUE SPECIFICITY.

************

FUNCTION, AND MUTAGENESIS OF VAL-381.

************

REVIEW ON ROLE IN CELL CYCLE.

************

INTERACTION WITH NEDD8.

************

INTERACTION WITH IVNS1ABP.

************

VARIANT LYS-554.

************

VARIANTS LYS-554 AND ILE-570.

************

VARIANTS LYS-554 AND VAL-786.

************

VARIANTS SER-517 AND ILE-570.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND VARIANTS ILE-324; LEU-348; LEU-471; SER-533; LEU-589 AND ALA-758.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 10-36; 232-261; 335-350 AND 636-646, AND VARIANTS ILE-324; LEU-348; LEU-471; SER-533; LEU-589 AND ALA-758.

************

NUCLEOTIDE SEQUENCE, AND VARIANTS ILE-324; LEU-348; VAL-375; LEU-471; SER-533; LEU-589 AND ALA-758.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, VARIANTS ILE-324; LEU-348; VAL-375; LEU-471; SER-533; LEU-589 AND ALA-758, AND CHARACTERIZATION OF VARIANTS ILE-324; VAL-375; LEU-471; SER-533 AND LEU-589.

************

NUCLEOTIDE SEQUENCE, FUNCTION, VARIANTS ILE-324; LEU-348; VAL-375; LEU-471; SER-533; LEU-589; ALA-758; VAL-808; ASP-821 AND VAL-824, AND CHARACTERIZATION OF VARIANTS LEU-348 AND VAL-375.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-348; VAL-375; ILE-589 AND ALA-758.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-324; LEU-348; VAL-375; LEU-471; SER-533; ILE-589 AND ALA-758.

************

PROTEIN SEQUENCE OF 10-36.

************

INTERACTION WITH MYBBP1A.

************

INTERACTION WITH NEDD8, LACK OF NEDDYLATION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 236-251 AND 702-708, FUNCTION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HAN/WISTAR ALA-497; HAN/WISTAR-DV; HAN/WISTAR-SIV AND HAN/WISTAR-LIV.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 67-338.

************

INTERACTION WITH VSV G, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

INTERACTION WITH HSPCA, MASS SPECTROMETRY, AND INDUCTION.

************

INTERACTION WITH HSPCA.

************

INTERACTION WITH GCH1.

************

INTERACTION WITH SRPK1.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3 AND LYS-212, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] THR-248.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 34-89.

************

STRUCTURE BY NMR OF 1-90, AND X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH HBA.

************

STRUCTURE BY NMR OF 2-102 OF WILD TYPE AND MUTANT ALA-30.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH HBA.

************

IDENTIFICATION AS PROBABLE DUBIOUS PREDICTION.

************

PROTEIN SEQUENCE OF 47-160, FUNCTION, AND MASS SPECTROMETRY.

************

INTERACTION WITH HIV-1 GP120 AND SIV GP130.

************

MUTAGENESIS OF ILE-51; GLN-79; GLN-117 AND GLN-155.

************

PROTEIN SEQUENCE OF 316-354; 412-423 AND 428-436, AND REPRESSION BY WATER STRESS.

************

PROTEIN SEQUENCE OF 2-20, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

MUTAGENESIS OF ASP-13; LYS-48 AND ILE-142.

************

X-RAY CRYSTALLOGRAPHY (1.26 ANGSTROMS) OF 4-730 IN COMPLEX WITH IRON-SULFUR (4FE-4S), TUNGSTEN AND MOLYBDOPTERIN, AND REACTION MECHANISM.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 89-262.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-522, AND MASS SPECTROMETRY.

************

SPLICING.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, DNA-BINDING, AND HETERODIMERIZATION.

************

SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

INTERACTION WITH AFP1; AFP2 AND AFP3.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND HETERODIMERIZATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 37-262, IDENTIFICATION, AND DISRUPTION PHENOTYPE.

************

INTERACTION WITH AFP2; AFP3 AND AFP4.

************

NUCLEOTIDE SEQUENCE [MRNA], DNA-BINDING, AND INDUCTION.

************

INTERACTION WITH ABI3.

************

PHOSPHORYLATION BY CPK4 AND CPK11.

************

FUNCTION, TISSUE SPECIFICITY, INDUCTION, AND DISRUPTION PHENOTYPE.

************

INTERACTION WITH ARIA, AND SUBCELLULAR LOCATION.

************

FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INDUCTION, AND DISRUPTION PHENOTYPE.

************

ACTIVATION BY PHOSPHORYLATION, AND MUTAGENESIS OF SER-26; SER-86; SER-94 AND THR-135.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), DNA-BINDING, AND INDUCTION.

************

INTERACTION WITH CPK32, AND PHOSPHORYLATION AT SER-110 BY CPK32.

************

MUTAGENESIS OF SER-39.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANTS HIGM2 TRP-24; ARG-80; PRO-106; VAL-139 AND SER-151.

************

INTERACTION WITH CTNNBL1, FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-38, MASS SPECTROMETRY, AND MUTAGENESIS OF 39-ALA--PHE-42 AND SER-38.

************

INTERACTION WITH CTNNBL1, FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-10; VAL-18; ARG-19; TRP-20; ARG-50; ARG-112 AND PHE-193, AND CHARACTERIZATION OF VARIANT TRP-24.

************

VARIANT CYS-25.

************

FUNCTION, AND MUTAGENESIS OF HIS-56 AND GLU-58.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 50-56.

************

PROTEIN SEQUENCE OF 112-117; 338-352; 388-393; 396-405; 408-414; 473-480; 520-530; 679-685; 691-698; 797-804; 822-836 AND 847-855.

************

PROTEIN SEQUENCE OF 847-856; 927-934 AND 948-964.

************

TOPOLOGY OF THE TRANSLOCATOR DOMAIN.

************

FUNCTION, AND GLYCOSYLATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3-306 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-144, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH AXIN.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND INDUCTION.

************

PROTEIN SEQUENCE OF 195-204, FUNCTION, DNA-BINDING, COFACTOR, AND SUBUNIT.

************

DNA-BINDING, DOMAIN, AUTOREGULATION, AND INDUCTION.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH FAD, FUNCTION, COFACTOR, SUBUNIT, AND MUTAGENESIS OF ARG-437 AND ARG-518.

************

X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS), FUNCTION, SUBCELLULAR LOCATION, LACK OF CALCIUM-BINDING, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3), AND ALTERNATIVE SPLICING.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-14.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-14.

************

FUNCTION, INTERACTION WITH ACTIN, AND TISSUE SPECIFICITY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-11, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 17-123 OF APOPROTEIN.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH LCP1.

************

X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEX WITH CALCIUM IONS, CALCIUM BINDING, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND ALTERNATIVE SPLICING.

************

PROTEIN SEQUENCE OF 55-59, SUBCELLULAR LOCATION, AND PROTEOLYTIC CLEAVAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 171-613.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EIF3G.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-105 AND SER-268, AND MASS SPECTROMETRY.

************

UBIQUITINATION BY XIAP/BIRC4, AND INTERACTION WITH XIAP/BIRC4.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-268, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-295, AND MASS SPECTROMETRY.

************

UBIQUITINATION AT LYS-255 BY XIAP/BIRC4.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 121-613 IN COMPLEX WITH FAD, SUBCELLULAR LOCATION, AND DNA-BINDING.

************

VARIANT COXPD6 ARG-201 DEL, CHARACTERIZATION OF VARIANT COXPD6 ARG-201 DEL, AND FUNCTION.

************

VARIANT COXPD6 GLU-308.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF N-TERMINUS, PROTEIN SEQUENCE OF 322-336, FUNCTION, COFACTOR, MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 378-386, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-592, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 108-610 IN COMPLEX WITH FAD, NAD-BINDING, AND MUTAGENESIS OF LYS-176 AND GLU-313.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 23-373 (ISOFORM 2).

************

FUNCTION, AND COFACTOR.

************

MYRISTOYLATION AT GLY-2.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 5).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 104-165.

************

STRUCTURE BY NMR OF 2-165.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 16-581 (ISOFORM 2).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 59-498.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 24-33.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 20-160.

************

INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

FUNCTION, COMPOSITION OF THE MINOS/MITOS COMPLEX, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

COPURIFICATION WITH RIBOSOMAL COMPLEXES, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 366-465.

************

SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND DEGRADATION.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-86, NUCLEOTIDE SEQUENCE [MRNA] OF 87-1723, AND VARIANTS PRO-293; ALA-1196 AND TYR-1395.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-827; SER-832; SER-836; SER-837; SER-840 AND SER-841, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-75 AND THR-525, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.88 ANGSTROMS) OF 1022-1117.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-58, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-18; SER-36; THR-58; THR-85; SER-183; THR-277; SER-625 AND SER-678, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-18; THR-58; THR-84; SER-119; SER-183; SER-257; THR-277 AND SER-625, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-18; SER-19; SER-25; SER-36; THR-58; THR-60; SER-61; SER-83; THR-84; THR-85; SER-104; SER-119; THR-121; SER-167; THR-180; SER-183; SER-185; SER-231; SER-257; THR-277; SER-281; THR-282; SER-284; SER-324; SER-476; SER-477; SER-517; THR-552; SER-567; SER-576; SER-620; SER-623; SER-625; SER-659; SER-667; SER-671 AND SER-675, AND MASS SPECTROMETRY.

************

PREDICTION OF FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INDUCTION BY IFNG.

************

SUBCELLULAR LOCATION, INDUCTION BY IFNG, AND SUBUNIT.

************

ROLE IN COLON CANCER, AND VARIANTS LYS-32 AND TYR-304.

************

FUNCTION, INDUCTION, DNA-BINDING, SUBCELLULAR LOCATION, INTERACTION WITH PYCARD, AND MUTAGENESIS OF LEU-14 AND PHE-165.

************

FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PYCARD, AND SELF-ASSOCIATION.

************

FUNCTION, SUBCELLULAR LOCATION, DNA-BINDING, AND INTERACTION WITH PYCARD.

************

INTERACTION WITH IFI16.

************

INTERACTION WITH MAPRE1.

************

INTERACTION WITH EIF2AK2.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 144-343 IN COMPLEX WITH DOUBLE-STRANDED DNA, ENZYME REGULATION, AND MUTAGENESIS OF LYS-160; LYS-162; LYS-163; LYS-198; LYS-204; ARG-244; LYS-251; LYS-309; ARG-311; LYS-335 AND ILE-337.

************

INTERACTION WITH RVS167, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-805 AND SER-915, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-729 AND THR-826, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-669; THR-805; SER-842 AND SER-843, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57; SER-58; SER-64; SER-476; THR-729; SER-842; SER-843; SER-847; THR-861; TYR-914; SER-915 AND SER-919, AND MASS SPECTROMETRY.

************

ASSOCIATION WITH THE NUCLEAR PORE COMPLEX, MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.

************

FUNCTION, COMPOSITION OF THE MINOS/MITOS COMPLEX, INTERACTION WITH OM45 AND POR1, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-137, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-79.

************

FUNCTION, AND INTERACTION WITH RARS.

************

SUBCELLULAR LOCATION, AND CLEAVAGE.

************

REGIONS INVOLVED IN FIBROBLAST PROLIFERATION; ENDOTHELIAL CELL DEATH AND ENDOTHELIAL MIGRATION.

************

INTERACTION WITH RARS.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-33, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN HLD3.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 147-312.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 148-312, AND FUNCTION.

************

PROTEIN SEQUENCE OF 145-164, AND FUNCTION.

************

CLEAVAGE.

************

FUNCTION, INTERACTION WITH HSP90B1, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, INTERACTION WITH SMURF2, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 197-320.

************

INTERACTION WITH KARS.

************

INTERACTION WITH FUBP1.

************

FUNCTION, INTERACTION WITH PARK2, AND UBIQUITINATION.

************

INTERACTION WITH TP53, VARIANTS VAL-92; 97-ASP--SER-99 AND SER-209, AND MUTAGENESIS OF 163-GLU-ASN-164 AND 172-GLN-ASN-173.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-92.

************

PROTEIN SEQUENCE OF 46-83; 105-111; 121-130; 139-145; 216-228; 279-288; 323-330; 339-367; 378-397 AND 407-430, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-290, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] GLN-110.

************

PROTEIN SEQUENCE OF 17-24; 29-39; 46-83; 92-130; 139-145; 152-177; 202-210; 216-228; 270-288; 291-300; 310-316; 323-366; 378-430; 431-438 AND 471-487, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-72 AND SER-335, AND MASS SPECTROMETRY.

************

GLYCOSYLATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 46-83; 92-104; 121-130; 152-161; 216-228; 270-278; 291-300; 323-330; 339-366; 387-397; 399-430 AND 439-447, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS), AND PROTEIN SEQUENCE OF 2-826.

************

PROTEIN SEQUENCE OF 2-18.

************

X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS), AND PROTEIN SEQUENCE OF 43-175.

************

PROTEIN SEQUENCE OF 44-61.

************

INTERACTION WITH COFILIN, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-354 AND TYR-355, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS), AND WD REPEATS.

************

NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH ABI3, AND TISSUE SPECIFICITY.

************

FUNCTION, INTERACTION WITH ABI3, SUBCELLULAR LOCATION, AUTOUBIQUITINATION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF CYS-230 AND CYS-231.

************

INTERACTION WITH NUB1.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), VARIANT HIS-90, AND VARIANT LCA4 ARG-239.

************

INTERACTION WITH NUB1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MUTAGENESIS OF ARG-53; MET-79; VAL-96; ALA-197; ILE-206 AND GLY-262, CHARACTERIZATION OF VARIANT LEU-302, AND CHARACTERIZATION OF VARIANT LCA4 ARG-239.

************

VARIANT LCA4 HIS-270, AND VARIANT LEU-302.

************

VARIANTS HIS-90 AND GLU-309 DELINS ASP-LEU-ASN-ARG-ARG-GLU-LEU.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-307.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS LYS-228 AND ARG-307.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS LYS-228 AND ARG-307, AND INVOLVEMENT IN PITUITARY ADENOMAS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS 47-GLY--ARG-54 DEL; HIS-16; GLU-241 AND TRP-271, AND INVOLVEMENT IN GHSPA.

************

INVOLVEMENT IN PAP.

************

INVOLVEMENT IN GHSPA, AND VARIANT LYS-228.

************

INTERACTION WITH RET.

************

VARIANTS HIS-16 AND GLN-304, INVOLVEMENT IN ACTH-SECRETING PITUITARY ADENOMA, AND INVOLVEMENT IN GHSPA.

************

VARIANT TYR-248 DEL, AND INVOLVEMENT IN GHSPA.

************

PROTEIN SEQUENCE OF 291-304, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 68-78; 242-260 AND 291-304, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, AND DEVELOPMENTAL STAGE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-252.

************

GPI-ANCHOR [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.

************

FUNCTION, SUBUNIT, AND INTERACTION WITH CID14.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12 AND SER-16, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH HMT1 AND NPL3.

************

IDENTIFICATION IN THE TRF4 COMPLEX, MASS SPECTROMETRY, AND FUNCTION OF THE TRF4 COMPLEX.

************

IDENTIFICATION IN THE TRAMP5 COMPLEX, MASS SPECTROMETRY, AND FUNCTION OF THE TRAMP5 COMPLEX.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21 AND SER-37, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.

************

FUNCTION, AND INTERACTION WITH ZEN-4.

************

FUNCTION, AND INTERACTION WITH ICP-1.

************

IDENTIFICATION IN A COMPLEX WITH ICP-1; CSC-1 AND BIR-1.

************

FUNCTION, AND INTERACTION WITH TLK-1.

************

INTERACTION WITH BMK-1.

************

IDENTIFICATION IN TRAMP COMPLEX, AND FUNCTION OF THE TRAMP COMPLEX.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-16, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-49, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-15; THR-16 AND SER-49, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-15; THR-16; SER-31 AND SER-49, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 118-198 IN COMPLEX WITH PAP2 AND ZINC IONS, FUNCTION, AND INTERACTION WITH PAP2.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT APS1 GLU-83.

************

PARTIAL PROTEIN SEQUENCE, SUBUNIT STRUCTURE, DNA-BINDING, AND PHOSPHORYLATION.

************

SUBCELLULAR LOCATION, AND VARIANTS APS1 LEU-80; CYS-85; TYR-311 AND GLN-326.

************

SUBCELLULAR LOCATION, TRANSCRIPTION ACTIVATION, MUTAGENESIS OF CYS-302 AND CYS-437, AND CHARACTERIZATION OF VARIANT APS1 PRO-28.

************

SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS APS1 LEU-15; MET-16; VAL-21; PRO-28; PRO-29; ARG-78; LEU-80; GLU-83; CYS-90; ARG-93; TRP-228 AND GLN-326.

************

INTERACTION WITH HISTONE H3 NON-METHYLATED OR MONO-METHYLATED AT LYS-4, FUNCTION, MUTAGENESIS OF ASP-297 AND ASP-312, AND CHARACTERIZATION OF VARIANTS APS1 MET-301 AND TYR-311.

************

STRUCTURE BY NMR OF 293-354 IN COMPLEX WITH ZINC IONS, AND CHARACTERIZATION OF VARIANTS APS1 MET-301; TYR-311 AND GLN-326.

************

STRUCTURE BY NMR OF 293-354 IN COMPLEX WITH ZINC IONS AND UNMETHYLATED HISTONE H3 N-TERMINUS, MASS SPECTROMETRY, MUTAGENESIS OF ASN-295; GLU-298; ARG-303; ASP-304 AND GLU-307, AND INTERACTION WITH HISTOME H3.

************

STRUCTURE BY NMR OF 294-347 IN COMPLEX WITH ZINC IONS AND UNMETHYLATED HISTONE H3 N-TERMINUS, AND CHARACTERIZATION OF VARIANTS APS1 MET-301; TYR-311; LEU-326 AND GLN-326.

************

VARIANT APS1 PRO-28.

************

VARIANT ARG-278.

************

VARIANT APS1 LEU-326.

************

VARIANTS APS1 LEU-15; MET-16; PRO-28; PR0-29; ARG-78; LEU-80; GLU-83; CYS-85; CYS-90; ARG-93; MET-301; TYR-311 AND GLN-326, AND VARIANT ARG-278.

************

The MEWPE-APECED study group;

************

VARIANT APS1 TRP-228.

************

VARIANT APS1 PRO-29.

************

VARIANT APS1 CYS-15, AND VARIANT ARG-278.

************

VARIANTS APS1 ARG-78; LEU-252 AND LEU-539.

************

VARIANTS APS1 VAL-21; CYS-85 AND TYR-311.

************

VARIANTS APS1 22-VAL-ASP-23 DEL; SER-77 AND ARG-78, AND CHARACTERIZATION OF VARIANTS APS1 LEU-15; MET-16; 22-VAL-ASP-23 DEL; SER-77 AND ARG-78.

************

CHARACTERIZATION OF VARIANT APS1 TRP-228.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1A).

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1A).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A; 1B; 1C; 1D; 2A; 2B; 2C; 2D; 3A; 3B; 3C AND 3D).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND SUBCELLULAR LOCATION.

************

SUBUNIT STRUCTURE, AND PHOSPHORYLATION.

************

FUNCTION, INTERACTION WITH THE N-TERMINUS OF UNMODIFIED HISTONE H3, INTERACTION WITH NUCLEOSOMES, DNA-BINDING, AND MUTAGENESIS OF ASP-299; VAL-303; CYS-312; CYS-313 AND PRO-328.

************

INDUCTION BY ZINC.

************

INDUCTION BY BASR.

************

FUNCTION, INDUCTION BY BASR, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION, TOPOLOGY, AND INTERACTION WITH CDH1 AND CTNNB1.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 179-411.

************

FUNCTION, AND VARIANT ARG-263.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-237 AND SER-239, AND MASS SPECTROMETRY.

************

SUBCELLULAR LOCATION, MUTAGENESIS OF LEU-303; TYR-350; TYR-368; TYR-380; LEU-396 AND 396-LEU--ILE-397, AND INTERACTION WITH AP1M2.

************

FUNCTION, AND INTERACTION WITH BSG.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 8-13; 64-73 AND 109-141, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-64, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 19-40.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SAV AND WTS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AURKA.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CTNNA1 AND F-ACTIN.

************

FUNCTION, AND INTERACTION WITH TRAF6; PRKCZ AND SQSTM1.

************

SUBCELLULAR LOCATION, FUNCTION, AND INTERACTION WITH LATS2.

************

SUBCELLULAR LOCATION, FUNCTION, AND INTERACTION WITH SNAG-DOMAIN.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND MASS SPECTROMETRY.

************

INTERACTION WITH SNAI1.

************

IDENTIFICATION WITH IN THE GFI1-AJUBA-HDAC1 COMPLEX, INTERACTION WITH GFI1; HDAC1; HDAC2 AND HDAC3, SUBCELLULAR LOCATION, AND FUNCTION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-155 AND SER-159, AND MASS SPECTROMETRY.

************

FUNCTION, AND INTERACTION WITH LATS1; LATS2 AND SAV1.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EIF4E; EIF2C1; EIF2C2; DCP2 AND DDX6.

************

FUNCTION, AND INTERACTION WITH EGLN1/PHD2; EGLN3/PHD3 AND VHL.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, FUNCTION, AND INTERACTION WITH GRB2.

************

INTERACTION WITH PIP5K1B.

************

FUNCTION, AND INTERACTION WITH SNAI1; SNAI2/SLUG AND SCRT1.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 177-548, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH SLC1A2.

************

MASS SPECTROMETRY, AND IDENTIFICATION IN A COMPLEX WITH THE SPLICEOSOME.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537 AND SER-633, AND MASS SPECTROMETRY.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ZRANB2 AND SFRS1.

************

FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DOMAIN, AND MUTAGENESIS OF 438-LEU-LEU-439 AND 445-LYS-LYS-446.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-304.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-673, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 2-325.

************

MUTAGENESIS OF TYR-50; LYS-80; HIS-113; ILE-299 AND VAL-300.

************

FUNCTION, AND CHARACTERIZATION OF VARIANTS SER-52 AND ASP-55.

************

X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS).

************

PROTEIN SEQUENCE OF 2-13 AND 244-251, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 204-218; 222-240 AND 313-325, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 14-30; 62-77; 81-97; 135-145 AND 146-157, GLYCATION AT LYS-23; LYS-68; LYS-85; LYS-141 AND LYS-153, AND ABSENCE OF GLYCATION AT LYS-13; LYS-30; LYS-34; LYS-61; LYS-80; LYS-97; LYS-127; LYS-134; LYS-145; LYS-157; LYS-240; LYS-257; LYS-263; LYS-287; LYS-294 AND LYS-308.

************

PROTEIN SEQUENCE OF 204-218; 222-240; 270-287 AND 313-325, AND MASS SPECTROMETRY.

************

ACETYLATION AT THR-2, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASP-313.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-313.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 232-316, AND VARIANT ASP-313.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-27; LYS-69; LYS-95; LYS-125; LYS-179 AND LYS-263, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) IN COMPLEX WITH TOLRESTAT AND NADP, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND MUTAGENESIS OF LYS-125 AND VAL-301.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-323.

************

PROTEIN SEQUENCE OF 10-31; 40-61; 69-126; 137-153; 162-206; 209-230; 250-267; 271-289 AND 295-323, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 18-323, AND PROTEIN SEQUENCE OF 18-31; 105-131; 176-193 AND 271-294.

************

X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH NADP AND 20ALPHA-HYDROXY-PROGESTERONE, AND MUTAGENESIS OF GLU-127; HIS-222; ARG-304; TYR-305; THR-307 AND ASP-309.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND PROTEIN SEQUENCE OF 2-26; 40-123; 137-172; 271-282 AND 295-323.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT TYR-46.

************

PROTEIN SEQUENCE OF 2-31; 40-62; 69-100; 105-131; 137-153; 162-206; 209-231; 250-269 AND 271-323, FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 10-29; 40-55; 76-101; 105-128; 137-146; 162-197; 208-223; 259-270 AND 305-322.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1; LYS-4; LYS-161 AND LYS-179, AND MASS SPECTROMETRY.

************

TISSUE SPECIFICITY, VARIANTS SRXY8 VAL-79; GLN-90; GLN-222 AND THR-300, AND CHARACTERIZATION OF VARIANTS SRXY8 VAL-79; GLN-90; GLN-222 AND THR-300.

************

X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) IN COMPLEX WITH NADP AND URSODEOXYCHOLATE.

************

X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) IN COMPLEX WITH NADP AND TESTOSTERONE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLN-5 AND ILE-175.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CHARACTERIZATION, TISSUE SPECIFICITY, AND VARIANTS GLN-5 AND ILE-175.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-5.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, TISSUE SPECIFICITY, AND VARIANT GLN-5.

************

NUCLEOTIDE SEQUENCE [MRNA], NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 124-190, CHARACTERIZATION, TISSUE SPECIFICITY, AND VARIANT GLN-5.

************

NUCLEOTIDE SEQUENCE [MRNA], BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND VARIANT GLN-5.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-5.

************

CHARACTERIZATION, TISSUE SPECIFICITY, CHARACTERIZATION OF VARIANT ILE-175, AND MUTAGENESIS OF LYS-75.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH PROSTAGLANDIN H(2); NADPH AND RUTIN.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH FLUFENAMIC ACID AND INDOMETHACIN.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH NADP AND DELTA4 -3 ANDROSTENE-3,17-DIONE, AND IMPORTANCE OF TRP-227 AND PHE-306 IN LIGAND RECOGNITION AND PRODUCT RELEASE.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-250.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND VARIANT ARG-250.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS CYS-145; ARG-250 AND VAL-311.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT ARG-250.

************

NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION OF 3-ALPHA-HSD ACTIVITY, TISSUE SPECIFICITY, AND VARIANT ARG-250.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 2-323, AND VARIANT ARG-250.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-323, PROTEIN SEQUENCE OF 5-29; 76-131; 184-201 AND 271-294, AND VARIANT ARG-250.

************

PROTEIN SEQUENCE OF 40-54; 105-121; 162-175; 184-196; 277-291 AND 307-321, AND CHARACTERIZATION AS 3-ALPHA-HSD.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-196, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-75 AND LYS-270, AND MASS SPECTROMETRY.

************

INVOLVEMENT IN SRXY8.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-23; 69-116; 137-153; 184-246 AND 250-323.

************

PROTEIN SEQUENCE OF 201-209, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-88 AND SER-89, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) IN COMPLEX WITH NADP, FUNCTION, AND MUTAGENESIS OF ALA-24.

************

X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH NADP.

************

X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-323 IN COMPLEX WITH EPITESTOSTERONE, MUTAGENESIS OF LYS-31, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INDUCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) IN COMPLEXES WITH NADP; TESTOSTERONE; PROGESTERONE AND CORTISONE, MUTAGENESIS OF TYR-58 AND GLU-120, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

VARIANTS CBAS2 PHE-106 AND LEU-198.

************

VARIANTS CBAS2 ARG-133 AND CYS-261.

************

PROTEIN SEQUENCE OF 51-129.

************

SEQUENCE REVISION TO 11.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 553-588.

************

X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 61-569 IN COMPLEX WITH SUBSTRATE ANALOG AND ALLOSTERIC REGULATORS, AND SUBUNIT.

************

SEQUENCE REVISION TO 399.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-10.

************

REGULATION BY DEGRADATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-27.

************

SUBUNIT, INVOLVEMENT OF C-TERMINUS IN DIMERIZATION, AND MUTAGENESIS OF LYS-8; GLU-119; ARG-198 AND ASP-202.

************

X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN SUBSTRATE-BOUND ACTIVE AND LYS-BOUND INACTIVE STATES, SUBUNIT, AND ENZYME REGULATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-52 AND SER-187, AND MASS SPECTROMETRY.

************

VARIANT VAL-646, AND INVOLVEMENT IN SUSCEPTIBILITY TO SCD.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 160-662 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-52, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 630-1901.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1121-1469.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-448; THR-1100; SER-1169 AND SER-1242, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-422; SER-433; SER-448; THR-1100; THR-1104; SER-1337 AND SER-1340, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1100 AND SER-1242, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-448; THR-1100; SER-1169; SER-1240 AND SER-1242, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-433; SER-448; THR-1100 AND SER-1242, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLU-117; GLN-216 AND SER-987.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS GLU-117; GLN-216 AND ASP-1600.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS GLN-216; GLY-920 AND LYS-1355.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 43-1782, AND VARIANTS GLU-117 AND GLN-216.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1478-1782.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219; SER-312; SER-565; SER-566; SER-568; SER-569; SER-598 AND SER-612, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-253; SER-283; SER-286; SER-627; SER-629 AND SER-1331, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-388; SER-505; SER-732 AND SER-887, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-283; THR-285; SER-286; THR-289; SER-388; SER-483; SER-554; SER-557; SER-566; SER-568; SER-598; SER-612; THR-642; SER-644; SER-645; THR-646; SER-651; THR-1116; SER-1331; SER-1390; SER-1391; SER-1395 AND THR-1760, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-597; SER-598; SER-627; SER-696 AND SER-1395, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] LYS-240.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-605 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-22 AND SER-584, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631; THR-632; SER-634; SER-682; SER-683 AND SER-684, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543; SER-598; SER-613; SER-615; SER-682; SER-683 AND SER-684, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-353, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), SUBUNIT, TISSUE SPECIFICITY, AND MUTAGENESIS OF LEU-43 AND VAL-47.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MYRISTOYLATION AT GLY-2, AND PALMITOYLATION AT CYS-5 AND CYS-6.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA), FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA).

************

FUNCTION, INTERACTION WITH PRKCA, AND MUTAGENESIS OF 2-GLY--CYS-6.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, MYRISTOYLATION AT GLY-2, AND PALMITOYLATION AT CYS-5 AND CYS-6.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-348, FUNCTION, RII-BINDING, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, AND INTERACTION WITH PRKCA.

************

NUCLEOTIDE SEQUENCE [MRNA], RI-ALPHA-BINDING, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-41; LYS-43; LEU-265 AND LEU-269.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA), PKA-RII-ALPHA SUBUNIT BINDING, SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, TISSUE SPECIFICITY, MUTAGENESIS OF LEU-308, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 88-292 IN COMPLEX WITH AMP AND CMP.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-533, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-169, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-70; SER-151 AND THR-533, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-429 AND THR-533, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 5 AND 6).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; SER-101 AND SER-103, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT SER-561.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 539-859 (ISOFORMS 1/3/4).

************

ALTERNATIVE SPLICING (ISOFORM 3).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152 AND SER-720, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-748, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-393 AND SER-720, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121; SER-152; SER-393; SER-631; SER-720 AND SER-748, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152; SER-411 AND SER-631, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152; SER-324; SER-393; SER-461; SER-479; SER-720 AND SER-748, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND MUTAGENESIS OF ALA-590 AND ILE-598.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-799, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-858.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANTS GLU-118; SER-464 AND LYS-525.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANTS GLU-118; SER-464; THR-500 AND LYS-525.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-464 AND LYS-525.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLU-118.

************

INTERACTION WITH ROPN1 AND ROPN1L, AND MUTAGENESIS OF LEU-131.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-208; SER-403; TYR-404; SER-440; SER-612; SER-635 AND SER-636, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] CYS-831.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND 3).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62; SER-63; SER-64; SER-65; SER-151; THR-265; SER-268; SER-272; SER-293; SER-300; TYR-303; SER-304; SER-447; TYR-448; SER-450; SER-492; SER-536; SER-539; SER-665 AND SER-667, AND MASS SPECTROMETRY.

************

INTERACTION WITH PRKAR1A AND PRKAR2A, AND DOMAIN.

************

IDENTIFICATION BY MASS SPECTROMETRY, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 170-428.

************

NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS, AND VARIANT ILE-203.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-203.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-203.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 332-427.

************

PALMITOYLATION AT CYS-36 AND CYS-129, INTERACTION WITH ADCY8, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 251-714.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-1492.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1666-2319.

************

VARIANTS [LARGE SCALE ANALYSIS] MET-910; ILE-1192; GLN-1702 AND THR-1839.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-323; SER-328 AND SER-339, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-323 AND SER-328, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-538, AND MASS SPECTROMETRY.

************

VARIANT [LARGE SCALE ANALYSIS] HIS-664.

************

SUBCELLULAR LOCATION, INTERACTION WITH FIGN, AND DISRUPTION PHENOTYPE.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320 AND SER-336, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320; SER-325 AND SER-336, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320 AND SER-325, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT GLN-1347 INS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANTS ILE-475 AND SER-2983.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 323-3911 (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF 2157-3911 (ISOFORM 6), AND VARIANT SER-2983.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2212-3911 (ISOFORMS 2/3), AND VARIANT SER-2983.

************

INTERACTION WITH CLIC1; CLIC4 AND CLIC5.

************

INTERACTION WITH CSNK1D, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH CIP4 AND FNBP1, AND SUBCELLULAR LOCATION.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3869, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165 AND SER-3846, AND MASS SPECTROMETRY.

************

VARIANTS [LARGE SCALE ANALYSIS] ILE-2421 AND GLN-3301.

************

VARIANT LQT11 LEU-1582.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-582 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 257-269 AND 315-323.

************

PROTEIN SEQUENCE OF 233-243; 252-269 AND 315-323.

************

PROTEIN SEQUENCE OF 3-21.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 5), BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 3-69; 92-131; 171-185; 188-223 AND 253-298, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 169-301 (ISOFORM LONG).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 199-465.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 431-1911 (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1563-1911 (ISOFORM 4).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-724 (ISOFORM 1), AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-573.

************

FUNCTION, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

PROTEIN SEQUENCE OF 23-32.

************

PROTEIN SEQUENCE OF 26-32.

************

PROTEIN SEQUENCE OF 36-63.

************

PROTEIN SEQUENCE OF 23-63.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND BIOPHYSICOCHEMICAL PROPERTIES.

************

ENZYME REGULATION, AND MUTAGENESIS OF ILE-441; GLN-443; ILE-522 AND GLN-524.

************

PROTEIN SEQUENCE OF 23-30.

************

PROTEIN SEQUENCE OF 34-61.

************

PROTEIN SEQUENCE, AND PROTEOLYTIC PROCESSING.

************

PROTEIN SEQUENCE, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE, TISSUE SPECIFICITY, MASS SPECTROMETRY, PYROGLUTAMATE FORMATION AT GLN-1, AND AMIDATION AT TRP-8.

************

PROTEIN SEQUENCE, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, MASS SPECTROMETRY, PYROGLUTAMATE FORMATION AT GLN-1, AND AMIDATION AT TRP-8.

************

PROTEIN SEQUENCE OF 23-30, AND AMIDATION.

************

PROTEIN SEQUENCE, AND SYNTHESIS.

************

PROTEIN SEQUENCE OF 20-28.

************

PROTEIN SEQUENCE, PYROGLUTAMATE FORMATION AT GLN-1, AND AMIDATION AT TRP-8.

************

PROTEIN SEQUENCE, AND AMIDATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-1016.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 540-1089, AND VARIANT MET-1016.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 549-1089, AND VARIANT MET-1016.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-737, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-738, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LYS-23.

************

TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INTERACTION WITH PRKACA.

************

FUNCTION, INTERACTION WITH RELA, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH AURORA-A.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-22 AND THR-72, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-21, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH YWHAB, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF SER-31; THR-103; SER-111; SER-119 AND SER-131.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; SER-41; SER-67; SER-123 AND SER-129, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-521; SER-1048 AND SER-1051, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1048 AND SER-1051, UBIQUITINATION AT LYS-1008 AND LYS-1046, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-541; SER-801 AND SER-1072, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-504, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-518; SER-521; SER-879; SER-884; SER-960 AND SER-1072, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-12; SER-407; THR-471; SER-496; SER-501; SER-504; SER-511; SER-521; SER-533; THR-538; SER-541; SER-801; SER-846 AND SER-1072, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 5; 6 AND 7).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-624.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 8), AND VARIANTS LEU-624; GLN-1119 AND PRO-1303.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 762-1395, FUNCTION, SUBCELLULAR LOCATION, DNA-BINDING, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-839 AND SER-848, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-52 AND SER-534, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 175-1404 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT ASN-61.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ASN-61 AND LYS-616.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-61.

************

The Cancer Genome Anatomy Project (CGAP) at the National Cancer Institute;

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH RHOA, AND VARIANTS CYS-574 AND SER-2457.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH RHOA; RHOB AND RHOC, MUTAGENESIS OF ALA-1251; ILE-1260 AND TYR-2153, AND VARIANTS VAL-624; MET-897 AND SER-2457.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-452; ARG-494; CYS-574; LYS-689; ALA-845; MET-897; ALA-1062; ASN-1086 AND THR-1216.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1385-2813 (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH ESR1; THRA AND PPARA, AND VARIANT SER-2457.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1827-2813 (ISOFORM 3), FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1913-2335 (ISOFORM 3).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 754-1768, PKA AND RII BINDING, AND MUTAGENESIS OF ALA-1265.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1486-2813 (ISOFORM 3), AND VARIANT SER-2457.

************

FUNCTION, AND INTERACTION WITH ESR2.

************

INTERACTION WITH NME2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1929 AND SER-1932, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983 AND SER-2728, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983; SER-1559; SER-1645; SER-1647; SER-1876; SER-1929; SER-1932; SER-2398; SER-2402; SER-2703; SER-2709 AND SER-2728, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983; SER-1929; SER-1932; SER-2709 AND SER-2728, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983; SER-1642; SER-1645; SER-1647; SER-1876; SER-1895 AND SER-2728, AND MASS SPECTROMETRY.

************

STRUCTURE BY NMR OF 493-516.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-458.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLN-458.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLN-458.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLN-458.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-358 (ISOFORM 1), AND SUBCELLULAR LOCATION.

************

INTERACTION WITH TMPO-BETA.

************

INTERACTION WITH RNF43.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-292; THR-294; SER-297; SER-300; SER-302 AND THR-308, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-552, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-292; SER-297; SER-300 AND THR-308, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-257, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 511-520, AND MASS SPECTROMETRY.

************

INTERACTION WITH PRPF40A, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 1-156 AND 172-757.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-759.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 26-346, INDUCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND FUNCTION.

************

FUNCTION, SUBCELLULAR LOCATION, ACTIVE SITE, AND MUTAGENESIS OF 497-ASP--HIS-498 AND CYS-500.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51 AND SER-57, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH APX3 AND GRF6, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH NADP, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) IN COMPLEX WITH NADP, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 12-315 (ISOFORM 1).

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-295, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INDUCTION BY LIGHT.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), INTERACTION WITH EMB506, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.

************

PROTEIN SEQUENCE OF 1-5, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 79-857.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 106-857.

************

FUNCTION, INTERACTION WITH AKT2 AND KAT3, AND INDUCTION.

************

FUNCTION, INTERACTION WITH CIPK23, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.

************

FUNCTION, INTERACTION WITH CIPK23, AND PHOSPHORYLATION.

************

FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH AIP1; CIPK6; CIPK16 AND CIPK23.

************

DEPHOSPHORYLATION AT SER-473 BY PHLPP.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B), FUNCTION, MUTAGENESIS OF ALA-183, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, ENZYME REGULATION, INTERACTION WITH PDK-1; SGK-1; AKT-2 AND DAF-16, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE INITIATION (ISOFORMS A AND C), ENZYME ACTIVITY, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

GENOME REANNOTATION, AND ALTERNATIVE INITIATION.

************

FUNCTION, MUTAGENESIS OF PHE-408, AND DISRUPTION PHENOTYPE.

************

FUNCTION, AND MUTAGENESIS OF LYS-295.

************

FUNCTION, AND PHOSPHORYLATION AT SER-586.

************

FUNCTION, AND MUTAGENESIS OF GLY-180 AND PHE-408.

************

DEPHOSPHORYLATION AT SER-586.

************

PHOSPHORYLATION AT SER-586.

************

NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 63-480, FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

FUNCTION IN PHOSPHORYLATION OF CREB1.

************

ENZYME REGULATION, AND PHOSPHORYLATION AT SER-473.

************

MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND SER-473.

************

FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1.

************

FUNCTION IN PHOSPHORYLATION OF FOXO1.

************

FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1.

************

FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2.

************

INTERACTION WITH MTCP1; TCL1A AND TCL1B.

************

INTERACTION WITH TCL1A.

************

FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5.

************

INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION.

************

INTERACTION WITH CDKN1B, AND FUNCTION.

************

PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474.

************

INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473.

************

FUNCTION IN PARTICIPATION IN KIT SIGNALING.

************

INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473.

************

PHOSPHORYLATION AT SER-473.

************

INTERACTION WITH AKTIP.

************

INTERACTION WITH AGAP2.

************

PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING.

************

FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A.

************

PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR.

************

FUNCTION, AND INTERACTION WITH RARA.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND MASS SPECTROMETRY.

************

FUNCTION IN PHOSPHORYLATION OF CDKN1A.

************

INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

FUNCTION, AND INTERACTION WITH STK4/MST1.

************

FUNCTION IN PHOSPHORYLATION OF PROHIBITIN.

************

UBIQUITINATION BY TTC3.

************

FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2.

************

UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17.

************

FUNCTION, AND INTERACTION WITH STK3/MST2.

************

FUNCTION, AND INTERACTION WITH CLK2.

************

FUNCTION IN PHOSPHORYLATION OF PALLD.

************

FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE SPECIFICITY.

************

INTERACTION WITH TRIM13, AND UBIQUITINATION.

************

INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION.

************

REVIEW ON ROLE IN KIT SIGNALING.

************

INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20.

************

GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312.

************

X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, INTERACTION WITH PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, AND MUTAGENESIS OF LYS-14; ARG-25 AND ARG-86.

************

X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, AND INTERACTION WITH PTDINS(1,3,4,5)P4.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT THR-308, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT THR-308, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND.

************

X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ENZYME REGULATION.

************

VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17.

************

CHARACTERIZATION OF VARIANT PROTEUSS LYS-17.

************

VARIANT PROTEUSS LYS-17.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, PHOSPHORYLATION AT SER-473, DISRUPTION PHENOTYPE, AND DEVELOPMENTAL STAGE.

************

FUNCTION, AND MUTAGENESIS OF LYS-179.

************

FUNCTION IN PHOSPHORYLATION OF PDE3B.

************

PHOSPHORYLATION IN RESPONSE TO FLT3 SIGNALING.

************

FUNCTION IN PHOSPHORYLATION OF PTPN1.

************

INTERACTION WITH THEM4.

************

INTERACTION WITH CCDC88A, AND PHOSPHORYLATION AT THR-308 AND SER-473.

************

GLYCOSYLATION AT SER-473.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND MASS SPECTROMETRY.

************

FUNCTION, GLYCOSYLATION AT SER-473, AND PHOSPHORYLATION AT THR-308.

************

INTERACTION WITH CLK2.

************

PHOSPHORYLATION AT THR-450.

************

FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND SER-473, MUTAGENESIS OF TYR-176, AND INTERACTION WITH TNK2.

************

FUNCTION, UBIQUITINATION BY ZNRF1, AND MUTAGENESIS OF THR-308 AND SER-473.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 76-935, AND TISSUE SPECIFICITY.

************

FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.

************

FUNCTION, AND MUTAGENESIS OF LYS-179; THR-308 AND SER-473.

************

FUNCTION, PHOSPHORYLATION AT THR-308 AND SER-473, AND MUTAGENESIS OF LYS-179; THR-308 AND SER-473.

************

FUNCTION IN PHOSPHORYLATION OF ACLY.

************

FUNCTION IN PHOSPHORYLATION OF PIKFYVE.

************

CHARACTERIZATION, AND TISSUE SPECIFICITY.

************

INTERACTION WITH KAT1.

************

INTERACTION WITH PP2CA.

************

INTERACTION WITH PP2CA, DEPHOSPHORYLATION BY PP2CA, AND TISSUE SPECIFICITY.

************

MUTAGENESIS OF HIS-243; SER-286 AND ILE-289.

************

FUNCTION, INTERACTION WITH AKT1 AND KAT3, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.

************

FUNCTION, ENZYME REGULATION, INTERACTION WITH PDK-1; SGK-1; AKT-1 AND DAF-16, AND DISRUPTION PHENOTYPE.

************

CHARACTERIZATION, AND PHOSPHORYLATION AT THR-309 BY PDPK1.

************

MUTAGENESIS OF THR-309 AND SER-474, AND PHOSPHORYLATION AT THR-309 AND SER-474.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PBH2.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126, AND MASS SPECTROMETRY.

************

UBIQUITINATION BY TTC3, PHOSPHORYLATION AT THR-309 AND SER-474, AND MUTAGENESIS OF THR-309 AND SER-474.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447; THR-451; SER-474 AND SER-478, AND MASS SPECTROMETRY.

************

UBIQUITINATION, AND INTERACTION WITH TRAF6.

************

INVOLVEMENT IN CANCER.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480.

************

X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 146-467 IN COMPLEX WITH PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER AND MANGANESE, AND PHOSPHORYLATION AT THR-309.

************

X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 143-481, ATP-BINDING, SUBSTRATE-BINDING, AND DISULFIDE BOND.

************

STRUCTURE BY NMR OF 1-111.

************

X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 146-467, AND INHIBITOR-BINDING.

************

X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 146-480, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480, AND ENZYME REGULATION.

************

VARIANT NIDDM HIS-274.

************

VARIANTS [LARGE SCALE ANALYSIS] VAL-188 AND LYS-208.

************

ASSOCIATION OF VARIANT NIDDM HIS-274 WITH TYPICAL METABOLIC DYSLIPIDEMIA.

************

VARIANT HIHGHH LYS-17.

************

FUNCTION IN PHOSPHORYLATION OF PTIX2.

************

NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND MUTAGENESIS OF THR-305 AND THR-447.

************

CHARACTERIZATION, AND PHOSPHORYLATION AT THR-305 BY PDPK1.

************

PHOSPHORYLATION AT SER-472.

************

INVOLVEMENT IN TUMORS.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-120 AND SER-123, AND MASS SPECTROMETRY.

************

INTERACTION WITH TRAF6.

************

X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) OF 1-118.

************

VARIANT [LARGE SCALE ANALYSIS] ARG-171.

************

VARIANT MELANOMA LYS-17, AND CHARACTERIZATION OF VARIANT MELANOMA LYS-17.

************

MUTAGENESIS OF ASP-219, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-454.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], CHARACTERIZATION, TISSUE SPECIFICITY, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 407-888.

************

IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE FHF COMPLEX, FUNCTION, ASSOCIATION WITH THE HOPS COMPLEX, AND MUTAGENESIS OF 106-TRP-PHE-107.

************

INTERACTION WITH 14-3-3, TISSUE SPECIFICITY, AND PHOSPHORYLATION AT THR-246.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183 AND THR-246, AND MASS SPECTROMETRY.

************

FUNCTION, IDENTIFICATION IN THE TORC1 COMPLEX, AND INTERACTION WITH RPTOR.

************

FUNCTION, IDENTIFICATION IN THE TORC1 COMPLEX, AND MUTAGENESIS OF THR-246.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88 AND SER-92, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88; SER-92; SER-183; SER-202; SER-203; SER-211; SER-212 AND THR-246, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183; THR-198; SER-202; SER-203; SER-211; SER-212 AND THR-246, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88; SER-92; SER-183; SER-202; SER-212 AND THR-246, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; SER-204 AND SER-213, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117; SER-203; SER-204; SER-212 AND SER-213, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88; SER-92; SER-203 AND SER-204, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 158-421.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 297-421.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 198-412.

************

DOMAIN RPE1.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-326 AND THR-328, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333 AND SER-441, AND MASS SPECTROMETRY.

************

FUNCTION, INTERACTION WITH ARL14 AND MYO1E, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 29-49.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-121.

************

PROTEIN SEQUENCE OF 2-501, AND ACETYLATION AT SER-2.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 162-501.

************

PROTEIN SEQUENCE OF 266-273, ACTIVE SITES GLU-269 AND CYS-303, AND NAD-BINDING SITE CYS-456.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-91; LYS-128; LYS-252; LYS-353; LYS-367; LYS-410; LYS-419; LYS-435 AND LYS-495, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 23-52; 140-156; 211-230; 309-320; 330-349; 400-410; 421-435 AND 477-490.

************

PROTEIN SEQUENCE OF 2-19; 80-91; 96-121; 205-225; 237-258 AND 394-438.

************

X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-518.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-348.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT ILE-348.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 302-518 (ISOFORMS 1/2), AND VARIANT ILE-348.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-518.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-119 AND THR-122, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-518.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 20-518.

************

PROTEIN SEQUENCE OF 2-15; 253-263; 407-421; 432-446 AND 488-501, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.

************

FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 284-409.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-253.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-253.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-107 AND MET-253.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-107.

************

VARIANTS VAL-86 AND ARG-107.

************

PROTEIN SEQUENCE OF 55-75; 162-174; 327-340 AND 444-453, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-613, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-307 IN COMPLEX WITH 6-FORMYLTETRAHYDROPTERIN, AND ACTIVE SITE.

************

VARIANT [LARGE SCALE ANALYSIS] VAL-511.

************

PROTEIN SEQUENCE OF N-TERMINUS, AND MUTAGENESIS OF ASP-142.

************

MUTAGENESIS OF CYS-707, FUNCTION, AND SUBUNIT.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-354, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-309, AND CATALYTIC ACTIVITY.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 397-902 IN COMPLEX WITH NADP, CATALYTIC ACTIVITY, MUTAGENESIS OF GLU-673, AND ACTIVE SITE.

************

X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 397-902 IN COMPLEX WITH NADP, ACTIVE SITE, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-752 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 221-511 (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 762-923 (ISOFORM 1).

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-903, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 9-125.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 322-501.

************

FUNCTION, AND MUTAGENESIS OF GLY-152 AND GLY-416.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH RAB5A, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3; 4 AND 6).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-392 (ISOFORM 1), AND VARIANT GLN-45.

************

FUNCTION, HOMODIMERIZATION, INTERACTION WITH ALS2, AND SUBCELLULAR LOCATION.

************

VARIANTS [LARGE SCALE ANALYSIS] GLU-280 AND PHE-576.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH RAB5A, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

HOMODIMERIZATION, INTERACTION WITH ALS2, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-278 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 29-301 (ISOFORM 1).

************

NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLN-376.

************

VARIANT [LARGE SCALE ANALYSIS] MET-123.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-43.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-376, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-140.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-134.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-134.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-134.

************

PROTEIN SEQUENCE OF 62-453.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3; LYS-178; LYS-194 AND LYS-269, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) IN COMPLEX WITH INHIBITOR, MUTAGENESIS OF CYS-244, AND ACTIVE SITE.

************

VARIANT ALA-329.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND VARIANTS ALD3A1C ASN-154; ARG-305 AND VAL-352.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND VARIANTS SLS.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).

************

VARIANT SLS SER-315.

************

VARIANTS SLS ARG-106; TRP-226; ASN-245; SER-315; LEU-365 AND ARG-412.

************

VARIANTS SLS PHE-45; ASP-64; ARG-106; LEU-114; LEU-121; ARG-184; MET-184; ALA-185; CYS-228; TYR-237; ASN-245; ASN-266; ASN-279; SER-315; ILE-328; LEU-365; ARG-406; TYR-411; ASN-415; SER-419; HIS-423 AND GLU-447.

************

VARIANT SLS SER-386.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 93-110; 236-255 AND 408-427.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-368, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 20-468.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 331-468.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-52; ARG-203; GLY-220 AND ARG-361.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-203; GLY-220 AND TRP-276.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASN-52; ARG-203; GLY-220 AND ARG-361.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 5-484, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT ILE-470.

************

PROTEIN SEQUENCE OF 25-35.

************

PROTEIN SEQUENCE OF 94-99; 105-113; 125-139; 176-191; 251-273; 339-347; 354-365 AND 510-526.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 18-563 OF WILD-TYPE; MUTANT ALA-352 AND VARIANT HP-2 LEU-352, CATALYTIC ACTIVITY, FUNCTION, PATHWAY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, ACTIVE SITE, CHARACTERIZATION OF VARIANT HP-2 LEU-352, AND MUTAGENESIS OF SER-352.

************

VARIANT HP-2 LEU-352, AND VARIANT LEU-16.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-98; LYS-113 AND LYS-401, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.24 ANGSTROMS) OF 21-562.

************

X-RAY CRYSTALLOGRAPHY (1.30 ANGSTROMS) OF 21-562 IN COMPLEXES WITH GLUTAMATE AND NAD, SUBUNIT, AND ACTIVE SITE.

************

PROTEIN SEQUENCE OF 79-89 AND 318-337, AND MASS SPECTROMETRY.

************

SUSCEPTIBILITY TO MYOCARDIAL INFARCTION, AND SUSCEPTIBILITY TO ISCHSTR.

************

LACK OF ASSOCIATION WITH MYOCARDIAL INFARCTION.

************

INTERACTION WITH LTC4S AND ALOX5, AND SUBCELLULAR LOCATION.

************

X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) IN COMPLEXES WITH LEUKOTRIENE BIOSYNTHESIS INHIBITOR MK-591, TOPOLOGY, SUBUNIT, MUTAGENESIS OF VAL-20; ALA-27; VAL-30; ASP-62; THR-66; TYR-112; ILE-113; LYS-116 AND PHE-123, AND DOMAIN.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-153.

************

SUBCELLULAR LOCATION, FUNCTION, AND INTERACTION WITH ALOX5.

************

PROTEIN SEQUENCE OF 1-39; 90-121 AND 126-146.

************

PROTEIN SEQUENCE, CATALYTIC ACTIVITY, COFACTOR, AND SUBUNIT.

************

PROTEIN SEQUENCE OF 2-16.

************

PROTEIN SEQUENCE, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 233-268, AND TISSUE SPECIFICITY.

************

X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 30-526, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ALTERNATIVE SPLICING, AND SUBCELLULAR LOCATION.

************

VARIANTS PDE VAL-199 AND GLN-427, AND FUNCTION.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 2-31 AND 386-404, AND INDUCTION.

************

PROTEIN SEQUENCE OF 53-66 AND 144-154, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 312-539, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-116.

************

PROTEIN SEQUENCE OF 2-15; 247-258; 299-310; 315-326 AND 472-481, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 259-274; 353-366; 412-426 AND 434-453, NUCLEOTIDE SEQUENCE [MRNA] OF 29-494, CHARACTERIZATION, TISSUE SPECIFICITY, AND VARIANT SER-116.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 33-494, AND PARTIAL PROTEIN SEQUENCE.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-298, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 39-59; 74-82; 88-101; 228-239; 247-274; 317-338; 348-366; 412-426 AND 472-494, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND CHARACTERIZATION.

************

PROTEIN SEQUENCE OF 50-59; 199-223; 275-293 AND 412-426, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, SUBCELLULAR LOCATION, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 591-1107.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1050, AND MASS SPECTROMETRY.

************

FUNCTION, MUTAGENESIS OF ASP-381, SUBCELLULAR LOCATION, AND INTERACTION WITH ALIS1; ALIS3 AND ALIS5.

************

NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 197-206 AND 308-317.

************

FUNCTION, MUTAGENESIS OF ASP-413, DISRUPTION PHENOTYPE, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH ALIS1; ALIS3 AND ALIS5.

************

FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ALIS1; ALIS3 AND ALIS5.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-674, AND MASS SPECTROMETRY.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-625 AND LYS-717, AND MASS SPECTROMETRY.

************

FUNCTION AS AN AMINOTRANSFERASE AND IN ALANINE BIOSYNTHESIS, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, INDUCTION, AND NOMENCLATURE.

************

INDUCTION BY SGRR.

************

FUNCTION IN ALANINE BIOSYNTHESIS.

************

FUNCTION IN ALANINE EXPORT, SUBCELLULAR LOCATION, INDUCTION, DISRUPTION PHENOTYPE, AND GENE NAME.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 75-543.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3-543.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 448-543.

************

INDUCTION BY CADMIUM [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].

************

FUNCTION, TISSUE SPECIFICITY, INDUCTION BY HYPOXIC STRESS, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-14.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-14.

************

PROTEIN SEQUENCE OF 2-496.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 4-496.

************

GLYCATION AT LYS-11.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 9-540 (ISOFORM 1).

************

TISSUE SPECIFICITY, AND INDUCTION BY HYPOXIC STRESS.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.

************

FUNCTION IN EDITING DEFECTIVE E.COLI, AND MUTAGENESIS OF LYS-232 AND LYS-234.

************

FUNCTION AS TRNA(ALA) EDITING PROTEIN, AND MUTAGENESIS OF 232-LYS--LYS-234.

************

X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS), FUNCTION AS TRNA(ALA) EDITING PROTEIN, SUBUNIT, AND COFACTOR.

************

X-RAY CRYSTALLOGRAPHY (1.88 ANGSTROMS) OF THE APO FORM, IN COMPLEX WITH ZINC WITH AND WITHOUT NON-COGNATE SERINE, CHARACTERIZATION, SUBUNIT, COFACTOR, AND MUTAGENESIS OF THR-30.

************

X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS), COFACTOR, AND SUBUNIT.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 27-63, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 70-122, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 27-63, AND FUNCTION.

************

STRUCTURE BY NMR OF 27-63, AND DISULFIDE BONDS.

************

SEQUENCE REVISION TO 64.

************

STRUCTURE BY NMR OF 20-56, MUTAGENESIS OF ARG-35; VAL-48 AND PHE-50, AND FUNCTION.

************

FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE PRE-60S RIBOSOME, AND INTERACTION WITH ARX1.

************

PROTEIN SEQUENCE, FUNCTION, SUBUNIT, HEME-BINDING, AND X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) IN COMPLEX WITH CALCIUM.

************

PROTEIN SEQUENCE OF 1-40, CRYSTALLIZATION, AND PRELIMINARY X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).

************

PROTEIN SEQUENCE, FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.

************

SEQUENCE REVISION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, AND ASSOCIATION WITH THE LHCII COMPLEX AND PSAE.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3-525.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 423-566.

************

SUBCELLULAR LOCATION, AND INTERACTION WITH SCY1.

************

INTERACTION WITH CPFTSY AND CPSRP COMPLEX.

************

INTERACTION WITH SECE1 AND SCY1.

************

INTERACTION WITH CAO/CPSRP43.

************

INTERACTION WITH CAO/CPSRP43; FFC/CPSRP54; CPFTSY AND LHCP.

************

INTERACTION WITH CAO/CPSRP43, AND MUTAGENESIS OF 376-LYS-ARG-377 AND 454-LYS-ARG-455.

************

INTERACTION WITH PAM68.

************

INTERACTION WITH CAO/CPSRP43, AND SUBUNIT.

************

CHARACTERIZATION OF DIMER CONFORMATIONS, AND MUTAGENESIS OF PRO-8 AND PRO-62.

************

BINDING TO RNA, AND SUBCELLULAR LOCATION.

************

ACETYLATION AT SER-2 AND LYS-17, REGULATION OF ACTIVITY, MASS SPECTROMETRY, AND MUTAGENESIS OF LYS-16 AND LYS-17.

************

X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS), AND MUTAGENESIS OF ASN-10; LYS-11; LEU-18 AND PHE-54.

************

PROTEIN SEQUENCE, FUNCTION, MASS SPECTROMETRY, AND AMIDATION AT LYS-18.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-48.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 458-556.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 3-607.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 459-557.

************

NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-214.

************

PROTEIN SEQUENCE OF 1-32.

************

PROTEIN SEQUENCE OF 19-28.

************

PROTEIN SEQUENCE, AND SEQUENCE REVISION TO 118-119 AND 180.

************

PROTEIN SEQUENCE OF 25-424 AND 429-607, AND VARIANT THR-214.

************

SEQUENCE REVISION TO 190-195.

************

PROTEIN SEQUENCE OF 25-64.

************

PROTEIN SEQUENCE OF 163-172.

************

PROTEIN SEQUENCE OF 165-173.

************

PROTEIN SEQUENCE OF 402-433.

************

PROTEIN SEQUENCE OF 437-451.

************

NUCLEOTIDE SEQUENCE [MRNA], AND ALLERGEN.

************

PROTEIN SEQUENCE OF 25-48.

************

PROTEIN SEQUENCE OF 25-38.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 215-478, AND ALLERGEN.

************

PROTEIN SEQUENCE OF 1-15, AND INDUCTION.

************

PROTEIN SEQUENCE OF 16-90.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28.

************

PROTEIN SEQUENCE OF 19-30.

************

ALLERGEN.

************

PROTEIN SEQUENCE OF 31-41; 45-340; 344-565 AND 569-607.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 25-608.

************

NUCLEOTIDE SEQUENCE [MRNA], AND X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LYS-420.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLY-121.

************

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIROSHIMA-1 LYS-378.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT TYR-27.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-455.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-167.

************

PROTEIN SEQUENCE OF 25-609.

************

PROTEIN SEQUENCE OF 25-44 AND 480-499.

************

PROTEIN SEQUENCE OF 45-75; 98-130; 162-183; 239-254; 265-281; 287-298; 348-372; 397-434; 438-452; 500-543; 550-558; 570-581 AND 599-609, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 166-174.

************

PROTEIN SEQUENCE OF 222-229, AND ASPIRIN-ACETYLATION AT LYS-223.

************

PROTEIN SEQUENCE OF 250-264, GLYCATION AT LYS-75; LYS-161; LYS-186; LYS-249; LYS-257; LYS-300; LYS-337; LYS-347; LYS-375; LYS-402; LYS-437; LYS-468; LYS-560; LYS-549; LYS-569 AND LYS-597, LACK OF GLYCATION AT LYS-28; LYS-44; LYS-65; LYS-88; LYS-97; LYS-117; LYS-130; LYS-160; LYS-183; LYS-198; LYS-205; LYS-214; LYS-219; LYS-229; LYS-236; LYS-264; LYS-286; LYS-298; LYS-310; LYS-383; LYS-396; LYS-413; LYS-426; LYS-438; LYS-456; LYS-460; LYS-490; LYS-499; LYS-524; LYS-543; LYS-548; LYS-562; LYS-565; LYS-581; LYS-584; LYS-588 AND LYS-598, AND MASS SPECTROMETRY.

************

BILIRUBIN-BINDING SITE.

************

GLYCATION AT LYS-223 AND LYS-549.

************

GLYCATION AT LYS-549.

************

GLYCATION AT LYS-36; LYS-223; LYS-257; LYS-305; LYS-341; LYS-375; LYS-463; LYS-549 AND LYS-558.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-108 AND TYR-164, AND MASS SPECTROMETRY.

************

FUNCTION, AND ZINC-BINDING SITES.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294 AND SER-297, TISSUE SPECIFICITY, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-164, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-443; THR-444 AND THR-446, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (6.0 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS).

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-609.

************

VARIANT CANTERBURY ASN-337.

************

VARIANTS NASKAPI/MERSIN GLU-396 AND MEXICO GLY-574.

************

VARIANTS NAGASAKI-3 GLN-27 YANOMAMA-2 GLU-396; NAGASAKI-2 ASN-399 AND MAKU GLU-565.

************

VARIANTS FUKUOKA-2 HIS-23; CHRISTCHURCH/HONOLULU-2 GLN-24; TAGLIACOZZO ASN-337 AND ALBUMIN B/OSAKA-2/PHNOM PHEN LYS-594.

************

VARIANTS HONOLULU-2 GLN-24; NAGASAKI-1 GLY-293; HIROSHIMA-1 LYS-378; TOCHIGI LYS-400; HIROSHIMA-2 LYS-406 AND OSAKA-2 LYS-594.

************

VARIANTS HONOLULU-1 PRO-24; HONOLULU-2 GLN-24; NAGOYA LYS-143; NEW GUINEA ASN-337; MANAUS-1/LAMBADI LYS-525; FUKUOKA-1 ASN-587; OSAKA-1 LYS-589 AND OSAKA-2 LYS-594.

************

CHARACTERIZATION OF VARIANT REDHILL.

************

VARIANTS VARESE HIS-23; TORINO LYS-84 AND VIBO VALENTIA LYS-106.

************

CHARACTERIZATION OF VARIANT VENEZIA.

************

VARIANTS KOMAGOME-3 HIS-23; IOWA CITY-2 VAL-25; KOMAGOME-2 ARG-152; IOWA CITY-1 VAL-389 AND KOMAGOME-1 GLU-396.

************

VARIANT CASEBROOK ASN-518.

************

VARIANTS SONDRIO LYS-357 AND PARIS-2 ASN-587.

************

VARIANTS MALMO-I CYS-23; MALMO-95 ASN-87; MALMO-10 ARG-292; MALMO-47 LYS-342; MALMO-5 GLN-400 AND MALMO-61 ALA-574.

************

VARIANT HERBORN GLU-264.

************

VARIANT HAWKES BAY PHE-201.

************

VARIANT ORTONOVO LYS-529.

************

VARIANTS LARINO TYR-27; TRADATE-2 GLN-249 AND CASERTA ASN-300.

************

VARIANT FDH HIS-242.

************

VARIANT FDH HIS-242, AND PROTEIN SEQUENCE OF 25-51.

************

VARIANT FDH PRO-90.

************

VARIANT TYR-73, AND MASS SPECTROMETRY.

************

CHARACTERIZATION OF VARIANT KENITRA.

************

NUCLEOTIDE SEQUENCE [MRNA], AND IDENTIFICATION BY MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA], AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-205.

************

PROTEIN SEQUENCE OF 25-44.

************

PROTEIN SEQUENCE OF 35-57; 66-75; 89-105; 243-257; 299-309; 348-372; 422-434; 439-452; 470-483; 509-524; 550-558 AND 570-602, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 99-516.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 477-551.

************

PROTEIN SEQUENCE OF 25-57 AND 144-157.

************

SEQUENCE REVISION TO 322-323 AND 506-507.

************

PROTEIN SEQUENCE OF 1-38, AND PROTEOLYTIC PROCESSING.

************

PROTEIN SEQUENCE OF 25-222.

************

PROTEIN SEQUENCE OF 35-57; 66-75; 89-97; 168-181; 247-264; 287-298; 361-372; 376-383; 414-434; 439-452; 470-483; 509-524; 528-545; 570-581 AND 585-602, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 223-288 AND 572-608.

************

STRUCTURE BY NMR OF 1-60.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, INDUCTION, AND DISRUPTION PHENOTYPE.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 115-210 (ISOFORMS 1/2), TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 55-136.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, INDUCTION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.

************

X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) IN COMPLEX WITH NADP, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF HIS-269.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH NADPH.

************

X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH NADPH AND INHIBITOR.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 39-54; 75-83; 153-161; 182-184 AND 336-343, MUTAGENESIS OF GLY-19; GLY-22 AND ALA-25, AND FUNCTION.

************

PROTEIN SEQUENCE OF 2-25, FUNCTION, AND ENZYME REGULATION.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TRANSCRIPTION REGULATION.

************

PROTEIN SEQUENCE OF 1-10, CHARACTERIZATION, MASS SPECTROMETRY, AND MUTAGENESIS OF ARG-197.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND DISRUPTION PHENOTYPE.

************

FUNCTION, MUTAGENESIS OF TYR-123, AND COFACTOR.

************

CATALYTIC ACTIVITY, AND COFACTOR.

************

X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH NAD, FUNCTION, AND HOMOTETRAMERIZATION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 92-520.

************

PROTEIN SEQUENCE OF 22-34.

************

X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS).

************

ERRATUM, AND SEQUENCE REVISION TO N-TERMINUS.

************

PROTEIN SEQUENCE OF 18-517.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 119-517.

************

PROTEIN SEQUENCE OF 160-172 AND 325-338, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 196-226 AND 325-338.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 214-500, AND VARIANT VAL-337.

************

DESCRIPTION OF ORIGIN OF CONFLICTS BETWEEN THE SEQUENCE DESCRIBED IN PUBMED:4065146 AND DNA SEQUENCES.

************

X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS).

************

VARIANT LYS-504.

************

VARIANT LYS-496.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 10-31.

************

PROTEIN SEQUENCE OF 54-80; 87-96; 162-174; 198-228; 260-282; 327-340; 349-370; 386-409; 417-428; 431-438 AND 444-453, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 472-509.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-370, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-29.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 10-519, AND VARIANTS ARG-86 AND LYS-498.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 32-519.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 77-519.

************

PROTEIN SEQUENCE OF 162-174; 198-228; 260-340; 327-340; 358-370; 397-409 AND 495-508, AND MASS SPECTROMETRY.

************

PROTEIN SEQUENCE OF 327-340.

************

STRUCTURE BY NMR OF 12-22.

************

SEQUENCE REVISION TO 163.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 269-347.

************

PROTEIN SEQUENCE OF 25-65.

************

PROTEIN SEQUENCE OF 25-34 AND 378-386.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-216 AND SER-500, AND MASS SPECTROMETRY.

************

INDUCTION, AND OPERON STRUCTURE.

************

CHARACTERIZATION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.

************

PROTEIN SEQUENCE OF 76-79 AND 482-488.

************

PROTEIN SEQUENCE OF 2-16, AND CHARACTERIZATION.

************

UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-3, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-491, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-250; THR-251 AND SER-262, AND MASS SPECTROMETRY.

************

SEQUENCE REVISION TO 73; 153-166; 334-336 AND 424.

************

NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND INDUCTION.

************

SEQUENCE REVISION TO 66; 74; 95; 110; 114-121; 158-165 AND 367.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-258.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA], PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.

************

FUNCTION, TISSUE SPECIFICITY, SUBSTRATE SPECIFICITY, AND CATALYTIC ACTIVITY.

************

SUBUNIT, CATALYTIC ACTIVITY, AND IDENTIFICATION BY MASS SPECTROMETRY.

************

BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND CATALYTIC ACTIVITY.

************

NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 235-272; 591-611 AND 1234-1249, AND TISSUE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 533-1358.

************

FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 758-1321, AND TISSUE SPECIFICITY.

************

TISSUE SPECIFICITY, AND SUBSTRATE SPECIFICITY.

************

SUBUNIT, AND SUBSTRATE SPECIFICITY.

************

NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT, TISSUE SPECIFICITY, AND INDUCTION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 347-1332, AND TISSUE SPECIFICITY.

************

FUNCTION, INDUCTION, TISSUE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.

************

FUNCTION, TISSUE SPECIFICITY, AND MUTANT AAO3.

************

FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF 821-LEU--LYS-826.

************

FUNCTION, DISRUPTION PHENOTYPE, AND INDUCTION BY SALT STRESS AND ABA.

************

INTERACTION WITH PUB44.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1082-1337.

************

FUNCTION, DISRUPTION PHENOTYPE, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND ENZYME REGULATION.

************

PROTEIN SEQUENCE OF 2-364.

************

PROTEIN SEQUENCE OF 2-63 AND 148-358.

************

PROTEIN SEQUENCE OF 2-22.

************

PROTEIN SEQUENCE OF 2-13; 29-42; 44-56; 61-69; 88-99; 154-173; 244-258 AND 332-342, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 139-364.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-204, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-65, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-13 AND LYS-42, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-3; TYR-5 AND TYR-223, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-235; THR-241; SER-354 AND SER-356, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-9; SER-36; THR-37 AND SER-46, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-364, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-39 AND SER-46, AND MASS SPECTROMETRY.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-42; LYS-108 AND LYS-330, AND MASS SPECTROMETRY.

************

MALONYLATION AT LYS-111 AND LYS-312.

************

VARIANT GSD12 GLY-129, AND CHARACTERIZATION OF VARIANT GSD12 GLY-129.

************

CHARACTERIZATION OF VARIANT GSD12 GLY-129.

************

VARIANT GSD12 LYS-207.

************

VARIANT GSD12 TYR-339.

************

VARIANT GSD12 SER-347, BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANTS GSD12 LYS-207 AND SER-347.

************

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-266 AND 295-364.

************

PROTEIN SEQUENCE OF 2-22; 29-57; 61-109; 112-134; 154-258; 260-312 AND 323-364, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 99-355.

************

NITRATION [LARGE SCALE ANALYSIS] AT TYR-174, AND MASS SPECTROMETRY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND SER-39, AND MASS SPECTROMETRY.

************

PRELIMINARY PROTEIN SEQUENCE OF 2-364.

************

PROTEIN SEQUENCE OF 2-165.

************

PROTEIN SEQUENCE OF 174-201, AND SEQUENCE REVISION.

************

PROTEIN SEQUENCE OF 252-364, AND SEQUENCE REVISION.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 38-56 AND 350-364.

************

SUBSTRATE-BINDING SITE.

************

X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 3-345 IN COMPLEX WITH SUBSTRATE, AND MUTAGENESIS OF GLU-35; ARG-43; LYS-147 AND ARG-304.

************

X-RAY CRYSTALLOGRAPHY (2.46 ANGSTROMS), AND MUTAGENESIS OF GLU-188; GLU-190 AND LYS-230.

************

X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) IN COMPLEX WITH WAS, AND FUNCTION.

************

X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 5-344 OF MUTANT VAL-129, AND SUBUNIT.

************

X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH SNX9, INTERACTION WITH SNX9, SUBUNIT, AND CATALYTIC ACTIVITY.

************

PROTEIN SEQUENCE OF 2-13; 15-22; 29-42; 70-99; 154-173; 209-215; 244-258; 290-312 AND 332-364, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 324-356, AND TISSUE SPECIFICITY.

************

PROTEIN SEQUENCE OF 2-33 AND 357-364.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 238-364.

************

VARIANT HFI PRO-150.

************

VARIANT HFI ASP-175.

************

VARIANT HFI ARG-135.

************

VARIANT ARG-148.

************

VARIANT HFI PRO-257.

************

VARIANT HFI LYS-335.

************

VARIANTS HFI PRO-150; ASP-175; PRO-257; TRP-304; LYS-335 AND VAL-338.

************

VARIANTS HFI GLN-304 AND TRP-304, CHARACTERIZATION OF VARIANTS HFI GLN-304 AND TRP-304, AND KINETIC PARAMETERS.

************

VARIANTS HFI PRO-150; ASP-175; ARG-185 AND LYS-335.

************

VARIANTS HFI THR-74; 120-ASN-LYS-121 DEL; PRO-150; ASP-175; PHE-222; PRO-229; PRO-257; LYS-335 AND VAL-338, AND CHARACTERIZATION OF VARIANTS HFI THR-74; PHE-222 AND PRO-229.

************

VARIANTS HFI PRO-150; ASP-175; ARG-178; PRO-284 AND LYS-335.

************

PROTEIN SEQUENCE OF 2-12 AND 108-120, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS).

************

NUCLEOTIDE SEQUENCE OF 185-364.

************

PROTEIN SEQUENCE OF 41-68.

************

INTERACTION WITH ATP6V1E1.

************

INTERACTION WITH PLD2.

************

ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-147, AND MASS SPECTROMETRY.

************

X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 1-364, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 1-227.

************

PROTEIN SEQUENCE OF 2-13; 29-57; 61-69; 73-96; 102-108; 112-134; 154-215; 244-258; 260-289; 305-315; 319-330 AND 332-363, AND MASS SPECTROMETRY.

************

NUCLEOTIDE SEQUENCE [MRNA] OF 281-363, AND TISSUE SPECIFICITY.

************

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39, AND MASS SPECTROMETRY.